Back grey_arrow_rt.gif
 
Recent articles on HIV. Check out articles on HIV related Bone Issues and HIV and Aging.
 
null.gif
 
 
  1. Glasgow Manifesto; recorded aging webinars: IAS; Global Action on aging ICOPE
     
  2. CROI: Summary from CROI 2023 for HIV and liver disease What is new in viral hepatitis coinfection? Is fatty liver disease a growing concern? New insights from CROI 2023. - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/16/23)
     
  3. CROI: Clinical Pharmacology at CROI 2023 - Courtney V. Fletcher, Pharm.D. Professor UNMC Center for Drug Discovery University of Nebraska Medical Center - (03/31/23)
     
  4. CROI: Summary from CROI 2024 for HIV and liver disease - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/25/24)
     
  5. HIVR4P Switching between oral and injectable pre-exposure prophylaxis (PrEP) regimens in the United States: an investigation of reasons for switching in the real world - (10/12/24)
     
  6. HIVR4P Early implementation of long-acting injectable cabotegravir for HIV prevention in a safety net primary care center in U.S. South at Grady in Atlanta - (10/12/24)
     
  7. HIVR4P Pharmacokinetic superiority of a 3-month dapivirine vaginal ring (100 mg) compared to the 1-month dapivirine vaginal ring (25 mg) - (10/12/24)
     
  8. HIVR4P Short-term combination immunotherapy with broadly neutralizing antibodies and CCR5 blockade mediates ART-free viral control in infant rhesus macaques - (10/11/24)
     
  9. Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV-1 infected patients in 2020-2023 - (10/11/24)
     
  10. HIVR4P 17-Clinic US Study Pinpoints Keys to Giving Long-Acting Injected PrEP: Overcoming Challenges Integrating Injectable PrEP Into Care: Key Strategies From The PILLAR Study - Mark Mascolini (10/11/24)
     
  11. HIVR4P High CAB-LA PrEP On-Time and Retention Rates in US Urban Safety-Net Clinic Population. SF, Ward-86 - Mark Mascolini (10/11/24)
     
  12. HIVR4P Long-acting injectable Cabotegravir (CAB-LA) pilot implementation at primary healthcare level in resource-limited settings: early real-world evidence from the USAID DISCOVER-Health Project in Zambia - (10/11/24)
     
  13. HIVR4P HIV pre-exposure prophylaxis (PrEP) access preference among men who have sex with men in China: a discrete choice experiment - (10/10/24)
     
  14. HIVR4P Phase 1 dose-escalation trial to evaluate the safety, tolerability, pharmacokinetics and neutralization activity of PGDM1400LS in combination with VRC07-523LS and PGT121.414.LS in healthy participants without HIV (HVTN 140/HPTN 101) - (10/10/24)
     
  15. HIVR4P HIV Trends in Metropolitan US Cities from 2014-2022: Baseline For The Ending The Epidemic Initiative - (10/10/24)
     
  16. HIVR4P Early virologic success on ART following breakthrough infection on CAB-LA PrEP - Mark Mascolini (10/10/24)
     
  17. HIVR4P Gilead Lenacapavir Access Statement & Voluntary Licensing Agreement - (10/10/24)
     
  18. HIVR4P PURPOSE-2 & Other PURPOSE Studies - (10/10/24)
     
  19. HIVR4P Global racial, ethnic, and gender diversity among participants enrolled in the PURPOSE-2 trial of lenacapavir for pre-exposure prophylaxis (PrEP) - (10/10/24)
     
  20. HIVR4P Development of a long-acting biodegradable hydrogel injectable system for single or multi-purpose prevention of HIV and/or pregnancy - (10/10/24)
     
  21. HIVR4P Safety and tolerability of oral islatravir (ISL) once-monthly (QM) as pre-exposure prophylaxis (PrEP) in cisgender men and transgender women at elevated risk for acquiring HIV-1 - (10/10/24)
     
  22. HIVR4P Safety and tolerability of oral islatravir (ISL) once-monthly (QM) as pre-exposure prophylaxis (PrEP) in cisgender women at elevated risk for acquiring HIV-1 - (10/10/24)
     
  23. HIVR4P Scaling a non-human primate physiologically-based pharmacokinetic model of extended-release MK-2048 and combination MK-2048/vicriviroc (MK-2048A) intravaginal rings into humans using phase 1 MTN-027 and MTN-028 studies - (10/09/24)
     
  24. HIVR4P Weekly oral prophylaxis with MK-8527 protects rhesus macaques from rectal challenge with simian-human immunodeficiency virus - (10/09/24)
     
  25. HIVR4P ViiV HEALTHCARE TO TRIPLE ANNUAL SUPPLY OF LONG-ACTING HIV PREP FOR LOW- AND MIDDLE-INCOME COUNTRIES - (10/06/24)
     
  26. HIVR4P Preferences for starting daily, on-demand, and long-acting injectable HIV pre-exposure prophylaxis among transfeminine persons in the United States: results from the Transgender Women's Internet Survey and Testing (TWIST) study - (10/06/24)
     
  27. HIVR4P Preferences for telePrEP among people who access HIV self-testing in Philadelphia - (10/06/24)
     
  28. HIVR4P Implementing long-acting cabotegravir for HIV Pre-Exposure Prophylaxis in a large academic hospital-based urban HIV clinic - (10/06/24)
     
  29. HIVR4P Examples of studies - CATALYST South Africa - (10/06/24)
     
  30. HIVR4P Examples of studies - DCE results on service delivery preferences - (10/06/24)
     
  31. HIVR4P Examples of studies - Project PrEP - (10/06/24)
     
  32. HIVR4P Implementing PrEP Choice: Experiences from South Africa - (10/06/24)
     
  33. HIVR4P History of injectable contraception was associated with women's willingness to use long-acting injectable PrEP: findings from US women across nine cities - (10/06/24)
     
  34. HIVR4P Characterizing the Levels of Knowledge, Attitudes, and Behaviors Regarding the Use and Risks Associated with Oral HIV-1 Pre-Exposure Prophylaxis (PrEP) Among People Prescribed PrEP in Canada - (10/06/24)
     
  35. HIVR4P Understanding preferences for pre-exposure prophylaxis (PrEP) among people who would benefit from PrEP in the United States - (10/06/24)
     
  36. HIVR4P Interest in long-acting PrEP modalities among women in the United States with a history of injectable medication use: findings from the MACS/WIHS combined cohort study - (10/06/24)
     
  37. HIVR4P Safety, Pharmacokinetics, and Degradation of Ultra-Long-Acting Injectable, Biodegradable, and Removable In-Situ Forming Implant with Cabotegravir for HIV Prevention - (10/06/24)
     
  38. Untangling the causal ties between antiretrovirals and obesity: Comment. 'Body Weight Changes CASCADE Cohort' - (09/25/24)
     
  39. HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomized, controlled, phase 3 trial; Commentary - (09/25/24)
     
  40. Gilead's Twice-Yearly Lenacapavir for HIV Prevention
    Reduced HIV Infections by 96% and Demonstrated Superiority
    to Daily Truvada® in Second Pivotal Phase 3 Trial
     - (09/14/24)
     
  41. Updated Statement on Access Planning in High-Incidence, Resource-Limited Countries for Lenacapavir for HIV Prevention - (09/14/24)
     
  42. HRSA Issues Aging/HIV Letter on Older HIV; Long-Term Survivors in Ryan White HIV/AIDS Program - (09/05/24)
     
  43. HIV Infection Is Associated With Progression of Subclinical Carotid Atherosclerosis - (09/03/24)
     
  44. Patterns of HIV treatment preferences (oral, LA, implant) among people with diverse demographic, social, and behavioral characteristics who are living with HIV in the United States - (08/26/24)
     
  45. Missed Opportunities: Characteristics of People Who Received a Concurrent HIV/AIDS Diagnosis in New York State From 2016 to 2021....19.0% had a CDX (late diagnosis) - (08/26/24)
     
  46. Switching to long-acting cabotegravir/rilpivirine: data from an Italian monocentric cohort - (08/26/24)
     
  47. Aging with HIV - An Epidemiological Profile of Persons with Diagnosed HIV Aged 50 Years and Older in New York State, 2012-2021, new HIV more likely to have late diagnosis/stage 3 HIV, female white, heterosexual sex, IDU....heart disease/cancers leading cause of death NYC - (08/26/24)
     
  48. Prevalence and correlates of frailty among older people with and without HIV in rural Uganda - (08/26/24)
     
  49. THE ASSOCIATION OF ANEMIA WITH SURVIVAL AMONG PEOPLE WITH HIV FOLLOWING ANTIRETROVIRAL INITIATION IN THE NA-ACCORD 2007-2016 - (08/26/24)
     
  50. IAS: The DoxyPEP Debate: To DoxyPEP or not to DoxyPEP? - (08/26/24)
     
  51. IAS: Negative Perception of Self & Stigma & Depression associated with Worse Expectations of Aging in Brazil - (08/26/24)
     
  52. FRAX assessment in people ageing with HIV - (08/19/24)
     
  53. Impact of rosuvastatin on pulse-wave velocity in men with HIV at moderate cardiovascular risk, plus Editorial Comment - (08/19/24)
     
  54. Association between switching to integrase strand transfer inhibitors and incident diabetes in people with HIV - (08/19/24)
     
  55. Medical comorbidities and lower myelin content are associated with poor cognition in young adults with perinatally acquired HIV - (08/19/24)
     
  56. IAS: Differences between integrase strand transfer inhibitors on glucose tolerance: a role for mitochondrial stress - (08/19/24)
     
  57. IAS: New HIV Drug Development at IAS 2024 - (08/19/24)
     
  58. IAS: Aging, Metabolics & Weight Studies at IAS 2024 - (08/12/24)
     
  59. IAS: Switching to doravirine in the absence of genotypic resistance tests in people living with HIV virally suppressed on antiretroviral treatment at a London HIV clinic - (08/06/24)
     
  60. IAS: Phase 1, open-label study to evaluate the drug interaction between MK-8527, an HIV-1 nucleoside reverse transcriptase translocation inhibitor, and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females - (08/06/24)
     
  61. IAS: Population pharmacokinetics (POPPK) for thigh as alternative Rilpivirine Long-Acting (RPV LA) injection site - (08/06/24)
     
  62. IAS: Cabotegravir/rilpivirine long-acting therapy real world experience in a large clinical cohort of HIV patients - (08/06/24)
     
  63. IAS: CAB/RPV-LA in patients with history of failure and/or drug resistance mutations to NNRTIs or INSTIs: the experience of a French university hospital - (08/06/24)
     
  64. IAS: Resistance Analyses During Treatment of Lenacapavir with Broadly Neutralizing Antibodies in People with HIV - (08/06/24)
     
  65. IAS: Assessment of Longitudinal Changes in Renal Function of HIV-1 Oral Pre-Exposure Prophylaxis Users Using Real-World Data in the United States - (08/06/24)
     
  66. IAS: Assessment of Longitudinal Changes in Renal Function of HIV-1 Oral Pre-Exposure Prophylaxis Users Using Real-World Data in the United States - (08/06/24)
     
  67. IAS: Experiences and Quality of Life with Long-Acting Lenacapavir from People with Multidrug-Resistant HIV-1 Enrolled in the Phase 2/3 CAPELLA Study - (08/06/24)
     
  68. IAS: Predicting Retention in Care Before and After the COVID-19 Pandemic Among People With HIV - (08/06/24)
     
  69. IAS: Long-acting oral PrEP is preferred to injections: findings from an online sample of American gay, bisexual, and other men who have sex with men - (08/06/24)
     
  70. IAS: Weight Gain and Health-Related Quality of Life in PWH on ART - (08/06/24)
     
  71. IAS: Lack of Understanding of Undetectable Equals Untransmittable (U=U) is High Among PLWH in US - (08/06/24)
     
  72. IAS: Bone health in Malaysian women living with HIV: uncovering the pores in osteoporosis screening and management in a high-risk population - (08/05/24)
     
  73. Low Compliance (10%) with Bone Mineral Density Screening Recommendations for People with HIV Despite High Fracture Rates...."critical to prioritize health screenings" (08/04/24)
     
  74. IAS: ART Use and HTLV-1 Tied to hrHPV Persistence in Kenyan Women With HIV - Mark Mascolini (08/03/24)
     
  75. IAS: Changes in body mass index before and after starting dolutegravir and compared to protease inhibitors in children and adolescents living with HIV in Europe and Thailand - (08/03/24)
     
  76. IAS: PAIRED - PAtIent Reported Experiences and perceiveD Benefit of Treatment With Dolutegravir/Lamivudine (DTG/3TC) - Qualitative Interviews: Diverse Group of People With HIV-1 (PWH) Reflect on Life and Health - (08/03/24)
     
  77. IAS: Prenatal Dolutegravir-Based Regimen Use, and Pregnancy and Birth Outcomes: Data From The Antiretroviral Pregnancy Registry - (08/03/24)
     
  78. IAS: Effectiveness and durability of dolutegravir/rilpivirine in older people with HIV from the Veterans Aging Cohort Study (VACS) - (08/03/24)
     
  79. IAS: Adolescents and young adults with HIV using long-acting injectable cabotegravir/rilpivirine as a standard of care: outcomes of the observational cohort at 26 months - (08/03/24)
     
  80. IAS: Increased incidence of emergent integrase drug resistance with cabotegravir versus dolutegravir in randomised switching trials - (08/03/24)
     
  81. IAS: Early experiences with usage of injectable cabotegravir (CAB-LA) among Kenyan and Ugandan adults participating in the SEARCH Dynamic Choice HIV Prevention trial: a qualitative study....self & external stigma, convenience, feeling healthy - (08/03/24)
     
  82. IAS: Pre-Exposure Prophylaxis product choice of participants in HPTN 083 - (08/03/24)
     
  83. IAS: Changes in sexual behavior among adolescent girls receiving long-acting injectable cabotegravir for HIV prevention: the HPTN 084-01 study - (08/03/24)
     
  84. IAS: CAB-LA for PrEP Earns High Satisfaction Rates (90%) in Rural Kenya and Uganda - Mark Mascolini (08/03/24)
     
  85. IAS: HCV incidence among MSM using HIV PrEP and MSM with HIV in a New York City Health Care System over 2 decades - (08/02/24)
     
  86. IAS: (Implants) Preference for long-acting HIV prevention methods among transgender women at greatest risk for HIV acquisition in eastern and southern United States: findings from the LITE cohort - (08/02/24)
     
  87. IAS: An assessment of clinical frailty and early aging among a cohort of people living with HIV in Ontario, Canada - (08/01/24)
     
  88. IAS: Comprehensive geriatric assessment for people living with HIV and frailty: a feasibility randomized controlled trial - (08/01/24)
     
  89. IAS: Perceptions on frailty and frailty screening of people living with HIV and their healthcare professionals in Ethiopia: a qualitative study - (08/01/24)
     
  90. IAS: Frailty and multimorbidity in mid-aged and older adults living with HIV: a cross-sectional study in Zimbabwe - (08/01/24)
     
  91. IAS: Polypharmacy Contributes to Frailty & Falls - CHANGE-Rx: frailty, falls, polypharmacy, and inappropriate medication use in a Canadian cohort of people aged 65 and older living with HIV....53% of older PWH have frailty - (08/01/24)
     
  92. IAS: Hypertension management and risk of dementia in people with and without HIV infection - (08/01/24)
     
  93. IAS: Preference for long-acting HIV prevention methods among transgender women at greatest risk for HIV acquisition in eastern and southern United States: findings from the LITE cohort - (08/01/24)
     
  94. Dolutegravir with recycled nucleoside reverse transcriptase inhibitors maintains better viral suppression than protease inhibitor based antiretroviral therapy over 144 weeks: VISEND Trial - (08/01/24)
     
  95. IAS: Influencers and Decision-Making Factors for Choosing Injectable PrEP Among Men Who Have Sex With Men and Transgender Men in the United States - (08/01/24)
     
  96. IAS: Location preferences for accessing long-acting injectable pre-exposure prophylaxis (LA-PrEP) among men who have sex with men (MSM) in the U.S currently using daily-oral PrEP - (08/01/24)
     
  97. IAS: Need for Improved HIV Testing Prior to and During Pre-Exposure Prophylaxis with Cabotegravir Long-Acting Injections in Routine Clinical Care in the United States: Low Rates of HIV Tesing - (08/01/24)
     
  98. IAS: Only 9% PrEP Use Among Transfeminine Persons: HIV pre-exposure prophylaxis awareness, willingness, and use among transfeminine persons with high likelihood of HIV in the United States: results from the Transgender Women's Internet Survey and Testing (TWIST) - (08/01/24)
     
  99. IAS: "The simplest way to go:" A mixed methods analysis of why women who inject drugs selected long-acting injectable cabotegravir instead of daily oral PrEP.....95% of women initiated CAB Lai PrEP !!! - (07/31/24)
     
  100. IAS: Efficacy of dolutegravir/lamivudine (DTG/3TC) in adults with HIV-1 and isolated reactive hepatitis B core antibody (anti-HBc): results from the phase 3/3b GEMINI-1/-2, STAT, TANGO, and SALSA - (07/31/24)
     
  101. IAS: Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024 - (07/31/24)
     
  102. IAS: Switching from a second-line ritonavir-boosted protease inhibitor (PI/r)-based regimen to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): results of a randomized clinical trial - (07/31/24)
     
  103. IAS: Extended efficacy and safety of dolutegravir and darunavir containing regimens at week 96 in the international randomised clinical trial: D2EFT - (07/31/24)
     
  104. IAS: Efficacy and Safety of B/F/TAF in Hispanic/Latine Adults With HIV-1 Initiating First-Line Therapy: 5-Year Follow-up From Two Phase 3 Studies - (07/31/24)
     
  105. IAS: What drives Comorbidities in PWH ? Highlights From Aging Pre-Conference Talks, at AIDS 2024 - (07/31/24)
     
  106. IAS: Assessing Comorbid Conditions in HIV/AIDS Patients: Insights from the CHAO (Comorbidities of HIV/AIDS Outpatients) Study in Meru County, Kenya and Their Role in Shaping Integrated Health Care Approaches - (07/31/24)
     
  107. IAS: Prevalence and associated factors of chronic kidney disease in young people living with HIV in Uganda - (07/31/24)
     
  108. IAS: Increased cardiovascular risk in perinatally HIV-acquired adolescents (PHIV) may linked to proinflammatory NK cells - (07/31/24)
     
  109. IAS: ViiV HEALTHCARE ANNOUNCES POSITIVE NEW DATA FOR APRETUDE USE DURING PREGNANCY AT AIDS 2024 - (07/30/24)
     
  110. IAS: ViiV HEALTHCARE ANNOUNCES POSITIVE DATA DEMONSTRATING 2-DRUG REGIMEN DOVATO IS AS EFFECTIVE AS 3-DRUG REGIMEN BIKTARVY FOR MAINTENANCE THERAPY OF HIV-1 - (07/30/24)
     
  111. IAS: ViiV HEALTHCARE PREMIERES EARLY DATA SHOWING ANTIVIRAL ACTIVITY AGAINST INTEGRASE RESISTANCE FROM ITS INVESTIGATIONAL, THIRD-GENERATION INTEGRASE INHIBITOR - (07/30/24)
     
  112. IAS: Switching to B/F/TAF in a Real-World Cohort of Older People With HIV and a High Burden of Non-AIDS-Related Comorbidities - (07/30/24)
     
  113. IAS: Fine Differences Among Five Anal Cancer Screening Strategies in HIV Group - Mark Mascolini (07/30/24)
     
  114. IAS: Preclinical Assessments of a Cabotegravir Prodrug Predicting Human Dosing Durations of >6 Months - (07/30/24)
     
  115. IAS: Prevalence of high risk penile human papillomavirus in men who have sex with men (MSM) and transgender women (TGW) - (07/30/24)
     
  116. IAS: Pre-Clinical Profiles of HIV-1 Capsid Inhibitors VH4004280 (VH-280) and VH4011499 (VH-499) - (07/30/24)
     
  117. IAS: GS-8588, A Novel Envelope-Targeting Bispecific T-Cell Engager for HIV Cure - (07/30/24)
     
  118. IAS: Injection Site Reactions with Subcutaneous Lenacapavir Administration at Alternate Injection Sites - (07/30/24)
     
  119. IAS: Nonclinical Pharmacology Profile of GS-1720, a Novel, Highly Potent, Once-Weekly Oral HIV-1 Integrase Strand Transfer Inhibitor in Clinical Development - (07/29/24)
     
  120. IAS: Safety and Pharmacokinetic Profile of Single and Multiple Ascending Doses of GS-4182, an Oral Prodrug of Lenacapavir, in Participants without HIV-1 - (07/29/24)
     
  121. IAS: Clinical Pharmacokinetics and Safety of Orally Administered VH4004280 (VH-280), a Novel HIV-1 Capsid Inhibitor, in Adults Without HIV - (07/29/24)
     
  122. IAS: Clinical Outcomes at Month 12 After Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an Observational Real-World Study (BEYOND) - (07/29/24)
     
  123. IAS: Perspectives of People With HIV (PWH) 12 Months Following a Switch to Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND) - (07/29/24)
     
  124. IAS: Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment Experienced Individuals in Europe: Data from COMBINE-2 Cohort Study - (07/29/24)
     
  125. IAS: 12-Month Outcomes of Cabotegravir Plus Rilpivirine Long-Acting Every 2 Months in a Real-World Setting: Effectiveness, Adherence to Injections, and Patient-Reported Outcomes From People With HIV-1 in the German CARLOS Study Who Switched Off Suppressive Oral Daily ART - (07/29/24)
     
  126. IAS: Phase 1 study of VH4524184 (VH-184), a new third-generation integrase strand transfer inhibitor (INSTI) with a unique resistance profile - (07/29/24)
     
  127. IAS: In vitro characterization of VH4524184 (VH-184, S-365598), a new third-generation integrase strand transfer inhibitor (INSTI) with a unique resistance profile - (07/29/24)
     
  128. IAS: The next Berlin patient: sustained HIV remission surpassing five years without antiretroviral therapy after heterozygous CCR5 WT/Δ32 allogeneic hematopoietic stem cell transplantation - (07/29/24)
     
  129. IAS: Subcutaneous injections of cabotegravir + rilpivirine in virally suppressed adults with HIV-1: a substudy of the Phase 3 FLAIR study - (07/29/24)
     
  130. IAS: Long-acting cabotegravir (CAB) plus rilpivirine (RPV) in the first, virologically-suppressed adolescents with HIV-1 to receive an every 8-week, all-injectable regimen in a multicenter, multinational Study: IMPAACT 2017 week 48 outcomes - (07/29/24)
     
  131. IAS: CAB LA Plus RPV Every 2 Months Controls HIV in Adolescents - Mark Mascolini (07/29/24)
     
  132. IAS: Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide-48-week results from the DYAD study - (07/29/24)
     
  133. IAS: Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide-48-week results from the DYAD study - (07/29/24)
     
  134. IAS: Abacavir is associated with elevated risk for cardiovascular events in the REPRIEVE trial - (07/28/24)
     
  135. IAS: Detailed modelling of viremia exposure does not independently predict cardiovascular disease in people with HIV - (07/28/24)
     
  136. IAS: Risk of major cardiovascular events with dolutegravir versus efavirenz-based antiretroviral therapy: retrospective cohort analyses using routine, de-identified data from South Africa - (07/28/24)
     
  137. IAS: Integrating non-communicable disease screening and treatment in antiretroviral clinics: insights from Malawi - (07/28/24)
     
  138. IAS: A pilot study assessing changes in cerebral function parameters in persons with insomnia switching integrase inhibitors - (07/28/24)
     
  139. IAS: Third-Generation Integrase Inhibitor Remains Active Against Resistant HIV in Lab - Mark Mascolini (07/27/24)
     
  140. IAS: Efficacy and safety of bictegravir plus lenacapavir: 48-week outcomes in virologically suppressed people with HIV-1 on complex antiretroviral regimens at baseline - (07/27/24)
     
  141. IAS: Bictegravir Plus Lenacapavir Keep Control of HIV in People on Complex Regimens - Mark Mascolini (07/27/24)
     
  142. IAS: Dolutegravir-containing antiretroviral therapy and incident hypertension: findings from a prospective cohort in Kenya, Nigeria, Tanzania, and Uganda - (07/27/24)
     
  143. IAS: Additional Time PostIntegrase Inhibitor to Protease Inhibitor Switch Shows Trend to Weight Loss: DEFINE 48-week Results - (07/27/24)
     
  144. IAS: Non-inferior efficacy and less weight gain when switching to DTG/3TC than when switching to BIC/FTC/TAF in virologically suppressed people with HIV (PWH): the PASO-DOBLE (GeSIDA 11720) randomized clinical trial. - (07/27/24)
     
  145. IAS: Viral suppression, viral failure and safety outcomes in children and adolescents on dolutegravir (DTG) in Europe and Thailand - (07/27/24)
     
  146. IAS: Failure to achieve undetectable viral load caused by HIV expression from defective proviruses and large reservoir size - (07/27/24)
     
  147. IAS: Antimicrobial resistance (AMR) in Neisseria gonorrhoeae (GC) infections among MSM on Doxycycline post-exposure prophylaxis. - (07/24/24)
     
  148. IAS: Performance characteristics of HIV RNA screening with long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) in the multicenter global HIV Prevention Trials Network 083 (HPTN 083) Study - (07/24/24)
     
  149. IAS: No Confirmed Virological Failures (CVF) for 144 Weeks When Switching 2-/3-/4-Drug ART to DTG/3TC in Heavily Treatment-Experienced PLWHA with Prior M184V/I and Multiple Virological Failures in the Prospective SOLAR-3D Study - (07/24/24)
     
  150. Virologic Failure and Drug Resistance After Programmatic Switching to Dolutegravir-based First-line Antiretroviral Therapy in Malawi and Zambia - (07/10/24)
     
  151. 21% of adults with diagnosed HIV were out-of-care - (07/05/24)
     
  152. Prevalence of anal HPV infection and anal HSIL among MSM 50 years and older living with or without HIV - (07/05/24)
     
  153. CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024 - (07/05/24)
     
  154. Food Is Medicine for Human Immunodeficiency Virus: Improved Health and Hospitalizations in the Changing Health Through Food Support (CHEFS-HIV) Pragmatic Randomized Trial - (06/21/24)
     
  155. Dasatinib + Quercetin Drugs Reduced Senescent-Associated Secretory Phenotype (SASP) in PLWH PBMCs - (06/21/24)
     
  156. Age-associated dementia (30%) among older people aging with HIV in the United States: a modeling study - (05/24/24)
     
  157. Comparison of dementia risk after age 50 between individuals with and without HIV infection: 58% Higher Risk, 10 years Earlier - (05/24/24)
     
  158. CROI: Rethinking the Definition of Late HIV Diagnosis Using Florida Surveillance Data, 2015-2021 - (05/28/24)
     
  159. CROI: A Multistate Analysis of Longitudinal Care Outcomes Among People Newly Linked to HIV Care in Missouri - (05/28/24)
     
  160. EuroHIV-HepMtg2024: Prevalence of HIV1 Resistance
    Mutations to Rilpivirine and Cabotegravir in Treatment-Naïve Patients     - (05/24/24)
     
  161. Extrapolating Expected Efficacy, Safety, and Pharmacokinetics of Dolutegravir/Lamivudine in Pregnant People Living With HIV-1 From Pregnancy Data With Combination Dolutegravir and/or Lamivudine Antiretroviral Therapies - (05/24/24)
     
  162. EuroHIV-HepMtg2024: Efficacy of Dolutegravir (DTG) and Lamivudine (3TC) in Adults With HIV-1 and Isolated Reactive Hepatitis B Core Antibody (Anti-HBc): Results From the Phase 3 GEMINI-1/-2, TANGO, and SALSA Studies - (05/24/24)
     
  163. The relationship between anti-LGBTQ+ legislation and HIV prevention among sexual and gender minoritized youth - (05/23/24)
     
  164. Impact of HIV pre-exposure prophylaxis prescriptions on HIV diagnoses in New York city: disparities in new HIV diagnosis - (05/23/24)
     
  165. EuroHIV-HepMtg2024: Acute Hepatitis B Infections after Reducing ART among Vaccinated Patients Living with HIV: HBV "PrEP-effect" of TDF/FTC? - (05/23/24)
     
  166. EuroHIV-HepMtg2024: Multivariable Models to Identify Predictors of Virologic Response to Fostemsavir in BRIGHTE - (05/23/24)
     
  167. EuroHIVMtg2024: Evaluation of Weight Gain on Incident Hypertension Among People Living With HIV-1 (PLWH) Receiving Dolutegravir (DTG)-Based Regimens or Comparator Antiretroviral Therapy (cART) in Randomized Clinical Trials Through 96 Weeks - (05/23/24)
     
  168. 2 Doravirine+Islatravir Studies Published - (05/13/24)
     
  169. Incidence of non-AIDS defining comorbidities among young adults with perinatally-acquired HIV in North America, 2000-2019 - (05/13/24)
     
  170. FDA Approves Biktarvy®Label Update With Data for Pregnant Adults With HIV - (05/13/24)
     
  171. Trial Update of Pitavastatin to Prevent Cardiovascular Events in HIV Infection - (05/08/24)
     
  172. CROI: HIV Transcription Persists in the Brain of People With HIV and Viral Suppression - (05/01/24)
     
  173. CROI: Infected T-Cell Clones Are Shared Across CSF and Blood Compartments in PWH - (05/01/24)
     
  174. CROI: Low Levels of HIV-1 in CSF During ART Are Associated With Neurocognitive Impairment and Inflammation - (05/01/24)
     
  175. CROI: Carotid Inflammation on FDG-PET Is Associated With Lower Cognitive Function in Treated HIV Infection - (05/01/24)
     
  176. CROI: Mini-Lecture on HIV Persistence in the CNS: Considerations for Current Cure Strategies - (05/01/24)
     
  177. Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmacokinetic Modeling Study - (05/01/24)
     
  178. Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study - (05/01/24)
     
  179. Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study - (05/01/24)
     
  180. 3 New Papers on Integrase Inhibitors & TAF and Weight Changes, Metabolics - (05/01/24)
     
  181. 3 New Papers on Integrase Inhibitors & TAF and Weight Changes, Metabolics - (04/17/24)
     
  182. CROI: EPIGENETIC IMPACT IN CSF CELLS FROM 48 WEEKS OF ADJUNCTIVE TELMISARTAN IN ACUTE HIV - (04/15/24)
     
  183. CROI: Prevalence of HIV Testing and HIV Positivity in the Hispanic Community Health Study/Study of Latino - (04/15/24)
     
  184. Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV - (04/15/24)
     
  185. ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV - (04/15/24)
     
  186. CROI: EPIGENETIC IMPACT IN CSF CELLS FROM 48 WEEKS OF ADJUNCTIVE TELMISARTAN IN ACUTE HIV - (04/12/24)
     
  187. CROI: Epigenetic Age Advancement Is Associated With Cognition, Frailty, and Mortality in Older PWH - (04/12/24)
     
  188. CROI: Differential Expression Analysis Reveals Pervasive Transcriptional Changes in the Brains of PWH - (04/12/24)
     
  189. CROI: ANTIRETROVIRAL REGIMENS ARE ASSOCIATED WITH COGNITIVE FUNCTION IN PEOPLE WITH HIV - (04/12/24)
     
  190. CROI: CD4 Count Predicts Longitudinal Trajectories of Central Executive Network Connectivity in PLWH - (04/12/24)
     
  191. CROI: Pro-Inflammatory Glycomic Dysregulations Define HIV-Associated Neurocognitive Impairments - (04/12/24)
     
  192. CROI: Predictors of CD4/CD8 T-cell Inversion After 96 Weeks of ART Initiated During Acute HIV - (04/12/24)
     
  193. CROI: Immune Checkpoint Signatures Associated With Impaired Cognition in People Living With HIV - (04/12/24)
     
  194. CROI: A New Measure of ART Activity in CSF and Association with Persistence and Cognitive Function - (04/12/24)
     
  195. CROI: Cumulative exposure to CVD risk factors more adversely affects cognition in women than men with and without HIV - (04/12/24)
     
  196. CROI: ASCVD Risk score Predicts Lower Cognitive Function, Bigger Affect in Women- Atherosclerotic Cardiovascular Disease Risk Score and Cognition by HIV Serostatus and Sex - (04/11/24)
     
  197. CROI: Brain White Matter Hyperintensity Accumulation in an Acute HIV Cohort over Two Years - (04/11/24)
     
  198. CROI: HIV-1 Infection and Alzheimer's Disease Pathobiology in a Novel Humanized APP-Knock in Mouse Model - (04/11/24)
     
  199. CROI: Effects of Recent Air Pollution Exposure on Cognition, Inflammation, and Neurodegeneration in HIV - (04/11/24)
     
  200. CROI: ASYMPTOMATIC CSF HIV-1 ESCAPE: INCIDENCE AND EFFECTS ON CNS BIOMARKERS - (04/11/24)
     
  201. CROI: Anti-α4β7 antibody facilitates improved renal function during SIV infection in macaques - (04/11/24)
     
  202. CROI: Pattern of Age-Related Cognitive Decline in People With HIV Depends on Viral Suppression - (04/11/24)
     
  203. CROI: Clonal Hematopoiesis in HIV and Atherosclerosis, Arterial Inflammation, and Hematopoietic Activity - (04/11/24)
     
  204. CROI: Description of clonal hematopoiesis in a hospital-based cohort of people living with HIV - (04/11/24)
     
  205. CROI: Clonal Hematopoiesis and HIV Infection are Associated with Geriatric Outcomes: the ARCHIVE Study - (04/11/24)
     
  206. CROI: PWH 50% Unknown Causes of Death Latin America: Registered Causes of Death Remain Largely Unknown Among People with HIV in Latin America - (04/08/24)
     
  207. CROI: Older/Poor PWH Have Worse Hospital Readmission Rates vs PWoH: Trends in Hospital Readmissions Among Adults With (two-thirds higher) and Without HIV in the US, 2010-2020: indicates poor quality-of-care; women had higher rates - (04/08/24)
     
  208. CROI: CARE INTERRUPTIONS AND MORTALITY AMONG ADULTS ON ART IN EUROPE AND NORTH AMERICA - (04/08/24)
     
  209. CROI: Impact of accessing care at an advanced stage on mortality in PWH in France, 2002-2016 - (04/08/24)
     
  210. CROI: Life-Years Lost Associated With Mental Illness in People With HIV in South Africa and North America: anxiety, depression - (04/08/24)
     
  211. CROI: Prevalence of diagnosed and undiagnosed depression among U.S. adults with HIV - (04/08/24)
     
  212. CROI: Targeting Inflammation and Cardiovascular Disease in People with HIV: 2024 and onward, Priscilla Hsue MD - (04/03/24)
     
  213. CROI: Feasibility of Implementing a Low-Barrier Long-Acting Injectable Antiretroviral Program for HIV Treatment & Prevention for People Experiencing Homelessness - (04/03/24)
     
  214. CROI: Case Series Examining the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial - (04/03/24)
     
  215. CROI: EHE "May not be feasible in many US cities" - Charting Achievable Milestones for HIV Care Enhancement and Prevention in the US Through 2035 - (04/02/24)
     
  216. CROI: First Case of HIV Seroconversion With Emergence of InSTI Resistance on CAB-LA PrEP in Routine Care - (04/02/24)
     
  217. CROI: HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women - (04/02/24)
     
  218. CROI: Met and unmet health and welfare services needs amongst people with HIV in the UK: mental health, physical health, welfare - (04/02/24)
     
  219. CROI: Routine Collection of Patient-Reported Outcomes in HIV Clinics: Findings After >100,000 Assessments.....rates of depression, binge drinking, drug use, intimate partner violence CNICS Cohort - (04/02/24)
     
  220. CROI: Effect of Obesity on Response to Antiretroviral Therapy in SIV-infected Rhesus Macaques - (04/02/24)
     
  221. CROI: DOLUTEGRAVIR TARGETS THE HYPOTHALAMUS TO SUPPRESS ENERGY EXPENDITURE VIA ESTROGEN RECEPTOR - (04/02/24)
     
  222. CROI: Biomarkers Influence Kidney Function Estimates More So Than Race Among Persons with HIV - (04/02/24)
     
  223. CROI: Markers of Macrophage Activation and Kidney Function in People With and Without HIV - (04/02/24)
     
  224. CROI: Association Between Social Vulnerability, HIV Testing and Positivity, United States, 2020-2022: High Social Vulnerability, racial/economic disparities Worst Outcomes - (04/01/24)
     
  225. CROI: Evaluating Barriers to Care Among Adults Living with HIV Who Are Virally Unsuppressed in Philadelphia, Using Medical Monitoring Project Data, 2015-2021 - (04/01/24)
     
  226. CROI: Ending the HIV Epidemic in Atlanta: A Mixed-Methods Study to Support the Local HIV/AIDS Response racial/ethnic & geographic disparities-service delivery gaps - (04/01/24)
     
  227. CROI: Barriers to Early Enrollment and Rapid ART Initiation Among U.S. HIV Care Facilities: low rates for 1st appontment - (04/01/24)
     
  228. CROI: The HIV Care Cascade in Medicaid, 2001-2015: 35% adherent/retained in care; Black-white disparities - (04/01/24)
     
  229. CROI: Using the ICE Method to Examine Income/Racial Segregation and HIV Outcomes -US, 2021: structural racism - (04/01/24)
     
  230. CROI: The Opioid Use Disorder Care Cascade for PWH Experiencing Homelessness in Low-Barrier HIV Care - (04/01/24)
     
  231. CROI: The Impact of the COVID-19 Pandemic on Substance Use Disorder Risk among People with HIV in the US - (04/01/24)
     
  232. CROI: Preclinical Pharmacokinetics of a Novel Long-Acting Bictegravir Solid Injectable in Rats - (04/01/24)
     
  233. CROI: A Shape-Shifting Tail Decay is the Pharmacokinetic ; Profile of an Ultra-Long Acting Bictegravir Prodrug - (04/01/24)
     
  234. CROI: Switching to DTG+3TC vs 3-Drug Regimens in Routine Clinical Care: Long-term Swedish Data - (04/01/24)
     
  235. CROI: SHORT AND LONG-TERM BODY WEIGHT GAIN FOLLOWING SWITCH TO INTEGRASE INHIBITORS DIFFERS BY SEX - (04/01/24)
     
  236. CROI: Mechanisms to Therapeutics: TACK Molecules Kill HIV-Infected Cells Through Inflammasome Activation: "potential to cure HIV via reduction in viral reservoir" ? - (04/01/24)
     
  237. CROI: SHORT AND LONG-TERM BODY WEIGHT GAIN FOLLOWING SWITCH TO INTEGRASE INHIBITORS DIFFERS BY SEX - (03/28/24)
     
  238. CROI: Trends in Black-White Disparities in HIV Diagnosis: 2017-2021, United States; relative black-white disparities increase; increase for male-to-male sexual contact; for IDU - (03/28/24)
     
  239. CROI: Estimating Lifetime Risk of a Diagnosis of HIV Infection Among MSM: United States, 2017-2021: it persists with racial disparities - (03/28/24)
     
  240. CROI: Virologic Failure with Cabotegravir-Rilpivirine Injections: A Single-Site Experience; independent infusion center - (03/28/24)
     
  241. CROI: A Randomized Trial Switching Adults ≥ 60 Years Old From First-Line ART to B/F/TAF: Week 48 Results - (03/28/24)
     
  242. CROI: Disparities in HIV care among Hispanic/Latino persons by birthplace and social vulnerability-United States, 2021 - (03/28/24)
     
  243. CROI: TRENDS IN SUICIDE-RELATED EMERGENCY DEPARTMENT VISITS AMONG PEOPLE WITH AND WITHOUT HIV IN BRONX, NY: increasing among 50 yrs old+ - (03/28/24)
     
  244. CROI: Trends and Correlates of Methamphetamine Use Among Men Who Have Sex With Men in the US, 2014-2021 - (03/28/24)
     
  245. CROI: Prescription Opioid Use and Disorder Among Older Adults With HIV in the US From 2008-2019 - (03/28/24)
     
  246. CROI: HIGH COMPLETION AND CURE RATES WITH A DECENTRALIZED, INTEGRATED HCV TREATMENT APPROACH IN VIETNAM (PWH) - (03/28/24)
     
  247. CROI: Nationwide HCV Elimination Program and the Status of Microelimination in People With HIV in Taiwan - (03/28/24)
     
  248. CROI: High rate of Hepatitis C incidence in Vietnamese MSM living with HIV; substance use; group sex; STIs - (03/28/24)
     
  249. CROI: HIV-1 coinfection skews iNKT cells towards anergy and exhaustion in persons living with hepatitis C virus - (03/28/24)
     
  250. CROI: Trends in HIV and HCV Prevention Efforts and Incidence Among People Who Inject Drugs in Baltimore: not enough HCV treatment - (03/28/24)
     
  251. CROI: HIV and HCV Screen Rates for Hospitalized PWUD Are Heterogeneous & Suboptimal Across 11 States - (03/28/24)
     
  252. CROI: Inflammatory profile of B/F/TAF, DTG/ABC/3TC, and DTG+F/TAF over 5-years and effects of viral blips: 'transient viral blips may contribute to inflammation in Art-treated' - (03/27/24)
     
  253. CROI: The (no) Effect of Dolutegravir on Whole-Body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers - (03/27/24)
     
  254. CROI: Temporal Trends of Cardiovascular Disease Incidence in People with HIV from 2001-2021: high prevalence of risk factors - (03/27/24)
     
  255. CROI: Global Trends in CD4 Count Measurement and Prevalence of CD4 <200 cells/μL at ART Initiation: high prevalence remains for <200 cd4 at ART start (30%) - (03/27/24)
     
  256. CROI: Pregnancy History Affects Age-Related Comorbidity Burden in U.S. Women With and Without HIV - (03/27/24)
     
  257. CROI: Consequences of Low-Level Viremia by Sex Among People With HIV in the United States - (03/27/24)
     
  258. CROI: InSTI Switch During Menopause Is Associated With Accelerated Body Composition Change: 'early accelerated increases in waist circumference & BMI' - (03/27/24)
     
  259. CROI: Age Modifies the Association Between Sex and the Plasma Inflammatory Proteome in Treated HIV: HIV+ women have more inflammation at older ages in particular, mortality associated - (03/27/24)
     
  260. CROI: Cabotegravir Population Pharmacokinetic Analysis of Adults & Adolescents Living with HIV or at Risk for HIV Receiving PrEP - (03/27/24)
     
  261. CROI: Why Is Cabotegravir Rollout So Slow? - (03/27/24)
     
  262. CROI: HIV Post-exposure Prophylaxis (PEP) Prescription Trends (underutilized) - United States, 2013-2022 - (03/27/24)
     
  263. CROI: PEP2PrEP: an effective HIV risk-reduction strategyn - (03/27/24)
     
  264. CROI: Preclinical Characterization of GS-5894, a Potent NNRTI With Once Weekly Oral Dosing Potential - (03/26/24)
     
  265. CROI: 31st Conference on Retroviruses and Opportunistic Infection Eric S. Daar, M.D. - Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA - (03/26/24)
     
  266. CROI: Lipidome composition and weight changes at 48week 3TC-DTG and FTC/TAF/BIC: data of the ICONA cohort - (03/25/24)
     
  267. CROI: Switching to Integrase Strand Transfer Inhibitors and the Risk of Diabetes in Persons with HIV - (03/25/24)
     
  268. CROI: Weight Gain in People With HIV (PWH) vs People Without HIV (PWoH) Over a 3-Year Period - (03/25/24)
     
  269. CROI: Dolutegravir, Body Mass Index, and Metabolic Syndrome in the IeDEA Sentinel Research Network - (03/25/24)
     
  270. CROI: Weight Gain After Initiating ART Close to HIV Seroconversion: Is There a Return to Health Effect? - (03/25/24)
     
  271. CROI: Weight Change After Starting Doravirine Among ART-Experienced Individuals in the US - (03/25/24)
     
  272. CROI: Effect of TDF and TAF on Duodenal Enterocytes - a Hypothesis on Different Effect on Body Weight - (03/25/24)
     
  273. CROI: Virologic Outcomes with Tenofovir-Lamivudine-Dolutegravir for PI-Based Second-Line ART Failure - (03/22/24)
     
  274. CROI: SHORT AND LONG-TERM BODY WEIGHT GAIN FOLLOWING SWITCH TO INTEGRASE INHIBITORS DIFFERS BY SEX - (03/22/24)
     
  275. CROI: Resistance to second-Generation InSTIs in Mexican PLWH: Emergence of the R263K Mutant - (03/22/24)
     
  276. CROI: Emerging Dolutegravir Resistance in Lesotho - (03/22/24)
     
  277. CROI: Dolutegravir (DTG) resistance among ART-experienced viremic patients in Kenya receiving DTG-based ART - (03/22/24)
     
  278. CROI: ACTG 5381: Virologic and Resistance Outcomes After Switch to TLD for Failing 1st or 2nd Line ART - (03/22/24)
     
  279. CROI: Viremia and drug resistance over 2 years after routine switching to dolutegravir-based first-line ART - (03/22/24)
     
  280. CROI: Emerging Dolutegravir Resistance Among Children Being Investigated for Treatment Failure in Malawi - (03/22/24)
     
  281. CROI: Switching From a Second-Line Boosted PI Regimen to B/F/TAF: Results of a Randomized Clinical Trial - (03/22/24)
     
  282. CROI: 24-Week Viral Suppression in Patients Starting Long-Acting CAB/RPV Without HIV Viral Suppression - (03/22/24)
     
  283. CROI: Infected T-Cell Clones Are Shared Across CSF and Blood Compartments in PWH - (03/22/24)
     
  284. CROI: BIC/FTC/TAF as HIV PEP was well-tolerated with high adherence and no seroconversions - (03/22/24)
     
  285. CROI: Randomized Trial Shows Huge Uptake Success of HIV Prevention Choices in Kenya, Uganda - (03/22/24)
     
  286. CROI: Transaminase elevations among patients with occult HBV infection on two-drug antiretroviral regimens - (03/21/24)
     
  287. CROI: Hepatitis B Reactivation in PLWH With Anti-Core Antibody After Switch to an Anti-HBV Sparing Regimen - (03/21/24)
     
  288. CROI: HepB-CpG Vaccine Superior to HepB-alum in HIV Group With Prior Nonresponse - Mark Mascolini (03/21/24)
     
  289. CROI: A Shape-Shifting Tail Decay is the Pharmacokinetic Profile of an Ultra-Long Acting Bictegravir Prodrug - (03/20/24)
     
  290. CROI: 62% of new HIV infections and 63% of deaths now reported in countries outside Southern/East Africa - (03/20/24)
     
  291. CROI: ODYSSEY 192-Week Follow-Up Evidences Superior Efficacy of DTG for Children on First/Second-Line ART - (03/20/24)
     
  292. CROI: Predictors of weight gain in the ADVANCE, NAMSAL and WRHI trials; EFV, TDF, and baseline CD4 count - Mark Mascolini (03/20/24)
     
  293. CROI: More Than 60% of New HIV and HIV Deaths Now in "Low-Prevalence" Countries - Mark Mascolini (03/20/24)
     
  294. CROI: ODYSSEY 192-Week Follow-Up Evidences Superior Efficacy of DTG for Children on First/Second-Line ART - Mark Mascolini (03/20/24)
     
  295. CROI: Intramuscular Injection vs Intravenous Infusion of Ibalizumab for HTE PWH: The Results of TMB-302 - (03/20/24)
     
  296. CROI: Real-World Utilization of Cabotegravir + Rilpivirine in the US: Data From Trio Health Cohort - (03/20/24)
     
  297. CROI: Real-World Effectiveness of Cabotegravir + Rilpivirine vs Standard of Care Oral Regimens in the US in OPERA Cohort - (03/20/24)
     
  298. CROI: Effects of Pitavastatin on COVID-19 Incidence and Seriousness among People with HIV - (03/20/24)
     
  299. CROI: Hypertension in a randomized trial of DTG- vs EFV-based ART in pregnant and postpartum women - (03/19/24)
     
  300. CROI: Activated and exhausted CD8+ T Cell subsets associate with carotid atherosclerotic plaques in PLHIV - (03/19/24)
     
  301. CROI: Low Levels of HIV-1 in CSF During ART Are Associated With Neurocognitive Impairment and Inflammation - (03/19/24)
     
  302. CROI: Suppressing Asymptomatic CMV with Letermovir Reshapes Cardiometabolic Proteome in Treated HIV - (03/19/24)
     
  303. CROI: Plasma Proteome Signature of Immune Inhibition is Associated with CMV Coinfection in People with HIV - (03/19/24)
     
  304. CROI: Latent Viral Infections Are Associated With Veterans Aging Cohort Study Index in People With HIV - (03/19/24)
     
  305. CROI: Clinical Profiles Predicting Cognitive Decline (24%) over 10 years Among Older Adults with HIV in Canada - (03/19/24)
     
  306. CROI: High Plasma GFAP in older PWH with Low Nadir CD4 Support Legacy Brain Injury and Reactive Gliosis - (03/19/24)
     
  307. CROI: Application of STOPP Criteria in an Urban Cohort of People Aging with HIV, 50%+ PWH Taking Inappropriate Prescriptions - (03/19/24)
     
  308. CROI: Endothelial Dysfunction in HIV: Exploring Cytokine and Chemokine Dynamics - (03/19/24)
     
  309. CROI: ELEVATED TRIGLYCERIDES AND ENDOTHELIAL VASODILATOR DYSFUNCTION IN ADULTS LIVING WITH HIV-1 - (03/19/24)
     
  310. CROI: Biomarkers of Microbial Translocation and Inflammation Associated with Frailty among People with HIV 58% Frail/Prefrail - (03/19/24)
     
  311. CROI: OPTIMIZING LONG-TERM EXERCISE BENEFITS FOR OLDER ADULTS WITH HIV THE MOVIHNG STUDY - (03/19/24)
     
  312. CROI: Frailty and Health-Related Quality of Life (QOL 24% Lower) in an Aging Cohort of People with HIV 2012-2022 - (03/19/24)
     
  313. CROI: Neighborhood Vulnerability Predicts Non-Communicable Disease Risk Among People With HIV - (03/19/24)
     
  314. CROI: Semaglutide Trims Muscle Volume but Physical Function Not Lost - Mark Mascolini (03/19/24)
     
  315. CROI: Pitavastatin Has No Effect on Long-Term, Objective Physical Function in REPRIEVE - Mark Mascolini - (03/19/24)
     
  316. CROI: Pitavastatin Reduces Non-Calcified Plaque via Pro-Collagen PCOLCE Independently of LDL in REPRIEVE - (03/19/24)
     
  317. CROI: A Skewed NK Cell Repertoire Persists in People with HIV-1 Despite Long-Term ART - (03/19/24)
     
  318. CROI: Immunological Non-Responders have CD4+ Immunosenescence and Impaired Lymphocyte Cytokine production - (03/19/24)
     
  319. CROI: DNA Methylation-Based Telomere Length Is Associated with HIV Infection and Cancer in Relation to HIV Frailty and All-Cause Mortality - (03/19/24)
     
  320. CROI: Ultra-Low Level HIV p24 Production as a Driver of Immune Activation in Individuals Treated with ART - (03/19/24)
     
  321. CROI: CSF ART Exposure, Population Pharmacokinetic Approaches to Standardize Antiviral Exposure in the Cerebrospinal Fluid - (03/19/24)
     
  322. CROI: MRI With T2 Maps and Spectroscopy Show Chronic Progressive Brain Damage Despite HIV Suppression - (03/19/24)
     
  323. CROI: US States With More PrEP Coverage See Bigger Drops in HIV Diagnoses - Mark Mascolini (03/18/24)
     
  324. CROI: Safety Study of Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Early Pregnancy - (03/18/24)
     
  325. CROI: Strong Oral PrEP Uptake and Persistence in 3000 African Girls and Young Women in INSIGHT Cohort - Mark Mascolini (03/18/24)
     
  326. CROI: < HIV Incidence in Users of HIV Preexposure Prophylaxis in Australia: A Whole-of-Population Analysis - (03/18/24)
     
  327. CROI: HIV incidence in users of HIV preexposure prophylaxis in Australia: a whole-of-population analysis - Mark Mascolini (03/18/24)
     
  328. CROI: Associations between a polygenic risk score for Alzheimers disease and brain integrity in HIV - (03/18/24)
     
  329. CROI: Doxy-PEP Associated with Declines in Chlamydia and Syphilis in MSM and Trans Women in San Francisco.....increase in gonorrhea after SF Guidelines Oct 2022 - (03/18/24)
     
  330. CROI: Doxy-PEP Effectiveness in Men Who Have Sex with Men (MSM) and Transgender Women (TGW) on HIV PrEP - (03/18/24)
     
  331. CROI: Doxycycline Post-Exposure Prophylaxis (DoxyPEP): High uptake and Significant Decline in STIs after Clinical Implementation - (03/18/24)
     
  332. CROI: Randomized Trial Shows Huge Uptake Success of HIV Prevention Choices in Kenya, Uganda - Mark Mascolini (03/18/24)
     
  333. CROI: CSF ART Exposure, Population Pharmacokinetic Approaches to Standardize Antiviral Exposure in the Cerebrospinal Fluid - (03/16/24)
     
  334. CROI: No neurocognitive benefit of immediate vs delayed tesamorelin in virally suppressed people with HIV - (03/16/24)
     
  335. CROI: Socio-Demographics Were Stronger Classifiers of Cognitive Profiles Than Neuroimaging in HIV - (03/16/24)
     
  336. CROI: EXTRA-CVD: A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention - (03/16/24)
     
  337. CROI: Treatment of Prehypertension in People Living With HIV: A Randomized Controlled Trial - (03/16/24)
     
  338. CROI: Pitavastatin Has No Effect on Long-Term, Objective Physical Function in REPRIEVE - (03/16/24)
     
  339. CROI: Performance of the ACC/AHA Pooled Cohort Equations or Risk Prediction in the Global REPRIEVE Trial - (03/16/24)
     
  340. CROI: Factors Contributing to Risk of Major Adverse Cardiovascular Events among People with HIV in REPRIEVE - (03/16/24)
     
  341. CROI: Pitavastatin Reduces Non-Calcified Plaque via Pro-Collagen PCOLCE Independently of LDL in REPRIEVE - (03/16/24)
     
  342. CROI: Aging at CROI 2024 - (03/16/24)
     
  343. CROI: Semaglutide at CROI 2024 - (03/16/24)
     
  344. CROI: Relating Pitavastatin Effects on Inflammatory Biomarkers to Plaque Changes in REPRIEVE - (03/16/24)
     
  345. CROI: Carotid Inflammation on FDG-PET Is Associated With Lower Cognitive Function in Treated HIV Infection - (03/16/24)
     
  346. CROI: HepB-CpG vaccine is superior to HepB-alum in people with HIV and prior vaccine non-response (A5379) - (03/15/24)
     
  347. CROI: Factors Associated With HBV Response to B/F/TAF Versus DTG + F/TDF at Week 96 in People With HIV-1 and HBV - (03/15/24)
     
  348. Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study - (03/14/24)
     
  349. CROI: Amyloid-β PET Positivity Among Cognitively Impaired People with HIV Over Age 60 - (03/13/24)
     
  350. CROI: Plasma Inflammatory Biomarkers Link to Worse Cognition Among Africans Living With HIV - (03/13/24)
     
  351. CROI: Age-Adjusted Mortality Rates Among Persons With HIV, by Race and Ethnicity and Cause of Death....22% due to comorbidities - (03/13/24)
     
  352. CROI: Leading Causes of Death Among People With HIV in the US, 2001-20194x greater death risk than gen. pop., cancer & heart disease, HIV leading causes of death, Blacks have higher death rates - (03/13/24)
     
  353. CROI: Progress Toward Achieving National Goals for Improved Quality-of-Life Among Black Women With HIV.....worse unmet mental health needs, self-rated good or better health worsened - (03/13/24)
     
  354. CROI: Immunoregulatory Pathways Predict Mortality More Strongly in People With Versus Without HIV - (03/13/24)
     
  355. CROI: Prostate cancer characteristics and outcomes for veterans: Higher Advanced Prostate Cancer Risk in Veterans With Than Without HIV, 67% Blacks in Study - Mark Mascolini (03/13/24)
     
  356. CROI: Low-Level HIV Viremia Affects T-Cell Activation and Senescence in InSTI Era - (03/13/24)
     
  357. CROI: Excess Inflammation Associated with AIDS and Non-AIDS Complications in Adults on ART...deferring ART increased inflammation, complications & Death Rates - (03/13/24)
     
  358. CROI: Sleep Deprivation Contributes to Immune Activation in People With HIV Control - Mark Mascolini (03/13/24)
     
  359. CROI: Association Between Depressive Symptom Severity and Incident Stroke among People with HIV - (03/13/24)
     
  360. CROI: HIV Clinical Factors and Cardiovascular Disease Risk Predict White Matter Hyperintensity Burden (brain) - (03/13/24)
     
  361. CROI: Assessing Blood-Based Biomarkers as Predictors of Cognitive Decline in PWH: ACTG A5322 (HAILO) - (03/13/24)
     
  362. CROI: Associations between Nadir CD4 and Subsequent Immune Measures with Long-Term Cognitive Function in HAILO (ACTG 5322) - (03/13/24)
     
  363. CROI: Phone calls for PrEP persistence in Kenyan women in postabortal care: a cluster randomized trial. - Mark Mascolini (03/12/24)
     
  364. CROI: PrEP Non-Persistence and New HIV Diagnoses: A Real-World Analysis of >120,000 People Prescribed PrEP - (03/12/24)
     
  365. CROI: Safety of dapivirine vaginal ring and oral PrEP for HIV prevention in the second trimester. - Mark Mascolini (03/12/24)
     
  366. CROI: CHANGES IN HIV PREP AWARENESS & USE AMONG PWID IN 19 U.S. CITIES, 2018 & 2022 ....very low PrEP use - (03/12/24)
     
  367. CROI: Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: HPTN 083 - (03/12/24)
     
  368. CROI: Healthcare Staff Acceptability and Feasibility of Telehealth Delivery of Cabotegravir for PrEP - (03/12/24)
     
  369. CROI: Interest in Long-Acting Injectable PrEP Among Transgender Women in the United States - (03/12/24)
     
  370. CROI: Real-World Use of Cabotegravir Long-Acting for Preexposure Prophylaxis: Trio Health Cohort - (03/12/24)
     
  371. CROI: Preexposure Prophylaxis With Cabotegravir Long-Acting Injectable in the OPERA Cohort - (03/12/24)
     
  372. CROI: Hospital and Death Rate Almost Twice Higher After SARS-CoV-2 in Unvaccinated - Mark Mascolini (03/11/24)
     
  373. CROI: COVID Incidence and Severity in Persons with Reinfection vs Post-vaccination Breakthrough Infection....>65, comorbidities protected more - (03/11/24)
     
  374. CROI: Therapeutic Efficacy of a Triple Combination of HIV-1 Broadly Neutralizing Antibodies - (03/11/24)
     
  375. CROI: A DOSE ESCALATION STUDY OF SAFETY & PK OF TMB-365 & TMB-380 IN PEOPLE WITH SUPPRESSED HIV - (03/11/24)
     
  376. CROI: aHSIL and Nadir CD4s Below 200 Boost Invasive Anal Cancer Risk With HIV - Mark Mascolini (03/11/24)
     
  377. CROI: Implementing Long-Acting Cabotegravir for HIV Preexposure Prophylaxis in a Large Urban HIV Clinic - (03/11/24)
     
  378. CROI: Is the Weight Over?: GLP-1 Receptor Agonists Are Here - Background - (03/11/24)
     
  379. CROI: IMPAACT 2017 Adolescent/Parent Experiences with LA Cabotegravir Plus Rilpivirine for HIV Treatment - (03/11/24)
     
  380. CROI: EFFICACY, SAFETY, AND PK OF BIC/FTC/TAF IN ADULTS WITH HIV AND TUBERCULOSIS ON RIFAMPICIN AT WEEK 24 - (03/11/24)
     
  381. CROI: Twice-Daily BIC/FTC/TAF With Rifampicin Effective in People With HIV and TB - Mark Mascolini (03/11/24)
     
  382. CROI: Long-Acting CAB + RPV Gains Favor in UK Community, But Less in Blacks - Mark Mascolini (03/11/24)
     
  383. CROI: DoxyPEP Cuts Chlamydia and Syphilis Incidence in MSM Using PrEP - Mark Mascolini (03/11/24)
     
  384. CROI: Long-Acting Injectable CAB/RPV is Superior to Oral ART in PWH With Adherence Challenges: ACTG A5359 - (03/11/24)
     
  385. CROI: Bone Mineral Density in Children With HIV-1 Receiving TAF-Based Antiretroviral Therapy - (03/11/24)
     
  386. CROI: No Virologic Failures, Good Safety With LA I njected CAB + RPV for Adolescents IMPAACT 2017 MOCHA Study - Mark Mascolini (03/11/24)
     
  387. CROI: IMPAACT 2017 Adolescent/Parent Experiences with LA Cabotegravir Plus Rilpivirine for HIV Treatment - (03/11/24)
     
  388. CROI: New HIV Therapies, Drugs at CROI 2024 - (03/11/24)
     
  389. CROI: Impact of Semaglutide on Weight Change Among People with HIV: A Stratified Analysis by Baseline BMI - (03/11/24)
     
  390. CROI: Effects of Semaglutide on Inflammation and Immune Activation in HIV-Associated Lipohypertrophy....people with severe lipoatrophy were excluded from study, so were diabetics & CVD - (03/11/24)
     
  391. CROI: Four of 6 Early-Treated Infants Attain Sustained ART-Free Remission - Mark Mascolini (03/11/24)
     
  392. CROI: Weight Loss 5.7% at 1 Year With Semaglutide in HIV - Mark Mascolini (03/11/24)
     
  393. CROI: Associations Between Interest in Oral vs Long-Acting Injectable ART Among US Women With HIV - (03/11/24)
     
  394. CROI: Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Elderly Using PBPK Modelling - (03/11/24)
     
  395. CROI: Functional Brain Network Changes Among People With HIV and Viral Suppression - (03/11/24)
     
  396. CROI: One-Year Declines in Bone Mineral Density Among Young Women in Uganda Using TDF-Based PrEP and DMPA - (03/11/24)
     
  397. CROI: Chronic comorbidities in children and adolescents with perinatally acquired HIV infection in sub-Saharan Africa in the era of antiretroviral therapy - (03/07/24)
     
  398. CROI: Aging & Perinatally Acquired HIV: Cardiometabolic Risks and Comorbidities: Adolescents and Young Adults with Perinatally Acquired HIV - (03/07/24)
     
  399. CROI: Doxycycline PEP Study Extension: High uptake and significant decline in STIs after clinical implementation - Mark Mascolini - (03/07/24)
     
  400. CROI: Doxycycline PEP: High uptake and significant decline in STIs after clinical implementation - Mark Mascolini - (03/07/24)
     
  401. CROI: Final Results of ANRS 174 DOXYVAC: A Randomized trial to Prevent STIs in MSM on PrEP - (03/07/24)
     
  402. CROI: Lung Function, HIV and Mortality: Analyses From the AIDS Linked to the Intravenous Experience Cohort: age 51, 81% black, 84% current smokers, 34% (28%) current injectors -study demographics - (03/07/24)
     
  403. CROI: ViiV HEALTHCARE PRESENTS PHASE I CLINICAL TRIAL FINDINGS OF A CABOTEGRAVIR LONG-ACTING INJECTABLE INVESTIGATIONAL FORMULATION ALLOWING AT LEAST FOUR MONTHS BETWEEN DOSES - (03/07/24)
     
  404. CROI: InSTI Switch During Menopause Is Associated With Accelerated Body Composition Change - (03/07/24)
     
  405. CROI: Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24 - (03/07/24)
     
  406. CROI: High PrEP uptake and adherence with point of care tenofovir testing among young African women: Results from the INSIGHT cohort - (03/07/24)
     
  407. CROI: Randomized trial of Cabotegravir and Rilpivirine Long-acting in Africa (CARES):Week 48 Results - (03/07/24)
     
  408. CROI: Efficacy and Safety of Weekly Islatravir Plus Lenacapavir in PWH at 24 Weeks: A Phase II Study - (03/07/24)
     
  409. CROI: ViiV HEALTHCARE ANNOUNCES INTERIM DATA AT CROI INDICATING SUPERIOR EFFICACY OF LONG-ACTING INJECTABLE HIV TREATMENT CABENUVA (CABOTEGRAVIR + RILPIVIRINE) COMPARED TO DAILY ORAL THERAPY IN INDIVIDUALS LIVING WITH HIV WHO HAVE ADHERENCE CHALLENGES - (03/06/24)
     
  410. CROI: ABBV-382, an Anti-a4b7 Ab That Enhances HIV-1 Antigen Presentation for Immune-Mediated Viral Control - (03/06/24)
     
  411. CROI: Biomarker Signatures in Phase Ib Study With PD-1 Inhibitor, Budigalimab, in PLWH Undergoing ATI - (03/06/24)
     
  412. CROI: Safety and Efficacy of VRC07-523LS Plus Long-Acting Cabotegravir in the Phase II ACTG A5357 Trial - (03/06/24)
     
  413. CROI: Single Dose Administration of MK-8527, a Novel nRTTI, in Adults With HIV-1 - (03/06/24)
     
  414. CROI: Antiviral Activity, Safety, and Pharmacokinetics of GS-1720, a Novel Weekly Oral INSTI - (03/06/24)
     
  415. CROI: A First-in-Human Study of the Trispecific HIV-1 Broadly Neutralizing Antibody, SAR441236 - (03/06/24)
     
  416. CROI: Trispecific bNAb Hits 3 Targets but Has Modest Antiviral Activity in First Human Studies - Mark Mascolini - (03/06/24)
     
  417. Safety and Pharmacokinetics of MK-8527, a Novel nRTTI, in Adults Without HIV - (03/06/24)
     
  418. CROI: Safety and efficacy of VRC07-523LS plus long-acting cabotegravir in the phase II ACTG A5357 tria - Mark Mascolini (03/06/24)
     
  419. CROI: Lenacapavir Plus bNAbs for People with HIV and Susceptibility to Either Teropavimab or Zinlirvimab - (03/06/24)
     
  420. CROI: ViiV HEALTHCARE PRESENTS PHASE I CLINICAL TRIAL FINDINGS OF A CABOTEGRAVIR LONG-ACTING INJECTABLE INVESTIGATIONAL FORMULATION ALLOWING AT LEAST FOUR MONTHS BETWEEN DOSES - (03/06/24)
     
  421. CROI: Phase 1 Study of Cabotegravir Long-Acting Injectable Formulations Supports ≥4-Monthly Dose Interval - (03/06/24)
     
  422. CROI: VH3810109 (N6LS) in Antiretroviral Therapy-Naive Adults With HIV-1: Phase 2a BANNER Efficacy Data - (03/06/24)
     
  423. CROI: Longitudinal Analysis of Preexisting Resistance-Associated Mutations Prior to B/F/TAF Switch - (03/04/24)
     
  424. CROI: Model-Based Comparison of Cabotegravir Pharmacokinetics Following Thigh and Gluteal Injections - (03/04/24)
     
  425. CROI: Lenacapavir Efficacy in CAPELLA Patients with No Fully Active Agents in Optimized Background Regimen - (03/04/24)
     
  426. CROI: Impact of Archived Minority Populations With M184V/I on DTG/3TC for Maintenance of Viral Suppression - (03/04/24)
     
  427. CROI: Discovery of MK-8527, a long-acting HIV nucleoside reverse transcriptase translocation inhibitor - (03/04/24)
     
  428. CROI: Switching to Doravirine/Islatravir Maintains Viral Suppression Regardless of Archived Mutations - (03/04/24)
     
  429. CROI: The Preclinical Profile of Maturation Inhibitor VH3739937 - (03/04/24)
     
  430. CROI: High-Dose VH3810109 (N6LS) ± Recombinant Human Hyaluronidase PH20: Phase 1 SPAN Study Safety Results - (03/04/24)
     
  431. CROI: Next-Generation Maturation Inhibitor GSK3640254 Showed Broad Spectrum Potency Without MI Resistance - (03/04/24)
     
  432. CROI: Phase 2 Study of Switch to Daily BIC + LEN in Individuals on a Complex HIV Treatment Regimen - (03/04/24)
     
  433. CROI: Discovery of GS-9770 - a Novel, Unboosted, Once Daily Oral HIV-Protease Inhibitor - (03/04/24)
     
  434. New HHS HIV Treatment Guidelines on Statin Therapy in PWH - (02/29/24)
     
  435. U.S. FDA Approves Expanded Indication for Gilead's Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance - (02/27/24)
     
  436. Non-AIDS Deaths 80% of All deaths for PWH >60: Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies - (02/26/24)
     
  437. NIH LA CAB/RPV Superior to Daily for Non-Adherent PWH - (02/26/24)
     
  438. Latent Profile Analysis of Cognitive Performance and Depressive Symptoms Among People with HIV - (02/26/24)
     
  439. HIV-1 Remission after Allogeneic Hematopoietic-Cell Transplantation - (02/16/24)
     
  440. CD4 Non-Responders to ART; Older PWH with Limited ART Options - (02/15/24)
     
  441. Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy: 96-week pooled analysis - (02/15/24)
     
  442. PWH Internalized Stigma High Rates, 36%-48% - (02/15/24)
     
  443. Explaining racial and ethnic disparities in antiretroviral therapy adherence and viral suppression among U.S. men who have sex with men - (02/12/24)
     
  444. Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in Women, Editorial. Why it didn't work for women? - (02/12/24)
     
  445. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial - (02/12/24)
     
  446. PTSD is also a common mental disorder among individuals living with HIV/AIDS, 7 Times Greater. HIV itself can be a Traumatic PTSD Event - (02/12/24)
     
  447. Polypharmacy Is Associated With Slow Gait Speed and Recurrent Falls in Older People With HIV- in ACTG HAILO Cohort where average age is only 51 - (02/12/24)
     
  448. ViiV Healthcare announces new packaging option (blister pack) now available in the U.S. for Dovato(dolutegravir/lamivudine) - (02/07/24)
     
  449. Life expectancy of people with HIV on antiretroviral therapy in Spain: gap of 8.3 & 13.9 years persists in men & women compared to general population - (02/02/24)
     
  450. Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study & Commentary - (02/02/24)
     
  451. Rapid antiretroviral therapy in primary HIV-1 infection enhances immune recovery: each day that ART was delayed was associated with a lower likelihood of achieving a CD4>900 cells and CD4/CD8 >1.0 - (02/02/24)
     
  452. Study (Phase 2/3) to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen - (01/30/24)
     
  453. SARS-CoV-2 Reinfection Risk in Persons with HIV, Chicago, Illinois, USA, 2020-2022 - (01/29/24)
     
  454. LAI PrEP Barriers & Facilitators US Primary Care Setting - (01/29/24)
     
  455. Lenacapavir Safety - Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial - (01/29/24)
     
  456. Lenacapavir 5 PrEP Global Studies - (01/29/24)
     
  457. Unmet needs for HIV ancillary services among persons with diagnosed HIV aged 55 years and older - (01/19/24)
     
  458. Heavy arv exposure and exhausted/limited arv options: predictors and clinical outcomes - (01/19/24)
     
  459. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2 - (01/15/24)
     
  460. Long COVID: major findings, mechanisms and recommendations - (01/15/24)
     
  461. Tablet-Based Cognitive Impairment Screening for Adults With HIV Seeking Clinical Care: Observational Study - (01/15/24)
     
  462. Prenatal Social Disadvantage Affects Brain - (01/15/24)
     
  463. Non-AIDS Deaths/Comorbidities Lead Causes of Death for PWH - (01/15/24)
     
  464. Tablet-Based Cognitive Impairment Screening for Adults With HIV Seeking Clinical Care: Observational Study - (01/15/24)
     
  465. PWH Internalizing HIV Stigma, Depression - (01/15/24)
     
  466. Hypertension and one-year risk of all-cause mortality among women (WIHS) with treated HIV in the United States - (01/15/24)
     
  467. Diet & Hypertension/High Blood Pressure for PWH - (01/15/24)
     
  468. Selection of cognitive impairment screening tools for longitudinal implementation in an HIV clinical care setting - (01/15/24)
     
  469. Hypertension Among HIV-infected Patients in Clinical Care, 1996-2013 - (01/15/24)
     
  470. Higher Prevalence of Hypertension in HIV-1-Infected Patients on Combination Antiretroviral Therapy Is Associated With Changes in Body Composition and Prior Stavudine Exposure - (01/15/24)
     
  471. Effects of clinical, comorbid, and social determinants of health on brain ageing in people with and without HIV: a retrospective case-control study - (01/15/24)
     
  472. The Longitudinal Effects of Blood Pressure and Hypertension on Neurocognitive Performance in People Living With HIV - (01/15/24)
     
  473. Current and temporal exposure to integrase strand transfer inhibitors are not associated with hypertension or arterial stiffness in people with HIV - (01/10/24)
     
  474. Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial - (01/10/24)
     
  475. Brief Report: Outcomes of Individuals Using HIV Postexposure Prophylaxis-In-Pocket ("PIP") for Low-Frequency, High-Risk Exposures in Toronto, Canada - (01/10/24)
     
  476. TelePrEP in NYC - (01/10/24)
     
  477. Patient and Provider Perspectives on a Novel, Low-Threshold HIV PrEP Program for People Who Inject Drugs Experiencing Homelessness - (01/10/24)
     
  478. PrEP Use and HIV Incidence Among Youth At-Risk for HIV Infection in Los Angeles and New Orleans: Findings From ATN 149 - (01/10/24)
     
  479. Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants - (01/10/24)
     
  480. Preexposure Prophylaxis Use History in People With Antiretroviral Resistance at Human Immunodeficiency Virus (HIV) Diagnosis: Findings From New York City HIV Surveillance and Partner Services, 2015-2022 - (01/10/24)
     
  481. HHS EHE (PrEP) Leaders Reflect on 2023 and Look Ahead to 2024 - (01/09/24)
     
  482. Understanding Psychosocial Determinants (Beliefs, Attitudes) of PrEP Uptake Among Cisgender Women Experiencing Heightened HIV Risk: Implications for Multi-Level Communication Intervention - (01/09/24)
     
  483. Advancing the community plan to end the HIV Epidemic in Philadelphia: a qualitative descriptive evaluation of low-threshold PrEP services in sexual health clinics - (01/09/24)
     
  484. 2 Studies on PrEP for Women IDUs, Demonstrate PrEP is a Necessary Tool for Women, to EtE - (01/09/24)
     
  485. Aging-Related Comorbidity Burden Among Women and Men With or At-Risk for HIV in the US, 2008-2019 - (01/08/24)
     
  486. Prioritising the values of potential users to promote uptake of HIV pre-exposure prophylaxis - (01/08/24)
     
  487. Person-centered HIV PrEP for cisgender women - (01/08/24)
     
  488. Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women - (01/08/24)
     
  489. Cocaine Eats Up Brain Twice as Fast as Normal Aging - (01/08/24)
     
  490. Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence - (01/08/24)
     
  491. Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts - (01/08/24)
     
  492. Management and Prevention of CVD in HIV: Where are we in 2023? - (01/02/24)
     
  493. Best Use of Doravirine - Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials - (12/29/23)
     
  494. Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection - (12/28/23)
     
  495. Long COVID in people living with HIV - (12/28/23)
     
  496. NATAP/LongCOVIDWk: Current treatments for Long COVID - (12/28/23)
     
  497. Paxlovid Reduced Long COVID Conditions - (12/28/23)
     
  498. Long COVID Clinics by State - (12/28/23)
     
  499. NYC Post COVID Care Clinics, Rehabs - (12/28/23)
     
  500. HIV Infection is Associated with Higher Risk of Post-Acute Sequelae of SARS-CoV-2 (PASC) However Vaccination is Protective - (12/28/23)
     
  501. CDC study: People with HIV have elevated COVID reinfection rate - (12/28/23)
     
  502. Paxlovid Treatment for Long COVID Trial Ongoing - (12/28/23)
     
  503. Psychological Trauma and PTSD in HIV-Positive Women: A Meta-Analysis - (12/27/23)
     
  504. High Trauma Rates in PWH-MSM, Women, Drug Users - (12/27/23)
     
  505. High Trauma Rates African-American HIV+ MSM - (12/27/23)
     
  506. HIV Stigma and Health Care Discrimination Experienced by Hispanic or Latino Persons with HIV - United States, 2018-2020 - (12/27/23)
     
  507. Accelerated Health Declines among African Americans in the USA: "weathering" or traumas as we say in HIV - (12/27/23)
     
  508. "6-fold increase in PWH >75 Projected" The projected prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030 - (12/21/23)
     
  509. Long COVID in the United States - (12/21/23)
     
  510. EACS: Effect of doravirine on body weight and body mass index in treatment naïve adults with HIV-1 - (12/20/23)
     
  511. EACS: Efficacy and safety of topical trichloroacetic acid vs. electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive patients (TECAIN) - a randomized controlled trial - (12/20/23)
     
  512. Frailty screening is Feasible & Recommended by EACS. Implementation of frailty screening for older people living with HIV in Brighton, UK - (12/18/23)
     
  513. A study of the pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed pregnant women with HIV - (12/08/23)
     
  514. New IAS-USA Papers on Heart Disease in PWH,
    DoxyPEP, Infant Feeding Updated Guidelines     - (12/08/23)
     
  515. HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study - (12/05/23)
     
  516. The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants: a modelling study - (12/05/23)
     
  517. EACS: The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants: a modelling study - (12/4/23)
     
  518. Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants - (12/04/23)
     
  519. CDC Reports Disparities in PrEP USE: 'particularly Black and Hispanic/Latino men and women.' - (12/04/23)
     
  520. The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants: a modelling study - (12/04/23)
     
  521. Considerations for long-acting antiretroviral therapy in older persons with HIV - (12/04/23)
     
  522. AASLD: Food Insecurity, Low Income Drive MASLD in US Adolescents - Mark Mascolini (11/29/23)
     
  523. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial - (11/29/23)
     
  524. Ageism: the -ism affecting the lives of older people living with HIV - (11/29/23)
     
  525. AGE: High Rate of Metabolic Comorbidities in Young Adults With HIV Acquired Around Birth - (11/16/23)
     
  526. AASLD: Vir Biotechnology to Present Late-Breaking Data from
    Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials
    at AASLD's The Liver Meeting® 2023     - (11/14/23)
     
  527. Vascular injury markers associated with cognitive impairment in people with HIV on suppressive antiretroviral therapy - (11/08/23)
     
  528. Retaining PWH in Care; Mortality Increased with ART Interruptions >6 months - (11/08/23)
     
  529. Comparing cancer incidence in an observational cohort of Medicaid beneficiaries with and without HIV, 2001-2015 - (11/08/23)
     
  530. Brief Report: Outcomes of Individuals Using HIV Postexposure Prophylaxis-In-Pocket ("PIP") for Low-Frequency, High-Risk Exposures in Toronto, Canada - (11/08/23)
     
  531. Integrating a Resilience Framework to Assess Implementation of a Novel HIV Care Re-Engagement Model in NYC - (11/08/23)
     
  532. Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies - (11/08/23)
     
  533. AASLD: Increased Risk for NAFLD, MASLD to 34% - (11/08/23)
     
  534. EACS: To the liver and beyond: the impact of HCV clearance with direct antiviral agents in people living with HIV/HCV - (11/8/23)
     
  535. EACS: The status of hepatitis C micro-elimination among people living with HIV in Central and Eastern Europe in 2022 - data from Euroguidelines in Central and Eastern Europe Network Group - (11/8/23)
     
  536. EACS: Impact of directly acting-antivirals and behaviour change on HCV micro-elimination in MSM due to the COVID 19 pandemic in Germany - Results from the NoCo cohort - (11/8/23)
     
  537. EACS: Frailty Accelerates Aging/Mortality: INTEGRATE Care for Older PWH
    Integrating [differential] approaches to older people living with HIV     - (11/07/23)
     
  538. EACS: COVID-19 Associated with 35% Increased Risk for Major Cardiovascular events in PWH During Subsequent Yea - (11/06/23)
     
  539. EACS: Despite Very Early ART Inflammation is Reduced But Persists - (11/06/23)
     
  540. EACS: Mental health disorders in people living with HIV - (11/06/23)
     
  541. EACS: Early Onset Frailty in PWH at UK Silver Clinic; Implementation of Frailty Screening - (11/06/23)
     
  542. EACS: HIV in the elderly is becoming an easily manageable pathology: reality is contradictory. Much More Complex - (11/06/23)
     
  543. Association of Higher Intake of Plant-Based Foods and Protein With Slower Kidney Function Decline in Women With HIV - (11/06/23)
     
  544. Cervical Cancer Screening Positivity Among Women Living With HIV in CDC-PEPFAR Programs 2018-2022 - (11/06/23)
     
  545. Doravirine Plus Integrase Strand Transfer Inhibitors as a 2-Drug Treatment-Switch Strategy in People Living with HIV: The Real-Life DORINI Multicentric Cohort Study - (11/06/23)
     
  546. Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial - (11/06/23)
     
  547. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis - (11/06/23)
     
  548. AGE: HIV-1 Soluble GP120 Is Associated With Immune Dysfunction and Inflammation in Individuals With Undetectable Viremia - in 33% of PWH - (11/06/23)
     
  549. AGE: Epigenetic Age Advancement [5.4 years] is Associated with Lower CD4 T-cell Count, Increased Mortality Risk, and Frailty in Older Adults with HIV - (11/03/23)
     
  550. AGE: Immunogenicity of High Dose Flu Vaccine in Aging PWH, Premature Senesence - (11/03/23)
     
  551. AGE: The CD38-NAD+ Axis: A Key Mediator of Inflammaging in HIV Infection: immune exhaustion, age-associated comorbiditied - (11/03/23)
     
  552. Real-World Effectiveness and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) in Treatment-Experienced (TE) People With HIV With a History of CKD - (11/03/23)
     
  553. AGE: Aging with HIV: social Isolation & Loneliness, Animal Therapy Intervention - (11/02/23)
     
  554. AGE: CNS complications in people aging with HIV - (11/02/23)
     
  555. AGE: Session 5: Lightning Poster Presentations - (11/02/23)
     
  556. AGE: Plasma proteomic signatures capture unique cardiovascular risk phenotypes among persons living with and without HIV in the United States: Plasma Proteome [biomarkers] Offers Insights Beyond Traditional CVD Risk Factors - Reported by Mark Mascolini for NATAP and Academic Medical Education(11/02/23)
     
  557. AGE: Clustering Frailty Components May Enable Sharper Comorbidity Insights - (11/02/23)
     
  558. AGE: Multifactorial Risk Factors for Cognitive Impairment - (11/02/23)
     
  559. AGE: Cognitive Frailty in People Living With HIV and Its Association With Geriatric Syndromes - (11/02/23)
     
  560. AGE: Session 2: Sarcopenia and Frailty Prevention & Treatment - (11/02/23)
     
  561. AGE: Underlying Mechanisms of Asymptomatic Neurocognitive Impairment - (11/01/23)
     
  562. AGE: Emotional, Not Social, Loneliness Is Related to Objective Cognitive Function in Older People With HIV - (11/01/23)
     
  563. AGE: 2 Oral Talks - PLWH: Sarcopenia, Mitochondrial Function - (11/01/23)
     
  564. AGE: Underlying Mechanisms of Asymptomatic Neurocognitive Impairment - (11/01/23)
     
  565. AGE: Emotional, Not Social, Loneliness Is Related to Objective Cognitive Function in Older People With HIV - (11/01/23)
     
  566. AGE: 2 Oral Talks - PLWH: Sarcopenia, Mitochondrial Function - (11/01/23)
     
  567. EACS: Virus-Related and AIDS Cancer Incidence Fell in HIV Group But Still Exceed Rates in General Population - (10/31/23)
     
  568. EACS: Factors influencing discontinuation of care of women seeking Pre-Exposure Prophylaxis (PrEP) - (10/31/23)
     
  569. EACS: Doravirine Does Not Drive up ASCVD Risk Through 4 Years - Mark Mascolini (10/31/23)
     
  570. EACS: Temporal trends and impact of COVID-19 on the HIV cascade of care across Europe between 2016-2021 - Mark Mascolini (10/31/23)
     
  571. EACS: One in Eight Amsterdam ART Responders May Have PTSD - Mark Mascolini (10/31/23)
     
  572. AGE: HIV Smoking Quitters Older and Have More Comorbidities Than Current Smokers - Reported by Mark Mascolini for NATAP and Academic Medical Education (10/31/23)
     
  573. AGE: Switching to a Fixed-Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed, Treatment-Experienced People with HIV (PWH) ≥ 65 Years Old - (10/31/23)
     
  574. AGE: Relationships between plasma neurofilament light chain protein, cognition, and brain aging in people with HIV - (10/31/23)
     
  575. AGE: An integrated HIV-Geriatric Clinic Model: Lessons from Newlands Clinic, Harare Zimbabwe - (10/31/23)
     
  576. AGE: PWH Have Higher depression Rates Than People without HIV: Some Depressive Symptoms Wane With Age in HIV Group-Some Do Not - (10/31/23)
     
  577. AGE: The longitudinal impact of depressive symptoms and frailty on social support: depression contributes to declining social support - Reported by Mark Mascolini for NATAP and Academic Medical Education (10/31/23)
     
  578. AGE: Emotional (but not Social) Loneliness Tied to Cognition in Older People With HIV - Reported by Mark Mascolini for NATAP and Academic Medical Education (10/30/23)
     
  579. AGE: Implementation of a multidisciplinary approach to care for people living with HIV aged over 80 years - Reported by Mark Mascolini for NATAP and Academic Medical Education (10/30/23)
     
  580. AGE: Global Survey: "62% in low and middle income & 29% in high income countries are mostly unaware for developing health complications as they get older" - (10/30/23)
     
  581. AGE: Cognitive Function Fell in 25% of Canadian HIV Group Over 10 Years - Reported by Mark Mascolini for NATAP and Academic Medical Education (10/30/23)
     
  582. AGE: Long-term effect of dolutegravir use on more depressive symptoms among older people with HIV - Reported by Mark Mascolini for NATAP and Academic Medical Education (10/30/23)
     
  583. AGE: Cognitive Frailty Threatens People With HIV at a Younger Age - Reported by Mark Mascolini for NATAP and Academic Medical Education (10/30/23)
     
  584. AGE: Older Age, More Comorbidities Mean Lower Chance of ART With Medicare - Reported by Mark Mascolini for NATAP and Academic Medical Education (10/30/23)
     
  585. AGE: Prefrail or frail older people with HIV live in more disadvantaged areas than older HIV-positive nonfrail people - Reported by Mark Mascolini for Academic Medical Education and NATAP (10/30/23)
     
  586. AGE: High Rate of Metabolic Comorbidities in Young Adults With HIV Acquired Around Birth - Reported by Mark Mascolini for Academic Medical Education and NATAP (10/30/23)
     
  587. AGE: Aging, Comorbidities, Frailty, Polypharmacy for PLWH > 80 Years at Chelsea Westminster London HIV Clinic - Reported by Mark Mascolini for NATAP and Academic Medical Education (10/30/23)
     
  588. AGE: HIV in the Brain & Cognitive Impairment: Despite Viral Suppression [blood brain permeability] women with HIV have double stroke risk & non-Hispanic African-Americans have 3.5 higher stroke incidence - the 6Ms for managing PLWH in the clinic; neurotoxicity of ARTs - (10/30/23)
     
  589. EACS: Factors influencing discontinuation of care of women seeking Pre-Exposure Prophylaxis (PrEP) - (10/30/23)
     
  590. ViiV HEALTHCARE RECEIVES APPROVAL FROM CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) FOR VOCABRIA (CABOTEGRAVIR) USED IN COMBINATION WITH REKAMBYS (RILPIVIRINE), THE FIRST AND ONLY COMPLETE LONG-ACTING HIV-1 INJECTABLE TREATMENT - (10/26/23)
     
  591. EACS: Total and LDL Cholesterol Climb After HCV Cure in People With HIV - Mark Mascolini (10/26/23)
     
  592. EACS: HDV Prevalence 16% in French Group With HBV and HIV - Mark Mascolini (10/26/23)
     
  593. EACS: In 70 and Older HIV Group, Frailty Worsens in Some, Improves in Others - Mark Mascolini (10/26/23)
     
  594. EACS: Classic Fracture Risk Factors May Need Replacing in Older People With HIV - Mark Mascolini (10/26/23)
     
  595. EACS: Weight gain and loss and stable weight in relation to fat and lean mass in PWH - (10/26/23)
     
  596. EACS: Early and Durable Reductions in Soluble CD14 Concentrations Among Treatment-Experienced Persons With HIV-1 Through 96 Weeks of Fostemsavir Treatment in a Phase 2b Clinical Trial - (10/26/23)
     
  597. EACS: Bictegravir alters glucose tolerance and metabolism - (10/26/23)
     
  598. EACS: Persistent Low-Level Viremia May Increase Risk of Cardiovascular Disorders in PWH - (10/26/23)
     
  599. EACS: Lessons from the Swiss Cohort study: Metabolic and cardiovascular co-morbidities among people living with HIV - (10/26/23)
     
  600. EACS: Single center study on participants living with HIV with isolated anticore antibody (anti-HBc) switching to long acting cabotegravir-rilpivirine therapy: Results from the SCohoLART study - (10/25/23)
     
  601. EACS: Long-Acting CAB + RPV Fails With Resistance in 5 After Long Control on Oral Regimens - Mark Mascolini (10/25/23)
     
  602. EACS: Failure Rate Similar With Long-Acting CAB + RPV and Standard Oral Combos - Mark Mascolini (10/25/23)
     
  603. EACS: Fostemsavir use in the OPERA cohort: immunologic and virologic response - (10/25/23)
     
  604. EACS: EFFICACY AND DURABILITY OF FOSTEMSAVIR, IBALIZUMAB, OR LENACAPAVIR-INCLUDING REGIMENS IN PEOPLE LIVING WITH MULTIDRUG-RESISTANT HIV-1: RESULTS FROM THE PRESTIGIO REGISTRY - (10/25/23)
     
  605. EACS: FOSTEMSAVIR IN ASSOCIATION WITH DORAVIRINE FOR THE TREATMENT OF HEAVILY TREATMENT-EXPERIENCED (HTE) PLWH WITH MULTI-DRUG RESISTANT (MDR) HIV-1 INFECTION: DATA FROM CLINICAL PRACTICE - (10/25/23)
     
  606. EACS: How to choose the optimized background therapy with fostemsavir in viremic people with multidrug-resistant HIV? A clinical case - (10/25/23)
     
  607. EACS: Long-term Safety and Impact of Immune Recovery in Heavily Treatment-Experienced Adults Receiving Fostemsavir for up to 5 Years in the BRIGHTE Study - (10/25/23)
     
  608. EACS: Real-world Effectiveness of Dolutegravir + Lamivudine (DTG + 3TC) in Treatment-Naive People With HIV-1 and Low CD4+ Cell Count or High Viral Load at Baseline: A Systematic Literature Review - (10/25/23)
     
  609. EACS: Systematic Literature Review of Real-world Experience With the 2-Drug Regimen Dolutegravir + Lamivudine (DTG + 3TC) in People With HIV-1 Aged ≥50 Years - (10/25/23)
     
  610. EACS: Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir: The DOLOMITE-EPPICC Study - (10/25/23)
     
  611. EACS: One Third of French Group Has Not Changed Antiretrovirals for Over 10 Years - Mark Mascolini (10/25/23)
     
  612. EACS: Real-world retrospective observational study on the use of Doravirine (DOR) based regimens in clinical practice in Europe - (10/25/23)
     
  613. EACS: Annual Antiretroviral Switch Rate Jumps From 8% to 18% in Last Decade - Mark Mascolini (10/24/23)
     
  614. EACS: HBcAb positivity is a risk factor for failure to achieve complete virologic suppression of HIV-RNA after antiretroviral switch to 3TC+DTG - Mark Mascolini (10/24/23)
     
  615. EACS: Real-world 2-year weight changes among people with sustained HIV suppression: a multicenter French retrospective cohort study - Mark Mascolini (10/24/23)
     
  616. EACS: Cabotegravir/rilpivirine based long acting therapy with insufficient drug levels in routine drug monitoring - Mark Mascolini (10/24/23)
     
  617. EACS: Non-AIDS Non-Hepatitis Cancers Lead Causes of Death With HIV in Switzerland - Mark Mascolini (10/24/23)
     
  618. EACS: Effect of ART, Immunologic-virologic status and Prior TB on Mortality Among People with HIV in Europe - (10/24/23)
     
  619. EACS: Switch to Fixed-Dose Doravirine/Islatravir (100/0.75 mg) Once Daily in Adults with HIV-1 Virologically Suppressed on Biktarvy - week 96 results of a phase 3, randomized, double-blind, non-inferiority trial - (10/24/23)
     
  620. EACS: Below 200 Relevance of low-Level Viremia (50-200) in Participants on ART in the Swiss HV Cohort Study - (10/24/23)
     
  621. EACS: Prevalence and Clinical Impact of Doravirine-associated Resistance Mutations in a Real-World Population of NNRTI-Naive and NNRTI-Experience Individuals - (10/24/23)
     
  622. EACS: Failure Following Switch from Long-Term Suppressive Oral ART to Long Acting Cabotegravir/Rilpivirine injections - (10/24/23)
     
  623. EACS: Effectiveness of LA Injectable Cabotegravir+Rilpivirine for the Treatment of HIV-1: results from the Dutch Athena national observation cohort - (10/24/23)
     
  624. EACS: Uptake/Discontinuation of LA CAB/RPV Swiss HIV Cohort - (10/24/23)
     
  625. EACS: Sustained Improvements in Biomarkers Observed With Fostemsavir in Heavily Treatment-Experienced Adults With Multidrug-Resistant HIV-1 From the Phase 3 BRIGHTE Study Through Week 240 - (10/24/23)
     
  626. EACS: Persistent Low-Level Viremia Leads to Immune T-cell Exhaustion in PLWH - (10/24/23)
     
  627. EACS: A Screening Tool as Part of Routine Clinical Care Detects Post Traumatic Syndrome (PTSD) Symptoms in PWH - (10/24/23)
     
  628. EACS: Drivers of Discontinuation of Oral PrEP Within Europe: Findings From a Real-World Survey of PrEP Use - (10/24/23)
     
  629. EACS: Early virologic failure with Cabotegravir plus Rilpivirine in clinical practice - (10/24/23)
     
  630. EACS: Integrase inhibitor as cause of drug induced liver injury - (10/24/23)
     
  631. EACS: Efficacy and Safety of the HIV-1 Maturation Inhibitor GSK3640254 + 2 NRTIs in Treatment-Naive Adults: 24-Week Results From the Phase IIb, Dose-Range Finding DOMINO Study - (10/25/23)
     
  632. EACS: Efficacy and Safety of the HIV-1 Maturation Inhibitor GSK3640254 + Dolutegravir as a 2-Drug Regimen in Treatment-Naive Adults:24-Week Results From the Phase IIb DYNAMIC Study - (10/24/23)
     
  633. EACS: Cabotegravir-Rilpivirine Long acting : Data in real life setting in a French Cohort - (10/24/23)
     
  634. EACS: Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 infection switching to long-acting cabotegravir and rilpivirine - (10/24/23)
     
  635. EACS: Real-World Effectiveness of Cabotegravir + Rilpivirine in Virologically Suppressed Treatment Experienced Individuals in Europe: Data from COMBINE-2 for Cabotegravir + Rilpivirine Study - (10/24/23)
     
  636. EACS: Safety, pharmacokinetics, and exploratory efficacy of the PD-1 inhibitor budigalimab in antiretroviral treatment-suppressed people living with HIV-1: preliminary analysis of 2 Phase 1b studies including an analytical treatment interruption - (10/24/23)
     
  637. EACS: Doravirine Plus Dolutegravir 2-Drug Regimen as a Maintenance ART: results from a French cohort study - (10/24/23)
     
  638. EACS: Cardiovascular Risk Assessment After Continuing or Switching to a Doravirine-based Regimen Using the Atherosclerotic Cardiovascular (ASCVD) Risk Score Model - (10/24/23)
     
  639. EACS: Drivers of Satisfaction and Health-Related Quality of Life of People Living With HIV Within Europe: Findings From a Real-world Survey of People Living With HIV - (10/24/23)
     
  640. EACS: Penetration of doravirine combined to raltegravir in semen: preliminary results of the DORAL switch study - (10/24/23)
     
  641. EACS: New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV - press release - (10/23/23)
     
  642. EACS: Resistance Analysis of Long-Acting Lenacapavir in Heavily Treatment-Experienced People with HIV after 104 Weeks of Treatment - (10/23/23)
     
  643. EACS: Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities - press release - (10/23/23)
     
  644. EACS: CARAVEL: evaluation of real-world antiviral effectiveness and sustainability of the 2-drug regimen Dolutegravir/Lamivudine FDC in treatment-naïve adults and pre-treated adults who are virologicaly suppressed, in routine clinical care, in France. One-year interim analysis results. - (10/23/23)
     
  645. EACS: Real-world Effectiveness of Dolutegravir + Lamivudine (DTG + 3TC) in Treatment-Naive People With HIV-1 and Low CD4+ Cell Count or High Viral Load at Baseline: A Systematic Literature Review - (10/23/23)
     
  646. EACS: Effectiveness, Safety, and Implementation Outcomes of Cabotegravir + Rilpivirine Long-Acting by Country in the Cabotegravir And Rilpivirine Implementation Study in European Locations (CARISEL) - (10/23/23)
     
  647. EACS: SOLAR 12-Month European Results: Randomized Switch Trial of CAB + RPV LA vs. Oral BIC/FTC/TAF - (10/23/23)
     
  648. EACS: Restarting bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) after virologic rebound: a pooled analysis of studies in people with HIV-1 - Mark Mascolini (10/23/23)
     
  649. EACS: Assessing Phenotypic Effect of Integrase Strand Transfer Inhibitor (INSTI)-Based Resistance Substitutions Linked to Failures on Cabotegravir - (10/23/23)
     
  650. EACS: Restarting Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) After Virologic Rebound: A Pooled Analysis of Studies in People With HIV-1 - (10/23/23)
     
  651. EACS: Once-monthly islatravir has no meaningful effect on exposure to long-acting reversible contraceptives (LARCs) - (10/23/23)
     
  652. EACS: Efficacy and safety of doravirine-based regimens by sex and race: long-term results from three phase 3 clinical trials - (10/23/23)
     
  653. EACS: Investigational Studies to Understand the Decreases in Lymphocytes Seen Clinically with Islatravir (ISL) and Enabling 1the Initiation of New Clinical Trials - (10/23/23)
     
  654. EACS: Switch to fixed-dose doravirine (100 mg) with islatravir (0.75 mg) once daily in adults with HIV-1 virologically suppressed on antiretroviral therapy: week 96 results of a randomized, open-label, phase 3 trial - (10/23/23)
     
  655. EACS: Pharmacokinetics/Pharmacodynamics and Virological Activity of VH3810109 (N6LS) in Antiretroviral-Naive Viremic Adults From the Phase 2a BANNER Study - (10/23/23)
     
  656. EACS: No Relevant Difference in Incident Hypertension Observed by Gender, Race, Baseline BMI, or Other Key Subgroups Through Week 96 Among People Living With HIV-1 (PLWH) Receiving Dolutegravir (DTG)-Based Regimens or Comparator Antiretroviral Therapy (cART) in Pooled Randomized Clinical Trials - (10/23/23)
     
  657. EACS: Follow-Up of Injection Site Reactions in Clinical Studies of People Using Lenacapavir Every 6 Months for HIV Treatment - (10/23/23)
     
  658. EACS: Insights and Experiences from the CAPELLA Trial: Perspectives of Healthcare Professionals and Study Coordinators on Lenacapavir Use Amongst Heavily Treatment-Experienced People with HIV - (10/23/23)
     
  659. EACS: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Antiretroviral Treatment-Naïve (TN) and -Experienced (TE) People With HIV (PWH): 3-Year Effectiveness and Safety Outcomes in the BICSTaR Observational Cohort - (10/23/23)
     
  660. EACS: Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced People With HIV (PWH) With Baseline Symptoms of Depression/Anxiety and/or Insomnia in the Observational BICSTaR Study - (10/23/23)
     
  661. EACS: Final Results of VICDOR: EffectiVeness of SwItChing to DOR-based Antiretroviral Therapy Under Real-world Conditions in Germany - (10/23/23)
     
  662. EACS: Efficacy and safety by subgroup at week 48 after switch to doravirine/islatravir (100 mg/0.75 mg) once daily in two phase 3 trials - (10/23/23)
     
  663. EACS: Efficacy and safety of doravirine/islatravir (100 mg/0.75 mg) once daily in heavily treatment-experienced persons with HIV-1: Week 49 results from a phase 3 trial - (10/23/23)
     
  664. EACS: Renal safety parameters of doravirine/islatravir (100/0.75 mg) vs bictegravir/emtricitabine/tenofovir alafenamide once-daily as initial HIV-1 treatment: week 48 results from a randomized, double-blind phase 3 trial - (10/23/23)
     
  665. EACS: One-year frailty transitions among persons living with HIV aged 70 years or more on ART - (10/23/23)
     
  666. EACS: Estimated risk of all-cause mortality [higher] and cardiovascular events in a cohort of women living with HIV and socio-demographically similar HIV-negative controls ≥40 years old - (10/22/23)
     
  667. EACS: Evolution of cancers risk in PWH over 20 years and risks when immunity is restored and viral load is controlled Results from the ANRS CO4 FHDH cohort - (10/22/23)
     
  668. EACS: Frailty and Quality of Life for People with HIV in Cyprus: re-visiting the cascade of care: 70% Prefrail/frail at median age 41; 44% anxiety/depression - (10/22/23)
     
  669. EACS: Cognitive frailty in people living with HIV and its association with geriatric syndromes - (10/22/23)
     
  670. EACS: PREDICTORS OF QUALITY OF LIFE AMONG OLDER PEOPLE LIVING WITH HIV IN KAMPALA, UGANDA: assessmemt & mgt of frailty, low physical function, malnutrition & depression could improve QOL - (10/22/23)
     
  671. EACS: Uganda Elderly HIV+ Women Needs - (10/22/23)
     
  672. BMI vs body composition changes to predict metabolic outcomes in people with HIV - (10/22/23)
     
  673. EACS: LDL-c target achievement in people living with HIV according to individual cardiovascular risk: a retrospective single center observational study - (10/22/23)
     
  674. EACS: Suicide Mortality Trends and Predictors in the PISICS Cohort of People Living with HIV in Catalonia and the Balearic Islands, Spain; PWH >50 have highest rates - (10/22/23)
     
  675. EACS: Evolving trends in mortality patterns and predictors among people living with HIV in Catalonia and the Balearic Islands (Spain), 1998-2020: a multisite cohort study - Comorbidities ! - (10/22/23)
     
  676. EACS: Evolution of causes of death in people living with HIV: a retrospective single center observational study - CVD & Lung Cancer leading causes of death; 80% due to Comoridites - (10/22/23)
     
  677. EACS: Immunological and inflammatory profile of cerebrospinal fluid (CSF) and plasma of people living with HIV (PLWH) with or without Central Nervous System (CNS) involvement - (10/22/23)
     
  678. EACS: Subclinical coronary artery disease in persons living with HIV and uninfected controls: PWH at 2-3 fold higher risk - (10/22/23)
     
  679. EACS: NEW RISK FACTORS FOR FRAGILITY FRACTURES MUST BE CONSIDERED IN OLDER ADULTS WITH HIV - (10/22/23)
     
  680. EACS: Neurocognitve impairment & Anxiety Symptoms May Influence The Development of Prefrailty/Frailty in Japanese PLW Aged Over 40 Years 70% PreFrailty - (10/22/23)
     
  681. EACS: One-year frailty transitions among persons living with HIV aged 70 years or more on ART - (10/20/23)
     
  682. EACS: "Everyone seems already satisfied because people with HIV do not die from AIDS" iCOPe Global survey - (10/20/23)
     
  683. EACS: BICTEGRAVIR and DOLUTEGRAVIR have no impact on glucose levels 12 months after initiation - (10/20/23)
     
  684. EACS: Cognitive trajectories among people with HIV attending a dedicated memory clinic for PLWH - (10/20/23)
     
  685. EACS: Cardiovascular Risk Assessment with SCORE, SCORE2 and D.A.D in People Living with HIV with High Prevalence of Cardiovascular Risk Factors - (10/20/23)
     
  686. EACS: Statins and acetylsalicylic acid (ASA) use and LDL cholesterol value below 70 mg/dl in people living with HIV (PLWH): there is a gap between European AIDS Clinical Society guidelines and clinical practice - (10/20/23)
     
  687. EACS: Prevalence and predictors of non-alcoholic fatty liver disease (NAFLD) among Egyptian people living with HIV (PLHIV): A cross-sectional study - (10/20/23)
     
  688. EACS: Study of the Cardiovascular Disease Risk in People Living with HIV-1 in Portugal: high risk of CVD for PLWH 40-70 Years - (10/20/23)
     
  689. ID Week : High Death and Hospital Rates in US Group With HIV and Cirrhosis - Mark Mascolini (10/18/23)
     
  690. ID Week : Presence of mental health concerns is associated with poor adherence in people taking pre-exposure prophylaxis in real-world clinical practice in the United States - (10/18/23)
     
  691. ID Week : The First Ten Years of HIV Preexposure Prophylaxis Use and Missed Opportunities at an Urban Academic Children's Hospital - (10/18/23)
     
  692. ID Week : PEP-in-pocket (PIP): Long-term follow-up of on demand HIV post-exposure prophylaxis: Is PEP-in-Pocket Best Option for Low-Frequency High-Risk HIV Exposure? - Mark Mascolini (10/18/23)
     
  693. ID Week : Only Half Prescribed CAB PrEP Get at Least 1 Shot in US Outpatient Network - Mark Mascolini (10/18/23)
     
  694. ID Week : Expanding PrEP by Embedding Navigators in High STI Testing Clinical Sites - (10/18/23)
     
  695. ID Week : Racial and Sex PrEP Disparities Persist in US Veterans Study - (10/18/23)
     
  696. ID Week : Consequences of Low-Level Viremia (undetectable-199) Among Women with HIV in the United States: higher risk for viral failure & comorbidities - (10/17/23)
     
  697. ID Week : Pharmacist-Driven ART Start Cuts 37 Day Off Time From HIV Diagnosis to Undetectable - Mark Mascolini (10/17/23)
     
  698. ID Week : HBV Screening and Vaccination Dropping in PrEP Users; Vaccinations Adherence - Mark Mascolini (10/17/23)
     
  699. ID Week : Reasons Differ for Switch to DTG/3TC (Weight Concern) and B/F/TAF (Adherence, Substance Abuse, Poor HIV Control) - Mark Mascolini (10/17/23)
     
  700. ID Week : A Quality Improvement Initiative for HIV Prevention in Underserved Communities - (10/17/23)
     
  701. ID Week : Adherence to Antiretroviral Therapy and Its Effect on Quality of Life among Persons with HIV in the United States using Real-World Data - (10/17/23)
     
  702. ID Week : The Performance of a Multidimensional Frailty Index in Comparison to the Frailty Phenotype to Assess Frailty in an Urban HIV clinic......"most PLWH at clinic were pre-frail or frail" - (10/17/23)
     
  703. ID Week : Impact of Polypharmacy on Gait Speed and Recurrent Falls in Older People Living with HIV. - (10/17/23)
     
  704. ID Week : Association between integrase inhibitor plasma concentrations and body weight gain in women living with HIV - (10/17/23)
     
  705. ID Week : GLP-1 RECEPTOR AGONISTS PROMOTE WEIGHT LOSS AMONG PEOPLE WITH HIV - (10/17/23)
     
  706. ID Week : Clinical Outcome of People Living with HIV and Cirrhosis: A Clinical Cohort Study - (10/17/23)
     
  707. ID Week : A Prospective, Randomized Trial to Assess a Protease Inhibitor-based Regimen Switch Strategy to Manage Integrase Inhibitor-related Weight Gain: Post Hoc - (10/17/23)
     
  708. ID Week : Weight Loss or Gain Predictors Hard to Find in INSTI-to-PI Switch Trial - Mark Mascolini (10/17/23)
     
  709. ID Week : GLP-1 receptor agonists promote weight loss among people with HIV - Mark Mascolini (10/17/23)
     
  710. ID Week : Effects of Semaglutide on Adipose Tissue in HIV-Associated Lipohypertrophy - (10/17/23)
     
  711. ID Week : Predicted uptake of novel HIV treatment options in the United States - (10/17/23)
     
  712. ID Week : Predicted uptake of novel HIV treatment options in the United States - (10/16/23)
     
  713. ID Week : Tesamorelin reduces visceral tissue and liver fat in INSTI-treated persons with HIV - Mark Mascolini (10/16/23)
     
  714. ID Week : Factors driving decisions in the use of HIV Pre-Exposure Prophylaxis: Data from a real-world study in the United States - (10/16/23)
     
  715. ID Week : Increase in New HIV Diagnoses Following Decrease in Use of Pre-exposure Prophylaxis (PrEP) During the COVID-19 Pandemic - (10/16/23)
     
  716. ID Week : The Real-World Impact of Pre-Exposure Prophylaxis (PrEP) Prescription Uptake and Dispensing Status on HIV Infection Risk in the US - (10/16/23)
     
  717. ID Week : Evaluating Pre-Exposure Prophylaxis Use in a Large Integrated Rural US Health System - (10/16/23)
     
  718. ID Week : Facilitators and Barriers to Engaging in PrEP and Gender Affirming Therapy for Black and Latina Transgender Women in South Florida - (10/16/23)
     
  719. ID Week : A Quality Improvement Initiative for HIV Prevention in Underserved Communities - (10/16/23)
     
  720. ID Week : Black Race, Perceived Stress Affect CVD Risk Conditions in PLHIV - (10/16/23)
     
  721. ID Week : Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide -the DYAD study - (10/16/23)
     
  722. ID Week : Virological Suppression in People With HIV-1 (PWH) Receiving Dolutegravir/Lamivudine Was High and Similar Across Age Groups Despite Older PWH Having Increased Rates of Comorbidities and Polypharmacy (TANDEM Subgroup Analysis) - (10/16/23)
     
  723. ID Week : Dolutegravir/Rilpivirine STR Switch in Persons with HIV-1 and Chronic Kidney Disease: 48 Wk Results - (10/16/23)
     
  724. ID Week : SOLAR 12-Month North American Results: Randomized Switch Trial of CAB + RPV LA vs. Oral BIC/FTC/TAF - (10/16/23)
     
  725. ID Week : Clinical Outcomes at Month 6 After Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an Observational Real-World Study (BEYOND) - (10/16/23)
     
  726. ID Week : Durable Efficacy and Robust CD4+ T-cell Count Improvement Observed Across Age, Race, Sex, and Geographic Subgroups of Heavily Treatment-Experienced People With Multidrug-Resistant HIV-1 After 240 Weeks of Fostemsavir Treatment - (10/16/23)
     
  727. ID Week : Perspectives of People With HIV 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an Observational Real-World US Study (BEYOND) - (10/16/23)
     
  728. ID Week : Risk Factors, Risk Perception, and Long-Acting PrEP Awareness and Interest Among US Women: A National Survey - (10/16/23)
     
  729. ID Week : Exploring Cisgender Women's HIV Pre-Exposure Prophylaxis (PrEP) Needs and Preferences Across Settings: the Role of Social-Structural Factors - (10/16/23)
     
  730. ID Week : Integrating Long-Acting Injectable Cabotegravir for PrEP Into Standard of Care for Cisgender Women, Transgender Women, Transgender Men, and Men Who Have Sex With Men: Results From the PILLAR & EBONI Studies - (10/16/23)
     
  731. ID Week : Engaging Black Women on Cabotegravir LA for PrEP by Optimizing Novel Implementation Strategies (EBONI) Study: Provider Perceptions of Appropriateness of Cabotegravir LA for PrEP for Cis-and-Trans Black Women - (10/16/23)
     
  732. ID Week : Healthcare Staff Perceptions of Feasibility and Acceptability on Implementing Injectable HIV Pre-exposure Prophylaxis Into Standard of Care: Baseline Results From the PrEP Implementation Study for Cabotegravir Long Acting for Men in the Real World (PILLAR) - (10/16/23)
     
  733. ID Week : Steady-state PK of Fixed Dose Dolutegravir-Rilpivirine in Hemodialysis - (10/16/23)
     
  734. ID Week : Randomized-controlled trial evaluating the outcome between switching to tenofovir disoproxil fumarate(TDF)/lamivudine(3TC)/dolutegravir(DTG) versus maintaining the current NNRTI or boosted-PI-containing regimen in PLWH in Thailand - a pilot study from single center - (10/16/23)
     
  735. ID Week : Impact of Dolutegravir-based Regimen on Metabolic Syndrome and its Components in Adults living with HIV in Care at Hospital Roosevelt in Guatemala City - (10/16/23)
     
  736. ID Week : Stopping ARVs Tied to Weight Loss (EFV and TDF) Boosts Odds of Weight Gain on Integrase Drugs - Mark Mascolini (10/16/23)
     
  737. ID Week : Viral Blips While on Antiretroviral Therapy are Associated with Virologic Failure - (10/16/23)
     
  738. ID Week : Suppressed switch to bictegravir/emtricitabine/tenofovir alafenamide vs dolutegravir/lamivudine DTG/3TC Stopped More Than B/F/TAF After Switch From Suppressive Regimen - Mark Mascolini (10/16/23)
     
  739. ID Week : Hepatitis B Reactivation in Persons with HIV with Positive Hepatitis B Core Antibody after Switching to Antiretroviral Therapy without Hepatitis B Activity - (10/13/23)
     
  740. ID Week : HIV Following Oral Pre-Exposure Prophylaxis (PrEP) Initiation - (10/13/23)
     
  741. ID Week : Acceptability of an HIV Pre-Exposure Prophylaxis (PrEP) Shared Decision-Making Tool (SDT) for Diverse Populations and Healthcare Providers - (10/13/23)
     
  742. ID Week : Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA® Cohort - (10/13/23)
     
  743. ID Week : Over 80% With Detectable HIV Load Respond to CAB + RPV LA - Mark Mascolini (10/13/23)
     
  744. ID Week : At-Home vs. In-Clinic Receipt of Cabotegravir and Rilpivirine Long-Acting: An Implemtentation Science Trial - (10/13/23)
     
  745. ID Week : Real-World Adherence and Persistence with Cabotegravir + Rilpivirine Long Acting (CAB + RPV LA) compared with Oral ART among PWH in the US: The ABOVE Study - (10/13/23)
     
  746. ID Week : Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Versus Dolutegravir (DTG)-Based 3-Drug Regimens in Adults With HIV Who Have Suboptimal Antiretroviral Adherence - (10/13/23)
     
  747. ID Week : Real-World Effectiveness and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Treatment-Experienced People With HIV and a History of Antiretroviral Drug Resistance Mutations - (10/13/23)
     
  748. ID Week : Creating HCV Care Cascades in HIV Clinics in Real Time - (10/11/23)
     
  749. ID Week : Hepatitis C Virus infection and cure by priority population among New York City Ryan White HIV/AIDS Program Part A - (10/11/23)
     
  750. ID Week : Massachusetts HCV Treatment Report Card: Hepatitis C Virus Care Cascade for Females of Reproductive Age with Opioid Use Disorder, 2014-2021 - (10/11/23)
     
  751. ID Week : Hepatitis C Virus Among Inpatients in the Direct-acting Antiviral Era: Prevalence, Linkage to Care, Treatment Disparities, and Comorbidity Burden - (10/11/23)
     
  752. ID Week : Trends in viral hepatitis and hepatocellular carcinoma in New York City, 2001-2018 - (10/11/23)
     
  753. ID Week : An Analysis of Social Determinants of Health and their Implications for Hepatitis C Virus Treatment in People Who Inject Drugs: The Case of Baltimore. - (10/11/23)
     
  754. ID Week : Anti-HCV Therapy Starts Faster, Finishes More Often With Community Pharmacy Than Medicaid Mail-Order System - Mark Mascolini (10/11/23)
     
  755. ID Week : IMPACT OF AN INNOVATIVE COMMUNITY BASED CONTRACTED PHARMACY ON HCV ELIMINATION IN NEW JERSEY, USA - (10/11/23)
     
  756. ID Week : Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 104 Results - (10/11/23)
     
  757. ID Week : Weight and Metabolic Changes with Long-Acting Lenacapavir in a Combination Regimen in Treatment-Naïve People with HIV-1 at Week 80 - (10/11/23)
     
  758. ID Week : Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Versus Dolutegravir (DTG)-Based 3-Drug Regimens in Adults With HIV Who Have Suboptimal Antiretroviral Adherence - (10/11/23)
     
  759. ID Week : Impact of Subcutaneous Administration Sites on the Clinical Pharmacokinetics of Lenacapavir, a Long-Acting HIV Capsid Inhibitor: Does Body Site Matter? - (10/11/23)
     
  760. ID Week : Each Added Comorbidity Cuts 4 Points Off QOL Index in US Women With HIV - Mark Mascolini (10/11/23)
     
  761. ID Week : Only Half of MSM With HIV Getting Screened for Anal Cancer - Mark Mascolini (10/11/23)
     
  762. ID Week : Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide -the DYAD study - (10/11/23)
     
  763. ID Week : Virological Suppression in People With HIV-1 (PWH) Receiving Dolutegravir/Lamivudine Was High and Similar Across Age Groups Despite Older PWH Having Increased Rates of Comorbidities and Polypharmacy (TANDEM Subgroup Analysis) - (10/11/23)
     
  764. ID Week : Dolutegravir/Rilpivirine STR Switch in Persons with HIV-1 and Chronic Kidney Disease: 48 Wk Results - (10/11/23)
     
  765. Exploring implementation considerations for geriatric-HIV clinics: A secondary analysis from a scoping review on HIV models of geriatric care - (10/09/23)
     
  766. Integrating HIV, hypertension, and diabetes primary care in Africa - (10/09/23)
     
  767. Dolutegravir + Doravirine Nuke Sparing for PWH with Severe Kidney Disease, PK, Drug Levels - (10/09/23)
     
  768. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss - (10/09/23)
     
  769. Diabetes, Lipids, Heart Disease: Weight gain after antiretroviral therapy initiation and subsequent risk of metabolic and cardiovascular disease - (10/04/23)
     
  770. Weight gain after antiretroviral therapy initiation and subsequent risk of metabolic and cardiovascular disease - (10/02/23)
     
  771. Differences in epigenetic age by HIV status among patients with a non-AIDS defining cancer - (09/28/23)
     
  772. Association of CD4+ cell count and HIV viral load with risk of non-AIDS-defining cancers - (09/28/23)
     
  773. Updated mortality and causes of death in 2020-2021 in people with HIV: a multicenter study in France - (09/28/23)
     
  774. A novel formulation enabled transformation of 3 HIV drugs tenofovir-lamivudine-dolutegravir (TLD) from short-acting to long-acting all-in-one injectable - (09/28/23)
     
  775. Investing in National HIV PrEP Preparedness (Over-the-Counter free PrEP) - (09/28/23)
     
  776. Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1 - (09/28/23)
     
  777. CDC: Long COVID in Adults: United States, 2022 - (09/26/23)
     
  778. Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential - (09/24/23)
     
  779. Pharmacokinetics, Safety, and Tolerability of Obeldesivir (OBV; GS-5245) in Healthy Participants - (09/24/23)
     
  780. Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy - (09/24/23)
     
  781. Long-Acting Cabotegravir-Rilpivirine for People Not Taking Oral Therapy [viral failure]- Time to Modify Treatment Guidelines? - (09/24/23)
     
  782. NIH OAR Aging/HIV Virtual Meeting: HIV and Aging Research: Current Landscape and Opportunities, Sept 5 2023 - (09/24/23)
     
  783. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection - (09/24/23)
     
  784. Brief Report: Hepatitis B Infection or Reactivation After Switch to 2-Drug Antiretroviral Therapy: A Case Series, Literature Review, and Management Discussion - (09/19/23)
     
  785. Reversal of epigenetic aging and immunosenescent trends in humans - (09/19/23)
     
  786. EUROPEAN COMMISSION AUTHORISES ViiV HEALTHCARE'S APRETUDE (CABOTEGRAVIR LONG-ACTING AND TABLETS) FOR HIV PREVENTION - (09/19/23)
     
  787. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults; HIV Pipeline: GSK/ViiV, Gilead, Merck - (09/19/23)
     
  788. A formula for the end [of HIV], Paradigm Shift by Pharma - (09/19/23)
     
  789. Abbvie ABBV-382+ Budigalimab with ATI in PWH - (09/19/23)
     
  790. Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008-20: a national cohort study - (09/19/23)
     
  791. bNAb+Cabotegravir v SOC Phase 2b - (09/15/23)
     
  792. CROI: N6LS WITH RHUPH20 ENABLES SAFE HIGH DOSE MONOCLONAL ANTIBODY SUBCUTANEOUS DELIVERY - (09/15/23)
     
  793. CROI: Impact of Baseline Factors on Virologic Response to bNAb VH3810109 (N6LS) in BANNER - (09/15/23)
     
  794. Aging Begins at Time of HIV Infection, Frailty in PWH - (09/13/23)
     
  795. Age Exacerbates HIV-Associated White Matter Abnormalities - (09/12/23)
     
  796. The projected prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030 - (09/12/23)
     
  797. Associations of cardiovascular biomarkers and plasma albumin with exceptional survival to the highest ages - (09/12/23)
     
  798. White Matter Abnormalities Linked to Interferon, Stress Response, and Energy Metabolism Gene Expression Changes in Older HIV-Positive Patients on Antiretroviral Therapy - (09/12/23)
     
  799. The importance of exercise and physical activity in older adults with HIV, editorial to 'prevent accelerated aging' - (09/12/23)
     
  800. Physical activity [steps] is associated with adiposity in older adults with HIV in the modern HIV era - (09/12/23)
     
  801. The incidence and dynamic risk factors of chronic kidney disease among people with HIV - (09/12/23)
     
  802. Lenacapavir for PrEP - (09/12/23)
     
  803. FACT SHEET: Biden-Harris Administration Announces First Ten Drugs Selected for Medicare Price Negotiation - (09/12/23)
     
  804. HIV-positive Ukrainian refugees in the Czech Republic - (09/12/23)
     
  805. Metabolic implications and safety of dolutegravir use in pregnancy - (09/12/23)
     
  806. Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008-20: a national cohort study - (09/12/23)
     
  807. Antiretroviral treatment reveals a novel role for lysosomes in oligodendrocyte maturation - (08/31/23)
     
  808. Differential effects of integrase strand transfer inhibitors, elvitegravir and raltegravir, on oligodendrocyte maturation: A role for the integrated stress response - (08/31/23)
     
  809. Protease inhibitors, saquinavir and darunavir, inhibit oligodendrocyte maturation: Implications for Lysosomal Stress - (08/31/23)
     
  810. Twelve-year neurocognitive decline in HIV is associated with comorbidities, not age: a CHARTER study - (08/29/23)
     
  811. IAS: Innovations and implementation of long-acting antiretroviral therapy - (08/29/23)
     
  812. IAS: Long-acting PrEP and the potential for resistance - (08/27/23)
     
  813. IAS: Long-acting PrEP: Programmatic considerations for HIV testing - (08/27/23)
     
  814. IAS: HIV testing approaches: Current and new approaches and considerations for long-acting PrEP - (08/27/23)
     
  815. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis - (08/27/23)
     
  816. Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure - (08/27/23)
     
  817. FDA: Colchicine (marketed as Colcrys) Information - (08/27/23)
     
  818. Colchicine in Patients with Chronic Coronary Disease - (08/27/23)
     
  819. FDA Product Insert LODOCO (colchicine) tablets, for oral use - (08/27/23)
     
  820. IAS: Fostering cognitive and mental health in people aging and living with HIV while prioritizing the community and lived experience perspectives - (08/18/23)
     
  821. IAS: Venetoclax, alone and in combination with the BH3-mimetic S63845, depletes HIV latently infected cells and delays rebound in humanized mice - (08/15/23)
     
  822. IAS: Transformation of 3 current short-acting HIV drugs, Tenofovir, Lamivudine and Dolutegravir (TLD) into a novel, all-in-one long-acting TLD 3-drug-combination in a single injectable dosage that produces extended pharmacokinetics - (08/15/23)
     
  823. IAS: JABS 48 week results: Implementation of long-acting cabotegravir and rilpivirine in vulnerable populations with complex needs - (08/15/23)
     
  824. IAS: Incident Hypertension Risk in new Tenofovir Alafenamide Disoproxil users for HIV Pre-Exposure Prophylaxis: Analysis of data from an integrated health system in California - (08/15/23)
     
  825. IAS: Association Between Use of Tenofovir Alafenamide for HIV Pre-Exposure Prophylaxis and Statin Initiation in Adults in an Integrated Health System in California - (08/15/23)
     
  826. IAS: Immune activation is associated with low level viremia and noninfectious comorbidities in people living with HIV - (08/15/23)
     
  827. IAS: Hepatitis delta and liver disease among people living with hepatitis B in Senegal - (08/14/23)
     
  828. IAS: HIV-1 Low level viremia predicts virological failure in first-line and second-line ART experienced individuals in India - (08/14/23)
     
  829. IAS: Long COVID and HIV: Scientific and Biologic Intersections - (08/14/23)
     
  830. IAS: HIV-1 Low level viremia predicts virological failure in first-line and second-line ART experienced individuals in India - (08/14/23)
     
  831. IAS: Low-level viremia as a risk factor for virologic failure in children and adolescents living with HIV - (08/14/23)
     
  832. IAS: Thymosin α1 in restoring immune response in immunological nonresponders - (08/14/23)
     
  833. IAS: Persistent immune alterations in individuals with Long-COVID during a 6-months period - (08/14/23)
     
  834. IAS: Large decrease in the proportion of newly diagnosed HIV-1 infections grouping in large clusters in Spain - (08/14/23)
     
  835. IAS: PrEP Equity by sex and age, United States, 2012-2021 - (08/14/23)
     
  836. IAS: PrEP Equity by sex and age, United States, 2012-2021 - (08/14/23)
     
  837. IAS: Dynamics of cellular senescence markers after HCV elimination spontaneously or by DAAs in people living with HIV - (08/14/23)
     
  838. IAS: Accelerated biological aging is associated with intestinal barrier permeability and microbial translocation during antiretroviral therapy suppressed HIV infection - (08/14/23)
     
  839. IAS: Plasma derived extracellular vesicles modulate monocyte function in adults with HIV-related cognitive impairment - (08/14/23)
     
  840. IAS: Self-reported noncommunicable disease prevalence among older people living with HIV in Southern Africa - (08/14/23)
     
  841. IAS: Causes of mortality among people living with HIV: preliminary results from a cross-sectional study at 29 health facilities in Uganda - (08/14/23)
     
  842. IAS: CD4+ T lymphocyte recovery and cognitive function in women living with HIV: Cognitive Function WIHS Women: Viral Suppression/Menopause/Diabetes/HCV - (08/14/23)
     
  843. IAS: Determination of causes of deaths by verbal autopsy methods among people living with HIV in Nigeria - (08/14/23)
     
  844. IAS: Sustained aviraemia in the absence of anti-retroviral therapy in male children following in utero vertical HIV transmission - (08/11/23)
     
  845. DOH to Continue Medicaid Telehealth Coverage Through End of 2024 - (08/11/23)
     
  846. Free the PrEP - Over-the-Counter Access to HIV Preexposure Prophylaxis - (08/11/23)
     
  847. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Commentary. - (08/11/23)
     
  848. IAS: The prospect of elimination of HIV transmission through prevention programs - (08/09/23)
     
  849. IAS: Key REPRIEVE Results and the Utility of Statins Among PWH: What Have We Learned? - (08/09/23)
     
  850. IAS: 6 Key Aging/ HIV Messages at IAS 2023 - (08/08/23)
     
  851. IAS: Integrating hepatitis C services into ART clinics in low and middle income countries (LMICs) as an approach toward hepatitis C micro-elimination: pilot experience in Nigeria - (08/07/23)
     
  852. IAS: What's new in WHO guidelines ( HIV & hepatitis): innovations, treatment, integration and monitoring. Amplifying HIV Primary Care, Patent-Centered Care - (08/07/23)
     
  853. IAS: The REPRIEVE trial: Developing a cardiovascular disease prevention strategy for people living with HIV - "should be inserted in Guidelines" - (08/07/23)
     
  854. IAS: Unique aspects of cardiovascular disease among women with HIV: Lessons from REPRIEVE - (08/07/23)
     
  855. IAS: Blood pressure control among patients receiving Integrated care for HIV, diabetes and hypertension in primary health care facilities in Tanzania and Uganda - (08/07/23)
     
  856. IAS: The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review (IAS) - (08/07/23)
     
  857. IAS: New antiretrovirals and HIV treatment strategies - Plenary Long-acting technologies: A game changer? - (08/07/23)
     
  858. IAS: Cardiovascular disease among people living with HIV in high- and low-income countries: Can one strategy fit all? "put them in Guidelines globally" - (08/07/23)
     
  859. IAS: Scaling up cervical cancer prevention services among women living with HIV: lessons and experiences from FIKIA+ project in Mwanza, Tanzania - "99% with small & medium lesions were linked to treatment, large lesions 98%, lesions susceptible to cancer: linked to further care/diagnosis 99%" - (08/07/23)
     
  860. IAS: Willingness to access PrEP for adolescent girls and young women seeking emergency contraception at community pharmacies in Uganda - (08/07/23)
     
  861. Calendar Year (CY) 2024 Medicare Physician Fee Schedule Proposed Rule - NEW "Patient-Centered" Care Broad/Expanded Reimbursement Proposal - (08/04/23)
     
  862. Is the USA on track to end the HIV epidemic? - (08/04/23)
     
  863. IAS: Prevalence and risk factors for renal insufficiency among adults living with HIV in Tanzania: results from a cross-sectional study - (08/04/23)
     
  864. IAS: Group-based trajectory modelling to identify patterns and predictors of myocardial strain in people living with HIV: two-year longitudinal follow-up with speckle tracking echocardiography - (08/04/23)
     
  865. IAS: Ambulatory blood pressure abnormalities and its determinants in people living with HIV and AIDS in an African setting - (08/04/23)
     
  866. IAS: DoxyPEP use, acceptability, and associated health behaviors among a multisite sample of men who have sex with men and transgender women IAS - (08/04/23)
     
  867. IAS: Ethical issues regarding the implementation of doxycycline post-exposure prophylaxis - (08/04/23)
     
  868. IAS: Doravirine resistance patterns identified through week 192 in the DRIVE-FORWARD and DRIVE-AHEAD phase 3 clinical trials - (08/04/23)
     
  869. IAS: Interpretation of Doravirine Resistance by Algorithm in Antiretroviral-Naïve People with HIV in Haiti - (08/04/23)
     
  870. IAS: Incidence of infections across islatravir clinical development programs - (08/04/23)
     
  871. IAS: Islatravir (MK-8591) has no meaningful effect on the pharmacokinetics of atorvastatin and metformin following coadministration - (08/04/23)
     
  872. IAS: Risk of hepatitis C infection following bacterial sexually transmissible infections among gay and bisexual men in Australia 2016-2020 - Mark Mascolini (08/03/23)
     
  873. IAS: Meningitis B vaccine for prevention of gonorrhoea: What is the evidence? - (08/03/23)
     
  874. IAS: Doxycycline for STI prevention: Current research and future directions - (08/03/23)
     
  875. IAS: Lenacapavir at 2023 IAS -(08/03/23)
     
  876. IAS: A prospective, randomized trial to assess a protease inhibitor-based regimen switch strategy to manage integrase inhibitor-related weight gain - Mark Mascolini (08/03/23)
     
  877. IAS: Triple Test and Treat for HIV/HBV/HCV-Simple Way to Slow Hep Epidemics? - Mark Mascolini (08/03/23)
     
  878. IAS: Sleep Disorder 25% More Likely With Than Without HIV - Mark Mascolini (08/03/23)
     
  879. IAS: Under 2% of San Franciscans With HIV Have All 5 CVD Risk Factors Controlled - Mark Mascolini (08/03/23)
     
  880. IAS: Frailty Worsens in 25% of 50-and-Older Thai HIV Group-But Improves in Many-Through 5 Years - Mark Mascolini (08/03/23)
     
  881. IAS: NASH or NAFLD Tied to ASCVD-and NASH to Cognitive Impairment-With HIV - Mark Mascolini(08/03/23)
     
  882. IAS: A biodegradable, subcutaneous implant delivery platform to treat HIV for up to 6 months in young children - (08/03/23)
     
  883. IAS: JAK Inhibitor Ruxolitinib Reverses Immune Dysfunction and Depletes HIV Reservoir - Mark Mascolini (08/03/23)
     
  884. IAS: MEASURING INTRINSIC CAPACITY: A SCREENING TOOL FOR INTEGRATED CARE IN AGEING PEOPLE WITH HIV - (08/03/23)
     
  885. IAS: The identification of intact HIV proviral DNA in human cerebrospinal fluid - (08/03/23)
     
  886. IAS: Anatomic distribution of HIV-infected cells in tissues after long term antiretroviral therapy - (08/03/23)
     
  887. IAS: Psychiatric multimorbidity among people with HIV aged >40 years in low- and middle-income countries in the Sentinel Research Network of IeDEA - (08/03/23)
     
  888. IAS: Antiretroviral treatment as a protective factor for dysplasia and HPV infection in people living with HIV (PLHIV) - (08/02/23)
     
  889. IAS: The effect of unplanned care interruptions on the mortality of adults resuming antiretroviral therapy in South Africa: a survival analysis - Mark Mascolini (08/02/23)
     
  890. IAS: Global Meta-analysis Confirms Suboptimal Retention and HIV Suppression in Drug Users - Mark Mascolini (08/02/23)
     
  891. IAS: Willingness to use Long-Acting Injectable Cabotegravir (CAB-LA) or Oral TDF/FTC for Pre-Exposure Prophylaxis (PrEP) During Pregnancy in Africa: Findings from the HPTN-084 Qualitative Sub-study - (08/02/23)
     
  892. IAS: AGEING WITH HIV (IAS Plenary): Prioritizing person-centred care - (08/02/23)
     
  893. IAS: Gut dysfunction as an independent driver of neuroinflammation in ART-suppressed SIV - (08/02/23)
     
  894. IAS: Aging of brain network connectivity corresponds to cognitive impairment in persons with HIV - (08/02/23)
     
  895. IAS: Selected comorbidities and the risk of ART switch in the context of HIV-RNA suppressed to ≤50 copies/mL - (08/02/23)
     
  896. IAS: Vitamin D and calcium intake are associated with bone deficits among adolescents living with HIV in Zambia and Zimbabwe: low bone density higher among HIV+ (10% v 6%) - (08/02/23)
     
  897. IAS: Stigma and poor mental wellbeing: A global community approach to identifying and addressing common barriers to living well with HIV - Gilead Community Board Selects Barriers to Living Well with HIV - (08/02/23)
     
  898. IAS: Disability in people living with HIV (PLWH) in Asia: a prospective multi-centre case-control study: PWH had higher rates of frailty (6.8% v 1.3%), anxiety, stress, polypharmacy (14.7% v 7%), worse mood - men avg age 53+/-10 - (08/02/23)
     
  899. IAS: Frailty Worsens in 25% of 50-and-Older Thai HIV Group-But Improves in Many-Through 5 Years - Mark Mascolini (08/02/23)
     
  900. IAS: Sedative drug burden is associated with concurrent physical frailty in people aging with HIV in Canada: findings from the Positive Brain Health Now Study (+BHN) - (08/02/23)
     
  901. IAS: Association between non-alcohol steatohepatitis with significant activity and fibrosis and neurocognitive impairment in people with HIV - (08/02/23)
     
  902. IAS: Willingness to use Long-Acting Injectable Cabotegravir (CAB-LA) or Oral TDF/FTC for Pre-Exposure Prophylaxis (PrEP) During Pregnancy in Africa: Findings from the HPTN-084 Qualitative Sub-study - (08/01/23)
     
  903. IAS: Associations between antiretroviral regimen and changes in blood pressure: results from the D2EFT study - Mark Mascolini (08/01/23)
     
  904. IAS: Preexisting and Post-Baseline Resistance Analyses in Pooled Pediatric Studies of Emtricitabine/Tenofovir Alafenamide (F/TAF)-Based Antiretroviral Therapy - (08/01/23)
     
  905. IAS: Longitudinal Lymphocyte Dynamics in Virologically Suppressed Children With HIV Initiating Single-Tablet Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF) - (08/01/23)
     
  906. IAS: Evaluation of Therapeutic Concentrations of Anti-HIV Antibodies 3BNC117/Teropavimab and 10-1074/Zinlirvimab Through PK-PD Modeling and Prediction of the Washout Duration in HIV Cure Studies - (08/01/23)
     
  907. IAS: Evaluation of Cross-Sectional HIV Incidence Recency Testing in Samples from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial - (08/01/23)
     
  908. IAS: Development of the HIV Care Continuum & Beyond Initiative: Key Focus Areas to End HIV in the Asia-Pacific Region - ViiV Community Global Board Selects Focus Areas to Improve Health Outcomes - (08/01/23)
     
  909. IAS: Initial PrEP product choice: results from the HPTN 084 open-label extension - (08/01/23)
     
  910. IAS: Associations between antiretroviral regimen and changes in blood pressure: results from the D2EFT study - Bigger Blood Pressure Jump With DTG in 2nd-Line Therapy Trial - Mark Mascolini (08/01/23)
     
  911. IAS: Lifestyle Program Yields Modest CVD Benefits in HIV+ South African Women - Mark Mascolini (08/01/23)
     
  912. IAS: Healthcare provider experience of administering long-acting lenacapavir for people with HIV with heavy treatment experience, engaged through a compassionate use program in the United States - (08/01/23)
     
  913. IAS: Week-96 Results of ALLIANCE, a Phase 3, Randomized, Double-Blind Study Comparing B/F/TAF Versus DTG + F/TDF in Treatment-Naïve People With Both HIV-1 and Hepatitis B - (08/01/23)
     
  914. IAS: Association between HIV-related factors and hypertension and diabetes among people living with HIV in Cameroon - (08/01/23)
     
  915. IAS: Incident hypertension in adults initiating tenofovir alafenamide fumarate for HIV pre-exposure prophylaxis: analysis of data from an integrated health system in California - (08/01/23)
     
  916. IAS: Cardiovascular Health Among Persons with HIV without Existing Atherosclerotic Cardiovascular Disease (not good) - (08/01/23)
     
  917. IAS: Risk Characteristics, Risk Perception, and Long-Acting PrEP Awareness and Interest Among Black and Hispanic Men in the US: A National Social Media Survey - (08/01/23)
     
  918. IAS: Patient-Reported Outcomes After 12 Months of Maintenance Therapy With CAB + RPV LA Compared With BIC/FTC/TAF in the Phase 3b SOLAR Study - (08/01/23)
     
  919. IAS: Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine in the United States: Trio Cohort Study - (07/30/23)
     
  920. IAS: Inflammatory Markers After Switching to Cabotegravir + Rilpivirine Long-Acting vs. Continuing Bictegravir/Emtricitabine/Tenofovir Alafenamide: Data From the Phase 3b SOLAR Study - (07/30/23)
     
  921. IAS: Cabotegravir + Rilpivirine Long-Acting Outcomes by Sex at Birth, Age, Body Mass Index, Race, and Ethnicity: A Subgroup Analysis of the Phase 3b SOLAR Study - (07/30/23)
     
  922. IAS: Real-world observational study in Europe on the effectiveness and safety of two-drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor (COMBINE-2): Week 96 stable switch population results - (07/30/23)
     
  923. IAS: Efficacy and Safety of Dolutegravir/Lamivudine (DTG/3TC) in Antiretroviral Therapy (ART)-Naive Adolescents Living With HIV-1: DANCE Study Week 96 Results - (07/30/23)
     
  924. IAS: Acceptable Cost of CAB-LA vs TDF/FTC for PrEP in South African Girls, Young Women - Mark Mascolini - (07/30/23)
     
  925. IAS: Impact of GLP-1 receptor agonists on body weight in patients with type 2 diabetes and HIV - (07/29/23)
     
  926. IAS: Integrase strand inhibitors (INSTI) related changes in BMI and risk of diabetes - (07/29/23)
     
  927. IAS: Lifestyle Program Yields Modest CVD Benefits in HIV+ South African Women - Mark Mascolini (07/29/23)
     
  928. IAS: 96-week update: change in weight and BMI associated with switching to bictegravir/emtricitabine/tenofovir alafenamide vs. a dolutegravir-based regimen among virologically suppressed adults living with HIV - (07/29/23)
     
  929. IAS: Weight Change and Metabolic Assessment of Virologically Suppressed Children With HIV Aged ≥ 2 Years and Weighing 14 to < 25 Kg Who Received a TAF-Containing Regimen - (07/29/23)
     
  930. IAS: Effect on weight changes upon discontinuation of dolutegravir from antiretroviral regimens among persons with HIV who experienced weight gain - (07/29/23)
     
  931. IAS: Healthcare provider experience of administering long-acting lenacapavir for people with HIV with heavy treatment experience, engaged through a compassionate use program in the United States - (07/29/23)
     
  932. IAS: Week-96 Results of ALLIANCE, a Phase 3, Randomized, Double-Blind Study Comparing B/F/TAF Versus DTG + F/TDF in Treatment-Naïve People With Both HIV-1 and Hepatitis B - (07/27/23)
     
  933. IAS: Same-Day PrEP Popular With Adolescent MSM and TGW in Brazil - Mark Mascolini (07/27/23)
     
  934. IAS: Association of HIV pre-exposure prophylaxis (PrEP) use and bacterial sexually transmitted infections (bSTI) among men who have sex with men (MSM) and transgender women (TGW) in HVTN 704/HPTN 085 - (07/27/23)
     
  935. IAS: Initial PrEP product choice: results from the HPTN 084 open-label extension - (07/27/23)
     
  936. IAS: Positive Predictive Value of HIV Serological Tests in HPTN 084 Trial - (07/27/23)
     
  937. IAS: Acceptability of CAB-LA in cisgender female adolescents in South Africa, Uganda, and Zimbabwe (HPTN 084-01) - (07/27/23)
     
  938. IAS: High in-hospital mortality in SARS-CoV-2 infected patients living with HIV during pre-Delta, Delta and Omicron variant waves: finding from the WHO Global Clinical Platform for COVID-19 - (07/27/23)
     
  939. IAS: Doxycycline post-exposure prophylaxis for STIs: Time for implementation? - (07/27/23)
     
  940. IAS: Pharmacokinetic Bridging with Oral Lenacapavir for Missed Subcutaneous Q6M Dosing - (07/27/23)
     
  941. IAS: A Prospective, Randomized Trial to Assess a Protease Inhibitor-based Regimen Switch Strategy to Manage Integrase Inhibitor-related Weight Gain - (07/27/23)
     
  942. IAS: Risks of hypertension with first-line dolutegravir and tenofovir alafenamide in the NAMSAL and ADVANCE trials - (07/27/23)
     
  943. IAS: Impact of INSTI and TAF-related BMI changes and risk on hypertension and dyslipidemia in RESPOND - (07/27/23)
     
  944. IAS: Routine Hypertension Rx Nearly Erases Blood Pressure Disadvantage With DTG (mediated by weight gain) - Mark Mascolini (07/27/23)
     
  945. IAS: Prior M184V/I and Multiple Prior Virological Failures Have No Impact on the Efficacy of Switching HIV+ Adults to DTG/3TC Through 96Wks in SOLAR-3D - (07/27/23)
     
  946. IAS: Weight and body composition after switch to doravirine/islatravir (DOR/ISL) 100/0.75mg once daily: week 48 results from 2 randomized active-controlled phase 3 trials, MK8591A-017 (P017) and MK8591A-018 (P018) - (07/27/23)
     
  947. IAS: High rates of long-term HIV RNA re-suppression after virological failure on dolutegravir in the ADVANCE trial. - Mark Mascolini (07/27/23)
     
  948. IAS: Renal safety parameters after switch to doravirine/islatravir (DOR/ISL 100/0.75 mg) once daily: week 48 results from 2 randomized, active-controlled Phase 3 trials, MK8591A-017 (P017) and MK8591A-018 (P018) - (07/27/23)
     
  949. IAS: Feasibility of Long-Acting Injectable Cabotegravir PrEP Initiation and Administration by Community Health Workers and Early Aspects of the PrEP Injection Care Continuum in a Primary Care Center in Washington, D.C. - (07/27/23)
     
  950. IAS: Feasibility, Acceptability, and Preliminary Efficacy of LifeSteps for PrEP for Youth Pilot Study (ATN 158) - Fenway Clinic Boston USA - (07/27/23)
     
  951. IAS: Implementation of Doxycycline Post-Exposure Prophylaxis to Prevent Sexually Transmitted Infections at a Frontline Boston Community Health Center - (07/27/23)
     
  952. IAS: Initiation of pre-exposure prophylaxis (PrEP) among key populations in PEPFAR-supported countries during 2019-2022 - not good - (07/27/23)
     
  953. IAS: PrEP Use Up in Australian MSM With Regular Partners- Especially if They Also Have Casual Partners - Mark Mascolini (07/27/23)
     
  954. IAS: Two Thirds of Oral PrEP Users in Kenya Study Would Prefer Long-Acting Injectable - Mark Mascolini (07/27/23)
     
  955. IAS: Persistent accelerated epigenetic aging is associated with altered neuroimaging and immune biomarkers in a longitudinal cohort of vertically-acquired HIV-positive adolescents - (07/26/23)
     
  956. IAS: Two Thirds of Oral PrEP Users in Kenya Study Would Prefer Long-Acting Injectable - Mark Mascolini (07/26/23)
     
  957. IAS: No Rebound 20 Months After ART Stops After Novel Stem Cell Transplant - Mark Mascolini (07/26/23)
     
  958. IAS: Evaluation of Incident Hypertension and Blood Pressure Changes Among People Living With HIV-1 (PLWH) Receiving Dolutegravir (DTG)-Based Regimens or Comparator Antiretroviral Therapy (cART) in Randomized Clinical Trials Through 96 Weeks - (07/26/23)
     
  959. IAS: Dapivirine vaginal ring (DPV-R): An acceptable and feasible HIV prevention option. Evidence from Zimbabwe? - (07/26/23)
     
  960. IAS: HIV among mpox cases: clinical characteristics and outcomes in the WHO global surveillance 2022 - (07/26/23)
     
  961. IAS: High rate of hepatitis C and reinfection after direct-acting antiviral treatment among men-who-have-sex-with-men living with HIV in Bangkok, Thailand - (07/26/23)
     
  962. IAS: Lenacapavir Oral Bridging (300 mg QW) Maintains Efficacy with a Similar Safety Profile When SC LEN Cannot Be Administered - (07/26/23)
     
  963. IAS: Pharmacokinetic Bridging with Oral Lenacapavir for Missed Subcutaneous Q6M Dosing - (07/26/23)
     
  964. IAS: Comparison of Long-Acting Lenacapavir Phase 2/3 Regimen vs Simplified Regimen Using Population-PK Analysis and Simulation - (07/26/23)
     
  965. IAS: Recommendations for Missed Oral Lenacapavir Loading Doses Using Population-Pharmacokinetics-Based Simulations - (07/26/23)
     
  966. IAS: Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing: week 24 results of the randomized D2ARLING study - (07/26/23)
     
  967. IAS: Switching to Dolutegravir/Lamivudine (DTG/3TC) Is Non-inferior to Continuing Tenofovir Alafenamide (TAF)-Based Regimens at Week 196: TANGO Subgroup Analyses - (07/26/23)
     
  968. IAS: Pharmacokinetics (PK), Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed Pregnant Women With HIV - (07/26/23)
     
  969. IAS: People living with HIV not more likely to be hospitalized with mpox unless immunosuppressed, finds WHO analysis - (07/25/23)
     
  970. IAS: Cancer drug shows promise in HIV cure study in humanized mice - (07/25/23)
     
  971. IAS: Cisgender women in seven African countries prefer long-acting injectable to daily oral PrEP for HIV prevention - (07/25/23)
     
  972. IAS: Cardiovascular health among persons with HIV without existing atherosclerotic cardiovascular disease: low statin 44% & anti-hypertensives 39% use among eligible - poor control of risk factors. - (07/25/23)
     
  973. IAS: Early outcomes of successful integration of mental health screening into routine HIV care in Malawi - (07/25/23)
     
  974. IAS: Sleep disorder diagnoses in people with versus without HIV infection in an integrated healthcare system: Insomnia Most Common. PWH More Likely to have Sleep Disorder by 32%. - (07/25/23)
     
  975. IAS: Depressive symptoms and metabolic syndrome among people living with and without HIV in urban Zambia and Zimbabwe - (07/25/23)
     
  976. IAS: Estimating HIV incidence in the era of long-acting PrEP - (07/25/23)
     
  977. IAS: Experience with Using Recency Assay to estimate HIV Incidence in an HIV Prevention Trial - (07/25/23)
     
  978. IAS: Experience with using a registrational cohort to estimate HIV incidence: Lessons from PREPVAcc - (07/25/23)
     
  979. IAS: Costs and cost-effectiveness of immediate initiation of antiretroviral therapy upon diagnosis of HIV (Rapid Start) in the United States - (07/25/23)
     
  980. IAS: Starting ART Within 7 Days of Diagnosis Cuts Mortality in Thailand - Mark Mascolini - (07/25/23)
     
  981. IAS: Perceptions of Cabotegravir + Rilpivirine Long-Acting (CAB + RPV LA) From People Living With HIV (PLHIV) in the CARLOS Study - (07/25/23)
     
  982. IAS: Cabotegravir + Rilpivirine Long-Acting Outcomes by Sex at Birth, Age, Body Mass Index, Race, and Ethnicity: A Subgroup Analysis of the Phase 3b SOLAR Study - (07/25/23)
     
  983. IAS: Participant-Reported Outcomes With Long-Acting Lenacapavir-Based Regimens Among Heavily Treatment-Experienced People Living With HIV in the CAPELLA Clinical Trial - (07/25/23)
     
  984. IAS: Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV - (07/25/23)
     
  985. IAS: Pharmacokinetic Bridging with Oral Lenacapavir for Missed Subcutaneous Q6M Dosing - (07/25/23)
     
  986. IAS: ACTG Announces Publication of REPRIEVE Trial in New England Journal of Medicine and Presentation at IAS 2023 - (07/24/23)
     
  987. IAS: REPRIEVE Results published: Pitavastatin to Prevent Cardiovascular Disease in HIV Infection - (07/24/23)
     
  988. IAS: Each Higher Sedative Burden Unit Boosts Odds of Physical Frailty With HIV 35% - Mark Mascolini - (07/24/23)
     
  989. IAS: STIs Tied to Higher Risk of New HCV Infection in Gay and Bisexual Men - (07/24/23)
     
  990. IAS: ViiV HEALTHCARE'S CABOTEGRAVIR FOR HIV PREVENTION RECEIVES POSITIVE CHMP OPINION FROM EUROPEAN MEDICINES AGENCY - (07/24/23)
     
  991. IAS: New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic Press Releases - (07/24/23)
     
  992. IAS: DOR/ISL (100/0.75 MG) QD COMPARED TO B/F/TAF AS INITIAL HIV-1 TREATMENT: 48 WEEK RESULTS FROM A DOUBLE-BLIND PHASE 3 TRIAL - (07/24/23)
     
  993. Global and regional trends of people living with HIV aged 50 and over: Estimates and projections for 2000-2020 - (07/19/23)
     
  994. U.S. FDA Approves First Anti-Inflammatory Drug for Cardiovascular Disease - Colchicine 0.5 mg: Efficacy in Chronic Coronary Disease; Kidney Progression Risk Studies - (07/18/23)
     
  995. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients - (07/10/23)
     
  996. Dolutegavir Monotherapy in a Unique Unusual Patient Population - (07/07/23)
     
  997. Efficacy and safety of three antiretroviral therapy regimens (DTG v EFV) started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial - (06/19/23)
     
  998. ART Regimens: DTG/3TC; LA CAB/RPV; Biktarvy 5 Yrs - (06/16/23)
     
  999. Study Links viral infections to Alzheimer, Parkinsons - with many caveats - (06/14/23)
     
  1000. Does shingles vaccination cut dementia risk? Large study hints at a link - (06/14/23)
     
  1001. PWH had a higher prevalence of AD (alzheimers)/ADRD. PWH had a higher burden of dementia - (06/05/23)
     
  1002. Impact of Multiple Social Determinants of Health on Incident Stroke - (06/05/23)
     
  1003. Stroke Incidence among White, Black, and Hispanic Residents of an Urban Community - (06/05/23)
     
  1004. Daily statin medication was found to reduce the risk of cardiovascular disease by 35% among people living with HIV; substantial CVD risk in Young PWH - REPRIEVE Study - (06/05/23)
     
  1005. COVID at CDC Conference: Update on Rapid Assessment of SARS-CoV-2 Transmission at 2023 EIS Conference - (06/01/23)
     
  1006. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022 - (05/30/23)
     
  1007. Several cases of Apparent Mpox Reinfection in Europe - (05/29/23)
     
  1008. LENACAPAVIR DISRUPTS HIV-1 CORE INTEGRITY WHILE STABILIZING THE CAPSID LATTICE - (05/30/23)
     
  1009. Population-PK Analysis to Guide Dosing Window Following Lenacapavir SC Administration - (05/30/23)
     
  1010. CROI: NO ANTAGONISM OR CROSS-RESISTANCE OBSERVED BETWEEN ISLATRAVIR AND LENACAPAVIR - (05/30/23)
     
  1011. Diagnoses of HIV Infection in the United States and Dependent Areas, 2021 HIV Declines Among Young People and Drives Overall Decrease in New HIV Infections - (05/25/23)
     
  1012. Antiretroviral Therapy Intensification for Neurocognitive Impairment in HIV - (05/25/23)
     
  1013. CVD After Switch to DTG Reassuring Editorial Comment - Reassuring data for cardiovascular health after switching a boosted protease inhibitor to dolutegravir - (05/25/23)
     
  1014. Associations of Menstrual Cycle Regularity and Length With Cardiovascular Diseases: A Prospective Study From UK Biobank - (05/25/23)
     
  1015. FULMINANT HEPATITIS B AFTER SWITCH IN ANTIRETROVIRAL THERAPY - (05/24/23)
     
  1016. Perceived Cognitive Deficits in Patients With Symptomatic SARS-CoV-2 and Their Association With Post-COVID-19 Condition - (05/22/23)
     
  1017. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies - (05/22/23)
     
  1018. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong - (05/22/23)
     
  1019. COVID-19 Vaccination and Hospitalization Among Persons Living With Diagnosed HIV in New York State - (05/22/23)
     
  1020. Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015 2021 - (05/22/23)
     
  1021. Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV - (05/22/23)
     
  1022. Weight Change Following Switch to Dolutegravir for HIV Treatment in Rural Kenya During Country Roll-Out - (05/22/23)
     
  1023. Trajectories of Antiretroviral Therapy Adherence and Virologic Failure in Women With HIV in the United States - (05/22/23)
     
  1024. HIV incidence and mortality in transgender women in the eastern and southern USA: a multisite cohort study - (05/22/23)
     
  1025. Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy - (05/22/23)
     
  1026. Glasgow Manifesto; recorded aging webinars: IAS; Global Action on aging ICOPE - (05/22/23)
     
  1027. Long-acting antiretrovirals and HIV treatment adherence - Review - (05/19/23)
     
  1028. Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland - (05/19/23)
     
  1029. Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV - (05/18/23)
     
  1030. Long-Acting Cabotegravir and Rilpivirine: Every 2 Months, 152 Weeks ATLAS-2M. Innovation, New Challenges, and Opportunities - (05/17/23)
     
  1031. Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials - (05/17/23)
     
  1032. Compartmentalized HIV rebound in the central nervous system after interruption of antiretroviral therapy - (05/17/23)
     
  1033. Disparities in Adherence & Viral Suppression: "Racial and ethnic disparities in HIV care outcomes must be ameliorated if we are to meet the goals of the EHE and NHAS" - (05/15/23)
     
  1034. Incident diabetes in course of antiretroviral therapy - (05/15/23)
     
  1035. Comorbidities: HIV Controllers vs on ART - (05/12/23)
     
  1036. First two patients receive CAR T cell therapy for HIV - (05/12/23)
     
  1037. New NYS Clinical Guidance: Addressing the Needs of Older Patients in HIV Care - (05/11/23)
     
  1038. R.S.V. Vaccine Approved for Older Adults - (05/05/23)
     
  1039. PWH Suffer Increasing Depression & Anxiety with Age/Disease Duration - (05/02/23)
     
  1040. Dementias among older males and females in the U.S. Medicare system with and without HIV - (04/29/23)
     
  1041. AGING DOES NOT IMPACT DRUG-DRUG INTERACTION MAGNITUDES INVOLVING ANTIRETROVIRAL DRUGS - (04/26/23)
     
  1042. GREATER BURDEN OF INTRACRANIAL ARTERIAL-WALL ENHANCEMENT IN PERSONS LIVING WITH HIV - (04/26/23)
     
  1043. LA Cabotegavir & Rilpivirine During Pregnancy - (04/25/23)
     
  1044. Why we need to re-define long-term success for people living with HIV - (04/21/23)
     
  1045. Cancer Treatment in Patients With HIV Infection and Non-AIDS-Defining Cancers: A Survey of US Oncologists - (04/21/23)
     
  1046. People living with HIV at substantially higher risk of depression and suicide, especially in first 2 years after diagnosis.reported yesterday at 33rd ECCMID in Denmark - (04/20/23)
     
  1047. CROI: REBOUND DYNAMICS FOLLOWING IMMUNOTHERAPY WITH AN HIV VACCINE, TLR-9 AGONIST, AND BROADLY NEUTRALIZING ANTIBODIES - (04/20/23)
     
  1048. CROI: Heterologous ChAd/samRNA SIV Vaccine Induces Robust T-Cell Responses in Macaques - (04/20/23)
     
  1049. CROI: Vesatolimod Pharmacodynamic Response Associates With Time to HIV Rebound - (04/20/23)
     
  1050. CROI: THE IMPACT OF 3BNC117, 10-1074, AND LEFITOLIMOD ON HIV-1 PERSISTENCE: THE TITAN TRIAL - (04/20/23)
     
  1051. CROI: Topics in Antiviral Medicine: early e-publication versions of our first six 2023 CROI review articles - (04/19/23)
     
  1052. Recorded Webinar and Slides - Taking Global Action Toward Improved Care, Quality of Life, and Empowerment for Older People with HIV - A Webinar
     
  1053. Glasgow: The Glasgow Manifesto International Coalition of Older People with HIV (iCOPe HIV)
     
  1054. IAS Recorded Feb 7 webinar - Growing older with HIV in the Treat-All Era
     
  1055. Development of Frail RISC-HIV: a Risk Score for Predicting Frailty Risk in the Short-term for Care of People with HIV - (04/19/23)
     
  1056. Susceptibility to 3BNC117 and 10-1074 in ART suppressed chronically infected persons - (04/19/23)
     
  1057. Sleep disturbances and their correlation with cardiovascular risk, obesity, and mood disorders in people with HIV - (04/19/23)
     
  1058. People living with HIV at substantially higher risk of depression and suicide, especially in first 2 years after diagnosis - (04/18/23)
     
  1059. Rates and risk factors for suicidal ideation, suicide attempts and suicide deaths in persons with HIV: a systematic review and meta-analysis - (04/18/23)
     
  1060. CROI 2023 and HIV prevention: Drs. Connie Celum and Renee Heffron - Connie Celum, MD, MPH Professor, Global Health & Medicine, Adjunct Professor Epidemiology University of Washington - Renee Heffron, PhD, MPH Professor, Department of Medicine Director, Center for AIDS Research University of Alabama at Birmingham - (04/03/23)
     
  1061. Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis - (04/18/23)
     
  1062. Lenacapavir - recently published phase 2 safety/efficacy in treatment-naives; at CROI; + Preclinical Studies of New Prevention Interventions at CROI - (04/17/23)
     
  1063. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial - (04/17/23)
     
  1064. PLWH and Nursing Homes Report 5 Publications on Nursing Homes & PLWH - (04/13/23)
     
  1065. Daily statin reduces the risk of cardiovascular disease in people living with HIV, large NIH study finds - (04/11/23)
     
  1066. Premature Menopause & HRT, Alzheimers - Association of Age at Menopause and Hormone Therapy Use With Tau and β-Amyloid Positron Emission Tomography - (04/10/23)
     
  1067. EFFECTIVENESS OF SMALLPOX VACCINATION TO PREVENT MPOX IN MILITARY PERSONNEL - (04/10/23)
     
  1068. MPOX IN PEOPLE LIVING WITH HIV AND CD4 COUNTS < 350 CELLS/MM3: A GLOBAL CASE SERIES - (04/10/23)
     
  1069. Trends in mortality in people living with HIV in an
    international cohort (RESPOND): comorbidities, cancer, CD4/viral load     - (04/10/23)
     
  1070. Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections - (04/09/23)
     
  1071. Sudden Cardiac Death and Myocardial Fibrosis, Determined by Autopsy, in Persons with HIV - (04/09/23)
     
  1072. The number of new cases and deaths from liver cancer could rise by >55% by 2040. Global burden of primary liver cancer in 2020 and predictions to 2040 - (04/09/23)
     
  1073. Real world use of dolutegravir two drug regimens - (04/05/23)
     
  1074. Effectiveness of Dolutegravir + Lamivudine in Real-world Studies in People With HIV-1 With M184V/I Mutations: A Systematic Review and Meta-analysis - (04/05/23)
     
  1075. Lower anti-Müllerian hormone levels are associated with HIV in reproductive age women and shorter leukocyte telomere length among late reproductive age women - (04/04/23)
     
  1076. SPATIAL PROFILING OF CORONARY PLAQUE SUGGESTS UNIQUE IMMUNE PATHWAYS IN HIV, HIV Found in Coronary Arteries of Deceased PWH - (04/03/23)
     
  1077. U.S. at risk of mpox surge even worse than last year, CDC modelers warn - (03/31/23)
     
  1078. MEDICINES PATENT POOL SIGNS SUBLICENCES WITH AUROBINDO, CIPLA AND VIATRIS TO PRODUCE GENERIC VERSIONS OF ViiV HEALTHCARE'S INNOVATIVE LONG-ACTING HIV PREVENTION MEDICINE - (03/24/23)
     
  1079. In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation - (03/24/23)
     
  1080. Effectiveness of COVID-19 primary and booster vaccination in HIV-infected individuals - EDITORIAL - (03/31/23)
     
  1081. SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy - (03/31/23)
     
  1082. Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy - (03/31/23)
     
  1083. CROI: CROI Oral PrEP Session - All Modes to PrEP - (03/31/23)
     
  1084. CROI: A Loss of ERα Attenuates DTG-mediated Disruption of Thermogenesis in Brown Adipocytes - (03/30/23)
     
  1085. CROI: Weight Gain at CROI 2023 - (03/29/23)
     
  1086. CROI: SARCOPENIA, FRAILTY, NUTRITION AND HCV INFECTION AMONG OLDER PEOPLE WITH HIV - (03/29/23)
     
  1087. CROI: COVID at CROI 2023 - (03/22/23)
     
  1088. CROI: Psychiatric Symptoms In PLHIV: Prevalences, Interactions And Consequences - here are slides in Themed Discussion & poster. - (03/27/23)
     
  1089. CROI: THE SCIENCE OF AGING: LESSONS FOR HIV AT THE INTERFACE OF COMMONALITY AND HETEROGENEITY, George Kuchel - (03/27/23)
     
  1090. CROI: COMPLICATIONS Oral Abstract Session-06 at CROI 2023 - (03/27/23)
     
  1091. CROI: Weight Gain: Does what Goes Up Come Down ? Themed Discussion - (03/27/23)
     
  1092. CROI: Anal Cancer Prevention & Microbiome Biomarkers - (03/27/23)
     
  1093. CROI: HIV-1 Host Reservoir Reactivation after a
    CCR5Δ32/32 Allogeneic Hematopoietic Stem Cell Transplant     - (03/27/23)
     
  1094. CROI: Paxlovid Reduced by 98% Hospitalization: COVID-19 HOSPITALIZATION RISK AFTER SARS-CoV-2 VACCINATION AND OUTPATIENT TREATMENT - (03/27/23)
     
  1095. CROI: Psychiatric Symptoms In PLHIV: Prevalences, Interactions And Consequences - here are slides in Themed Discussion & poster. - (03/27/23)
     
  1096. CROI: VIRAL AND HOST MEDIATORS OF PERSISTENT LOW-LEVEL VIREMIA (NSV) - (03/27/23)
     
  1097. CROI: ADVANCES IN HIV CURE at CROI 2023, John Mellors - (03/27/23)
     
  1098. CROI: Predictors of Post-Switch Viremia in Patients on Injectable Cabotegravir/Rilpivirine - (03/27/23)
     
  1099. CROI: LENACAPAVIR WITH bNAbs GS-5423 AND GS-2872 DOSED EVERY 6 MONTHS IN PEOPLE WITH HIV - (03/27/23)
     
  1100. CROI: LENACAPAVIR WITH bNAbs GS-5423 AND GS-2872 DOSED EVERY 6 MONTHS IN PEOPLE WITH HIV - (03/27/23)
     
  1101. CROI: SOLAR 12-MONTH RESULTS: RANDOMIZED SWITCH TRIAL OF CAB+RPV LA VS ORAL B/FTC/TAF - (03/27/23)
     
  1102. CROI: Pharmacokinetics Inform Remdesivir Dosing for Patients With Severe Renal Impairment - (03/22/23)
     
  1103. CROI: MICROBIOME-DERIVED METABOLITES ARE POWERFUL BIOMARKERS FOR ANAL CANCER PREVENTION - (03/22/23)
     
  1104. CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy (ART) Regimens: Results From the Quebec Human Immunodeficiency Virus (HIV) Cohort Study - (03/24/23)
     
  1105. VV116, GS-5245 for COVID - (03/24/23)
     
  1106. Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition - (03/24/23)
     
  1107. Nonsuppressible viremia during HIV-1 therapy meets molecular virology - (03/22/23)
     
  1108. CROI: BULEVIRTIDE +/- PEG-IFN IN HIV/HBV/HDV CO-INFECTED PATIENTS IN REAL-LIFE SETTINGS - (03/22/23)
     
  1109. CROI: Persistent Low Level 'Non-Suppressible' HIV Viremia - (03/22/23)
     
  1110. CROI: VIRAL AND HOST MEDIATORS OF PERSISTENT LOW-LEVEL VIREMIA - (03/22/23)
     
  1111. CROI: Disparities in Mpox Vaccination Uptake in San Francisco Among PLWH and People on PrEP - (03/22/23)
     
  1112. CROI: CLINICAL AND LABORATORY OUTCOMES OF HEPATITIS C TREATMENT IN AN ACUTE HIV COHORT - (03/22/23)
     
  1113. CROI: Clonally expanded HIV-1 proviruses with 5'-leader defects can give rise to nonsuppressible residual viremia - (03/22/23)
     
  1114. CROI: Persistent HIV Low-Level Viremia Can Arise From An Active Proviral Clone - (03/22/23)
     
  1115. CROI: Low level viremia, Nonsuppressible - (03/22/23)
     
  1116. CROI: REMDESIVIR REDUCES MORTALITY IN IMMUNOCOMPROMISED PATIENTS HOSPITALIZED FOR COVID-19 - (03/22/23)
     
  1117. CROI: Remdesivir Retains Potent Antiviral Activity Against SARS-CoV-2 Variants of Concern - (03/22/23)
     
  1118. CROI: Any Level of Detectable Viremia is Associated with Serious Non-AIDS Events - (03/20/23)
     
  1119. CROI: Changes in Body Mass Index with Longer-Term Integrase Inhibitor Use in REPRIEVE - (03/20/23)
     
  1120. CROI: PSYCHIATRIC DISORDERS IN HIV EXPOSED UNINFECTED - VERSUS NON-HIV EXPOSED CHILDREN - (03/20/23)
     
  1121. CROI: HIV EXPOSED UNINFECTED (HEU) INFANTS DISPLAY UNIQUE PRO-INFLAMMATORY BIOPROFILES - (03/20/23)
     
  1122. CROI: Any Level of Detectable Viremia is Associated with Serious Non-AIDS Events - (03/20/23)
     
  1123. CROI: Academic Performance Among Children with Perinatal HIV Exposure in Botswana - (03/20/23)
     
  1124. CROI: PREGNANCY HORMONAL DYSREGULATION CORRELATES WITH HIV-EXPOSED INFANT GROWTH OUTCOMES - (03/20/23)
     
  1125. CROI: Effect of in-utero HIV and ART exposure on growth during infancy - (03/20/23)
     
  1126. CROI: CMV IgG is Associated with Muscle Function but not Quality or Mass in People with HIV - (03/20/23)
     
  1127. CROI: CLINICAL AND LABORATORY OUTCOMES OF HEPATITIS C TREATMENT IN AN ACUTE HIV COHORT - (03/16/23)
     
  1128. CROI: Risk factors for liver fibrosis progression in HIV: a multi-center longitudinal study - (03/16/23)
     
  1129. CROI: SEX DIFFERENCES IN THE ASSOCIATION OF HIV WITH METABOLIC-FATTY LIVER DISEASE - (03/16/23)
     
  1130. CROI: A 12-WEEK MULTICOMPONENT EXERCISE PROGRAM REVERSES FRAILTY IN OLDER ADULTS WITH HIV - (03/16/23)
     
  1131. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection - (03/16/23)
     
  1132. CROI: Any level of detectable viremia is associated with serious non-AIDS events Even Low-Level Viral Load Inflates Risk of Serious Non-AIDS Illness - Mark Mascolini (03/16/23)
     
  1133. CROI: Brain Aging Gap was significantly elevated in PWH compared to PWoH (p=0.001). - (03/16/23)
     
  1134. CROI: RACIAL AND HIV DISPARITIES IN HYPERTENSION CASCADE AMONG WOMEN - (03/14/23)
     
  1135. CROI: The BONDY Study: Bone density in youth living with perinatally acquired HIV - (03/14/23)
     
  1136. CROI: Metabolic Health and bone density in youth living with perinatal HIV - (03/14/23)
     
  1137. CROI: BEAT2 PRIMARY TRIAL OUTCOMES: PEG-IFN-A2B + 3BNC117 & 10-1074 IN CHRONIC HIV INFECTION - (03/14/23)
     
  1138. CROI: Safety and Efficacy of Inhaled Interferon-β1a
    (SNG001) in a Phase II Randomized Controlled Trial of Adults with Mild-to-Moderate COVID-19     - (03/14/23)
     
  1139. CROI: Ensitrelvir for mild-to-moderate COVID-19: Phase 3 part of Phase 2/3 study - (03/14/23)
     
  1140. CROI: BEAT2 PRIMARY TRIAL OUTCOMES: PEG-IFN-A2B + 3BNC117 & 10-1074 IN CHRONIC HIV INFECTION - (03/14/23)
     
  1141. CROI: Safety and Efficacy of Inhaled Interferon-β1a
    (SNG001) in a Phase II Randomized Controlled Trial of Adults with Mild-to-Moderate COVID-19     - (03/14/23)
     
  1142. CROI: Ensitrelvir for mild-to-moderate COVID-19: Phase 3 part of Phase 2/3 study - (03/14/23)
     
  1143. CROI: HIGH MORTALITY IN HOSPITALISED VIRALLY SUPPRESSED ADULTS WITH HIV IN SOUTH AFRICA - (03/14/23)
     
  1144. CROI: INFREQUENT DETECTION OF EMERGENT HIV DRUG RESISTANCE IN LOW VIRAL LOAD SPECIMENS - (03/14/23)
     
  1145. CROI: Sofosbuvir/Velpatasvir Pharmacokinetics in Pregnant Women with Hepatitis C Virus - (03/14/23)
     
  1146. Long COVID Incidence CDC 15%-20% - (03/14/23)
     
  1147. Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial - (03/13/23)
     
  1148. CROI: BONE DENSITY CHANGES WITH CAB-LA OR TDF/FTC PrEP IN MSM AND TGW IN HPTN 083 - (03/13/23)
     
  1149. CROI: Incidence of Long COVID Symptoms in Patients Previously Hospitalized With COVID-19 - (03/13/23)
     
  1150. CROI: Early Inflammatory Profiles Predict Maximal Disease Severity in COVID-19 - (03/13/23)
     
  1151. CROI: Inflammatory pathways associated with COVID-19 severity differ based on obesity status - (03/13/23)
     
  1152. CROI: LONG-TERM LIVER EVENTS IN PATIENTS WITH HCV CHRONIC INFECTION AFTER SVR - (03/13/23)
     
  1153. CROI: SYNDEMIC OF CHRONIC VIRAL INFECTIONS ON THE RISK OF END-STAGE RENAL DISEASE - (03/13/23)
     
  1154. CROI: ASSOCIATION OF HIV CONTROL AND IMMUNOSUPPRESSION WITH NADC RISK AMONG PATIENTS ON ART; CD4 Matters: >500 Better - (03/12/23)
     
  1155. CROI: Dolutegravir exposure and congenital anomalies in sub-Saharan Africa - (03/12/23)
     
  1156. CROI: Doubling dolutegravir dosage reduces HIV persistence markers in ART-treated adults - (03/12/23)
     
  1157. CROI: 15-MONTH ATTRIBUTES OF POST-COVID SYNDROME IN THERAPEUTICALLY VACCINATED OUTPATIENTS - (03/12/23)
     
  1158. CROI: CARDIOMETABOLIC RISK IN SOUTH AFRICAN POSTPARTUM WOMEN LIVING WITH HIV - (03/12/23)
     
  1159. CROI: 48 months anthropometric evolution of adolescents switching to Dolutegravir in Spain - (03/12/23)
     
  1160. CROI: Neurofilament light is related to cardiorespiratory and metabolic health in HIV - (03/12/23)
     
  1161. CROI: Weight change over 48 weeks after the transition to dolutegravir-based therapy- a prospective study in Uganda - (03/12/23)
     
  1162. CROI: RANDOMIZED CLINICAL TRIAL OF TRANSGENDER WOMEN SWITCHING TO B/F/TAF (MOBETTA TRIAL) - (03/12/23)
     
  1163. CROI: Intramuscular cabotegravir/ rilpivirine concentrations after switching from efavirenz - (03/12/23)
     
  1164. CROI: Neural tube and other birth defects by HIV status and ART regimen in Eswatini - (03/12/23)
     
  1165. CROI: Telomere Length in Aviremic PWH: How Different is it from Persons Without HIV? - (03/10/23)
     
  1166. Metformin Reduced Long COVID Incidence by 43% - (03/07/23)
     
  1167. CROI: Telomere Length in Aviremic PWH: How Different is it from Persons Without HIV? - (03/07/23)
     
  1168. CROI: PWH Had Worse Depression Scores than PWoH & IL-6 in Men Associated with Depression - (03/07/23)
     
  1169. CROI: Worse Brain Aging in PWH: factors - CVD, Social Determinants, HCV, Viral Load, Unemployment - (03/07/23)
     
  1170. CROI: Merck's MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study - (03/07/23)
     
  1171. CROI: PERICORONARY ADIPOSE TISSUE DENSITY AND SUBCLINICAL CORONARY ARTERY DISEASE IN HIV - (03/07/23)
     
  1172. CROI: INFUSION OF CCR5 GENE-MODIFIED T CELLS PROVIDES LONG-TERM HIV CONTROL - (03/07/23)
     
  1173. CROI: Proportion of deaths occurring outside of health facilities that is attributable to HIV/AIDS - (03/07/23)
     
  1174. CROI: Pharmacokinetics and X-ray Imaging of Long-acting Cabotegravir In Situ Forming Implant - (03/07/23)
     
  1175. CROI: Oral TDF/FTC Provides Early Mucosal Protection In Both On- Demand And Daily Regimen - (03/07/23)
     
  1176. CROI: KAPOSI SARCOMA IN ART-TREATED PLWH: DISTINCT VIRAL AND IMMUNE CHARACTERISTICS - (03/06/23)
     
  1177. CROI: Impact of COVID-19 and Host Factors on the Humoral Immune Repertoire in Treated HIV - (03/06/23)
     
  1178. CROI: Several InSTI Affect Immune Cell Mitochondrial, Proliferation and Apoptosis Ex Vivo - (03/06/23)
     
  1179. CROI: EXTENDED POST-EXPOSURE PROTECTION AGAINST SHIV VAGINAL INFECTION WITH TAF/EVG INSERTS - (03/06/23)
     
  1180. CROI: INCIDENCE OF NON-HEPATIC CANCERS IN HBV, HCV, AND HBV/HCV COINFECTED PERSONS - (03/06/23)
     
  1181. CROI: INCIDENCE OF NON-HEPATIC CANCERS IN HBV, HCV, AND HBV/HCV COINFECTED PERSONS - (03/06/23)
     
  1182. CROI: BURDEN OF CORONARY DISEASE IN TRANSGENDER WOMEN WITH AND WITHOUT HIV - (03/06/23)
     
  1183. CROI: Comorbidities and Symptoms Associated with Falls from 2020-2021 - (03/06/23)
     
  1184. CROI: Internalized HIV Stigma and Mental Health/Substance Use Over Time - (03/06/23)
     
  1185. CROI: US PATIENT PREFERENCES FOR LONG-ACTING HIV TREATMENT: A DISCRETE CHOICE EXPERIMENT - (03/06/23)
     
  1186. CROI: Mosaico (HPX3002/HVTN706) (Data as of Dec 12, 2022 as presented at a DSMB meeting on January 12, 2023) - (03/06/23)
     
  1187. CROI: DIFFERENTIAL ASSOCIATION OF CYTOMEGALOVIRUS WITH ACUTE AND POST-ACUTE COVID-19 - (03/06/23)
     
  1188. CROI: DOLUTEGRAVIR IS ASSOCIATED WITH MORE DEPRESSIVE SYMPTOMS IN OLDER PEOPLE WITH HIV - (03/06/23)
     
  1189. CROI: ONE-YEAR MORTALITY OF PEOPLE WITH HIV AFTER INTENSIVE CARE UNIT ADMISSION - (03/06/23)
     
  1190. CROI: ASSOCIATIONS BETWEEN PLASMA BIOMARKERS AND CHANGES IN COGNITIVE FUNCTION OVER 2 YEARS - (03/06/23)
     
  1191. CROI: Estradiol concentrations in trans women on INSTIs compared to those without HIV - (03/06/23)
     
  1192. CROI: ORAL AND INJECTABLE PrEP USE IN THE UNITED STATES, 2013 TO 2022 - (03/05/23)
     
  1193. CROI: CHARACTERIZATION OF SINGLE VERSUS DUAL ACTIVE MONOCLONAL ANTIBODIES AGAINST SARS-COV-2 - (03/05/23)
     
  1194. CROI: WHAT INFLUENCES SWITCHING TO DTG/3TC VS B/F/TAF IN CLINICAL PRACTICE? - (03/05/23)
     
  1195. CROI: Pre-Exposure Prophylaxis Product Choice in United States Participants in HPTN 083 - (03/05/23)
     
  1196. CROI: IN SILICO PHARMACOKINETICS EVALUATION OF FORGIVENESS FOR DORAVIRINE & RILPIVIRINE - (03/05/23)
     
  1197. CROI: VASCULAR AGE AND COGNITIVE OUTCOMES IN AN ACUTE HIV COHORT AFTER 5.5 YEARS OF ART - (03/05/23)
     
  1198. CROI: Non-AIDS Defining Malignancy Mortality In People Living With HIV; CD4 is biggest risk factor, next is smoking - (03/05/23)
     
  1199. CROI: Incidence of cancer among Medicaid beneficiaries with and without HIV: 2001-2015, PLWH have higher risks for certain cancers - (03/05/23)
     
  1200. CROI: Effects of eplerenone on myocardial perfusion and function: the Miracle HIV study: May Stall Worsening Subclinical Heart Disease With HIV - Mark Mascolini (03/05/23)
     
  1201. CROI: TRAJECTORY OF POST-COVID NEUROCOGNITIVE RECOVERY IN PEOPLE LIVING WITH AND WITHOUT HIV - (03/05/23)
     
  1202. CROI: OLFACTORY PERFORMANCE IN POST MILD-TO-MODERATE ACUTE COVID-19 ACROSS 2 YEARS - (03/05/23)
     
  1203. CROI: TRAJECTORY OF POST-COVID NEUROCOGNITIVE RECOVERY IN PEOPLE LIVING WITH AND WITHOUT HIV - (03/05/23)
     
  1204. CROI: Post Covid Cognitive Impairment Neuro imaging Abnormalities on MRI- A Potential Biomarker - (03/05/23)
     
  1205. CROI: NIRMATRELVIR USE AND HOSPITALIZATIONS OR DEATH IN INDIVIDUALS WITH COVID-19 - (03/05/23)
     
  1206. CROI: Non-AIDS Cancer Risk Varies by Age in Medicaid Group With vs Without HIV - Mark Mascolini (03/03/23)
     
  1207. CROI: MEASURING EXCESS MORTALITY ASSOCIATED WITH HIV: ESTIMATES FROM THE PHIA PROJECT - (03/03/23)
     
  1208. High frequency of memory stem cells with a distinct gene signature in HIV patients with treatment interruption - (03/02/23)
     
  1209. CROI: Cognitive, Motor, & Negative Valence Systems in Neurologic PASC: A Preliminary Study - (03/02/23)
     
  1210. CROI: EFFECTIVENESS OF SMALLPOX VACCINATION TO PREVENT MPOX IN MILITARY PERSONNEL - (03/02/23)
     
  1211. CROI: Screening approaches and clinical description of the anticholinergic burden & Symptoms in people with HIV - (03/02/23)
     
  1212. CROI: MUSCLE QUALITY IS ASSOCIATED WITH CORONARY ARTERY PLAQUE AND PHYSICAL FUNCTION IN PEOPLE WITH HIV - (03/02/23)
     
  1213. CROI: CMV IgG is Associated with Muscle Function but not Quality or Mass in People with HIV - (03/02/23)
     
  1214. CROI: EFFECT OF COMMON ANTIRETROVIRAL COMBINATIONS ON DEPRESSIVE SYMPTOMS IN WOMEN WITH HIV 2nd report - (03/02/23)
     
  1215. CROI: (NEURO)INFLAMMATORY BIOMARKERS MEDIATE THE ASSOCIATION BETWEEN HIV AND DEPRESSION - (03/02/23)
     
  1216. CROI: Screening approaches and clinical description of the anticholinergic burden & Symptoms in people with HIV, Polypharmacy - (03/02/23)
     
  1217. CROI: Screening approaches and clinical description of the anticholinergic burden in people with HIV - (03/02/23)
     
  1218. CROI: TAF and Cobicistat-Boosted Drugs Tied to More Somatic Depressive Symptoms - Mark Mascolini (03/02/23)
     
  1219. CROI: Syringe Service Program Boosts Chances of COVID Testing in Drug Injectors - Mark Mascolini (03/02/23)
     
  1220. CROI: Every 10% Uptick in Masking at School Halves SARS-CoV-2 Detections - Mark Mascolini (03/02/23)
     
  1221. CROI: Second-Line DTG + DRV/r Controls HIV Better Than DRV/r + 2 NRTIs - Mark Mascolini (03/02/23)
     
  1222. CROI: Intervention efficacy on COVID-19 testing and vaccination in people who inject drugs - Mark Mascolini (03/02/23)
     
  1223. CROI: Travel Strictures in Canada Slowed SARS-Cov-2 Variant Arrivals-Briefly - Mark Mascolini - (03/02/23)
     
  1224. Delivering Preexposure Prophylaxis to People Who Use Drugs and Experience Homelessness, Boston, MA, 2018-2020 - (03/01/23)
     
  1225. CROI: CROI 2023: Lenacapavir Treatment, Prevention - (03/01/23)
     
  1226. CROI: CROI 2023: LA CAB/RPV Treatment, CAB Prevention Updates, New Data - (03/01/23)
     
  1227. CROI: Sleep disturbances are associated with cognitive function in women living with HIV - (03/01/23)
     
  1228. CROI: COVID-19 bivalent booster effectiveness in people with and without immune dysfunction - Mark Mascolini (03/01/23)
     
  1229. CROI: VISCERAL FAT REDUCTION WITH TESAMORELIN ASSOCIATED WITH METABOLIC SYNDROME REVERSAL - (03/01/23)
     
  1230. CROI: PRIMARY HCV INCIDENCE AMONG MSM USING PREP AND MSM WITH HIV IN NEW YORK CITY 2012-2022 - (03/01/23)
     
  1231. CROI: Subcutaneous Adipose Tissue Cell Composition is Associated with Visceral Fat Volume - (03/01/23)
     
  1232. CROI: Coronary Artery Plaque Composition and Severity Relate to the Inflammasome in HIV - (03/01/23)
     
  1233. CROI: Four Distinct Biopsychosocial Phenotypes in HIV in the CHARTER Cohort-and Why They Matter - Mark Mascolini (03/01/23)
     
  1234. CROI: Islatravir at CROI 203: treatment, prevention, LA implant - (02/28/23)
     
  1235. CROI: Immune Activation Signals Similar in MSM With HIV and MSM on PrEP And Higher Than in HIV-Negative Controls - Mark Mascolini (02/28/23)
     
  1236. CROI: Dual-Active mAbs Better Than Single-Active Therapy in Stalling SARS-CoV-2 - Mark Mascolini (02/28/23)
     
  1237. CROI: LA CAB + RPV Every 4 Weeks Controls HIV in 131 of 133 With High Nonadherence Risk, Unstable Housing, Mental Illness, Homelessness, drug use - Mark Mascolini (02/28/23)
     
  1238. CROI: COVID in US Made HIV Diagnoses Plunge in 2020-But Why? - (02/28/23)
     
  1239. CROI: High Mpox Rate in MSM on PrEP, but MVA-BN Vax Stops Mpox Cold - Mark Mascolini (02/25/23)
     
  1240. CROI: Mpox Mortality 27% if CD4s Below 100 With HIV Infection - Mark Mascolini - (02/25/23)
     
  1241. CROI: Cocaine Tied to White Matter Lesions With HIV, a Factor in Poor Cognitive Function - Mark Mascolini (02/25/23)
     
  1242. CROI: Rates of Key Death Causes With HIV Falling in Europe/America. Deaths Due to Comorbidities - Mark Mascolini - (02/25/23)
     
  1243. CROI: Depression or Anxiety Linked to Type 1 or 2 MI in US People With HIV - Mark Mascolini - (02/25/23)
     
  1244. CROI: Effects of eplerenone on myocardial perfusion and function [subclinical heart disease]: the Miracle HIV study....."may prevent worsening of subclinical heart disease in HIV" - Mark Mascolini - (02/25/23)
     
  1245. CROI: New Heart Disease Rate Similar With Integrase Inhibitors and Other First ART - Mark Mascolini (02/25/23)
     
  1246. CROI: Good Rectal TAF/EVG Levels With Rectal Inserts in HIV-Negative Men and Women - Mark Mascolini (02/25/23)
     
  1247. CROI: Long-Acting CAB for PrEP Acceptable, Safe in Adolescent Female Africans - Mark Mascolini- (02/25/23)
     
  1248. CROI: Long-Acting Lenacapavir in a Combination Regimen for Treatment Naïve PWH: Week 80 - (02/25/23)
     
  1249. CROI: Week 52 Subgroup Efficacy of Lenacapavir in Heavily Treatment-Experienced PWH - (02/24/23)
     
  1250. CROI: Lenacapavir Protects Against Rectal SHIV Acquisition in Macaque Model - (02/24/23)
     
  1251. CROI: Antiviral Activity of Lenacapavir Against HIV-2 Isolates - (02/24/23)
     
  1252. CROI: Weight and Metabolic Benefits With TDF/FTC/DTG After 4 Years of TAF/FTC+DTG - Mark Mascolini (02/24/23)
     
  1253. CROI: FAVORABLE METABOLIC OUTCOMES 48 WEEKS AFTER SWITCH TO DTG/3TC - (02/24/23)
     
  1254. CROI: Weight Gain Among Participants Switching to a Dolutegravir-based HIV Regimen in Kenya - (02/24/23)
     
  1255. CROI: REVERSIBILITY OF TAF- AND/OR INSTI-ASSOCIATED WEIGHT GAIN - (02/24/23)
     
  1256. CROI: SWITCH TO DOR/ISL (100/0.75MG) QD: WEEK 48 RESULTS FROM AN OPEN-LABEL PHASE 3 TRIAL - (02/24/23)
     
  1257. CROI: SWITCH TO DOR/ISL (100/0.75MG) QD FROM B/F/TAF: WEEK 48 RESULTS FROM A PHASE 3 TRIAL - (02/24/23)
     
  1258. CROI: MODELING TO OPTIMIZE ISLATRAVIR QW DOSE IN HIV VIROLOGICALLY SUPRESSED PWH - (02/24/23)
     
  1259. CROI: Vaginal PrEP Efficacy of Biodegradable Islatravir Implants in Macaques Islatravir Implant Protects Macaques From Vaginal SHIV Infection - Mark Mascolini (02/24/23)
     
  1260. CROI: TARGET3D: glecaprevir-pibrentasvir for four weeks among people with recent HCV infection - (02/23/23)
     
  1261. CROI: Weight and Metabolic Changes With Cabotegravir + Rilpivirine Long-Acting or Bictegravir/Emtricitabine/Tenofovir Alafenamide - (02/23/23)
     
  1262. CROI: Heterologous ChAd/samRNA SIV Vaccine Induces Robust T-Cell Responses in Macaques - (02/23/23)
     
  1263. CROI: ULTRA LONG-ACTING REFILLABLE ISLATRAVIR IMPLANT FULLY PROTECTS NHP AGAINST SHIV - (02/23/23)
     
  1264. CROI: HIGH VIROLOGIC SUPPRESSION RATES ON LONG-ACTING ART IN A SAFETY-NET CLINIC POPULATION - (02/23/23)
     
  1265. CROI: Projected Benefits of Long-Acting ART (LA-ART) in PWH Viremic Not Taking Oral Therapy - (02/23/23)
     
  1266. CROI: EFFICACY AND SAFETY OF 8-WK TUBERCULOSIS TREATMENT REGIMENS IN THE TRUNCATE-TB TRIAL - (02/23/23)
     
  1267. CROI: Impact of integrase inhibitors on cardiovascular events in persons starting ART; INSTI did not increase CVD events in Swiss Cohort - Mark Mascolini(02/23/23)
     
  1268. CROI: ViiV HEALTHCARE ANNOUNCES POSITIVE DATA DEMONSTRATING LONG-ACTING INJECTABLE CABENUVA (CABOTEGRAVIR, RILPIVIRINE) IS AS EFFECTIVE AS DAILY ORAL BIKTARVY (BIC/FTC/TAF) FOR THE TREATMENT OF HIV-1 - (02/23/23)
     
  1269. CROI: SOLAR (Switch Onto Long-Acting Regimen) 12-Month Results - Randomized Switch Trial of CAB + RPV LA vs. Oral BIC/FTC/TAF - (02/23/23)
     
  1270. CROI: LENACAPAVIR WITH bNAbs GS-5423 AND GS-2872 DOSED EVERY 6 MONTHS IN PEOPLE WITH HIV - (02/23/23)
     
  1271. CROI: EFFECT OF ISLATRAVIR ON TOTAL LYMPHOCYTE AND LYMPHOCYTE SUBSET COUNTS - (02/23/23)
     
  1272. CROI: D2EFT: DOLUTEGRAVIR AND DARUNAVIR EVALUATION IN ADULTS FAILING FIRST-LINE NNRTI THERAPY - (02/23/23)
     
  1273. CROI: Susceptibility Screening to bNAbs Teropavimab (GS-5423) and Zinlirvimab (GS-2872) in ART-Suppressed Participants - (02/23/23)
     
  1274. CROI: Low trough concentrations of cabotegravir and rilpivirine in patients infected with HIV switching to long-acting treatment - (02/23/23)
     
  1275. CROI: Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1 - (02/23/23)
     
  1276. CROI: 8+ Year Pooled Analysis: Adherence and HIV Incidence in >6000 Women on F/TDF for PrEP - adherence matters - (02/23/23)
     
  1277. CROI: A Safety Study of a Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Pregnancy - (02/23/23)
     
  1278. CROI: CABOTEGRAVIR FOR HIV PrEP IN US BLACK MEN AND TRANSGENDER WOMEN WHO HAVE SEX WITH MEN - (02/23/23)
     
  1279. CROI: The LEVI Syndrome: Characteristics of early HIV infection with cabotegravir for PrEP - (02/23/23)
     
  1280. CROI: CAB LA FOR HIV PREVENTION IN AFRICAN CISGENDER FEMALE ADOLESCENTS (HPTN 084-01) - (02/23/23)
     
  1281. Recorded Webinar and Slides - Taking Global Action Toward Improved Care, Quality of Life, and Empowerment for Older People with HIV - A Webinar
     
  1282. Glasgow: The Glasgow Manifesto International Coalition of Older People with HIV (iCOPe HIV) - (10/26/22)
     
  1283. IAS Recorded Feb 7 webinar - Growing older with HIV in the Treat-All Era
     
  1284. CROI: Cabotegravir Pharmacology in the Background of Delayed Injections in HPTN 084 - (02/22/23)
     
  1285. CROI: PREVALENCE AND FACTORS ASSOCIATED WITH NAFLD IN PEOPLE WITH HIV - (02/21/23)
     
  1286. CROI: CONTROLLED ATTENUATION PARAMETER IS A VISCERAL ADIPOSITY MARKER IN HIV-RELATED NAFLD - (02/21/23)
     
  1287. CROI: SEX DIFFERENCES IN THE ASSOCIATION OF HIV WITH METABOLIC-FATTY LIVER DISEASE - (02/21/23)
     
  1288. CROI: NAFLD AND ITS COMBINATION WITH NASH PREDICT DM DEVELOPMENT IN PEOPLE WITH HIV - (02/21/23)
     
  1289. CROI: LIVER STEATOSIS AND FIBROSIS IN WOMEN WITH HIV BY INTEGRASE INHIBITOR USE - (02/21/23)
     
  1290. CROI: Comparison of Telomere Length Changes Over 48 Weeks in SALSA Study: DTG/3TC vs CAR - (02/21/23)
     
  1291. CROI: Six-Month Outcome of F/TAF Cobicistat-Boosted Darunavir in Children 14 to < 25 kg - (02/21/23)
     
  1292. CROI: Population-PK Analysis to Guide Dosing Window Following Lenacapavir SC Administration - (02/21/23)
     
  1293. CROI: SimpliciTB Results and Hepatic Safety of Pretomanid Regimens +/- Pyrazinamide - (02/21/23)
     
  1294. CROI: Editorial - Shortening Tuberculosis Treatment - A Strategic Retreat - (02/21/23)
     
  1295. CROI: Treatment Strategy for Rifampin-Susceptible Tuberculosis - TRUNCATE-TB Trial - (02/21/23)
     
  1296. CROI: STANDARD VERSUS DOUBLE DOSE DOLUTEGRAVIR WITH HIV-ASSOCIATED TUBERCULOSIS: WEEK 48 RESULTS - (02/21/23)
     
  1297. CROI: MUCOSAL PHARMACOLOGY OF DOXYCYCLINE FOR BACTERIAL STI PREVENTION IN MEN AND WOMEN - (02/21/23)
     
  1298. CROI: Doxy-PEP and antimicrobial resistance in S. aureus, N. gonorrhoeae, and commensal Neisseria - (02/21/23)
     
  1299. CROI: Doxycycline does not prevent STIs among cisgender women - (02/21/23)
     
  1300. CROI: Mortality 1 Year After ICU Admission Falls Over 20 Years in HIV Group - Mark Mascolini (02/20/23)
     
  1301. CROI: Trends in mortality in people living with HIV in an international cohort (RESPOND). - Mark Mascolini (02/20/23)
     
  1302. CROI: PREDICTORS OF HEPATITIS B TREATMENT RESPONSE IN PEOPLE WITH HIV/HBV COINFECTION - (02/20/23)
     
  1303. CROI: Potential impact and efficiency of doxy-PEP among people with or at risk of HIV - (02/20/23)
     
  1304. CROI: One Year of Doxycycline PEP After STI May Prevent 40% of New STIs - Mark Mascolini (02/20/23)
     
  1305. CROI: DOXYCYCLINE POSTEXPOSURE PROPHYLAXIS FOR PREVENTION OF STIs AMONG CISGENDER WOMEN - (02/20/23)
     
  1306. CROI: DoxyPEP and Meningococcal Vax Keep Protecting MSM PrEP Users From STIs - Mark Mascolini (02/20/23)
     
  1307. Aging & Disproportionate disability in people with HIV - (02/20/23)
     
  1308. Long-term evolution of comorbidities and their disease burden in individuals with and without HIV as they age: analysis of the prospective AGEhIV cohort study - (02/19/23)
     
  1309. Alzheimers Blood Markers - Plasma Aβ42/Aβ40 Ratios in Older People Living With Human Immunodeficiency Virus - (02/19/23)
     
  1310. Concentration-response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy - (02/15/23)
     
  1311. Lingering symptoms common after COVID hospitalization - (02/14/23)
     
  1312. CROI: ViiV Healthcare to present first head-to-head data for long-acting HIV treatment Cabenuva against daily oral Biktarvy at CROI 2023 - (02/14/23)
     
  1313. CROI: Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023 - (02/14/23)
     
  1314. IAS: In Vitro Release and In Vivo PK of Antiretroviral Drugs from Ultra-Long-Acting Polymeric Implants: Towards Better Outcomes for HIV Prevention and Treatment - (02/13/23)
     
  1315. IAS: Biodegradable Polymeric Solid Implants for Ultra-Long-Acting Delivery of Single or Multiple Antiretroviral Drugs - (02/13/23)
     
  1316. Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2 - (02/13/23)
     
  1317. Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors - (02/13/23)
     
  1318. Association of Race and Ethnicity With Initial Prescription of Antiretroviral Therapy Among People With HIV in the US - (02/03/23)
     
  1319. Only 36% (1507 of 4171) received any ART regimen during an average of 11.6 months in Nursing Homes in USA - (02/02/23)
     
  1320. US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease - (02/02/23)
     
  1321. Sex and Race Disparities in Mortality and Years of Potential Life Lost Among People With HIV: A 21-Year Observational Cohort Study - (02/02/23)
     
  1322. "no safe amount of alcohol consumption for cancers and health can be established" - (01/30/23)
     
  1323. No level of alcohol consumption is safe for our health - (01/30/23)
     
  1324. Antisense Reduced LPa by 35% to 72% - (01/30/23)
     
  1325. Weight gain during pregnancy among women initiating dolutegravir in Botswana - (01/30/23)
     
  1326. Lenacapavir in first-line therapy - (01/27/23)
     
  1327. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial - (01/27/23)
     
  1328. Diabetic Kidney Disease, HIV, Women - (01/24/23)
     
  1329. NYS Aging HIV RFP May 2022 - People Aging with HIV (PAWH) - (01/24/23)
     
  1330. Exercise Reduced Heart Attacks & All-Cause Mortality - (01/24/23)
     
  1331. HTPN 078: an enhanced case management study to achieve viral suppression among viremic HIV-positive men who have sex with men in the United States; can we reach ETE & 90/90/90 ? - (01/23/23)
     
  1332. kidney disease increases 4-fold in NYC Clinic from <50 to > 75 from 7% to 31%; high Rates Mental & physical of Comorbidities at large NYC HIV clinic - (01/23/23)
     
  1333. Global and regional trends of people living with HIV aged 50 and over: Estimates and projections for 2000-2020: doubling & tripling - (01/23/23)
     
  1334. - (01/23/23)
     
  1335. Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the European Prevention of Alzheimer's Disease (EPAD) cohort - (01/23/23)
     
  1336. The prevalence of mental health disorders (55% and increasing) in people with HIV and the effects on the HIV care continuun - (01/23/23)
     
  1337. Phase 3 Mosaic-Based Investigational HIV Vaccine Study Discontinued Following Disappointing Results of Planned Data Review - (01/18/23)
     
  1338. Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial - (01/18/23)
     
  1339. Immune restoration affects 10-year survival in people living with HIV/AIDS: CD4 >500 & nadir CD4 matter - (01/17/23)
     
  1340. New Anti-Aging Drugs Senolytics & Mitochondria/Aging HIV, Brain/diabetes, Muscles - (01/13/23)
     
  1341. Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US - CD4 <350 Increased Risk for Post Vaccine Severe Breakthrough - (01/13/23)
     
  1342. Long COVID Prevalence Outcomes - Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021 - (01/07/23)
     
  1343. Effects of the pandemic on HIV service provision - (01/07/23)
     
  1344. Most Long COVID Cases Started With Mild Symptoms: Study - (01/07/23)
     
  1345. NY sees a 30% spike in COVID deaths in December, most since early 2022 - (01/07/23)
     
  1346. Lecanemab in Early Alzheimer's Disease - (01/07/23)
     
  1347. FDA Grants Accelerated Approval for Alzheimer's Disease Treatment FDA NEWS RELEASE - (01/07/23)
     
  1348. IAS Recorded Feb 7 webinar - Growing older with HIV in the Treat-All Era - (02/09/23)
     
  1349. New ART Lenacapavir Update - FDA Approval - (01/05/23)
     
  1350.  "We can hardly even do it nowadays. So, what's going to happen in 5 years from now, 10 years from now?" The health and community care and support needs and preferences of older people living with HIV in Ontario, Canada: a qualitative study - (01/02/23)
     
  1351.  Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial - (01/02/23)
     
  1352. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial - (01/02/23)
     
  1353.  SGLT2 Reduced Death, Improved Kidney In Patients with Kidney Disease - Dapagliflozin in Patients with Chronic Kidney Disease - (01/02/23)
     
  1354. SGLT2 Improve Kidney Function - Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials - (01/02/23)
     
  1355. Empagliflozin in Patients with Chronic Kidney Disease - SGLT2 Empagliflozin Slows Kidney Disease - (01/02/23)
     
  1356. POTS, a debilitating heart condition is linked to COVID and to a lesser degree, vaccines - (01/02/23)
     
  1357. Transmitted drug resistance to integrase based first-line HIV antiretroviral regimens in the Mediterranean Europe - (12/29/22)
     
  1358. New Variant in NY - Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster - (12/29/22)
     
  1359. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial - (12/29/22)
     
  1360. FDA Product Insert - Sunlenca (lenacapavir) Receives FDA Approval - (12/29/22)
     
  1361. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster - (12/22/22)
     
  1362. Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV - (12/22/22)
     
  1363. New PrEP HRSA RFP   - (12/22/22)
     
  1364. FDA Approves New HIV Drug for Adults with Limited Treatment Options - (12/22/22)
     
  1365. 30 European HIV Specialists Review Aging/HIV Challenges, Recommendations - (12/19/22)
     
  1366. CD4/CD8 Ratio & Cancer Risk in PWH - (12/19/22)
     
  1367. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients - (12/15/22)
     
  1368. ViiV HEALTHCARE ANNOUNCES CHMP POSITIVE OPINION FOR TRIUMEQ PD, THE FIRST DISPERSIBLE SINGLE TABLET REGIMEN CONTAINING DOLUTEGRAVIR, A ONCE-DAILY TREATMENT FOR CHILDREN LIVING WITH HIV IN EUROPE - (12/15/22)
     
  1369. Doravirine Concentrations and Human Immunodeficiency Virus Type 1 RNA in the Genital Fluids of Virologically Suppressed Adults Switching to Doravirine Plus Emtricitabine/Tenofovir Alafenamide - (12/15/22)
     
  1370. Weight and metabolic changes after switching from tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC+DTG and TDF/FTC/efavirenz (EFV) to TDF/lamivudine (3TC)/DTG - (12/15/22)
     
  1371. Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review - (12/14/22)
     
  1372. NYS AIDS Institute Aging & HIV 2022 - (12/14/22)
     
  1373. My Brain Fog; What is Brain Fog ? - (12/14/22)
     
  1374. Two-drug regimens for HIV treatment - (12/13/22)
     
  1375. Accelerated or Premature Aging & Comorbidities for PLWH & The Need To Fix Healthcare - (12/12/22)
     
  1376. Depression and Sexual Stigma Are Associated With Cardiometabolic Risk Among Sexual and Gender Minorities Living With HIV in Nigeria - (12/12/22)
     
  1377. Physician Reimbursement and Retention in HIV Care: Racial Disparities in the US South - (12/12/22)
     
  1378. CROI-2016 - Neurotoxicity Screening of Antiretroviral Drugs With Human iPSC-Derived Neurons - (12/12/22)
     
  1379. 20 Minutes Daily exercise at age 70 may reduce heart disease risk - (12/12/22)
     
  1380. New PrEP Studies - Lenacapavir; Adolescent Girls, Young Women - (12/12/22)
     
  1381. Update on Gilead's HIV Prevention Trials - (12/12/22)
     
  1382. Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP) - (12/12/22)
     
  1383. Integrase Inhibitors Uniquely Target Thermogenesis In Brown Adipocytes And Combination Drugs Potentiate These Effects, Complications Workshop - (12/12/22)
     
  1384. Comparison of Recency Assays to Estimate HIV Incidence in the SIENA (Estimating HIV Incidence Among AGYW) Study in Uganda - (12/12/22)
     
  1385. Neurotoxicity Screening of Antiretroviral Drugs With Human iPSC-Derived Neurons CROI 2016 - (12/12/22)
     
  1386.  Dolutegravir and bictegravir-induced fat and adipocyte damage as a consequence of hypoxia-inducible factor 1 (HIF-1)-a activation. - (12/12/22)
     
  1387. Dolutegravir-containing HIV therapy reversibly alters mitochondrial health and morphology in cultured human fibroblasts and peripheral blood mononuclear cells - (12/09/22)
     
  1388. Prevalence and risk factors of frailty among adults living with HIV aged 70 years or older - (12/09/22)
     
  1389. Glasgow: Comparison of HIV Incidence as Determined by Different Recency Assays in Ugandan Women - (12/08/22)
     
  1390. Diabetes & HIV - Glucose Intolerance in Persons with HIV is Characterized by Subcutaneous Adipose Tissue Enriched For Lipid-processing Macrophages And Effector Memory T Cells With Discrete Transcriptional Phenotypes (Complications Workshop) - (12/07/22)
     
  1391. CHANGE IN BODY WEIGHT AFTER THE TRANSITION TO DOLUTEGRAVIR-BASED ANTIRETROVIRAL THERAPY, (COMPLICATIONS WORKSHOP) - (12/07/22)
     
  1392. Prevalence, incidence and risk factors for sarcopenic obesity in people with HIV, (Complications Workshop) - (12/07/22)
     
  1393. New HIV Guidelines IAS-USA Panel; Aging, Weight - (12/01/22)
     
  1394. Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens - (12/01/22)
     
  1395. Higher epicardial fat in older adults living with HIV with viral suppression and relationship with liver steatosis, coronary calcium and cardiometabolic risks - (12/01/22)
     
  1396. The HIV protease inhibitor darunavir prevents kidney injury via HIV-independent mechanisms - (12/01/22)
     
  1397. New HIV Drugs Include the LAI CAB+RPV & Lenacapavir, Merck restart of studying Islatravir, plus below I have included recent new study results from these therapies and Fostemsavir, the 2 drug combination of Dolutegravir/3TC, and 5-year update of Biktarvy (Bictegravir/TAF/3TC) - (12/01/22)
     
  1398. ViiV Healthcare unveils a new global study revealing three quarters of people believe there are still negative perceptions when it comes to people living with HIV - (12/01/22)
     
  1399. Elderly & Older PLWH Need New Standard of Care in Clinic & Support Social Services - (11/28/22)
     
  1400. The HIV healthcare system has ignored Aging Issues That Are Coming Back to Haunt Elderly PLWH Who Have Been Abandoned - (11/28/22)
     
  1401. NYS People Aging with HIV (PAWH) Pilot (NYC too) - (11/21/22)
     
  1402. Glasgow: Efficacy and Safety of Switching to Dolutegravir Plus Rilpivirine in Virologically Suppressed Older PLWH: Pooled Week 148 Results From SWORD-1 and SWORD-2 - (11/17/22)
     
  1403. Glasgow: Efficacy and Safety of Dolutegravir/Lamivudine (DTG/3TC) in Black and Asian Participants From TANGO and SALSA: Pooled 48-Week Data Analyzed by Race - (11/17/22)
     
  1404. Glasgow: Effectiveness of Dolutegravir + Lamivudine in Real-world Studies in People With HIV-1 With M184V/I Mutations: A Systematic Review and Meta-analysis - (11/17/22)
     
  1405. Glasgow: Risk of tuberculosis after initiation of antiretroviral therapy among people living with HIV in Europe - (11/17/22)
     
  1406. Glasgow: Treatment-Emergent Integrase Inhibitor Resistance Among Pediatric and Adolescent Populations With HIV-1: A Systematic Review - (11/17/22)
     
  1407. Glasgow: Real-world Experience With the 2-Drug Regimen Dolutegravir and Lamivudine in Women With HIV: A Systematic Literature Review - (11/17/22)
     
  1408. Glasgow: Initial plasma HIV-1 RNA and CD4+ T-cell count are determinants of virological outcomes with initial integrase inhibitor-based regimens: a prospective multinational RESPOND cohort consortium - (11/17/22)
     
  1409. Food Insecurity Is Associated with Key Functional Limitations and Depressive Symptoms in Older People Living with HIV - (11/15/22)
     
  1410. Press Release: Older people living with HIV cannot be ignored and must NOT be left behind - (11/14/22)
     
  1411. Long-acting capsid inhibitor protects macaques from repeat SHIV challenges (PrEP) - (11/14/22)
     
  1412. Long-acting capsid inhibitor protects macaques from repeat SHIV challenges (PrEP) - (11/14/22)
     
  1413. Evidence for "substantial" monkeypox transmission before symptoms - (11/10/22)
     
  1414. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease - (11/10/22)
     
  1415. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection - (11/10/22)
     
  1416. Glasgow: Risk Factors Associated With ≥ ±10% Weight Change in Treatment-Naïve and Treatment-Experienced People Living With HIV Initiating or Switching to an NNRTI- or INSTI-Based Antiretroviral Therapy in Four Large Cohort Studies - (11/07/22)
     
  1417. CDC Update: Monkeypox and HIV - (11/02/22)
     
  1418. HHS renews public health emergency for monkeypox outbreak - (11/02/22)
     
  1419. ID Week: Single-Tablet Regimens (STR) Offer Better Persistence and Adherence, With Lower Costs by Adherence Status, Than Multiple-Tablet Regimens (MTR) for People Living With HIV (PLWH) Enrolled in Medicaid - (11/02/22)
     
  1420. Glasgow: An Increase in Single-Tablet Regimen (STR) Utilization for People Living With HIV (PLWH) Enrolled in Medicaid Had Minimal Impact on Pharmacy Costs - (11/02/22)
     
  1421. Glasgow: ART Regimen Persistence Among Treatment-Experienced Patients With HIV Switching to a MTR or STR Since 2018 - (11/02/22)
     
  1422. Glasgow: Real-world Effectiveness And Tolerability Of Dolutegravir- Based Two-drug Regimens - (11/02/22)
     
  1423. Glasgow: Resolution of neuropsychiatric adverse events after switching to a doravirine-based regimen in the open-label extensions of the DRIVE-AHEAD and DRIVE-FORWARD trials - (11/02/22)
     
  1424. Glasgow: Effectiveness of switching to DOR-based antiretroviral therapy (ART) under real-world conditions in Germany - (11/02/22)
     
  1425. Glasgow: New-onset Diabetes in Persons With HIV on BIC/FTC/TAF in Real-World Clinical Practice - (11/02/22)
     
  1426. Glasgow: Virologic Failure Rate 1.4% in 3 Years of CAB + RPV Phase 3 Trials: Pre-existing RPV Resistance, CAB and RPV Troughs Predict Failure - Mark Mascolini (11/01/22)
     
  1427. Glasgow: Single Infusion of VH3810109 bNAb Controls HIV at Two Doses - Mark Mascolini (11/01/22)
     
  1428. Glasgow: Factors Associated With Weight Loss or Stable Weight After Continuing or Switching to a Doravirine-Based Regimen - (11/01/22)
     
  1429. Glasgow: Metabolic and hepatic safety in ART experienced PLWH switching to a DOR-based regimen vs rilpivirine. Data from a real-life setting - (11/01/22)
     
  1430. Glasgow: Long-term Efficacy and Resistance Analyses of D/C/F/TAF in the Phase 3 AMBER and EMERALD Studies: Post 96-week Data - (11/01/22)
     
  1431. Glasgow: Drug-Related Neuropsychiatric Adverse Events Across Phase 3/3b Studies of Long-Acting Cabotegravir + Rilpivirine Through Week 48 - (11/01/22)
     
  1432. Glasgow: HIV-1 RNA Blips, Low-Level Viral Replication, and Mean CD4+/CD8+ Ratio During Phase 3/3b Cabotegravir + Rilpivirine Long-Acting Studies Up to 152 Weeks of Therapy - (11/01/22)
     
  1433. Glasgow: Effects of the HIV-1 Maturation Inhibitor GSK3640254 on QT Interval in Healthy Participants - (11/01/22)
     
  1434. Glasgow: Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults With HIV-1: Week 240 Results of the Phase 3 BRIGHTE Study - (11/01/22)
     
  1435. Glasgow: Fostemsavir and QT Prolongation: Clinical Applications for Co-administration With Other Agents - (10/31/22)
     
  1436. Glasgow: A Multivariate Analysis of the Phase 3 BRIGHTE Trial, Through Week 24, to Identify Predictors of Virologic Response to Fostemsavir in Heavily Treatment-Experienced People Living With HIV - (10/31/22)
     
  1437. Glasgow: Adverse birth outcomes and risk of MTCT for dolutegravir versus efavirenz in 5 randomised trials of 1074 pregnant women - (10/31/22)
     
  1438. Glasgow: DTG Superior or Noninferior to PI/r After NNRTI Failure: Meta-Analysis of 4 Trials in Africa: VISEND, DAWNING, NADIA, 2SD - Mark Mascolini (10/31/22)
     
  1439. Glasgow: Obesity Risk Higher With DTG Than Other Regimens in 3 Big African Trials - ADVANCE, NAMSAL, VISEND - Mark Mascolini (10/31/22)
     
  1440. Glasgow: DTG Better Than PI or EFV for Resuppression of HIV After Apparent Virologic Failure in 4 African Trials - Mark Mascolini (10/31/22)
     
  1441. Glasgow: UK Survey: Monkeypox Vax Highly Acceptable, but Less Agreement on Public Health Measures - Mark Mascolini (10/31/22)
     
  1442. Glasgow: Low COVID Mortality in HIV+ Europeans Similar to General Population- COVID Testing Tied to Younger Age, Female Gender, CVD and TDF - Mark Mascolini (10/31/22)
     
  1443. Glasgow: Prevalence, risk factors and the impact of antiretroviral treatment in SARS-CoV-2 infection in people with HIV: A cross-sectional study - Mark Mascolini (10/31/22)
     
  1444. Glasgow: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for the Treatment of People Living With HIV: 24-Month Analyses by Age, Race, Sex, Adherence and Late Diagnosis in a Multi-Country Cohort Study - (10/31/22)
     
  1445. Glasgow: Patient-Reported Outcomes After 152 Weeks of HIV Maintenance Therapy With Long-Acting Cabotegravir + Rilpivirine in the Phase 3b ATLAS-2M Study - (10/31/22)
     
  1446. Glasgow: Severity of Some Multimorbidity Clusters on the Rise in People With HIV - Mark Mascolini (10/31/22)
     
  1447. Glasgow: Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy for the Treatment of People Living With HIV With a Range of Comorbidities - (10/29/22)
     
  1448. EUROPEAN MEDICINES AGENCY VALIDATES ViiV HEALTHCARE'S MARKETING AUTHORISATION APPLICATION FOR CABOTEGRAVIR LONG-ACTING INJECTABLE FOR HIV PREVENTION - (10/28/22)
     
  1449. Glasgow: Perceptions of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) From Patients in the CAB + RPV Implementation Study in European Locations (CARISEL) - (10/28/22)
     
  1450. Glasgow: Rapid ART Initiation Using B/FTF and TDF+3TC+EFV in HIV+ Patients in China - (10/28/22)
     
  1451. Glasgow: Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure Over 152 Weeks - (10/28/22)
     
  1452. Glasgow: 6-Month Outcomes of Every 2 Months Long-Acting Cabotegravir and Rilpivirine in a Real-World Setting - Effectiveness, Adherence to Injections, and Patient- Reported Outcomes of People Living With HIV in the German CARLOS Cohort - (10/28/22)
     
  1453. Glasgow: Impact of switch to 3TC/dolutegravir on the intact and total HIV-1 viral reservoir in the Rumba Study - (10/28/22)
     
  1454. Glasgow: Durable Efficacy of Switching From a 3-/4-Drug Tenofovir Alafenamide (TAF)-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine (DTG/3TC) in the TANGO Study Through Week 196 - (10/28/22)
     
  1455. Glasgow: Total Lymphocyte and lymphocyte subset changes in participants receiving islatravir (0.25, 0.75, and 2.25 QD) and doravirine (DOR) +/- lamivudine (3TC): post-hoc analysis from a phase 2b dose-ranging study (P011) - (10/28/22)
     
  1456. Glasgow: Modeling and Simulation to Optimize Islatravir Once Daily (QD) Doses in HIV Treatment Naive and Virologically Suppressed Populations - (10/28/22)
     
  1457. Glasgow: HIV Doubles Death Risk in National French Comparison With Matched Controls - Mark Mascolini (10/28/22)
     
  1458. Glasgow: External validation of the Dat'AIDS score for predicting 5-year mortality among elderly people living with HIV in the Swiss HIV Cohort Study - (10/28/22)
     
  1459. Glasgow: Common Adverse Events in Clinical Studies of People Using Lenacapavir for HIV Treatment - (10/28/22)
     
  1460. Glasgow: Patient-Reported Symptom Outcomes Following DTG/3TC Use in a Test-and-Treat Setting: Results From the STAT Study - (10/28/22)
     
  1461. Glasgow: 2-Year Outcomes of Dolutegravir (DTG) and Lamivudine (3TC) in Art-Naive and Pre-treated People Living With HIV in Germany: Real-world Data From the German URBAN Cohort - (10/28/22)
     
  1462. Glasgow: Age-Related Differences in Quality-of-Life Outcomes of People Living With HIV - (10/28/22)
     
  1463. Glasgow: Outcomes After Switching From 144 Weeks of Blinded DTG/ABC/3TC to 96 Weeks of Open-label B/F/TAF - (10/28/22)
     
  1464. Glasgow: Low Use of Preventive CVD Measures - Use of Preventive Measures for Cardiovascular Disease in People Living with HIV - (10/28/22)
     
  1465. Glasgow: High Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Treatment-Naive Adults With HIV-1 and High Baseline Viral Load (VL): 48-Week Subgroup Analyses of the GEMINI-1/-2 and STAT Trials - (10/28/22)
     
  1466. Glasgow: Older people with well-controlled HIV have similar antibody and higher T-cell responses after vaccination against SARS-CoV-2 compared to demographically and lifestyle-comparable people without HIV - Mark Mascolini (10/28/22)
     
  1467. Glasgow: ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV - (10/28/22)
     
  1468. Glasgow: Laboratory analysis of HIV infections in the year 1 unblinded period of HPTN 083: injectable cabotegravir for PrEP in MSM and TGW - (10/28/22)
     
  1469. Glasgow: Patterns of Doravirine Use in a US Cohort - (10/27/22)
     
  1470. Glasgow: Real World Utilisation of Doravirine Among People Living With HIV in England (DRIVE-REAL) - (10/27/22)
     
  1471. Glasgow: Week 52 Subgroup Efficacy Analyses of Long-Acting Subcutaneous Lenacapavir in Phase 2/3 in Heavily Treatment-Experienced People With Multidrug-Resistant HIV (CAPELLA Study) - (10/27/22)
     
  1472. Glasgow: Overcoming Barriers and Achieving Optimal Implementation of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA): Staff Study Participant (SSP) Results From the CAB + RPV Implementation Study in European Locations (CARISEL) - (10/27/22)
     
  1473. Glasgow: Implementation of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA): Primary Results From the CAB + RPV Implementation Study in European Locations (CARISEL) - (10/27/22)
     
  1474. Glasgow: ViiV HEALTHCARE PRESENTS POSITIVE DATA SHOWING VOCABRIA (CABOTEGRAVIR) AND REKAMBYS (RILPIVIRINE) CAN BE SUCCESSFULLY IMPLEMENTED ACROSS A RANGE OF EUROPEAN HEALTHCARE SETTINGS - (10/27/22)
     
  1475. Glasgow: The Glasgow Manifesto International Coalition of Older People with HIV (iCOPe HIV) - (10/26/22)
     
  1476. ID Week: Screening for Hepatitis C as Part of an Opioid Stewardship Initiative: Identifying Infected Patients and Analyzing Linkage to Care - (10/26/22)
     
  1477. ID Week: A Case Series of Lo-Level HBV Viremia After Switching to Long-Acting Injectable Cabotegravir/Rilpivirine in Patients with HIV, Hepatitis B Core Antibody Positivity, and Hepatitis B Surface Antigen Negativity - (10/26/22)
     
  1478. ID Week: Switching to an Integrase Inhibitor Tied to Liver Fibrosis Score in US Women - Mark Mascolini - (10/25/22)
     
  1479. ID Week: On-Demand and Long-Acting PrEP Both Stir Interest in US Survey of MSM - Mark Mascolini (10/25/22)
     
  1480. ID Week: High PrEP Awareness in US Women, But Only 20% Ever Used It - Mark Mascolini (10/25/22)
     
  1481. ID Week: B/F/TAF for 48 Weeks in US Group With Substance Use and Other Challenges - Mark Mascolini (10/25/22)
     
  1482. ID Week: CAB + RPV LA in Europe: HIV Control in 87% With Standard or Enhanced Support - Mark Mascolini (10/25/22)
     
  1483. ID Week: Ivermectin, Fluticasone, Fluvoxamine Can't Beat Placebo for Mild/Moderate COVID - Mark Mascolini (10/25/22)
     
  1484. ID Week: Postacute COVID Less Common in US Youth Than Reported Earlier - Mark Mascolini (10/25/22)
     
  1485. ID Week: Age, Immune Conditions, Comorbidities Drive Severe COVID Risk After Vaccination - Mark Mascolini (10/25/22)
     
  1486. ID Week: In Big US HIV Group, Hispanics, Blacks, Southerners, Overweight Run Higher COVID Risk - Mark Mascolini (10/25/22)
     
  1487. ID Week: Impaired Fitness Peaks 1 Month After COVID Onset but May Persist 12 Months - Mark Mascolini (10/25/22)
     
  1488. ID Week: CAB + RPV LA in Europe: HIV Control in 87% With Standard or Enhanced Support - Mark Mascolini (10/24/22)
     
  1489. ID Week: On-Demand and Long-Acting PrEP Both Stir Interest in US Survey of MSM - Mark Mascolini (10/24/22)
     
  1490. ID Week: Phase 3/3b Experience With Long-Acting Cabotegravir and Rilpivirine: Efficacy and Safety Outcomes Through Week 96 by Race - (10/24/22)
     
  1491. ID Week: B/F/TAF an Effective and Safe Switch for HIV/HBV: 24-Week Results - Mark Mascolini (10/24/22)
     
  1492. ID Week: Lenacapavir: 75% Sub-50 Response at 52 Weeks Despite Heavy ART Experience - Mark Mascolini (10/24/22)
     
  1493. ID Week: High Exposure to Antilipid Drugs Tied to Lower Mortality in Older HIV Group - Mark Mascolini (10/24/22)
     
  1494. ID Week: Some "Excess Risk" of Delayed ART in START Trial Persists for Years - (10/24/22)
     
  1495. ID Week: HIV, Dementia, Cognitive Concerns Tied to Death in COVID Patients - (10/24/22)
     
  1496. ID Week: CARISEL: A Hybrid Type III Implementation Effectiveness Study of Implementation of Cabotegravir + Rilpivirine Long-Acting (CAB + RPV LA) in European Health Care Settings; Key Clinical and Implementation Outcomes by Implementation Arm - (10/24/22)
     
  1497. ID Week: 76% of PLWH >50 Report Suboptimal Health - Clinical and Sociodemographic Characteristics Associated With Poor Self-rated Health Across Multiple Domains Among Older North American Adults Living With HIV - (10/24/22)
     
  1498. ID Week: Factors Associated with Viremia in Transgender Individuals Living with HIV - (10/24/22)
     
  1499. ID Week: Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US: Effectiveness in the First Year - (10/24/22)
     
  1500. ID Week: Update on PrEP Knowledge and Attitudes Among Adults Attending Public Health Clinics in Southern Arizona - (10/24/22)
     
  1501. ID Week: Life-years Gained among non-Hispanic Black and White Men who have Sex with Men in the United States with Improvements in the HIV Care Continuum A Simulation Modeling Study - (10/24/22)
     
  1502. ID Week: Relative patient preferences for starting daily, on-demand, and long-acting injectable HIV pre-exposure prophylaxis among US men who have sex with men, 2021-2022 - (10/24/22)
     
  1503. ID Week: PrEP Awareness and Use among Reproductive Age Women in Miami, Florida - (10/23/22)
     
  1504. ID Week: PrEP Interest and Preferences Among US Black and Hispanic Men - A 2021 National Survey - (10/23/22)
     
  1505. ID Week: Systematic Literature Review of Real-world Experience With the 2-Drug Regimen Dolutegravir and Lamivudine in People With HIV Who Would Not Have Met Inclusion Criteria for the Phase 3 Clinical Program - (10/23/22)
     
  1506. ID Week: Awareness and Interest in PrEP Options Among US Cisgender Women - A National Survey - (10/23/22)
     
  1507. ID Week: High PrEP Awareness in US Women, But Only 20% Ever Used It - Mark Mascolini (10/23/22)
     
  1508. ID Week: Awareness and Interest in PrEP Options Among US Cisgender Women - A National Survey - (10/23/22)
     
  1509. ID Week: High PrEP Awareness in US Women, But Only 20% Ever Used It - Mark Mascolini (10/23/22)
     
  1510. ID Week: A Real-World Observational Study on Patients With HIV Who Switched From Nevirapine + 2 Nucleoside Reverse Transcriptase Inhibitors to Dolutegravir/Lamivudine in British Columbia, Canada - (10/23/22)
     
  1511. ID Week: Durability and effectiveness of fostemsavir in heavily treatment-experienced people with HIV - (10/23/22)
     
  1512. ID Week: Effectiveness and Durability of Dolutegravir (DTG) Based Regimens in Older People Living With HIV (PLWH) From the Veterans Aging Cohort Study (VACS) - (10/23/22)
     
  1513. ID Week: Real-world Treatment Experience of Single-tablet Dolutegravir/Lamivudine in those Naïve to Treatment with Baseline Viral Loads ≥100,000 copies/mL the United States - (10/23/22)
     
  1514. ID Week: Suppressed Switch to DTG/3TC 2-Drug Regimen Vs. BIC- or DTG-Based 3-Drug Regimens - (10/23/22)
     
  1515. ID Week: Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People With Multi-Drug Resistant HIV: Week 52 Results - (10/23/22)
     
  1516. ID Week: Safety, Tolerability, and Pharmacokinetics of BRII-778, A Modified-Release Oral Formulation of Rilpivirine in Healthy Adult Subjects - (10/23/22)
     
  1517. ID Week: Safety, Tolerability, and Pharmacokinetics of BRII-732, A Medoxomil Carbonate Prodrug of Islatravir in Healthy Adult Subjects - (10/23/22)
     
  1518. ID Week: Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022 - (10/23/22)
     
  1519. ID Week: Real-world Treatment Experience of Treatment-naïve People Living with HIV who Initiated Treatment with Single-tablet Dolutegravir/Lamivudine in a Test and Treat Setting in the United States - (10/23/22)
     
  1520. ID Week: Real-world Geographic Variations of HIV Diagnosis Rates Among Individuals Prescribed and Not Prescribed Oral HIV Pre-Exposure Prophylaxis Regimens in the United States - (10/23/22)
     
  1521. ID Week: Estimated Background HIV Diagnosis Rates Among People Who Could Benefit From Pre-Exposure Prophylaxis at the Metropolitan Statistical Area Level in the United States, 2012-2019 - (10/23/22)
     
  1522. ID Week: Efficacy and Safety of Switching to DTG/3TC in Virologically Suppressed PLWH by Age, Including Those Aged ≥65 Years: Pooled Results From the TANGO and SALSA Studies - (10/23/22)
     
  1523. ID Week: 76% >50 PLWH Report Suboptimal Mental, Physical Health- Clinical and Sociodemographic Characteristics Associated With Poor Self-rated Health Across Multiple Domains Among Older North American Adults Living With HIV - (10/23/22)
     
  1524. ID Week: 5-Year Outcomes of Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial Treatment of HIV-1 in Adults With High Baseline HIV-1 RNA and/or Low CD4 Count in Two Phase 3 Randomized Clinical Trials - (10/23/22)
     
  1525. AGE: Brief Summary, Highlights- 13th Intl Aging & HIV Workshop - (10/20/22)
     
  1526. AGE: Brief Evaluation of Cognitive Impairment and IADL Among Art-Treated People With HIV in a Primary Care Setting - (10/19/22)
     
  1527. AGE: Frontostriatal white matter microstructure alterations in HIV and aging - (10/19/22)
     
  1528. AGE: TENOFOVIR ALAFENAMIDE IS ASSOCIATED WITH SHORTER TELOMERE LENGTH IN PEOPLE WITH HIV - (10/18/22)
     
  1529. AGE: "CD38 is a potential therapeutic target for mitigating chronic inflammation that likely drives cellular aging, comorbidities, and end organ disease in PWH." - (10/18/22)
     
  1530. AGE: Persistent CD38 expression on CD8+ T lymphocytes contributes to chronic inflammation in people with HIV, despite ART - (10/18/22)
     
  1531. AGE: Glucose Changes Among Aging Female PWH in Southeast United States - (10/18/22)
     
  1532. AGE: Aging Accelerates Brain Metabolic Abnormalities in HIV Clade-C Infected Young Adults - (10/18/22)
     
  1533. AGE: DTI and DKI Markers of Brain Microstructural Integrity Show Similar Aging Between HIV Clade-C Infected and Healthy Young Adults - (10/18/22)
     
  1534. AGE: Prevalence of Anal Human Papillomavirus and High-Grade Squamous Intraepithelial Lesions Among Men Who Have Sex With Men Ages 50+ - (10/18/22)
     
  1535. AGE: Non-White & Low Income HIV+ Women Take Less Vitamin D: Rates of Vitamin D Supplementation and Barriers to Uptake Among Women Living with and Without HIV In Canada - (10/18/22)
     
  1536. AGE: Comparing a Novel Virtual Reality Assessment Device, DETECT, to Best-Practices in Assessing HIV-Associated Cognitive Impairment and Mild Cognitive Impairment - (10/18/22)
     
  1537. AGE: Post COVID Frailty Reversible: Frailty transitions in people with post-acute COVID syndrome - (10/18/22)
     
  1538. AGE: Mortality among adult PLHIV in all PEPFAR-supported countries and regions-, October 2019-June 2022 - (10/17/22)
     
  1539. AGE: Aging/HIV: Early interruptions in treatment among PLHIV over 50 years of age starting antiretroviral therapy in PEPFAR-supported low and middle-income countries - (10/17/22)
     
  1540. AGE: Social support network factors linked to neuropsychological-verbal performance among disadvantaged persons living with HIV who use drugs - (10/17/22)
     
  1541. AGE: Aging and HIV: What Is the Gap Between Clinical Practice and Guideline Recommendations? In Europe - (10/17/22)
     
  1542. AGE: Prevalence of Geriatric Syndromes, Frailty and Comorbidities and their Association with Quality of Life in Older Adults with HIV in the Spanish FUNCFRAIL Cohort. - (10/17/22)
     
  1543. AGE: Needs and Involvement of HIV Specialists and Geriatricians in the Care of Older Adults with HIV - A National Survey - (10/17/22)
     
  1544. AGE: e-SMART/EST Telehealth Intervention to Reduce Depression in Older Women with HIV - (10/17/22)
     
  1545. AGE: An Exploration of the Role of Intersectional Stigma and Discrimination on Cardiovascular Risk, among Aging Women with HIV - (10/17/22)
     
  1546. AGE: New York State AIDS Institute Initiatives to Improve Care For Older People With HIV and Long-Term Survivors: An Example of a Government-Academic-Community Partnership - (10/17/22)
     
  1547. AGE: Exploring Experiences Engaging in Exercise from the Perspectives of Women Living with HIV: a Qualitative Study - Barriers, Challenges - (10/17/22)
     
  1548. AGE: Hormonal Intervention Combined with Allopregnanolone Alleviates Premature Age-Related Comorbidities in Female Mice Exposed to Ovarian Failure and HIV-1 Tat - (10/17/22)
     
  1549. AGE: Physical frailty among older HIV-positive and HIV-negative women in Mombasa, Kenya: A cross-sectional study - (10/17/22)
     
  1550. AGE: 50% Frail or Pre-Frail in Uganda: Risk Factors for Frailty in a Geriatric Cohort on Long Term Antiretroviral Treatment in Uganda - (10/17/22)
     
  1551. AGE: Frailty & Hospitalization Associated at Kaiser - Evaluation of an electronic health record-based frailty index in people with and without HIV in a primary care setting - (10/17/22)
     
  1552. AGE: Frailty and physical performance assessments as part of a comprehensive geriatric care model in an urban HIV clinic: 73% Pre-frail or Frail 50% Weak - (10/17/22)
     
  1553. AGE: Physical Functioning in Older Adults with HIV - 80% Impaired Physical Function in Baltimore Clinic SPBB & IADL Measured - (10/17/22)
     
  1554. AGE: Gaps in HIV Care Cascade for Older South Africans Raise Concern - Mark Mascolini - (10/15/22)
     
  1555. AGE: Clinical Care Priorities and Service Needs Among People Aging with HIV in the Bronx, NY - (10/15/22)
     
  1556. AGE: Assessing the Impact of HIV Status and Menstrual Abnormalities on Longitudinal Bone Density Loss in Women Living With and Without HIV - (10/15/22)
     
  1557. AGE: Overlap Between Cognitive and Physical Frailty in Persons with HIV - (10/15/22)
     
  1558. AGE: Aging, HAND & Alzheimers -Alzheimers pathology?? - (10/15/22)
     
  1559. AGE: Increasing Neuroinflammation in People With HIV Tied to Worse Neurodegeneration - Mark Mascolini - (10/15/22)
     
  1560. AGE: More Than Half of Kampala ART Responders Are Prefrail or Frail - Mark Mascolini - (10/15/22)
     
  1561. AGE: Use of Senolytics: Anti-Aging Drugs; in PLWH Study - (10/14/22)
     
  1562. AGE: Three Quarters of Spanish Geriatricians Uncomfortable With HIV Patients - Mark Mascolini - (10/14/22)
     
  1563. AGE: Survey in Italy Finds Lack of Special Care for Elderly With HIV - Mark Mascolini - (10/14/22)
     
  1564. AGE: Polypharmacy, Anxiety, Low Cognitive Score Tied to Frailty With HIV - Mark Mascolini - (10/14/22)
     
  1565. AGE: NRTIs Do Not Protect Against Alzheimer-Type Amyloidosis - Mark Mascolini - (10/14/22)
     
  1566. AGE: Critical Physical Function Loss in Three Quarters of Over-50 HIV Group - Mark Mascolini - (10/14/22)
     
  1567. AGE: Lower Verbal Fluency Tied to Poor Social Support in HIV+ Drug Users - Mark Mascolini - (10/13/22)
     
  1568. AGE: Standard Integrase Regimens Have Minimal Glucose Impact in Older Black Women - Mark Mascolini - (10/13/22)
     
  1569. AGE: Frailty Rate Falls Over Time During Postacute COVID Syndrome - Mark Mascolini - (10/13/22)
     
  1570. AGE: Heart Disease, HCV, Poverty, Early-Life Stress Tied to Brain Aging With HIV - Mark Mascolini - (10/13/22)
     
  1571. AGE: Depression Tied to Noncommunicable Disease Rate in People With HIV - Mark Mascolini - (10/13/22)
     
  1572. AGE: Hyperactivated CD38 Cells Higher With HIV and May Drive Chronic Inflammation - Mark Mascolini - (10/13/22)
     
  1573. AGE: People Over 50 Face High Risk of ART Suspension in First Months: PEPFAR - Mark Mascolini - (10/13/22)
     
  1574. FDA Approves Trogarzo for 30-Second IV Push, Simplifying HIV Treatment for Heavily Treatment-Experienced People - (10/13/22)
     
  1575. ViiV HEALTHCARE TO SHOWCASE INNOVATIVE HIV TREATMENT AND PREVENTION PORTFOLIO AT IDWEEK™ AND HIV GLASGOW - (10/11/22)
     
  1576. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial - (10/11/22)
     
  1577. Weightlifting & Aerobics Reduce Mortality Independently, Together Better - (10/11/22)
     
  1578. What It Means to Age With HIV Infection Years Gained Are Not Comorbidity Free - (10/11/22)
     
  1579. Trends and risk of lung cancer among people living with HIV in the USA: a population-based registry linkage study - (10/11/22)
     
  1580. Severe Manifestations of Monkeypox among People who are Immunocompromised Due to HIV or Other Conditions - (10/06/22)
     
  1581. CDC warns of severe illnesses from monkeypox as Ohio reports death of a monkeypox patient - (10/06/22)
     
  1582. CDC- Future MPX Trajectory - (10/06/22)
     
  1583. Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection - (10/06/22)
     
  1584. Projected Impact of Expanded Long-Acting Injectable PrEP Use Among Men Who Have Sex With Men on Local HIV Epidemics - (10/06/22)
     
  1585. Provision of HIV pre-exposure prophylaxis to female patients seeking family planning services in the United States - (10/06/22)
     
  1586. HIV and Cardiac End-Organ Damage in Women: Findings from an Echocardiographic Study Across the United States - (10/06/22)
     
  1587. Earlier menopause is associated with higher risk of incident frailty in community-dwelling older women in England - (10/03/22)
     
  1588. Lenacapavir: a first-in-class HIV-1 capsid inhibitor - (10/03/22)
     
  1589. A calculated risk: Evaluating HIV resistance to the broadly neutralising antibodies10-1074 and 3BNC117 - (10/03/22)
     
  1590. Causes and outcomes of hepatic fibrosis in persons living with HIV - (10/03/22)
     
  1591. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review - 2017 - (09/30/22)
     
  1592. Exciting New Alzheimer's Treatment Study Results - (09/28/22)
     
  1593. Brain Decline & Frailty in PLWH - (09/28/22)
     
  1594. Unraveling the mechanisms of HIV-induced hearing loss - (09/27/22)
     
  1595. (Fibroscan) Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis [with NASH] - (09/27/22)
     
  1596. Two Cases of Monkeypox-Associated Encephalomyelitis - Colorado and the District of Columbia, July August 2022 - (09/26/22)
     
  1597. Dementia Care, Screening Awareness Needs Attention. PLWH are at Risk - World Alzheimers Report - (09/22/22)
     
  1598. Aging in PLWH Increased Heart Attack Risk by 30% per Decade/BUT by 85% if HCV+ - (09/22/22)
     
  1599. Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection - (09/20/22)
     
  1600. NYC Daily New Cases Monkeypox as of 9/13/22 - (09/19/22)
     
  1601. The Future of Monkeypox- Cases in the US Are Falling. There's No One Reason Why - (09/19/22)
     
  1602. CDC opening applications for Monkeypox Vaccine Equity Pilot Program - (09/19/22)
     
  1603. CDC/IDSA Monkeypox: Sept 10 - Clinical Illness; Transmission; US & Global Case Count & Trends; Race/Ethnicity Characteristics - (09/19/22)
     
  1604. New CDC guidance: Only high-risk groups should get monkeypox antiviral - (09/19/22)
     
  1605. TPOXX Resistance Risk Guidance for Tecovirimat Use Under Expanded Access Investigational New Drug Protocol during 2022 U.S. Monkeypox Outbreak - (09/19/22)
     
  1606. 2 Press Briefings by White House Monkeypox Response Team and Public Health Officials - (09/19/22)
     
  1607. New York Announces Thousands of Additional Monkeypox Vaccine Doses - Where/How to Get Vaccine in NYC - (09/19/22)
     
  1608. 50,000 monkeypox vax appointments-NYC online Friday - (09/17/22)
     
  1609. CDC opening applications for Monkeypox Vaccine Equity Pilot Program - (09/17/22)
     
  1610. Monkeypox Vac Expanded Eligibility in New York - Sex Workers - (09/16/22)
     
  1611. The Impact of Frailty on All-Cause Mortality in Patients with HIV Infection: A Systematic Review and Meta-Analysis - (09/14/22)
     
  1612. Dying at Home Due to Coronavirus Disease 2019 - (09/14/22)
     
  1613. CDC TPOXX Study Results Monkeypox Treatment - (09/13/22)
     
  1614. Menopausal Hormone Therapy and Subclinical Cardiovascular Disease in Women With and Without Human Immunodeficiency Virus - (09/12/22)
     
  1615. Hormone therapy and fractures [VMS] in postmenopausal women - (09/12/22)
     
  1616. Menopausal Hormone Therapy and Subclinical Cardiovascular Disease in Women With and Without Human Immunodeficiency Virus - (09/12/22)
     
  1617. Monkeypox Treatment & Prophylaxis in PLWH; NIAID STOMP TPOXX Study - (09/12/22)
     
  1618. Paxlovid Outcomes during the Omicron Surge in Israel- Young vs Old - (09/09/22)
     
  1619. NIH Monkeypox Vaccine Study Evaluating Dose Reductions of MVA-BN - (09/09/22)
     
  1620. Obamacare can't require coverage for some HIV drugs, federal judge rules Texas judge rules HIV [PrEP] drug mandate violates religious freedom - (09/09/22)
     
  1621. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients - (09/03/22)
     
  1622. Prevalence and risk factors for falls and fall-related injuries in the 2018 National Post-acute and Long-term Care Study (25%) & for PLWH - (09/02/22)
     
  1623. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States - (09/02/22)
     
  1624. Compassionate Use [treatment results] of Tecovirimat for the Treatment of Monkeypox Infection - (08/31/22)
     
  1625. Nearly 40% of older adult brains studied showed signs of LATE pathology - (08/31/22)
     
  1626. Failure to Address Aging in New NHAS Strategy Implementation Plan - (08/31/22)
     
  1627. Social stress contributes to accelerated aging of the immune system, study finds - (08/31/22)
     
  1628. FDA Memo Monkeypox Dose Vaccine - JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Non- replicating) - (08/30/22)
     
  1629. Monkeypox Update: FDA Authorizes Emergency Use of JYNNEOS Vaccine to Increase Vaccine Supply - (08/30/22)
     
  1630. Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding - (08/30/22)
     
  1631. Altered adipose tissue macrophage populations in people with HIV on integrase inhibitor-containing antiretroviral therapy - (08/30/22)
     
  1632. High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I - (08/30/22)
     
  1633. Risk of premature death in adulthood influenced by patterns of early childhood adversity - (08/25/22)
     
  1634. Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine - (08/25/22)
     
  1635. HHS Facilitates Agreement to Accelerate Delivery of Additional Smallpox and Monkeypox Vaccines Using New U.S. Production Line - (08/25/22)
     
  1636. Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor - (08/25/22)
     
  1637. Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice- Yearly HIV Treatment Option - (08/25/22)
     
  1638. Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir - (08/25/22)
     
  1639. HIV & Monkeypox - (08/20/22)
     
  1640. Lean NAFLD can range from 7% to 10% in the United States - (08/18/22)
     
  1641. Non-Invasive Testing - Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis - (08/18/22)
     
  1642. Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency - (08/18/22)
     
  1643. ViiV HEALTHCARE ANNOUNCES SUPPORT FOR COMMUNITY-BASED ORGANIZATIONS WITH NEW MONKEYPOX EMERGENCY RESPONSE FUND IN THE US - (08/18/22)
     
  1644. Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity - (08/18/22)
     
  1645. Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care - (08/18/22)
     
  1646. Pharma Cos. Team Up With LGBTQI+ and HIV Organizations To Address Monkeypox - (08/17/22)
     
  1647. Asymptomatic Monkeypox Reported - (08/17/22)
     
  1648. HIV Infection and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus (HBV) Co-infection: a Propensity Score-matched Cohort Study HIV/HBV confected 1.2% HCC (n=7) vs HBV Monoinfected 3.2% (n=75). - (08/17/22)
     
  1649. Principles for Ending HIV as an Epidemic in the United States: A Policy Paper of IDSA and HIVMA - (08/16/22)
     
  1650. Estimating the period prevalence of SARS-CoV-2 infection during the Omicron (BA.1) surge in New York City (NYC), January 1-March 16, 2022 - (08/16/22)
     
  1651. Non-AIDS-events in individuals with spontaneous control of HIV-1: a systematic review - (08/16/22)
     
  1652. IAC: Randomised study of switch to DTG/RPV in subjects with HIV RNA <50c/ml and archived K103N over 48 weeks - (08/15/22)
     
  1653. IAC: Causes of death for persons with HIV in an integrated healthcare system in Northern California, 2013-2017 - (08/15/22)
     
  1654. IAC: WHO LA-CAB PrEP Guidelines at IAS 2022 - (08/13/22)
     
  1655. Low Dose Monkeypox Vaccine - (08/12/22)
     
  1656. IAC: A phase IV open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to HIV-1 - (08/11/22)
     
  1657. IAC: Supporting Achievement of the State of Georgia's 25% HIV Incidence Reduction Target Among MSM: A Mathematical Model to Evaluate the Potential Impact of Long-acting Pre-exposure Prophylaxis in Atlanta - (08/11/22)
     
  1658. IAC: Assessment of cardiovascular health using the "Life's Simple 7" among the Canadian HIV and Aging Cohort study participants: a cross-sectional observational study - (08/11/22)
     
  1659. IAC: Risk factors linked to age-related comorbidities among people living with HIV aged over 40 years - (08/11/22)
     
  1660. IAC: Advanced HIV infection in the US: immune response to ART initiation - (08/11/22)
     
  1661. IAC: Audience Segmentation of Preferences for Long-Acting Injectable PrEP Among U.S. MSM: A Latent Class Analysis - (08/11/22)
     
  1662. IAC: Willingness & Preferences for Long-Acting Injectable PrEP Among US Men Who Have Sex with Men: A discrete choice experiment - (08/11/22)
     
  1663. First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable HIV Viremia in an Urban HIV Clinic - (07/28/22)
     
  1664. IAC: High prevalence of asymptomatic Omicron carriage and correlation with CD4 T cell count among adults with HIV enrolling in COVPN 3008 Ubuntu clinical trial in sub-Saharan Africa - (08/10/22)
     
  1665. IAC: HIV/HBV coinfection in pregnancy and response to antiretroviral therapy - (08/09/22)
     
  1666. IAC: Incidence and disease severity of non-alcoholic fatty liver disease among people living with HIV in Thailand - (08/09/22)
     
  1667. IAC: HIV in 2022 and beyond: A view from NIAID - non-adherence, disengagement from care, PrEP, vaccine - cure research - (08/09/22)
     
  1668. IAC: Bacterial translocation of LPS is associated with lower cognitive abilities in men living with HIV receiving antiretroviral therapy - (08/09/22)
     
  1669. IAC: Use of the Patient Generated Index to identify physical health challenges among people living with HIV - (08/09/22)
     
  1670. IAC: Early Implementation and Clinical Outcomes of Long-Acting Injectable Cabotegravir and Rilpivirine in a Safety-Net Clinic - (08/09/22)
     
  1671. IAC: Assessment of cardiovascular health using the "Life's Simple 7" among the Canadian HIV and Aging Cohort study participants: a cross-sectional observational study - (08/09/22)
     
  1672. IAC: Burden of chronic comorbidities among people living with and without HIV: disability-adjusted life years in British Columbia, Canada - (08/09/22)
     
  1673. IAC: Selection of Cabotegravir Dosing Regimens For HIV Treatment and Pre-Exposure Prophylaxis (PrEP) in Adolescents by Leveraging Adult Data - (08/09/22)
     
  1674. IAC: Association of prenatal PrEP exposure with neurodevelopmental and growth outcomes beyond 24 months among Kenyan children - (08/09/22)
     
  1675. IAC: Determinants of long-term survival in late HIV diagnosed individuals: the PISCIS Cohort study - (08/09/22)
     
  1676. IAC: High HIV incidence and mortality in a multi-site cohort of transgender women in the eastern and southern United States - (08/09/22)
     
  1677. IAC: Prevalence of adverse birth outcomes and external birth defects among women living with HIV in Malawi - (08/09/22)
     
  1678. IAC: Chronic injection opioid use increases the systemic inflammation and T cell immune activation in virally suppressed people living with HIV - each separately HIV & Opioid Use increase immune activation, inflammation - (08/09/22)
     
  1679. IAC: Arterial remodeling is associated with CD4 T cell count and plasma IL-10 in persons with HIV - (08/08/22)
     
  1680. IAC: Age Associated with Comorbidites in Spain - Risk factors linked to age-related comorbidities among people living with HIV aged over 40 years - (08/08/22)
     
  1681. IAC: Comorbidity Rate Rose 1% to 2% Yearly in 2008-2018 for HIV+ in Hospital - Mark Mascolini (08/08/22)
     
  1682. IAC: Incidence of cardiometabolic outcomes among people living with HIV initiated on INSTI versus non-INSTI antiretroviral therapies Integrase Inhibitor in First ART Poses Some Cardio Risks in Big US Analysis - Mark Mascolini(08/07/22)
     
  1683. IAC: Characterization of the absorption, metabolism, and excretion of islatravir, an HIV nucleoside reverse transcriptase translocation inhibitor, in humans - (08/07/22)
     
  1684. IAC: No pharmacokinetic interaction between islatravir and methadone - (08/07/22)
     
  1685. IAC: Resistance mutations in the HIV integrase coding region among INSTI-naïve pregnant women in Argentina: a baseline survey - (08/07/22)
     
  1686. IAC: Weight Gain After Antiretroviral Therapy Initiation in People Living with HIV - (08/07/22)
     
  1687. IAC: Weight Gain After Non-nucleoside Reverse Transcriptase-to-Integrase Inhibitor Switch in the United States - (08/07/22)
     
  1688. IAC: Current Pain, Black Race, Age Tied to Higher Frailty Risk With HIV in USA - Mark Mascolini (08/07/22)
     
  1689. IAC: INSTIs Plus PIs-But Not INSTIs Alone-Tied to Rising Body Mass Index in Children - Mark Mascolini (08/07/22)
     
  1690. IAC: Alcohol, Smoking, Drugs, Liver Disease-But Not TDF-Predict Fracture With HIV - Mark Mascolini (08/07/22)
     
  1691. IAC: Long-term Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide (F/TAF) With a Third Agent in Children Living With HIV - (08/07/22)
     
  1692. IAC: Long-term Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide (F/TAF) With a Third Agent in Children Living With HIV - (08/06/22)
     
  1693. IAC: Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Long-Acting Lenacapavir for Treatment of HIV - (08/06/22)
     
  1694. IAC: One Year Outcome of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed Children ≥ 2 Years Weighing 14 to < 25 kg - (08/06/22)
     
  1695. IAC: Long-Acting Cabotegravir + Rilpivirine Injection Site Reactions: Pooled Week 96 Results - (08/06/22)
     
  1696. IAC: Factors Associated with Healthcare Providers' Preference for Forgoing an Oral Lead-in Phase when Initiating Long-acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial - (08/06/22)
     
  1697. IAC: Initiating long-acting cabotegravir and rilpivirine in a real-world setting: clinical characteristics and switch reasons from PLHIV and health care provider perspective in the German CARLOS cohort - (08/06/22)
     
  1698. IAC: Safety and Effectiveness From the CARISEL Study: Phase 3b Hybrid-III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings - (08/06/22)
     
  1699. IAC: What women want - results [survey] from discrete choice experiment about preferred PrEP method from Khomas region of Namibia - (08/06/22)
     
  1700. IAC: "Give It a Shot": Best Practices From HCPs for Administering Long-Acting Cabotegravir + Rilpivirine - (08/05/22)
     
  1701. IAC: Low Level of Virologic Failure and Resistance in ART-Experienced, Integrase Inhibitor-Naive Participants Receiving Dolutegravir (DTG) and Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Combined Regimens: 10-Year Follow-up in the SAILING Study - (08/05/22)
     
  1702. IAC: Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study in Spain - (08/05/22)
     
  1703. IAC: Efficacy and Safety of Switching to Dolutegravir/Lamivudine by Baseline Regimen in Virologically Suppressed Adults: 48-Week Pooled Analysis - (08/05/22)
     
  1704. IAC: Efficacy and Safety of Switching to Dolutegravir/Lamivudine (DTG/3TC) in Treatment-Experienced, Virologically Suppressed PLHIV Aged ≥50 Years: Pooled Results From the TANGO and SALSA Studies - (08/05/22)
     
  1705. IAC: REAL-WORLD TREATMENT EXPERIENCE OF SINGLE TABLET DOLUTEGRAVIR/LAMIVUDINE IN THE US: RESULTS FROM THE TANDEM STUDY - (08/05/22)
     
  1706. IAC: Switching to dolutegravir/lamivudine two-drug regimen: durability and virologic outcomes in routine U.S. clinical care - (08/05/22)
     
  1707. IAC: Improvements in Patient-Reported Outcomes in Older Adults Aged ≥50 Years With HIV-1 After Switching to a 2-Drug Regimen of Fixed-Dose Combination DTG/3TC: 48-Week Results From the SALSA Study - (08/05/22)
     
  1708. IAC: A multicentre observational study to determine the safety and effectiveness of dolutegravir (DTG) use during pregnancy: Data from DOLOMITE-NEAT ID Network study - (08/05/22)
     
  1709. IAC: Pharmacokinetics of a simplified subcutaneous lenacapavir regimen versus Phase 2/3 regimen - (08/05/22)
     
  1710. IAC: Simulations for once weekly dosing of oral lenacapavir - (08/05/22)
     
  1711. IAC: Exceptional Post-Treatment HIV Control in an Acute HIV-Infected Woman During More than 15 Yearsbr Exceptional post-treatment control associated with strong NK and gamma delta ? cytotoxic T cells - (08/05/22)
     
  1712. IAC: ViiV Healthcare presents positive five-year data at AIDS 2022, demonstrating the durability of fostemsavir in people living with HIV who are heavily treatment-experienced - (08/03/22)
     
  1713. IAC: An immunological signature for subclinical atherosclerosis in people living with HIV-1 receiving antiretroviral therapy - (08/03/22)
     
  1714. IAC: Putting HBV/HCV Testing and Treatment in HIV Clinics Has Benefits in Vietnam - Mark Mascolini - (08/03/22)
     
  1715. IAC: Changes in Inflammatory Biomarkers and Baseline Variables After Switching to Dolutegravir/Lamivudine (DTG/3TC) in 2 Randomized Clinical Trials of Virologically Suppressed Adults: 48-Week Pooled Analysis - (08/03/22)
     
  1716. IAC: Disappointing Results With VRC01 bNAb Plus ART to Limit Infant Reservoirs - Mark Mascolini - (08/03/22)
     
  1717. IAC: Arrests, City Stress, Life Events Tied to Suicide Attempts in Young With HIV - Mark Mascolini (08/03/22)
     
  1718. IAC: High Loneliness Score in Half of Ontario HIV Cohort-Tied to Poor ART Adherence - Mark Mascolini - (08/03/22)
     
  1719. IAC: View on Targeted Violence, Being a Teen, Tied to PTSD in US MSM - Mark Mascolini - (08/03/22)
     
  1720. IAC: Different Factors Drive Mental Health Desires and Referrals for Black MSM - Mark Mascolini - (08/03/22)
     
  1721. IAC: Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study - (08/03/22)
     
  1722. IAC: Exceptional Post-Treatment HIV Control in an Acute HIV-Infected Woman During More than 15 Years Exceptional post-treatment control associated with strong NK and gamma delta ? cytotoxic T cells - (08/03/22)
     
  1723. IAC: Resistance Analysis of Long-Acting Lenacapavir in Highly Treatment-Experienced People With HIV After 52 Weeks of Treatment - (08/03/22)
     
  1724. IAC: Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People With HIV at 54 Weeks - (08/03/22)
     
  1725. IAC: Transgender Women (TGW) in HPTN 083: An Evaluation of Safety, Efficacy, and Gender Affirming Hormonal Therapy (GAHT) Interactions with Long-acting Cabotegravir (CAB-LA) - (08/03/22)
     
  1726. IAC: The fast and the continuous: dolutegravir-based antiretroviral therapy achieves impressive viral load suppression in CALHIV in the short- and long-term - Mark Mascolini - (08/02/22)
     
  1727. IAC: Subcortical brain volumes of children who are HIV-exposed and uninfected in the first three years of life: a South African birth cohort study - (08/02/22)
     
  1728. IAC: MSM Used HIV Sex-Negotiating Skills to Protect Themselves From COVID - Mark Mascolini - (08/02/22)
     
  1729. IAC: Combining Illicit Drugs Tied to Risky Sex in Mexican MSM - Mark Mascolini - (08/02/22)
     
  1730. IAC: Simplified PrEP Dispensing Halves Clinic Visits, Maintains or Improves Adherence in Kenya - Mark Mascolini - (08/02/22)
     
  1731. IAC: Depression, Not Gender Identity, Tied to CVD Risk in US HIV+/HIV- Women - Mark Mascolini - (08/02/22)
     
  1732. IAC: Trial Finds Neither NTX nor SOF/DCV Can Prevent SARS-CoV-2 - Mark Mascolini - (08/02/22)
     
  1733. IAC: Macrophage Activation for 2 Years After Switch From 3 to 2 Antiretrovirals - Mark Mascolini - (08/02/22)
     
  1734. IAC: Integrated Screening/Diagnosis for Alcohol, Tobacco, Depression May Extend Life With HIV - Mark Mascolini - (08/02/22)
     
  1735. IAC: Smaller Volumes of 2 Brain Regions in Children Exposed to HIV in Utero - Mark Mascolini - (08/02/22)
     
  1736. IAC: Survival in advanced AIDS patients treated with efavirenz or dolutegravir in Brazil: a multicenter, observational study - (08/01/22)
     
  1737. IAC: Efficacy and safety of dolutegravir plus emtricitabine vs combined antiretroviral therapy for the maintenance of viral suppression: 144-week results of the SIMPL'HIV trial - (08/01/22)
     
  1738. IAC: Trends in PrEP Inequity by Race and Census Region, United States, 2012-2021 - (08/01/22)
     
  1739. IAC: Dual therapy based on DRVr plus 3TC in HIV-1 naïve patients: global 48 week results from ANDES Study - (08/01/22)
     
  1740. IAC: Combined Drinking, Smoking, Depression Tied to Higher Mortality in HIV+ US Women - Mark Mascolini (08/01/22)
     
  1741. IAC: Meta-Analysis Confirms Higher COVID Death Risk With HIV - Mark Mascolini (08/01/22)
     
  1742. IAC: Low CD4 Count Linked to DAA Failure in People With HIV - Mark Mascolini - (08/01/22)
     
  1743. IAC: Frailty Linked to Subclinical Cardio Risk in Older People With/Without HIV - Mark Mascolini - (08/01/22)
     
  1744. IAC: Younger Age at Diagnosis of CVD and HTN With HIV Suggests Premature Aging - Mark Mascolini - (08/01/22)
     
  1745. IAC: Dolutegravir versus efavirenz-400 as first-line ART in Cameroon: week 192 data of NAMSAL trial - (08/01/22)
     
  1746. IAC: Switching From Integrase Inhibitor to PI Trims Weight in HIV Patient Database - Mark Mascolini - (08/01/22)
     
  1747. IAC: US Team Offers Fourth Candidate for Stem Cell Transplant HIV Cure - Mark Mascolini - (08/01/22)
     
  1748. IAC: Lp(a) in people living with HIV - (08/01/22)
     
  1749. IAC: COVID Hospital Death Risk 50% Higher With HIV, WHO Says- Risk Factors Are Under 200 CD4s, CKD, Diabetes, Hypertension - Mark Mascolini - (08/01/22)
     
  1750. IAC: Final week 192 results from the ADVANCE trial: first-line TAF/FTC/DTG, TDF/FTC/DTG vs TDF/FTC/EFV - weight gain - (08/01/22)
     
  1751. IAC: A propensity-score matched cohort study investigating premature age in people living with HIV - (08/01/22)
     
  1752. IAC: Switching From Integrase Inhibitor to PI Trims Weight in HIV Patient Database - Mark Mascolini - (08/01/22)
     
  1753. IAC: Update on neural tube defects with antiretroviral exposure in the Tsepamo Study, Botswana - (08/01/22)
     
  1754. IAC: Real-World Utilization of HIV Pre-Exposure Prophylaxis (PrEP) by Cisgender and Transgender Individuals in the United States - (08/01/22)
     
  1755. IAC: Week 48 of a phase 3 randomized controlled trial of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs dolutegravir + emtricitabine/ tenofovir disoproxil fumarate (DTG+F/TDF) as initial treatment in HIV/HBV-coinfected adults (ALLIANCE) - Mark Mascolini - (07/30/22)
     
  1756. IAC: Long-Acting CAB Maintains Superiority to TDF/FTC in Preventing HIV in Women - Mark Mascolini - (07/30/22)
     
  1757. IAC: IBALIZUMAB LONG-TERM EFFICACY IS NOT IMPACTED BY PARTIALLY ACTIVE ANTIRETROVIRALS - (07/30/22)
     
  1758. IAC: Patrick Sullivan on AIDSVu's Landmark PrEP Use Data by Race/Ethnicity - (07/30/22)
     
  1759. IAC: Pharmacokinetic Modeling and Simulation of Intramuscular and Subcutaneous Ibalizumab Delivery - (07/30/22)
     
  1760. IAC: Doxycycline PEP Cuts Bacterial STI Rate Over 60% After Condomless Sex - Mark Mascolini - (07/30/22)
     
  1761. IAC: Trends in PrEP Inequity by Race and Census Region, USA, 2012-2021 - (07/30/22)
     
  1762. IAC: Long acting injectable cabotegravir: updated efficacy and safety results from HPTN 084 - (07/30/22)
     
  1763. IAC: Week 96 Weight and Lipid Changes From Baseline Among Participants Receiving Cabotegravir + Rilpivirine Long-Acting or Comparator Therapy in the ATLAS-2M and FLAIR Studies - (07/30/22)
     
  1764. IAC: Pharmacokinetics and Tolerability of Cabotegravir and Rilpivirine Long-Acting Intramuscular Injections to the Vastus Lateralis (Lateral Thigh) Muscles of Healthy Adult Participants - (07/29/22)
     
  1765. IAC: People With HIV Now Face Chronic Disease In Living Longer - (07/29/22)
     
  1766. IAC: Long-term Integrated Analysis of B/F/TAF in Treatment-Naïve Adults With HIV Through Five Years of Follow-up - (07/29/22)
     
  1767. IAC: Lipid Parameters and Lipid-Modifying Agent Use in Participants Initiating F/TAF or F/TDF for PrEP in the DISCOVER Trial - (07/29/22)
     
  1768. IAC: Real-World HIV Renal Outcomes With TDF to TAF Switch - (07/29/22)
     
  1769. IAC: Long-Acting Cabotegravir + Rilpivirine in Older Adults: Pooled Phase 3 Week 96 Results - (07/29/22)
     
  1770. IAC: Longitudinal Analysis of Weight Change in HIV-1 Treatment-Naïve and -Experienced People Living With HIV (PLWH) Initiating/Switching to an NNRTI- or INSTI-Based Antiretroviral Therapy in Four Large Cohort Studies - (07/29/22)
     
  1771. IAC: Injection-Site Reaction Experience in Clinical Studies of People Using Lenacapavir For HIV Treatment - (07/29/22)
     
  1772. IAC: Incidence of cardiometabolic outcomes among people living with HIV initiated on INSTI versus non-INSTI antiretroviral therapies - (07/29/22)
     
  1773. IAC: Can ART switch mitigate or reverse INSTI-related weight or BMI gain in high risk people living with HIV-1? - (07/29/22)
     
  1774. IAC: Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults With HIV-1: Week 240 Results of the Phase 3 BRIGHTE Study - (07/29/22)
     
  1775. IAC: ViiV Healthcare presents positive five-year data at AIDS 2022, demonstrating the durability of fostemsavir in people living with HIV who are heavily treatment-experienced - (07/29/22)
     
  1776. IAC: AIDS 2022 News Release: Doxycycline Reduced STIs; Functional cure case; Stem Cell Transplant Cure Care; TAF vs TDF for HBV in ART regimen. - (07/29/22)
     
  1777. IAC: AVAC, BMGF, CIFF, MEDACCESS, UNITAID AND VIIV HEALTHCARE ANNOUNCE COLLABORATION TO CATALYSE MORE AFFORDABLE ACCESS TO LONG-ACTING CABOTEGRAVIR FOR HIV PREVENTION - (07/29/22)
     
  1778. IAC: ViiV HEALTHCARE AND THE MEDICINES PATENT POOL SIGN NEW VOLUNTARY LICENSING AGREEMENT TO EXPAND ACCESS TO INNOVATIVE LONG-ACTING HIV PREVENTION MEDICINE - (07/29/22)
     
  1779. IAC: AIDS 2022: New insights into HIV latent cells yield potential cure targets - (07/29/22)
     
  1780. IAC: AIDS 2022: Two HIV Patients Appear to Have Beaten Virus, Offering Hope for Cure - (07/29/22)
     
  1781. Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084 - (07/28/22)
     
  1782. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial - (07/28/22)
     
  1783. Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir - (07/28/22)
     
  1784. IAC: ViiV HEALTHCARE TO PRESENT NEW DATA FROM INNOVATIVE HIV TREATMENT AND PREVENTION PORTFOLIO AT AIDS 2022 - (07/22/22)
     
  1785. ACE inhibitors: The secret to prevent cirrhosis complications and HCC in NAFLD? Editorial - (07/25/22)
     
  1786. IAC: Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic - (07/22/22)
     
  1787. Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022 - New clinical symptoms identified - (07/22/22)
     
  1788. Title: RFA 22-0003 People Aging with HIV - (07/21/22)
     
  1789. Skeletal muscle mitochondrial dysfunction in contemporary antiretroviral therapy: a single cell analysis - (07/19/22)
     
  1790. Integrase Strand Transfer Inhibitors Are Associated With Lower Risk (21%) of Incident Cardiovascular Disease in People Living With HIV - (07/19/22)
     
  1791. Integrase inhibitors hand us a new HIV clinical puzzle - Comment - (07/18/22)
     
  1792. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium - (07/18/22)
     
  1793. Pfizer and BioNTech Announce Omicron-Adapted (BA.5) COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron - (07/14/22)
     
  1794. Pfizer and BioNTech Announce Omicron-Adapted (BA.5) COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron - (07/14/22)
     
  1795. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children - (07/11/22)
     
  1796. Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study - (07/07/22)
     
  1797. Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers - (07/07/22)
     
  1798. Accelerated aging [by 5 years] with HIV begins at the time of initial HIV infection - (07/05/22)
     
  1799. EASL: Simvastatin May Boost Beta Blocker Carvedilol Impact on Portal Hypertension, Modulates Systemic Inflammation - Mark Mascolini - (07/01/22)
     
  1800. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial - (06/30/22)
     
  1801. EASL: Health-related quality of life is impaired in people living with HIV and hepatic steatosis - (06/30/22)
     
  1802. Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor - (06/27/22)
     
  1803. Greater risk of post-vaccination breakthrough severe COVID-19 illness in people with HIV and CD4 <350 - (06/13/22)
     
  1804. Failing Fragmented HIV Care Continuum for Aging & Elderly PLWH & all PLWH - (06/13/22)
     
  1805. Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States - (06/13/22)
     
  1806. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19 - (06/13/22)
     
  1807. Greater risk of post-vaccination breakthrough severe COVID-19 illness in people with HIV and CD4 <350 - (06/13/22)
     
  1808. CROI: Clinical Pharmacology at CROI 2022 - Courtney V. Fletcher, Pharm.D. Professor UNMC Center for Drug Discovery University of Nebraska Medical Center - (03/28/22)
     
  1809. CROI: CROI 2022 and HIV prevention - NATAP Report by Renee Heffron, PhD and Connie Celum, MD, University of Washington (03/28/22)
     
  1810. CROI: Summary from virtual CROI 2022 for HIV and liver disease Hepatitis elimination for 2030 on track? Is fatty liver disease a growing concern? New insights from CROI 2022. - Prof. Dr. Jurgen K. Rockstroh Department of Medicine I University Hospital Bonn Venusberg-Campus 1 53127 Bonn Germany - (03/21/22)
     
  1811. CROI: HIV Prevention and Resistance on PrEP - By Christina K. Psomas MD PhD - (04/20/22)
     
  1812. Health Department Launches Monkeypox Vaccine Clinic for People Who May Have Been Exposed to Monkeypox - (06/25/22)
     
  1813. Lenacapavir for HIV-1 - Potential Promise of a Long-Acting Antiretroviral Drug - EDITORIAL - (06/25/22)
     
  1814. Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV - (06/25/22)
     
  1815. A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) - (06/21/22)
     
  1816. THE EFFECT OF MENOPAUSAL STATUS, AGE, AND HIV ON NON-AIDS COMORBIDITY BURDEN AMONG U.S. WOMEN - (06/20/22)
     
  1817. Disability Measured in PLWH in London: 39.5% Severe Disability; 70.5% Moderate Disability - (06/03/22)
     
  1818. bNabs Combination Study new reports & antibody-resistance - (06/02/22)
     
  1819. PLWH Had 3 X Worse Fatigue. Fatigue associated with Worse Cognition, Daily Functioning - (06/02/22)
     
  1820. Medicines Patent Pool, ViiV Healthcare enter negotiations over voluntary licensing of cabotegravir Long-Acting for HIV pre-exposure prophylaxis - (06/01/22)
     
  1821. PLWH Had 3x Worse Fatigue. Fatigue Associated with Worse Cognition (but not in HIV-neg.) & Worse Daily Function in PLWH - (06/01/22)
     
  1822. COVID 5th Wave So Africa - Boosters "Stay Up-To-date" White House Briefing - (06/01/22)
     
  1823. Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors - (06/01/22)
     
  1824. Brain Affects by Integrase Inhibitors & ARTs - Altered neuropsychological performance and reduced brain volumetrics in people living with HIV on integrase strand transfer inhibitors - (05/31/22)
     
  1825. Maraviroc-Does it Improve Cognitive Function? New Research This Week in Mice - (05/31/22)
     
  1826. Interferon therapy shows striking results against COVID-19 - (05/31/22)
     
  1827. Peginterferon Lambda Single Injection for Newly Diagnosed COVID - TOGETHER Phase 3 Study - (05/31/22)
     
  1828. Interferon [lambda] therapy shows striking results against COVID-19 - (05/31/22)
     
  1829. Biden Administration Announces Launch of First COVID Federally-Supported Test to Treat Site - (05/26/22)
     
  1830. CDC 2020 HIV Surveillance report - COVID Impact, Racial Disparities in Low Viral Suppression Rates, Death Rates, Linkage to care, Care, PrEP, Geography - (05/26/22)
     
  1831. Maraviroc Restores Middle Age Memory Loss in Mice, "Could Be Used To Reverse Cognitive Deficits Caused by HIV" - (05/26/22)
     
  1832. CROI: Increased Physical Strength is Associated with Improved Brain Integrity in Older People Living with HIV - (05/23/22)
     
  1833. Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapies - (05/24/22)
     
  1834. Molnupiravir for the Treatment of COVID-19 in Immunocompromised Patients: Efficacy, Safety, and Virology Results from the Phase 3 MOVe-OUT Trial - (05/24/22)
     
  1835. PrEP for Individuals who Inject Drugs - (05/18/22)
     
  1836. Associations Between Central Obesity and Lifelong Antiviral Therapy in Adults Living With HIV Acquired From Early Childhood - (05/16/22)
     
  1837. FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV - Press Release - (05/16/22)
     
  1838. Carotid Intima-Media Thickness and Midlife Cognitive Function- - (05/16/22)
     
  1839. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection - (05/13/22)
     
  1840. NAFLD Is Increasingly Affecting Patients With HIV - (05/11/22)
     
  1841. Duke's Klotman is under consideration as the next NIH head - (05/09/22)
     
  1842. New Funding for HIV+ Women's Program: HIV Prevention & Care for Black Women - (05/05/22)
     
  1843. Abnormal cognitive aging in people with HIV: Evidence from Data Integration between two countries' cohort studies - (05/03/22)
     
  1844. HIV is associated with elevated FibroScan-AST (FAST) score - (05/03/22)
     
  1845. TaiMed Receives from Theratechnologies Notification of Returning Commercialization Rights for Trogarzo in European Territory - (04/28/22)
     
  1846. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study - (04/28/22)
     
  1847. THERATECHNOLOGIES TO FOCUS ITS COMMERCIALIZATION ACTIVITIES ON THE NORTH AMERICAN TERRITORY - Trogarza - (04/27/22)
     
  1848. HIV Neurocognitive Impairment Starts at 40-50 Years Old - (04/22/22)
     
  1849. Coronavirus (COVID-19) Update: FDA Authorizes First COVID-19 Diagnostic Test Using Breath Samples - (04/20/22)
     
  1850. Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis - (04/20/22)
     
  1851. Screening HIV patients at risk for NAFLD using MRI-PDFF and transient elastography: a European multicenter prospective study - patients with MetS had the highest prevalence of NAFLD (71%) - (04/20/22)
     
  1852. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association - (04/20/22)
     
  1853. Testosterone Therapy is Associated With Depression, Suicidality, and Intentional Self-Harm: Analysis of a National Federated Database - (04/18/22)
     
  1854. Real-world safety of pre-exposure prophylaxis for HIV - Comment - (04/18/22)
     
  1855. HIV Death Rates Almost Double in NYC Compared to General Population; Heart Disease is A Leading Increasing Cause of Death in NYC - (04/18/22)
     
  1856. Overall vertical transmission of HCV, transmission net of clearance, and timing of transmission. - (04/18/22)
     
  1857. "clinicians must recognize that patients with HIV have a unique CVD risk profile that may dictate different approaches" - need for tailored cardiovascular prevention strategies in patients with HIV - (04/18/22)
     
  1858. Brain Decline in Frail PLH Not Detectable By Standard Neuropsych Tests - (04/18/22)
     
  1859. Coronavirus (COVID-19) Update: FDA Authorizes First COVID-19 Diagnostic Test Using Breath Samples - (04/18/22)
     
  1860. New York State Department of Health Announces Emergence of Recently Identified, Highly Contagious Omicron Subvariants in New York and Urges Continued Vigilance Against COVID-19 - (04/18/22)
     
  1861. Reduced Cardiac Strain Among Women with HIV Relates to Inflammatory Monocyte Activation - (04/13/22)
     
  1862. SUBCLINICAL ATHEROSCLEROSIS AND IMMUNE ACTIVATION AMONG US FEMALES VS MALES WITH HIV women have more immune activation - (04/13/22)
     
  1863. Aging & Immune System: Women-Specific Aspects (higher inflammation; estrogen; menopause; response to HIV by women) - (04/13/22)
     
  1864. CV Risk Factors Common Among 50 Yr Old PLWH - "Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial" - (04/13/22)
     
  1865. Among WWH in the REPRIEVE trial, more advanced reproductive age is associated with metabolic dysregulation and region of residence - (04/13/22)
     
  1866. Health systems must adapt to the special needs of ageing people with HIV and comorbid diseases to improve both patient-centred and population-centred health outcomes - (04/13/22)
     
  1867. Double the Relative Risk for HIV+ Women for Heart Attacks Highest rates at 65-74 Years Old - (04/12/22)
     
  1868. Arc of Aging with HIV 1996-2022: from promise to disappointment & despair: a broken HIV healthcare system. Slide talk by Jules Levin - (04/11/22)
     
  1869. SAGE-718 in Parkinson's Disease Mild Cognitive Impairment: Results from the Phase 2 PARADIGM Study (Part A) - Improvements Observed in Study - (04/08/22)
     
  1870. NYC DOH COVID PrEP, Treatment - Evusheld for pre-exposure prophylaxis - (04/08/22)
     
  1871. Therapeutic Management of Nonhospitalized Adults With COVID-19 - (04/06/22)
     
  1872. HIV Funding from Lil Was X & Elton John at Oscar Post Party
     
    Lil Nas X Teams Up with Gilead COMPASS Initiative® to Raise Nearly $500,000 for Community Organizations Addressing HIV in the Southern United States     - (04/05/22)
     
  1873. SARS-CoV-2 Humoral and Cellular Immune Responses of Patients With HIV After Vaccination With BNT162b2 mRNA COVID-19 Vaccine in the Tel-Aviv Medical Center - (04/05/22)
     
  1874. Cognitive Impairment at Midlife in Long-Term Cannabis Users - (04/05/22)
     
  1875. Quality of Life Worse for Long-Term Survivors; Frailty/Function worse for >65 - (04/01/22)
     
  1876. CROI: Oral TDF/FTC Provides Early Mucosal Protection In Both On- Demand And Daily Regimen - (04/01/22)
     
  1877. CROI: Contributions to the Decline in HIV Incidence among GBM in the UK: A Modelling Study - HIV Elimination in 25 Years - (03/31/22)
     
  1878. CROI: DEEPHIV: DEEP LEARNING TO PREDICT DDI RELEVANCE FOR ARVS - (03/31/22)
     
  1879. CROI: Machine Learning Quantifies Accelerated White Matter Aging in Persons with HIV - (03/31/22)
     
  1880. ViiV HEALTHCARE ANNOUNCES US FDA APPROVAL OF TRIUMEQ PD, THE FIRST DISPERSIBLE SINGLE TABLET REGIMEN CONTAINING DOLUTEGRAVIR, A ONCE-DAILY TREATMENT FOR CHILDREN LIVING WITH HIV - (03/29/22)
     
  1881. ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg - (03/29/22)
     
  1882. CROI: Long acting doravirine for treatment and prevention of vaginal HIV transmission - (03/30/22)
     
  1883. CROI: CROI 2022 Key Aging & Comorbidities Highlights - (03/28/22)
     
  1884. CROI: CROI 2022 Aging & HIV Symposium - (03/28/22)
     
  1885. Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere - (03/28/22)
     
  1886. Gilead's Aging Positively 2nd Round Grantees Announced - (03/28/22)
     
  1887. Excess cancer prevalence in men with HIV: A nationwide analysis of Medicaid data - (03/28/22)
     
  1888. Mortality Is Greater For Some PLWH: African-Americans, Elderly, Frail, Comorbidities, Women - (03/28/22)
     
  1889. ViiV HEALTHCARE ANNOUNCES LABEL UPDATE FOR ITS LONG-ACTING HIV TREATMENT, CABENUVA (CABOTEGRAVIR, RILPIVIRINE), TO BE INITIATED WITH OR WITHOUT AN ORAL LEAD-IN PERIOD - (03/24/22)
     
  1890. Senolytics for Poets - (03/24/22)
     
  1891. Jak-STAT Inhibition: Therapeutic Intervention for Inflammaging and Comorbidities in PWH - (03/24/22)
     
  1892. ViiV HEALTHCARE ANNOUNCES LABEL UPDATE FOR ITS LONG-ACTING HIV TREATMENT, CABENUVA (CABOTEGRAVIR, RILPIVIRINE), TO BE INITIATED WITH OR WITHOUT AN ORAL LEAD-IN PERIOD - (03/24/22)
     
  1893. CROI: IMPACT OF SVR WITH DAAs IN COINFECTED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS - (03/22/22)
     
  1894. CROI: CROI Symposium: Aging & HIV "care of PLWH has NOT kept up with the reality of this aging population" - (03/23/22)
     
  1895. CROI: IMPACT OF SVR WITH DAAs IN COINFECTED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS - (03/22/22)
     
  1896. CROI: ADHERENCE IN THE ACTG A5360 HCV MINIMAL MONITORING (MINMON) TRIAL - (03/22/22)
     
  1897. CROI: CANNABIS USE AND HEPATIC STEATOSIS BY MRI-PDFF - (03/22/22)
     
  1898. CROI: Regional Variation in HBV Prevalence in People Living with HIV in Botswana - (03/22/22)
     
  1899. CROI: LOW RATES OF HEPATITIS B VACCINATION AMONG PEOPLE WITH HIV - (03/22/22)
     
  1900. CROI: Randomized Trial of HBV Revaccination in MSM Born in the Neonatal Vaccination Era - (03/22/22)
     
  1901. Alzheimer's disease and related dementias among older U.S. Medicare beneficiaries with and without HIV - (03/21/22)
     
  1902. CROI: NEW HEPATITIS B INFECTION AMONG HIV PATIENTS: WHO IS AT RISK? - (03/21/22)
     
  1903. CROI: ACTG A5324: A RANDOMIZED TRIAL OF ART INTENSIFICATION FOR COGNITIVE IMPAIRMENT IN PWH - Mark Mascolini (03/21/22)
     
  1904. CROI: FEASIBILITY AND VIRAL RESPONSE TO TREATING ACUTE/EARLY HIV IN A MULTINATIONAL STUDY - (03/21/22)
     
  1905. CROI: IMPACT OF SVR WITH DAAs IN COINFECTED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS - (03/21/22)
     
  1906. CROI: Integration of HIV and HCV Services with Medication for Opioid Use Disorder in the U.S. - (03/21/22)
     
  1907. EACS: SOLAR 3D: A PROSPECTIVE STUDY SWITCHING TO DTG/3TC FROM 3- OR 4-DRUG ART FOR MAINTENANCE OF VIRAL SUPPRESSION WITH HISTORIC M184V/I MUTATION AND PRIOR VIROLOGICAL FAILURES: 48 WEEK PRIMARY ENDPOINT RESULTS - (03/21/21)
     
  1908. CROI: Integration of HIV and HCV Services with Medication for Opioid Use Disorder in the U.S. - (03/18/22)
     
  1909. CROI: A RETROSPECTIVE ANALYSIS OF BONE LOSS IN EMTRICITABINE/TENOFOVIR THERAPY FOR HIV PrEP - (03/18/22)
     
  1910. Finding the 'Tipping Point' to Permanent Kidney Damage - (03/15/22)
     
  1911. Long- Covid in PLWH & Immune Responses in PLWH Recovering From COVID Prior to Vaccine Availability - (03/15/22)
     
  1912. CROI: SARS-CoV-2 CSF N Antigen Detection is Associated with CNS Inflammation in Neuro-COVID - (03/15/22)
     
  1913. CROI: NIH Launches Clinical Trial of Three mRNA HIV Vaccines - (03/14/22)
     
  1914. South Africa Approves Dapivirine Vaginal Ring for Use by Women - (03/14/22)
     
  1915. CROI: HIV-1 RNA TRANSCRIPTS IN CSF CD4+ T CELLS, NOT MONOCYTES, ARE LINKED TO BRAIN INJURY - (03/14/22)
     
  1916. 210,000 PLWH in USA Over >60 years Old - (03/11/22)
     
  1917. CROI: Treatment with Broadly Neutralizing Antibodies in Children with HIV in Botswana (The Tatelo Study) - (03/11/22)
     
  1918. CROI: NON-OBESE NAFLD IS ASSOCIATED WITH HIGHER SCD14 CONCENTRATIONS IN ADULTS WITH HIV - (03/11/22)
     
  1919. CROI: 11% - HIGH INCIDENCE RATE OF CT-MEASURED NAFLD IN MACS MEN WITH AND WITHOUT HIV INFECTION - (03/11/22)
     
  1920. CROI: DETERMINANTS OF LIVER STEATOSIS IN PEOPLE LIVING WITH HIV ON ANTIRETROVIRAL THERAPY - ALT matters - (03/11/22)
     
  1921. CROI: IMPACT OF NASH ON THE SURVIVAL OF PEOPLE LIVING WITH HIV - (03/11/22)
     
  1922. CROI: PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE VERTICALLY HIV-INFECTED YOUTHS - (03/11/22)
     
  1923. CROI: Effect of Tenofovir on T-cell Maturational Subsets in Long Term Aviraemic HIV Adults - (03/11/22)
     
  1924. CROI: NEUROSYMPTOMATIC HIV-1 CSF ESCAPE ASSOCIATES WITH REPLICATION IN CNS CD4+ T CELLS - (03/11/22)
     
  1925. Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose - (03/08/22)
     
  1926. More alcohol, less brain: Association begins with an average of just one drink a day - (03/07/22)
     
  1927. CROI: Effect of Tenofovir on T-cell Maturational Subsets in Long Term Aviraemic HIV Adults - (03/08/22)
     
  1928. CROI: NEUROSYMPTOMATIC HIV-1 CSF ESCAPE ASSOCIATES WITH REPLICATION IN CNS CD4+ T CELLS - (03/07/22)
     
  1929. CROI: PBR28 PET IMAGING IN PEOPLE WHO STARTED ART DURING ACUTE VERSUS CHRONIC HIV INFECTION - (03/07/22)
     
  1930. CROI: HPV Genotyping in a Study of Adjunctive Vaccine For Treatment of Cervical Dysplasia - (03/07/22)
     
  1931. More alcohol, less brain: Association begins with an average of just one drink a day - (03/07/22)
     
  1932. Evaluation of Computerized Cognitive Training and Cognitive and Daily Function in Patients Living With HIVA Meta-analysis - (03/07/22)
     
  1933. Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment - (03/07/22)
     
  1934. More alcohol, less brain: Association begins with an average of just one drink a day - (03/07/22)
     
  1935. Evaluation of Computerized Cognitive Training and Cognitive and Daily Function in Patients Living With HIVA Meta-analysis - (03/07/22)
     
  1936. Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment - (03/07/22)
     
  1937. CROI: STATIN USE IN ART-TREATED HIV REVEALS AN ALTERED MACROPHAGE TRANSCRIPTOMIC PROFILE - (03/04/22)
     
  1938. CROI: PREVALENCE OF ANEMIA AND RISK FACTORS IN PEOPLE WITH HIV IN THE MODERN ART ERA: aging, Blacks, women, Hispanics have higher risk - (03/04/22)
     
  1939. CROI: Impaired response of memory Treg to HDL is associated with high cardiovascular disease risk in persons with HIV - (03/04/22)
     
  1940. CROI: Carl Dieffenbach Highlights Aging & Comorbidities for PLWH, Frailty & Research & the Need for Better Care: "care of people living with HIV has NOT kept up with the reality of this aging population" - (03/04/22)
     
  1941. Booster Waning Benefit vs Omicron UK Study NEJM just published - Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant - (03/04/22)
     
  1942. CROI: PERINATAL HIV-1 TRANSMISSION IN FRANCE: U=U FOR MOTHERS ON ART FROM CONCEPTION....no perinatal transmission in this analysis - (03/03/22)
     
  1943. CROI: LONG-ACTING INJECTABLE FOR PREVENTION OF HIV AND UNPLANNED PREGNANCY - (03/02/22)
     
  1944. CROI: Phase 2b Efficacy Trial of Mosaic HIV-1 Vaccine Regimen in African Women (Imbokodo) - (03/02/22)
     
  1945. CROI: PERINATAL HIV-1 TRANSMISSION IN FRANCE: U=U FOR MOTHERS ON ART FROM CONCEPTION - (03/02/22)
     
  1946. CROI: ARCHIVED RESISTANCE AND RESPONSE TO <40 C/ML AND TND - DTG/3TC FDC AT WEEK 48 IN SALSA - (03/01/22)
     
  1947. CROI: Estimating the Lifetime Risk of a Diagnosis of HIV Infection in the United States, Blacks have highest risk - (03/01/22)
     
  1948. Risk, resiliency in aging brain focus of $33 million grant - (03/01/22)
     
  1949. Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir Due to Vial Compatability Issues - (03/01/22)
     
  1950. CROI: Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques Ad26/MVA+PGT121+Vesatolimod - (03/01/22)
     
  1951. CROI: Development of Viral Biomarkers in SHIV Infected Non-Human Primates in Reservoirs - (03/01/22)
     
  1952. CROI: Adolescent and Parent Experiences with Long-acting Injectables in the MOCHA Study - (03/01/22)
     
  1953. CROI: The FUNCFRAIL Score to discriminate Frailty in Older Adults with HIV - (02/28/22)
     
  1954. CROI: Potent Targeted Activator of Cell Kill (TACK) Molecules Eliminate HIV Infected Cells - (02/28/22)
     
  1955. CROI: 2DR vs. 3DR INTEGRASE INHIBITOR-BASED REGIMENS INITIATION AND CD4+/CD38+ RATIO RECOVERY - (02/26/22)
     
  1956. CROI: CORONARY FLOW RESERVE ON DTG/ABC/3TC AT BASELINE AND AFTER SWITCH TO BIC/FTC/TAF - (02/26/22)
     
  1957. CROI: EFdA OFFERS COMPLETE PROTECTION FROM REPEATED PENILE HIV CHALLENGES - (02/26/22)
     
  1958. CROI: Association of Sleep Disruption with Kynurenine Pathway Activation in Women Living with HIV - (02/26/22)
     
  1959. CROI: Lifetime HIV Risk 1 in 120 in US, Highest in Black and Hispanic Males - Mark Mascolini (02/26/22)
     
  1960. CROI: REVERSIBILITY OF CENTRAL NERVOUS SYSTEM ADVERSE EVENTS IN COURSE OF ART - (02/25/22)
     
  1961. CROI: Atrial Fibrillation Risk Factors Among Patients in HIV Care in the United States - (02/25/22)
     
  1962. CROI: Sleep and Frailty Among Men with and Without HIV - poor sleep for PLWH - (02/25/22)
     
  1963. CROI: POOR SLEEP IS LINKED TO CVD RISK IN PLWH IN A SOUTHWESTERN US CLINIC - 40% Have Sleeping Difficuties - (02/25/22)
     
  1964. CROI: A novel comorbidity index predicts cognitive change in people with chronic HIV - (02/24/22)
     
  1965. CROI: Aging Symposium 2022 - Jules Levin slides, talk - NATAP - National AIDS Treatment Advocacy Project (02/24/22)
     
  1966. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants (02/24/22)
     
  1967. CROI: Impact of Rheumatologic Therapies on Cardiovascular Outcomes in People with HIV (02/24/22)
     
  1968. CROI: Inflammatory clusters are associated with multimorbidity and Cardiovascular disease in People with HIV on effective treatment (02/24/22)
     
  1969. CROI: Effects of Air Pollutants on Neuroimaging Measures Diverge by HIV Status: poverty-neighborhood area & HIV effect brain structure (02/24/22)
     
  1970. CROI: HIV-INDUCED CELLULAR SENESCENCE IN PLWH IS DECREASED EX VIVO BY D+Q SENOLYTIC DRUGS (02/24/22)
     
  1971. CROI: Associations Between Plasma Biomarkers and Neurocognition in ART-Treated PWH (02/24/22)
     
  1972. CROI: COUNTERFACTUAL ESTIMATION OF CAB-LA EFFICACY AGAINST PLACEBO USING EXTERNAL TRIAL DATA (02/24/22)
     
  1973. CROI: INFLAMMATION AND IMMUNE ACTIVATION NOT DRIVEN BY ON-ART HIV-SPECIFIC IMMUNE RESPONSES - "Die is Cast Before ART" HIV Long-Lasting Immune Dysreguation (02/24/22)
     
  1974. CROI: A RANDOMIZED TRIAL OF DTG PLUS DRV/c AS A SWITCH STRATEGY IN SUBJECTS WITH MDR HIV-1 (02/24/22)
     
  1975. CROI: Associations Between Plasma Biomarkers and Neurocognition in ART-Treated PWH (02/24/22)
     
  1976. CROI: PRECLINICAL STUDIES TOWARD A PHASE I/IIA TRIAL USING ANTI-HIV DUOCAR-T CELL THERAPY (02/24/22)
     
  1977. CROI: Choice and Adherence to Dapivirine Ring or Oral PrEP by Young African Women in REACH (02/23/22)
     
  1978. CROI: The Bi-directional Effects of Hormone Therapy and PrEP in Transgender Individuals (02/23/22)
     
  1979. CROI: NEURAL TUBE DEFECTS AND PRENATAL EXPOSURE TO DOLUTEGRAVIR: UNITED STATES, 2008-2019 (02/23/22)
     
  1980. CROI: No Interactions Between Hormone Therapy and PrEP in Transgender Women or Men - Mark Mascolini (02/23/22)
     
  1981. CROI: IMPACT OF MATERNAL HIV/HBV CO-INFECTION ON PREGNANCY AND INFANT OUTCOMES (02/23/22)
     
  1982. Young PLWH at Low-Risk for CVD: 50% have Plaque 23% Vulnerable Plaque, CAC in 35% - (02/22/22)
     
  1983. CROI: IMPACT OF MATERNAL HIV/HBV CO-INFECTION ON PREGNANCY AND INFANT OUTCOMES (02/23/22)
     
  1984. CROI: The role of HIV/HBV/HCV triple infection in end stage liver disease (ESLD) and all cause mortality in Europe (02/23/22)
     
  1985. CROI: Growth of infants with perinatal exposure to maternal DTG vs EFV and TDF vs TAF: the randomized IMPAACT 2010 trial - (02/22/22)
     
  1986. CROI: ACTG A5351s: Effect of Immune-Modulatory Interventions on CMV Replication during ART - (02/22/22)
     
  1987. CROI: More Adverse Birth Outcomes With COVID Plus HIV in Botswana - Mark Mascolini (02/22/22)
     
  1988. CROI: Post-COVID19 Quality of Life: Low Satisfaction With Physical and Mental Health Status - (02/22/22)
     
  1989. CROI: SARS-CoV-2 Prevalence Similar in Adults and Children in 15-Site US Study - Mark Mascolini (02/22/22)
     
  1990. CROI: From NAFLD to MAFLD: implications of change in terminology in PWH - (02/22/22)
     
  1991. CROI: NAFLD IS COMMON AND ASSOCIATED WITH CARDIOVASCULAR RISK IN REPRIEVE PARTICIPANTS - (02/22/22)
     
  1992. CROI: HBIg-Free Strategy Prevents Vertical HBV Transmission-If Mothers Start TDF Soon Enough - Mark Mascolini (02/22/22)
     
  1993. CROI: Proteinuria Is Common Among People with HIV With Controlled Viremia - (02/22/22)
     
  1994. CROI: MUSCLE QUALITY AND PHYSICAL FUNCTION IN MEN WITH AND WITHOUT HIV - (02/22/22)
     
  1995. CROI: IS THERE A ROLE OF NOVEL ART REGIMENS IN THE DECLINING PREVALENCE OF HAND? HAND 22% Today in Italy- Asymptomatic Remains Prevalent 10%-24% - (02/22/22)
     
  1996. CROI: SERUM AND CSF ULTRA-SENSITIVE DETECTION OF NFL AND ALZHEIMER'S BIOMARKERS IN PLWH - (02/22/22)
     
  1997. CROI: Triple & Double bNAbs Studies - (02/21/22)
     
  1998. CROI: Injectable, Biodegradable, Removable PrEP/Contraceptive Tested in Mice - Mark Mascolini (02/21/22)
     
  1999. CROI: HIV-Infected Cells Recirculate Throughout Organs During Suppressive ART - Mark Mascolini (02/21/22)
     
  2000. CROI: Lenacapavir Shots or Tabs Control HIV in First-Line ART Combinations - Mark Mascolini (02/21/22)
     
  2001. CROI: Most Large HIV Molecular Clusters in US Primarily Involve MSM - Mark Mascolini (02/21/22)
     
  2002. CROI: Dolutegravir Pharmacokinetics In People with HIV Receiving Daily 1HP for Latent TB Treatment (ACTG A5372) - (02/20/22)
     
  2003. CROI: The Impact of COVID-19 on Adverse Birth Outcomes in Botswana by HIV Status - (02/20/22)
     
  2004. CROI: Role of Renin-Angiotensin-Aldosterone System Activation in Arterial Inflammation in HIV - (02/20/22)
     
  2005. Sex differences in type 2 diabetes mellitus prevalence among persons with HIV: women with HIV appear to have greater risk & >65 worse - (02/18/22)
     
  2006. CROI: DURABILITY OF SARS-COV-2 mRNA VACCINE IMMUNE RESPONSE IN PLWH WITH ADVANCED DISEASE - (02/18/22)
     
  2007. CROI: Immunogenicity and reactogenicity to COVID-19 mRNA vaccine additional dose in PLWH - (02/18/22)
     
  2008. CROI: SARS-CoV-2 Vaccine Immunogenicity in PLWH in The Netherlands & age, CD4, HIV viral load effects - (02/18/22)
     
  2009. CROI: Sotrovimab mAb Limits Progression to Severe COVID Regardless of Serostatus - Mark Mascolini (02/18/22)
     
  2010. CROI: Intramuscular Sotrovimab Noninferior to IV for Mild/Moderate COVID - Mark Mascolini (02/18/22)
     
  2011. CROI: One Quarter Ordering Free HIV Self-Tests in US Never Tested Before - Mark Mascolini (02/18/22)
     
  2012. CROI: Choice and Adherence to Dapivirine Ring or Oral PrEP by Young African Women in REACH: 67% prefer ring vs 31% oral PrEP - (02/18/22)
     
  2013. CROI: PHASE III TRIAL OF MOLNUPIRAVIR IN ADULTS WITH MILD SARS-COV2 INFECTION IN INDIA - (02/18/22)
     
  2014. CROI: PREDICTORS OF NEURODEVELOPMENT IN HIV-EXPOSED UNINFECTED INFANTS - (02/18/22)
     
  2015. CROI: Casirivimab and Imdevimab Combination Provides Long-Term Protection Against COVID-19 - phase 3 study in preventing COVID in household contacts of infected individuals - (02/18/22)
     
  2016. CROI: Camostat Does Not Relieve COVID Symptoms or Clear Virus in Placebo Trial - Mark Mascolini(02/17/22)
     
  2017. CROI: Dolutegravir Reversibly Induces Mitochondrial Fragmentation and Toxicity In Vitro - (02/17/22)
     
  2018. CROI: IMPROVING INTESTINAL BARRIER USING GLP-2 AGONIST REDUCES ARTERIAL INFLAMMATION IN PWH - (02/16/22)
     
  2019. CROI: Dual Monoclonal Antibody Cuts COVID Risk in 8-Month Placebo Trial - Mark Mascolini (02/16/22)
     
  2020. CROI: COVID-19 BOOSTER VACCINE EFFECTIVENESS IN PEOPLE WITH AND WITHOUT IMMUNE DYSFUNCTION - in reducing breakthrough, duration of benefit (02/16/22)
     
  2021. CROI: 00136: A RANDOMIZED TRIAL OF SWITCHING TREATMENT-EXPERIENCED ADULTS FROM PI/r TO DTG - (02/17/22)
     
  2022. CROI: Bolstering ART With DTG +/- MVC Does Not Help Neurocognitive Performance - Mark Mascolini (02/16/22)
     
  2023. CROI: LONGITUDINAL MODELING OF EARLY HIV BURDEN IN THE CENTRAL NERVOUS SYSTEM (02/16/22)
     
  2024. CROI: New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor - press release (02/16/22)
     
  2025. CROI: Lenacapavir as part of a Combination Regimen in Treatment-Naï ve People with HIV: Week 54 Results (02/16/22)
     
  2026. CROI: Big Drops in HIV/STI Testing (But Sometimes Not Diagnoses) When COVID Arrived - Mark Mascolini (02/16/22)
     
  2027. CROI: African NADIA Trial Favors 2nd-Line TDF Over ZDV, and DRV/r Over DTG - Mark Mascolini (02/16/22)
     
  2028. CROI: Switching From NNRTI to DTG-Even With Same NRTIs-Superior to PI - Mark Mascolini (02/16/22)
     
  2029. CROI: Phase 1 Study of Long-Acting 3BNC117 and 10-1074 in Viremic Adults Living With HIV (02/16/22)
     
  2030. CROI: Lenacapavir as part of a Combination Regimen in Treatment-Naï ve People with HIV: Week 54 Results (02/16/22)
     
  2031. POST-ACUTE SEQUELAE AND ADAPTIVE IMMUNE RESPONSES IN PEOPLE LIVING WITH HIV RECOVERING FROM SARS-COV-2 INFECTION - (02/16/22)
     
  2032. CROI: PHASE I PK, SAFETY, AND ACCEPTABILITY STUDY OF A 90-DAY TENOFOVIR VAGINAL RING (02/16/22)
     
  2033. CROI: EFFECT OF DIRECT-ACTING ANTIVIRALS ON HCV INCIDENCE AMONG PEOPLE LIVING WITH HIV (02/16/22)
     
  2034. CROI: COVID Pushes USA Farther Off Course to Meet HCV Elimination Goals - Mark Mascolini (02/16/22)
     
  2035. CROI: Asymptomatic SARS-CoV-2 Infection is Extremely Common among People with HIV (02/16/22)
     
  2036. CROI: Long COVID Definition - POST-ACUTE SEQUELAE OF SARS-COV-2: CLINICAL CONDITION COMPARISON IN A MATCHED COHORT (02/16/22)
     
  2037. CROI: COVID Symptoms Reported Lasting Longer in US Than South Africa, Peru - Mark Mascolini (02/16/22)
     
  2038. CROI: Treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer (02/15/22)
     
  2039. CROI: Treating Anal Lesions in HIV+ Cuts Anal Cancer Rate 57% in Randomized Trial - Mark Mascolini (02/15/22)
     
  2040. CROI: Outpatient Clinics Efficient in Spotting Recent HIV in 3 African Countries - Mark Mascolini (02/15/22)
     
  2041. CROI: RNA Assay Spots HIV Earlier in CAB-LA PrEP Users, May Avert Resistance - Mark Mascolini (02/15/22)
     
  2042. CROI: CAB-LA PrEP Keeps Advantage Over TDF/FTC in 1-Year Unblinded Phase- Seven Breakthrough Infections Despite On-Time CAB-LA Injections - Mark Mascolini (02/15/22)
     
  2043. CROI: ISLATRAVIR DISTRIBUTION IN MUCOSAL TISSUES, PBMC & PLASMA AFTER MONTHLY ORAL DOSING (02/15/22)
     
  2044. CROI: PHASE IIA TRIAL OF ISLATRAVIR QM FOR HIV PrEP: WEEK 24 METABOLIC AND RENAL OUTCOMES (02/15/22)
     
  2045. CROI: THE IMPACT OF 3BNC117 AND ROMIDEPSIN TREATMENT AT ART INITIATION ON HIV-1 PERSISTENCE - Mark Mascolini (02/15/22)
     
  2046. CROI: Long COVID Definition - Cardiac Rhythm Upsets, Diabetes, GU Symptoms Emerge as Persistent COVID Problems (02/15/22)
     
  2047. CROI: ANGIOGENIC FACTORS IN RNA-SEQ OF SKIN AND GASTROINTESTINAL KAPOSI SARCOMA LESIONS (02/15/22)
     
  2048. CROI: NONSMALL CELL LUNG CARCINOMA IN PLWH HARBORS IMMUNOREGULATORY TUMOR MICROENVIRONMENT (02/15/22)
     
  2049. CROI: GUT MICROBIOTA, PLASMA METABOLOMICS, AND ATHEROSCLEROSIS IN HIV INFECTION (02/15/22)
     
  2050. CROI: MI Risk Not Falling in HIV Group, as It Is in non-HIV Peers - Mark Mascolini (02/15/22)
     
  2051. CROI: CROI Monday Feb 14: 5 Key Aging & Metabolic Oral Presentation Studies - (02/15/22)
     
  2052. CROI: TENOFOVIR ALAFENAMIDE IS ASSOCIATED WITH SHORTER TELOMERE LENGTH IN PEOPLE WITH HIV - (02/15/22)
     
  2053. CROI: Macrophage-specific arterial infiltration relates to plaque type and immune activation in HIV - (02/14/22)
     
  2054. CROI: PLWH Have Higher levels of Fat Tissue Fibrosis - INFLAMMATION AND KYNURENINE PATHWAY LINKED TO TYPE 2 DIABETES AND FAT FIBROSIS IN HIV - (02/14/22)
     
  2055. CROI: Trends in Myocardial Infarction Risk by HIV Status in Two US Healthcare Systems - (02/14/22)
     
  2056. Effect of HIV and Interpersonal Trauma on Cortical Thickness, Cognition, and Daily Functioning - (02/14/22)
     
  2057. CROI: One Third on ART 48 Hours From Birth Eligible for ART Interruption - Mark Mascolini (02/14/22)
     
  2058. CROI: TREATMENT WITH SOF/VEL/VOX IN HIV-HCV COINFECTED PATIENTS PREVIOUSLY EXPOSED TO DAAs - (02/14/22)
     
  2059. CROI: Impact of HCV cure on depressive symptoms in the HIV-HCV co-infected population - (02/14/22)
     
  2060. CROI: Two or More Anticholinergics Tied to Falls, Frailty in People With HIV - Mark Mascolini (02/14/22)
     
  2061. CROI: Geographical Differences in Functional Impairment of PLWH: Over One Third in Global HIV Analysis Have Impaired Physical Function - Mark Mascolini (02/14/22)
     
  2062. CROI: IV PUSH ADMINISTRATION OF IBALIZUMAB: PHARMACOKINETICS, SAFETY, AND EFFICACY - (02/14/22)
     
  2063. CROI: Infant Stunting Worse With Maternal EFV Than DTG, Similar With TAF and TDF - Mark Mascolini (02/14/22)
     
  2064. CROI: IMPACT OF TREATMENT INTERRUPTION ON COLONIC MUCOSA IN ACUTELY TREATED PARTICIPANTS - (02/14/22)
     
  2065. CROI: COVID Vax More Likely in Older, Heavier Men (vs Women) in Global HIV Trial - Mark Mascolini (02/14/22)
     
  2066. CROI: COVID mRNA Vaccines Appear to Protect Against Infection Transmission - Mark Mascolini (02/14/22)
     
  2067. CROI: COVID Vax Booster Cuts Breakthrough Infections, Hospital Use, Death - Mark Mascolini (02/14/22)
     
  2068. CROI: Post-Acute Long COVID: Lower Heart Rates During Exercise Point to Autonomic Dysfunction Causing Symptoms - Mark Mascolini (02/14/22)
     
  2069. CROI: Impact of the COVID-19 Pandemic on HIV Outpatient Care and Viral Suppression in NYC - (02/14/22)
     
  2070. CROI: PREVALENCE OF ANEMIA AND RISK FACTORS IN PEOPLE WITH HIV IN THE MODERN ART ERA - (02/14/22)
     
  2071. Long-term cardiovascular outcomes of COVID-19 - (02/13/22)
     
  2072. CROI: Assessing health-related quality of life in people with HIV and cognitive issues - (02/13/22)
     
  2073. CROI: Impact of COVID outbreak on prevention and care for HIV and other STI's at a large hospital - (02/13/22)
     
  2074. CROI: SARS-COV-2 VACCINATION: IMPACT ON HIV-1 RNA LEVELS AND ANTIBODY RESPONSE AMONG PLWH - (02/13/22)
     
  2075. CROI: Impact of COVID outbreak on prevention and care for HIV and other STI's at a large hospital - (02/13/22)
     
  2076. CROI: SARS-COV-2 VACCINATION: IMPACT ON HIV-1 RNA LEVELS AND ANTIBODY RESPONSE AMONG PLWH - (02/13/22)
     
  2077. CROI: PETRAM RESULTS: BONE TURNOVER CHANGES ON 18F-NaF PET/CT AFTER A RANDOMISED SWITCH TO TAF - (02/13/22)
     
  2078. CROI: Decreased Myelin Content and Cognitive Performance in Adults with Perinatal HIV - (02/13/22)
     
  2079. CROI: SAFETY AND PK OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE IN ADOLESCENTS - (02/13/22)
     
  2080. CROI: EFFECT OF L74I POLYMORPHISM ON FITNESS OF HIV-1 SUBTYPE A6 RESISTANT TO CABOTEGRAVIR - (02/13/22)
     
  2081. CROI: Birth Outcomes following Prenatal Exposure to Dolutegravir: the Dolomite-EPPICC study - (02/13/22)
     
  2082. CROI: IMPAACT 2019: PK & Safety of Dispersible ABC/DTG/3TC in Children with HIV 6 to <14kg - (02/13/22)
     
  2083. CROI: COGNITIVE PREDICTORS OF EVERYDAY FUNCTIONING IN THE WOMEN'S INTERAGENCY HIV STUDY - (02/12/22)
     
  2084. CROI: ADHERENCE TO ANTIRETROVIRAL THERAPY IN MEDICARE FEE-FOR-SERVICE BENEFICIARIES WITH HIV - (02/12/22)
     
  2085. CROI: Islatravir does not prolong QTc in a thorough QT study in healthy participants - (02/12/22)
     
  2086. CROI: Kinetics of Lenacapavir in Participants With Severe Renal Impairment - (02/12/22)
     
  2087. CROI: Evaluation of Potential Drug-Drug Interactions Between Islatravir and Lenacapavir - (02/12/22)
     
  2088. CROI: Absence of Cross-Resistance to Lenacapavir in HIV Entry Inhibitor-Resistant Isolates - (02/12/22)
     
  2089. CROI: Immunogenicity and Prophylactic Efficacy of Arenavirus-Based SIV Vaccine in Macaques - (02/12/22)
     
  2090. CROI: LONG ACTING LENACAPAVIR PROTECTS AGAINST INTRAVENOUS CHALLENGE WITH SIMIAN-TROPIC HIV - (02/12/22)
     
  2091. CROI: WEEK 48 METABOLIC HEALTH AFTER SWITCH TO DTG/3TC VS CAR BY BASELINE REGIMEN (SALSA) - (02/12/22)
     
  2092. CROI: B/F/TAF Five-Year Outcomes in Treatment-Naïve Adults - (02/12/22)
     
  2093. CROI: COVID-19 and the HIV continuum in people living with HIV enrolled in Collaborating Consortium of Cohorts Producing NIDA Opportunities (C3PNO) cohorts - (02/12/22)
     
  2094. CROI: Long-Acting Lenacapavir in People With Multidrug-Resistant HIV-1: Week 52 Results - (02/12/22)
     
  2095. CROI: FEMINIZING HORMONAL THERAPIES WORSEN CARDIOMETABOLIC PROFILES IN TRANSGENDER WOMEN - (02/12/22)
     
  2096. CROI: IMPACT OF INTEGRASE STRAND TRANSFER INHIBITORS ON COGNITION IN THE HAILO COHORT - (02/12/22)
     
  2097. CROI: Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults - (02/12/22)
     
  2098. CROI: Abnormal cognitive aging is detected despite clinically defined cognitive stability - (02/12/22)
     
  2099. CROI: LONG-ACTING CABOTEGRAVIR+RILPIVIRINE EVERY 2 MONTHS: ATLAS-2M WEEK 152 RESULTS - (02/12/22)
     
  2100. CROI: VIIV HEALTHCARE TO PRESENT NEW LONG-TERM FINDINGS FROM ITS INNOVATIVE 2-DRUG AND LONG-ACTING HIV MEDICINES PORTFOLIO AT CROI 2022 - (02/12/22)
     
  2101. CDC - HIV+ Black Adults More Social Vulnerabilty; Higher Mortality; More Commorbidites - (02/10/22)
     
  2102. Fatty Liver (NAFLD) in HIV+ Young, Children, Adolescents - (02/08/22)
     
  2103. CROI: Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs - (02/08/22)
     
  2104. Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs - (02/08/22)
     
  2105. A New Class of Antiviral Therapy Could Treat COVID-19 - (02/08/22)
     
  2106. PLWH in NYC-COVID Vaccinations Disparities - (02/08/22)
     
  2107. Undertreated midlife symptoms for women living with HIV linked to lack of menopause discussions with providers - menopausal hormone therapy under-utilized - (02/07/22)
     
  2108. Transitioning to Frailty for PLWH 2 fold higher, Risk Factors - (02/06/22)
     
  2109. ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals - (02/06/22)
     
  2110. PCSK9 (Repatha) in HIV+, Affect on Plaque - (02/06/22)
     
  2111. Long-Haul COVID Cases Could Spike after Latest Wave - (02/05/22)
     
  2112. Mortality & Elderly PLWH - (02/05/22)
     
  2113. Updated cholesterol guidelines offer more personalized risk assessment, additional treatment options for people at the highest risk - risk factors - (02/05/22)
     
  2114. HIV CVD Guidelines - 2019 - Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association - (02/05/22)
     
  2115. FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year - (02/05/22)
     
  2116. NIA: Data shows racial disparities in Alzheimer's disease diagnosis between Black and white research study participants - (02/03/22)
     
  2117. Protection by 4th dose of BNT162b2 against Omicron in Israel - (02/04/22)
     
  2118. Merck readies oral, macrocyclic PCSK9 inhibitor for phase II test - (02/03/22)
     
  2119. NIA: Data shows racial disparities in Alzheimer's disease diagnosis between Black and white research study participants - (02/03/22)
     
  2120. ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment - (02/03/22)
     
  2121. Fatty Liver in HIV: higher prevalence, progresses faster, ALT/AST Predict - (02/02/22)
     
  2122. Cabenuva Long-Acting New Paradigm in HIV Treatment - (02/01/22)
     
  2123. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study - (02/01/22)
     
  2124. Perceived Barriers to Long-Acting Cabotegravir/Rilpivirine Better Than Expected - (02/01/22)
     
  2125. IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology - (01/27/22)
     
  2126. Impact of long-acting therapies on the global HIV epidemic - (01/27/22)
     
  2127. Evolocumab (PCSK9 Inhibitor for Heart Disease) in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study - (01/27/22)
     
  2128. Peripheral artery disease and physical function in women with and without HIV - (01/27/22)
     
  2129. Evolocumab (PCSK9 Inhibitor for Heart Disease) in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study - (01/27/22)
     
  2130. Peripheral artery disease and physical function in women with and without HIV - (01/27/22)
     
  2131. PLWH Survival Declines with Comorbidities Danish Cohort - (01/25/22)
     
  2132. Mutimorbidity Increases 50% in PLWH Over Past Several Years; 76% of HIV Have Polypharmacy. - (01/25/22)
     
  2133. HIV Care Fragmentation - PLWH Did Not Receive Good Specialty Care for Hypertension & Hyperlipidemia - (01/25/22)
     
  2134. HIV infection is associated with an increased risk of PAD, Peripheral Artery Disease - (01/25/22)
     
  2135. Telomere Length, Traditional Risk Factors, HIV-related Factors and Coronary Artery Disease Events in Swiss Persons Living with HIV - (01/25/22)
     
  2136. 26%, 10x HIGHer Prevalence of Peripheral Artery Disease in African-American Women with HIV in WIHS - (01/25/22)
     
  2137. What is Frailty in PLWH ? 25% of HIV+ Men in MACS >65 Were Frail in 2013; 42% of HIV+ Women >60 in WIHS in 2019 were Frail/Pre-Frail. Frailty Increases Mortality - (01/25/22)
     
  2138. EHE Goals Unmet - Two-Thirds of New HIV Infections Occur Among MSM - Inequities & Disparities - (01/25/22)
     
  2139. Genital Inflammation is Not Associated with Decreased Vaginal Tenofovir Concentrations in Women Taking Oral PrEP - (01/20/22)
     
  2140. One Alcohol Drink A Day Increases Cancers Risk - (01/20/22)
     
  2141. No amount of alcohol is good for the heart, new report says, but critics disagree on science - (01/20/22)
     
  2142. Deaths Attributable to Cancer in the US Human Immunodeficiency Virus Population During 2001 2015 - (01/19/22)
     
  2143. Menopause Is Associated With Immune Activation in Women With HIV - (01/19/22)
     
  2144. Gilead says counterfeiting network sold $250 mln worth of its HIV drugs - (01/18/22)
     
  2145. NYS Guidelines COVID Oral & Monoclonal Antibodies Treatments Eligibility - (01/18/22)
     
  2146. Fall & Frailty Increase Mortality in Older PLWH Frailty Assessments In Routine Care - (01/18/22)
     
  2147. Doravirine/3TC/TDF In EACS Initial Combination ART Guidelines as well as Raltegravir - (01/16/22)
     
  2148. Older adult opioid overdose death rates on the rise - 4 times higher for African-American Men - (01/16/22)
     
  2149. San Francisco Dept of Public Health: 71% >50, 29% >65 PLWH - (01/16/22)
     
  2150. HIV Capsid Lenacapavir Review Treatment & Prevention, PK, Mechanism, Resistance - (01/15/22)
     
  2151. 2 Recent study publications from Kaiser on Dementia & Heart Failure in PLWH - (01/15/22)
     
  2152. Long-term HIV Pre-exposure Prophylaxis Trajectories Among Racial & Ethnic Minority Patients: Short, Declining, & Sustained Adherence - (01/15/22)
     
  2153. Transgender Women and PrEP Care in NYC - (01/15/22)
     
  2154. Impact of Heroin and HIV on Gut Integrity and Immune Activation - (01/15/22)
     
  2155. Reduced Levels of NAD in Skeletal Muscle and Increased Physiologic Frailty Are Associated With Viral Coinfection in Asymptomatic Middle-Aged Adults - (01/13/22)
     
  2156. Comparison of Moderna Versus Pfizer-Biontech COVID-19 Vaccine Outcomes: A Target Trial Emulation Study In the U.S. Veterans Affairs Healthcare System - (01/12/22)
     
  2157. Life Expectancy Decreases with Comorbidities - Comorbidity-Adjusted Life Expectancy: A New Tool to Inform Recommendations for Optimal Screening Strategies - (01/12/22)
     
  2158. Preeminence of Dolutegravir-Based Antiretroviral Therapy in Children and Adolescents - (01/12/22)
     
  2159. Life expectancy estimates based on comorbidities and frailty to inform preventive care - (01/11/22)
     
  2160. 60% in NYC >50 years old & 30% > 60 years old - (01/09/22)
     
  2161. Sex Differences in People Aging With HIV - women have worse quality of life & physical function & suffer more exhaustion - (01/09/22)
     
  2162. Women with HIV Have More Comorbidities, Worse Physical Function, & Inflammation - (01/07/22)
     
  2163. Faces of Frailty [women] in Aging with HIV Infection - (01/07/22)
     
  2164. Body Changes for Young Adults Acquiring HIV at Early Age & Perinatally - (01/06/22)
     
  2165. Life Expectancy for PLWH: disparities for Blacks, Women; Frailty High Rates in MACS, Physical Impairments by Age Worsen; Cognitive Impairment in Older PLWH - (01/04/22)
     
  2166. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children - (01/03/22)
     
  2167. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data - (01/03/22)
     
  2168. More evidence for worse COVID-19 outcomes in people with HIV - (01/03/22)
     
  2169. Comparison of dementia incidence and prevalence between individuals with and without HIV infection in primary care from 2000 to 2016 - (01/03/22)
     
  2170. CVD Score Predicts Frailty? - Cardiovascular risk score associations with frailty in men and women with or at risk for HIV - (01/03/22)
     
  2171. Sexually transmitted infections and depot medroxyprogesterone acetate do not impact protection from simian HIV acquisition by long-acting cabotegravir in macaques - (01/03/22)
     
  2172. Tenofovir alafenamide plasma concentrations are reduced in pregnant women living with HIV: data from the PANNA Network - (12/30/21)
     
  2173. 25% PLWH Report Discrimination Experience in Health Care Setting - (12/30/21)
     
  2174. Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment - (12/29/21)
     
  2175. Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US - (12/29/21)
     
  2176. New CDC Vital Signs Report Reveals a Decade of Continuing HIV Inequities on Eve of World AIDS Day - (12/28/21)
     
  2177. PLWH - Women; Life Expectancy-disparities; Social Determinants; Frailty; Physical & Cognitive Impairment - (12/28/21)
     
  2178. Pfizer COVID Protease & DDIs with HIV ARTs - (12/28/21)
     
  2179. FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year - (12/23/21)
     
  2180. Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment - (12/23/21)
     
  2181. Merck and Ridgeback's Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19 - (12/23/21)
     
  2182. ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention - (12/23/21)
     
  2183. PLWH who adhere to ART but smoke are substantially more likely to die from lung cancer than from AIDS-related causes - (12/23/21)
     
  2184. Excess Black Deaths PLWH & Higher Morbidity - (12/23/21)
     
  2185. Social Determinants of Health & African-Americans Associated with Chronic Comorbidities & Brain Aging - (12/23/21)
     
  2186. The shifting age distribution of people with HIV using antiretroviral therapy in the United States, 2020 to 2030......23% >65y, 20% >70y (200,000+) and Impact - (12/23/21)
     
  2187. Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns - (12/21/21)
     
  2188. PrEP Barriers & Challenges - (12/21/21)
     
  2189. COVID-19 Vaccination Rates in a Global HIV Cohort - (12/13/21)
     
  2190. "I'm Just Forgetting and I Don't Know Why": Exploring How People Living With HIV-Associated Neurocognitive Disorder View, Manage, and Obtain Support for Their Cognitive Difficulties - study interviewing 25 PLWH average age 51 diagnosed with HAND (HIV-associated neurocognitive disorder) - (12/13/21)
     
  2191. Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter? - (12/13/21)
     
  2192. SARS-CoV-2 Infection Among People Living With HIV Compared With People Without HIV: Survey Results From the MACS-WIHS Combined Cohort Study - (12/10/21)
     
  2193. Experimental mRNA HIV Vaccine Safe, Shows Promise in Animals NIAID Scientists Developed Vaccine Platform - (12/10/21)
     
  2194. EACS: Distinct groupings of people with HIV and pain associate differently with pain-related healthcare use and health-related quality-of-life (HRQoL): findings from the Pharmacokinetic and Clinical Observations in People Over Fifty (POPPY) study - (12/03/21)
     
  2195. Safety & Efficacy of SARS-CoV-2 Monoclonal Neutralizing Anibodies BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients - (12/03/21)
     
  2196. Remdesivir For the Treatment of High-Risk Non-Hospitalized Individuals with COVID-19: A Randomized, Double, Blind, Placebo-Controlled Trial PINETREE Study -RDV for 3 day 87% reduction in hospitalization, there were no deaths in either arm - (12/03/21)
     
  2197. New Aging/HIV Language in New US AIDS Strategy 2022-2026 - (12/02/21)
     
  2198. Gender Inequity-Inappropriate Prescribing for Elderly PLWH in Swiss Cohort - (11/30/21)
     
  2199. Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study - (11/30/21)
     
  2200. The Clinical Safety, Pharmacokinetics, and LDL-Cholesterol Lowering Efficacy of MK-0616, an Oral PCSK9 Inhibitor - (11/30/21)
     
  2201. Einstein and Montefiore Researchers Awarded $7.6 Million in NIH Grants to Study Depression in People Living with HIV - (11/22/21)
     
  2202. "I'm Just Forgetting and I Don't Know Why": Exploring How People Living With HIV-Associated Neurocognitive Disorder View, Manage, and Obtain Support for Their Cognitive Difficulties - (11/21/21)
     
  2203. High-Dose Marine Omega-3s Raise Risk for Atrial Fibrillation - (11/19/21)
     
  2204. The Esperanza Patient: More Hope for a Sterilizing HIV-1 Cure: A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation - (11/17/21)
     
  2205. AASLD: INSTIs and DAAs Boost Liver Transplant Survival in HIV+ and HIV+/HCV+ in US - (11/16/21)
     
  2206. AASLD: Simple Tool Tells Primary Care Docs When to Refer People With NAFLD - Mark Mascolini - (11/15/21)
     
  2207. AASLD: HIV is independently associated with elevated FibroScan-AST (FAST) score, a non-invasive measurement of non-alcoholic steatohepatitis with significant activity and fibrosis - Mark Mascolini - (11/15/21)
     
  2208. AASLD: Simple Tool Tells Primary Care Docs When to Refer People With NAFLD - Mark Mascolini - (11/15/21)
     
  2209. AASLD: HIV is independently associated with elevated FibroScan-AST (FAST) score, a non-invasive measurement of non-alcoholic steatohepatitis with significant activity and fibrosis - Mark Mascolini - (11/15/21)
     
  2210. Weight Change in NEAT-022, Switch to dolutegravir from boosted PI, 96 weeks at Glasgow 2018 - (11/11/21)
     
  2211. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV - (11/10/21)
     
  2212. No overall impact on rate of weight gain with integrase inhibitor-containing regimens in antiretroviral-naïve adults - (11/10/21)
     
  2213. EACS: Efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in patients with pre-existing nrti resistances: real world data - (11/10/21)
     
  2214. EACS: Integrase inhibitor drug resistance in clinical practice in the United Kingdom - (11/10/21)
     
  2215. Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults - (11/08/21)
     
  2216. EACS: Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study - (11/06/21)
     
  2217. EACS: People with HIV and suppressed viremia on ART are not at increased risk for acquiring SARS-CoV-2 infection SARS-CoV-2 Risk No Higher With Well-Controlled HIV Than in HIV-Negatives - Mark Mascolini (11/06/21)
     
  2218. EACS: Tolerability and antiviral activity of bictegravir/tenofovir alafenamide/emtricitabine (Biktarvy) treatment switch in patients aged 55 years or older with HIV: the BIO study - (11/06/21)
     
  2219. EACS: Gender-related differences in safety after switching to BICTEGRAVIR/TAF/FTC in "real life" - (11/06/21)
     
  2220. EACS: Efficacy and safety of switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically-suppressed HIV patients (EBONY Study) - (11/06/21)
     
  2221. EACS: Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study - (11/06/21)
     
  2222. EACS: More than half of well-treated persons living with HIV have angiography verified coronary artery disease Angiography Confirms Coronary Artery Disease in Over Half With HIV in Copenhagen - Mark Mascolini (11/06/21)
     
  2223. EACS: Increased neurocognitive impairment and white matter damaged in young adults with perinatal HIV infection. A case-control study - (11/06/21)
     
  2224. EACS: EACS: Long-Acting Injectable Cabotegravir + Rilpivirine. - (11/06/21)
     
  2225. EACS: A fog that impacts everything: understanding quality of life in people living with HIV and cognitive impairment - poor mental & physical function - (11/06/21)
     
  2226. EACS: Long-term HIV survivors and adults 65 or over with HIV: two separate profiles with different needs - (11/03/21)
     
  2227. EACS: Comorbidities in women living with HIV: a systematic review - higher rates for kidney, bone, heart, neurocognitive diseases - (11/03/21)
     
  2228. EACS: Themes of Aging from Older PLWH: A fog that impacts everything: understanding quality of life in people living with HIV and cognitive impairment - (11/03/21)
     
  2229. EACS: Comparison of baseline characteristics and cardiovascular outcomes of a multicentre UK cohort of people living with HIV with previously reported cohorts - (11/03/21)
     
  2230. EACS: Correlation between inflammatory biomarkers with four cardiovascular disease (CVD) risk models in aging patients living with HIV - (11/03/21)
     
  2231. EACS: Incidence of diabetes mellitus in PLWHIV: impact of antiretroviral therapy - (11/03/21)
     
  2232. EACS: Subclinical atherosclerosis burden in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors - (11/03/21)
     
  2233. EACS: Liver disease in people living with HIV (PLWHIV) after the microelimination of HCV infection: non-viral hepatitis & NAFLD - (11/02/21)
     
  2234. EACS: Factors associated with excess depressive disorders in women and men living with HIV in south-western France compared to the general French population - see slides below - (11/02/21)
     
  2235. EACS: Faster lung function decline in well-treated people living with HIV compared with uninfected controls: a longitudinal matched cohort study - Mark Mascolini (11/02/21)
     
  2236. EACS: Decreasing incidence and determinants of Bacterial Pneumonia in people with HIV: The Swiss HIV Cohort Study (SHCS) - (11/02/21)
     
  2237. EACS: Stigma Drives Higher Depression Rate in HIV+ Men and Women in France - Mark Mascolini (11/02/21)
     
  2238. New HRSA Funding Opportunities Focus on HIV and Aging Oct 28 published - (11/02/21)
     
  2239. EACS: Bacterial Pneumonia Incidence Drops Sharply in Swiss HIV Cohort Study - Mark Mascolini (11/02/21)
     
  2240. EACS: Incidence and risk factors for suicide, violent/accidental deaths, and substance abuse deaths in persons living with HIV - (11/02/21)
     
  2241. EACS: Change in body mass index (BMI) and association with clinical outcomes after initiation of contemporary HIV antiretroviral (ARV) regimens in EuroSIDA - (11/02/21)
     
  2242. EACS: Maraviroc or Metformin Does Not Lower Liver Fat in People With HIV and NAFLD - Mark Mascolini (11/02/21)
     
  2243. EACS: Hepatitis C elimination in time of COVID-19 pandemic: the experience of University Hospital Center in Paris, France - (11/01/21)
     
  2244. EACS: Maraviroc or Metformin Does Not Lower Liver Fat in People With HIV and NAFLD - Mark Mascolini (11/01/21)
     
  2245. EACS: Hepatic steatosis associated with integrase strand transfer inhibitors - does the substance matter? - (11/01/21)
     
  2246. EACS: Insulin resistance in PWH is associated with abdominal obesity and prior exposure to thymidine analogues and/or didanosine - (11/01/21)
     
  2247. EACS: Safety Profile of Cabotegravir + Rilpivirine During Oral Lead-In and Through Long-Acting Therapy: Pooled Analysis of the Phase 3 FLAIR, ATLAS, and ATLAS-2M Studies - (11/01/21)
     
  2248. EACS: UNDERSTANDING THE PERCEIVED THERAPEUTIC NEED AND VALUE ASSOCIATED WITH NOVEL LONG-ACTING ANTIRETROVIRAL REGIMENS AMONG PEOPLE LIVING WITH HIV IN 12 EUROPEAN COUNTRIES - (11/01/21)
     
  2249. EACS: European Phase 3/3b Experience With Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes - (11/01/21)
     
  2250. EACS: Highly Effective Two-drug Regimens of an Integrase Inhibitor and Reverse Transcriptase Inhibitor in Real-World Setting - Data from COMBINE-2 Study - (11/01/21)
     
  2251. EACS: 12-month outcomes - patient satisfaction - of Dolutegravir (DTG) + Lamivudine (3TC) in ART-naïve and pre-treated PLHIV in Germany: Real-world data from the German URBAN cohort - (11/01/21)
     
  2252. EACS: Evaluating the relationship between inflammation biomarker interleukin-6 (IL-6) levels and residual, low-Level viraemia in HIV-1 suppressed participants in the TANGO study at week 96 (WK96) - (11/01/21)
     
  2253. EACS: The potential clinical impact of the observed differences in IL-6, a marker of inflammation, associated with some antiretroviral regimens - (11/01/21)
     
  2254. EACS: Angiography Confirms Coronary Artery Disease in Over Half With HIV in Copenhagen - Mark Mascolini (11/01/21)
     
  2255. EACS: PLW Presented Late To Care in WHO European Region 2019 - (11/01/21)
     
  2256. EACS: Viral Suppression in 40 Countries in Europe & Central Asia 2020 - (11/01/21)
     
  2257. EACS: Angiography Confirms Coronary Artery Disease in Over Half With HIV in Copenhagen - Mark Mascolini (11/01/21)
     
  2258. EACS: SWITCHING TO DTG/3TC IS NON-INFERIOR TO CONTINUING CURRENT ANTIRETROVIRAL REGIMEN AT WEEK 48: SALSA SUBGROUP ANALYSES - (10/31/21)
     
  2259. EACS: SWITCHING TO DTG/3TC IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN AT WEEK 144: TANGO SUBGROUP ANALYSES - (10/31/21)
     
  2260. EACS: 2 year outcomes of dolutegravir/rilpivirine in virologically suppressed HIV-infected PLHIV: Real-world data from the German JUNGLE cohort - (10/31/21)
     
  2261. EACS: Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL): Examining Healthcare Staff Attitudes During a Hybrid III Implementation-Effectiveness Trial Implementing Cabotegravir + Rilpivirine Long-Acting Injectable (CAB + RPV LA) for People Living With HIV - (10/30/21)
     
  2262. EACS: Perspectives on the Acceptability, Appropriateness, Feasibility, Barriers, and Facilitators From Patients Receiving Cabotegravir + Rilpivirine Long-Acting Injectable Treatment (CAB + RPV LA): Interim Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) - (10/30/21)
     
  2263. EACS: Healthcare Staff Perspectives on the Implementation of HIV Injectable Treatment: Interim Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) - (10/30/21)
     
  2264. EACS: Characteristics, treatment patterns, and viral load for treatment-experienced people living with HIV and switching to an MTR or STR ARV after 2018 - (10/30/21)
     
  2265. EACS: Long-term efficacy of bictegravir/emtricitabine/tenofovir alafenamide after switch from boosted protease inhibitor-based regimens including in those with preexisting resistance and viral blips - (10/30/21)
     
  2266. EACS: Prevalence and risk factors of preexisting TAMs in clinical trial participants and sustained viral suppression after switching to bictegravir/emtricitabine/tenofovir alafenamide - (10/30/21)
     
  2267. EACS: Evaluating virological outcomes in people with HIV on stable ART with reduced frequency of HIV viral load monitoring during the COVID-19 pandemic Less Viral Load Tracking During COVID Has No Immediate Ill Effects - Mark Mascolini (10/30/21)
     
  2268. EACS: Domestic abuse (DA) screening in people living with HIV (PLWH) More Domestic Abuse Screening in HIV+ During COVID Discloses Spike in Reports - Mark Mascolini (10/30/21)
     
  2269. EACS: Immunogenicity of mRNA vaccination against SARS-CoV-2 in persons living with HIV (PLWHs) with low CD4 count or previous AIDS Immune Response to mRNA COVID Vaccines Weaker in HIV+ With Low CD4s - Mark Mascolini (10/30/21)
     
  2270. EACS: Chemsex practice in men who have sex with men: reduction or relapse during lockdown? Results of the CheRRLock study COVID Lockdown Boosts Chemsex Use, Cuts Sex Partners in Paris MSM - Mark Mascolini (10/30/21)
     
  2271. EACS: New HCV Diagnoses Down by Two Thirds in HIV+ Swiss MSM 2010-2020 - Mark Mascolini (10/30/21)
     
  2272. EACS: Chemsex practice in men who have sex with men: reduction or relapse during lockdown? Results of the CheRRLock study COVID Lockdown Boosts Chemsex Use, Cuts Sex Partners in Paris MSM - Mark Mascolini (10/29/21)
     
  2273. EACS: Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy® in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting - (10/29/21)
     
  2274. EACS: Progression to Anal Cancer Precursor 11 Per 100 Person-Years in HIV+ MSM - Mark Mascolini (10/29/21)
     
  2275. EACS: Renal Safety of On-demand and Daily TDF-FTC for HIV Pre-exposure Prophylaxis in the ANRS-PREVENIR Study - (10/29/21)
     
  2276. EACS: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV: 12-month effectiveness, persistence, and safety in a multi-country cohort study - (10/29/21)
     
  2277. EACS: Patient-reported outcome (PRO) measures at 12 months in a real-world cohort of people living with HIV with a high prevalence of comorbidities receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Europe, Canada, and Israel - (10/29/21)
     
  2278. EACS: COMPARATIVE EFFICACY OF FOSTEMSAVIR VERSUS IBALIZUMAB IN HEAVILY TREATMENT-EXPERIENCED HIV PATIENTS - (10/29/21)
     
  2279. EACS: LONG-TERM INFLAMMATION BIOMARKER CHANGES WITH FOSTEMSAVIR IN HEAVILY TREATMENT-EXPERIENCED ADULTS WITH HIV-1: EXPLORATORY ANALYSES OF THE PHASE 3 BRIGHTE STUDY - (10/29/21)
     
  2280. EACS: IMPACT OF TREATMENT ADHERENCE ON EFFICACY OF DTG + 3TC AND DTG + TDF/FTC: POOLED WEEK 144 ANALYSIS OF THE GEMINI-1 AND GEMINI-2 CLINICAL STUDIES - (10/29/21)
     
  2281. EACS: Subgroup efficacy analyses of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV (CAPELLA study) - (10/29/21)
     
  2282. EACS: EMERGENT RESISTANCE TO ANTIRETROVIRAL AGENTS USED IN OPTIMIZED BACKGROUND THERAPY WITH FOSTEMSAVIR: WEEK 96 RESULTS OF THE PHASE 3 BRIGHTE STUDY IN HEAVILY TREATMENT-EXPERIENCED ADULTS LIVING WITH MULTIDRUG-RESISTANT HIV-1 - (10/29/21)
     
  2283. EACS: Recent Abacavir Use and Incident Cardiovascular Disease in Contemporary Treated PLWH within the RESPOND Cohort Consortium - (10/29/21)
     
  2284. EACS: Efficacy and Safety Outcomes by BMI Category Over 48 Weeks in Phase 3/3b Cabotegravir and Rilpivirine Long-Acting Trials - (10/29/21)
     
  2285. EACS: Outcomes for Participants During Long-Term Follow-Up After Discontinuation of Cabotegravir + Rilpivirine Long-Acting in the Phase 3/3b Clinical Trials - (10/29/21)
     
  2286. EACS: Efficacy and Safety of Islatravir in Combination With Doravirine Through 144 Weeks for Treatment-Naïve Adults With HIV-1 Infection in a Phase 2b Trial - (10/29/21)
     
  2287. EACS: Resistance analysis of long-acting lenacapavir in highly treatment-experienced people with HIV after 26 weeks of treatment - (10/28/21)
     
  2288. EACS: Recent abacavir use and incident cardiovascular disease in contemporary treated people living with HIV (PLWH) within the RESPOND cohort consortium - Mark Mascolini - (10/28/21)
     
  2289. EACS: Multiclass Resistance to Antiretrovirals Waning in Europe - Mark Mascolini - (10/28/21)
     
  2290. EACS: High HIV Positivity Rate When Self-Tests Distributed by LGBT Health Center Clients - Mark Mascolini - (10/28/21)
     
  2291. EACS: Kidney Toxicity Rare With Daily or On-Demand (As-Needed) PrEP - Mark Mascolini - (10/28/21)
     
  2292. EACS: Safety and Efficacy of Doravirine in Treatment-Naïve Adults with HIV-1: 4 Years of Experience From the DRIVE-FORWARD and DRVIVE-AHEAD Clinical Trials - (10/28/21)
     
  2293. EACS: ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine) can be implemented successfully in a variety of European healthcare settings - (10/28/21)
     
  2294. EACS: ViiV Healthcare announces European Commission Decision for Vocabria (cabotegravir) and Rekambys (rilpivirine) injections to be initiated with or without an oral lead-in period for the long-acting treatment of HIV - (10/28/21)
     
  2295. The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries - (10/27/21)
     
  2296. Trends in Cardiovascular Risk Factors in US Adults by Race and Ethnicity and Socioeconomic Status, 1999-2018 - (10/27/21)
     
  2297. EACS: Evaluating the relationship between inflammation biomarker interleukin-6 (IL-6) levels and residual, low-Level viraemia in HIV-1 suppressed participants in the TANGO study at week 96 (WK96) - (10/27/21)
     
  2298. EACS: Durable efficacy and safety of DTG + 3TC in treatment-naive people with HIV-1 stratified by age: 144-week results from GEMINI-1 and -2 - (10/27/21)
     
  2299. EACS: Incidence of hypertension in people living with HIV receiving InSTI versus other third-drug ART regimens in the RESPOND cohort - (10/27/21)
     
  2300. EACS: High incidence of subclinical peripheral artery disease in people living with HIV in Denmark: a 2-year follow-up study - (10/27/21)
     
  2301. EACS: Outcomes 48 weeks after switching from DTG/ABC/3TC or DTG+F/TAF to B/F/TAF - (10/27/21)
     
  2302. EACS: Week 192 bone and renal markers from the ADVANCE trial - (10/27/21)
     
  2303. EACS: ViiV Healthcare presents real-world evidence at EACS 2021 reinforcing the use of its 2-drug regimens Dovato (dolutegravir/lamivudine) and Juluca (dolutegravir/rilpivirine) for the treatment of people living with HIV - (10/27/21)
     
  2304. EACS: Subclinical atherosclerosis burden in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors - (10/27/21)
     
  2305. EACS: GENDER DIFFERENCES OF SUBCLINICAL ATHEROSCLEROSIS BURDEN IN CAROTID AND FEMORAL TERRITORIES IN PEOPLE LIVING WITH HIV: A SUBANALYSIS OF THE VASI STUDY - (10/27/21)
     
  2306. EACS: Comorbidities and antiretroviral utilization among people living with HIV in the United States - (10/27/21)
     
  2307. EACS: Change in body mass index (BMI) and association with clinical outcomes after initiation of contemporary HIV antiretroviral (ARV) regimens in EuroSIDA - (10/27/21)
     
  2308. EACS: Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Safety of Investigational Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 Treatment at EACS 2021 - (10/27/21)
     
  2309. EACS: Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection - (10/25/21)
     
  2310. Trends in Cardiovascular Risk Factors in US Adults by Race and Ethnicity and Socioeconomic Status, 1999-2018 - (10/27/21)
     
  2311. Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults - (10/26/21)
     
  2312. EACS: Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection - (10/25/21)
     
  2313. U.S. Food and Drug Administration Approves Expanded Indication of Gilead's Biktarvy® for Treatment of HIV-1 in Pediatric Populations - (10/22/21)
     
  2314. Less talk, more action: New report sponsored by ViiV Healthcare provides roadmap to achieve health equity by 2040 - (10/20/21)
     
  2315. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data - (10/20/21)
     
  2316. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study - (10/20/21)
     
  2317. Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization - (10/20/21)
     
  2318. Focus Groups - 2015 - WIHS-Wash DC - Women want Pre-Exposure Prophylaxis but are Advised Against it by Their HIV-positive Counterparts - (10/17/21)
     
  2319. Black Cisgender Women's PrEP Knowledge, Attitudes, Preferences, and Experience in Chicago - (10/17/21)
     
  2320. "PrEP"ing for a PrEP demonstration project: understanding PrEP knowledge and attitudes among cisgender women - (10/17/21)
     
  2321. Co-located HIV Services Can Help Women Who Inject Drugs Access PrEP, Study Shows - (10/17/21)
     
  2322. Perceived HIV Acquisition Risk and Low Uptake of PrEP Among a Cohort of Transgender Women With PrEP Indication in the Eastern and Southern United States - (10/17/21)
     
  2323. Barriers and Facilitators to PrEP Initiation and Adherence Among Transgender and Gender Non-Binary Individuals in Southern California - (10/17/21)
     
  2324. IDWeek: Reasons for not using PrEP and actions that may facilitate PrEP uptake in Ontario and British Columbia, Canada - (10/17/21)
     
  2325. IDWeek: Barriers to PrEP Implementation Among Patient-Facing Staff in Three Urban Clinics - (10/17/21)
     
  2326. IDWeek: A Survey of HIV PrEP Prescribing Practices at an Academic Medical Center in the Pacific Northwest United States - (10/17/21)
     
  2327. IDWeek: SUBOPTIMAL UPTAKE, RETENTION, AND ADHERENCE OF DAILY ORAL PREP AMONG PEOPLE WITH OUD RECEIVING HCV TREATMENT - (10/17/21)
     
  2328. IDWeek: Bridging the Gap in PrEP Provider Training: An Implementation Science Study. insurance navigation for PrEP - (10/17/21)
     
  2329. Renal impairment in a large-scale HIV pre-exposure prophylaxis implementation cohort - (10/14/21)
     
  2330. Task Force Issues Draft Recommendation Statement on Aspirin Use to Prevent Cardiovascular Disease - (10/12/21)
     
  2331. Providers PrEP: Identifying Primary Health care Providers' Biases as Barriers to Provision of Equitable PrEP Services - (10/07/21)
     
  2332. IDWeek: Preliminary Findings from a HIV Self-Testing Program among People Who Use Drugs - (10/06/21)
     
  2333. PLWH Have Higher COVID Testing, Diagnosis & Hospitalization at Kaiser Permanente So. Calif. - (10/07/21)
     
  2334. IDWeek: Racial and Ethnic Disparities in COVID-19 Incidence among Persons with HIV in a Multisite-Cohort - (10/05/21)
     
  2335. Cross-sectional study of correlates and prevalence [high rates] of functional and high-risk multimorbidity in an academic HIV practice in New York City at Cornell-Weill HIV Clinic - (10/05/21)
     
  2336. Menopause Is Associated With Immune Activation in Women With HIV; mortality, heart disease, discrimination, stigma - (10/05/21)
     
  2337. IDWeek: Lower SARS-CoV-2 IgG and Surrogate Virus Neutralization Titers Post-mRNA Vaccination among People Living with HIV - (10/05/21)
     
  2338. IDWeek: Switch to DTG/3TC Noninferior to Maintaining TAF Regimen for 144 Weeks - Mark Mascolini (10/04/21)
     
  2339. IDWeek: In Vitro Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence - (10/04/21)
     
  2340. IDWeek: Increasing trends in multimorbidity and polypharmacy over a 5-year period in people living with HIV in the United States - Big US Study Confirms Ballooning Multimorbidity, Polypharmacy With HIV - (10/04/21)
     
  2341. Weight Increases with Reyataz & Efavirenz in Treatment-Naives A5202 - (09/27/21)
     
  2342. Effects of Growth Hormone-Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults - Results of a Controlled Trial - (09/22/21)
     
  2343. CROI: Summary from virtual CROI 2021 for HIV and liver disease HIV and the liver: hot topics - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (04/10/21)
     
  2344. IDWeek: EFFICACY AND SAFETY OF LONG-ACTING CABOTEGRAVIR + RILPIVIRINE IN PARTICIPANTS WITH HIV/HCV CO-INFECTION: ATLAS-2M 48-WEEK RESULTS - (10/04/21)
     
  2345. IDWeek: Indirect Treatment Comparison of 48-Week Efficacy and Safety of Cabotegravir + Rilpivirine Long-Acting Every 2 Months to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Suppressed HIV-1-Infected Participants - (10/03/21)
     
  2346. IDWeek: Implementation of Long-acting Injectable Cabotegravir-Rilpivirine for HIV-1 treatment at a Ryan White-funded Clinic in the U.S. South - (10/03/21)
     
  2347. IDWeek: Renal function, Lipid profile, and Cardiovascular Events After Switching to Abacavir-containing Regimen in Antiretroviral-therapy-experienced People Living with HIV in Northern Thailand - (10/03/21)
     
  2348. IDWeek: Use of tenofovir disoproxil fumarate shows weight loss vs placebo: a meta-analysis of 7 clinical trials in 19,359 HIV-negative individuals - (10/03/21)
     
  2349. IDWeek: Interim Analysis of Real-World Community-Based HIV Rapid Start Antiretroviral with BFTAF Versus Conventional HIV Antiretroviral Therapy Start The RoCHaCHa Study a Pilot Study - (10/03/21)
     
  2350. IDWeek: Long-term clinical outcomes following SARS-CoV-2 infection include persistent symptoms and cardiovascular disease beyond 3 months post-infection - (10/03/21)
     
  2351. IDWeek: Monoclonal Regdanvimab Cuts COVID Progression Risk in Placebo Trial - Mark Mascolini (10/03/21)
     
  2352. IDWeek: CHARACTERIZATION OF HEAVILY TREATMENT-EXPERIENCED HIV-1-INFECTED CLINICAL TRIAL PARTICIPANTS INFECTED WITH SARS-COV-2 COVID-19: FOSTEMSAVIR BRIGHTE PHASE 3 CLINICAL TRIAL - (10/03/21)
     
  2353. IDWeek: Improvement in Diet Attenuates Antiretroviral Therapy (ART) Associated Weight Gain in Persons with Human Immunodeficiency Virus (PWH) Improved Diet Tied to Lower ART-Related Weight Gain in 870-Person US Study - Mark Mascolini (10/02/21)
     
  2354. IDWeek: EFFECTIVENESS AND TOLERABILITY OF DTG+3TC IN CLINICAL PRACTICE: EVIDENCE IN PLHIV FROM REAL-WORLD DATA - (10/02/21)
     
  2355. IDWeek: COVID-19 Symptoms Persist Beyond 1 Month in 25% of US Military Group - Mark Mascolini (10/02/21)
     
  2356. IDWeek: Incidence of metabolic complications among treatment-naive adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 weeks. Low and Similar Rates of New Metabolic Problems: 3 Years With 3 ART Regimens - Mark Mascolini (10/02/21)
     
  2357. IDWeek: Sex and race disparities in premature mortality among people with HIV: a 21-year observational cohort study - Premature Mortality Higher in Women and Blacks in US HIV Group - (10/01/21)
     
  2358. IDWeek: Risk of Virologic Failure Among Treatment-experienced Suppressed People with HIV (PWH) Treated with Single-Tablet 2-Drug (2DR) vs 3-Drug (3DR) Regimens - Mark Mascolini (10/01/21)
     
  2359. IDWeek: EFFECTS OF THE "UNDETECTABLE = UNTRANSMITTABLE" ("U=U") EDUCATIONAL CAMPAIGN ON TREATMENT OUTCOMES AND PERCEPTIONS AMONG PEOPLE LIVING WITH HIV IN NORTH AMERICAN COUNTRIES - (10/01/21)
     
  2360. IDWeek: Strong HIV Control for 72 Weeks With B/F/TAF in US Blacks - Mark Mascolini (10/01/21)
     
  2361. IDWeek: North American Phase 3/3b Experience With Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes - (10/01/21)
     
  2362. IDWeek: REAL-WORLD PERSISTENCY OF PATIENTS RECEIVING TENOFOVIR-BASED PRE-EXPOSURE PROPHYLAXIS FOR THE PREVENTION OF HIV INFECTION IN THE US - (10/01/21)
     
  2363. IDWeek: Adherence to F/TDF for PrEP in Dried Blood Spots and HIV Infection Rates: A Pooled Analysis of Global PrEP Studies - (10/01/21)
     
  2364. IDWeek: Pre-exposure prophylaxis (PrEP) prescriptions among individuals at high risk for HIV in the United States, 2012-2018 - (10/01/21)
     
  2365. IDWeek: Persistence on F/TAF versus F/TDF for HIV Pre-Exposure Prophylaxis (PrEP): A Real-World Evidence Analysis in the United States - (10/01/21)
     
  2366. IDWeek: Offering Drug Injectors PrEP While ID Inpatients Not Successful - Mark Mascolini (10/01/21)
     
  2367. IDWeek: Lower CD4s and Higher Viral Load-Not Antiretrovirals-Tied to Excessive Weight Gain - Mark Mascolini (10/01/21)
     
  2368. IDWeek: COVID Brings Drops in HIV Care Visits, Viral Load Measures, and ART Stops - Mark Mascolini (09/30/21)
     
  2369. IDWeek: Remdesivir Linked to Viral Clearance Only in Certain Subsets - Mark Mascolini (09/30/21)
     
  2370. IDWeek: Treatment with molnupiravir in the MOVe-In and MOVe-Out clinical trials results in an increase in transition mutations across the SARS-CoV-2 genome - (09/30/21)
     
  2371. IDWeek: Use of immune-viral dynamics modeling to understand molnupiravir drug effect for COVID-19 - (09/30/21)
     
  2372. IDWeek: Clinical Characteristics of Patients Living with HIV Hospitalized for COVID-19 - PLWH have Higher Mortality Rate - (09/30/21)
     
  2373. IDWeek: Molnupiravir maintains antiviral activity against SARS-CoV-2 variants in vitro and in early clinical studies - (09/30/21)
     
  2374. IDWeek: Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021 - (09/30/21)
     
  2375. IDWeek: CHARACTERISTICS, COMORBIDITIES, AND MEDICATION BURDEN AMONG PEOPLE LIVING WITH HIV IN THE US MEDICARE PROGRAM - (09/30/21)
     
  2376. IDWeek: Increasing trends in multimorbidity and polypharmacy over a 5-year period in people living with HIV in the United States - (09/30/21)
     
  2377. IDWeek: The Efficacy and Safety of Maintenance With Doravirine Plus Two NRTIs After Initial Suppression in Adults With HIV-1 in the DRIVE-FORWARD Clinical Trial: Results From the Study Extension Through 192 Weeks - (09/30/21)
     
  2378. IDWeek: High Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide in African-American Adults With HIV Including Those with Preexisting Resistance, Viral Blips, and Suboptimal Adherence - (09/30/21)
     
  2379. IDWeek: QUALITATIVE PATIENT-PARTICIPANT PERSPECTIVES ON IMPLEMENTATION OF MONTHLY CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING (CAB+RPV LA) INJECTABLE IN THE UNITED STATES (CUSTOMIZE) - (09/30/21)
     
  2380. IDWeek: Pregnancy Outcomes and Pharmacokinetics in Pregnant Women Living With HIV Exposed to Long-Acting Cabotegravir and Rilpivirine in Clinical Trials - (09/30/21)
     
  2381. IDWeek: MATERNAL DOLUTEGRAVIR (DTG) USE, AND PREGNANCY AND BIRTH OUTCOMES: THE ANTIRETROVIRAL PREGNANCY REGISTRY (APR) - (09/29/21)
     
  2382. IDWeek: HIGH RATES OF VIROLOGIC SUPPRESSION WITH DTG/3TC IN NEWLY DIAGNOSED ADULTS WITH HIV-1 INFECTION AND BASELINE VIRAL LOAD ≥500,000 C/ML: 48-WEEK SUBGROUP ANALYSIS OF THE STAT STUDY - (09/29/21)
     
  2383. IDWeek: Interim Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People with HIV at 28 Weeks (CALIBRATE) - (09/29/21)
     
  2384. IDWeek: SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN IN MAINTAINING VIROLOGIC SUPPRESSION THROUGH 144 WEEKS (TANGO STUDY) - (09/29/21)
     
  2385. IDWeek: Long-term Outcomes of Participants on F/TAF for Pre-Exposure Prophylaxis: Results for 144 Weeks of Follow-Up in the DISCOVER Trial - (09/29/21)
     
  2386. IDWeek: Incidence of metabolic complications among treatment-naive adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 weeks. Low and Similar Rates of New Metabolic Problems: 3 Years With 3 ART Regimens - Mark Mascolini (09/29/21)
     
  2387. IDWeek: Monoclonal Lenzilumab Cuts Need for Ventilation in Phase 3 COVID Trial - Mark Mascolini (09/29/21)
     
  2388. IDWeek: Invasive Pneumococcal Disease Rate 17-Fold Higher With HIV in US - Mark Mascolini - (09/29/21)
     
  2389. IDWeek: ViiV Healthcare to present key data that provides further support for the use of 2-drug regimens, including long-term efficacy, alongside new insights into living with HIV at IDWeek 2021 - (09/29/21)
     
  2390. PWH -Higher Rates of Frailty Transitioning & Deaths - (09/28/21)
     
  2391. ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals - (09/28/21)
     
  2392. FDA grants Priority Review to ViiV Healthcare's New Drug Application for cabotegravir long-acting for prevention of HIV - (09/28/21)
     
  2393. AGE: Factors influencing psychological distress during the COVID-19 pandemic in people aging with HIV - (09/28/21)
     
  2394. AGE: Rapid Aging of HIV Immune System Reported in 2011 and Earlier by Rita Effros & UCLA Researchers. - (09/28/21)
     
  2395. AGE: Frailty and resilience in people living with HIV during the COVID era: two complementary constructs? Sarcopenia, frailty & % of adipose tissue worsened. 37% were Frail & Non-Resilient - (09/28/21)
     
  2396. AGE: Factors influencing psychological distress during the COVID-19 pandemic in people aging with HIV - (09/27/21)
     
  2397. Pharm: Tenofovir alafenamide concentrations are reduced by half in pregnant women living with HIV: data from the PANNA Network. - By Mark Mascolini - (09/27/21)
     
  2398. AGE: Pain Linked to Depression, Worse Physical Function, Falls, Frailty and Inflammation in Older People With HIV - By Mark Mascolini - (09/27/21)
     
  2399. AGE: Burden of age-associated chronic comorbidities among people living with and without HIV: Years of life lost to premature mortality in British Columbia, Canada - (09/27/21)
     
  2400. AGE: COVID Vaccine Effectivity in Aging & HIV Populations - (09/27/21)
     
  2401. AGE: NYC Ryan White Part A: Program Model of Care for HIV and Aging - (09/25/21)
     
  2402. AGE: Black and Hispanic women in the United States are disproportionally affected by the HIV infection - (09/25/21)
     
  2403. AGE: Preliminary Hearing Data in Older Adults Living with 1HIV from 2the DETECT Study - (09/25/21)
     
  2404. AGE: Survey of Consumers, Clinicians and Service Providers about Needs of Long-Term Survivors and People Aging with HIV in New York State - (09/25/21)
     
  2405. AGE: Cognitive Impairment in Aging PLWH - Bruce Brew, MD lecture - (09/25/21)
     
  2406. AGE: NAFLD Independently Tied to Worse Physical Quality of Life With HIV - By Mark Mascolini - (09/25/21)
     
  2407. AGE: NAFLD Independently Tied to Worse Physical Quality of Life With HIV - (09/24/21)
     
  2408. AGE: Polypharmacy Halves Odds of Nonadherence to ART-Frailty Boosts Odds - (09/24/21)
     
  2409. AGE: Life Years Lost Due to Comorbidities 2.5 Time Greater With HIV - (09/24/21)
     
  2410. AGE: Less Healthy Response to Skeletal Muscle Damage in Older Men With HIV - Mark Mascolini (09/23/21)
     
  2411. AGE: Higher Viral Load Predicts Thromboembolism in People With HIV - Mark Mascolini (09/23/21)
     
  2412. AGE: Rare Menopausal Hormone Therapy in HIV+ Women Tied to Lack of Clinician Discussion - Mark Mascolini (09/23/21)
     
  2413. Intl Wrkshp Clin Pharm: Clinical Application for Coadministration of FTR and HCV medications - (09/22/21)
     
  2414. Intl Wrkshp Clin Pharm: Special Populations Including End Organ Failure: Focus on Long-Acting Cabotegravir and Rilpivirine - (09/22/21)
     
  2415. Intl Wrkshp Clin Pharm: Prevalence of clinically significant drug-drug interactions with antiretrovirals against HIV over time: a systematic review of the literature - (09/21/21)
     
  2416. Intl Wrkshp Clin Pharm: Risk of Low-Level HIV Rises With Each Worse TDF Adherence Level - Mark Mascolini - (09/21/21)
     
  2417. Intl Wrkshp Clin Pharm: Proposed Fostemsavir Precautions With HCV Meds - Mark Mascolini - (09/21/21)
     
  2418. Intl Wrkshp Clin Pharm: Dolutegravir Troughs Higher With 3TC, Lower With TAF - Mark Mascolini - (09/21/21)
     
  2419. Intl Wrkshp Clin Pharm: First 2 Reports of Bictegravir in Pregnancy Suggest Efficacy - Mark Mascolini - (09/21/21)
     
  2420. Intl Wrkshp Clin Pharm: No Drop in Rate of Drug-Drug & Interactions With HIV Drugs Since 1985 - Mark Mascolini - (09/21/21)
     
  2421. Congresswoman Barbara Lee and Jenniffer González continue to fight for those living with HIV Congressional HIV/AIDS Caucus Co-chairs introduce bipartisan bill (supporting aging/HIV & goals of HIV Awareness Ageing Day) - (09/21/21)
     
  2422. IAS: COMORBIDITIES AND AGEING; IMMUNOMETABOLISM AND HIV PATHOGENESIS; TB & HIV; HIV Natural Controllers - Christina K. Psomas, MD (09/20/21)
     
  2423. Intl Wrkshp Clin Pharm: Drug-Drug Interaction Risk High With COVID Meds in Hospital - Mark Mascolini - (09/20/21)
     
    2424. Intl Wrkshp Clin Pharm: New Oral Ribonucleoside Optimal at 800 mg Twice Daily vs SARS-CoV-2 - Mark Mascolini - (09/20/21)
     
    Intl Wrkshp Clin Pharm: Phase 1 Trial Suggests Antidiarrheal Nitazoxanide Dose for COVID - Mark Mascolini - (09/20/21)
     
  2424. COVID-19 Disease Severity among People with HIV Infection or Solid Organ Transplant in the United States: A Nationally-representative, Multicenter, Observational Cohort Study - (09/20/21)
     
  2425. Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial - (09/20/21)
     
  2426. CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz - (09/17/21)
     
  2427. Life-long Antiretroviral Therapy: Playing the Long Game (weight gain) - (09/17/21)
     
  2428. Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults - (09/16/21)
     
  2429. Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial - (09/16/21)
     
  2430. Behavioral and Clinical Characteristics of Persons Living with Diagnosed HIV Infection-Medical Monitoring Project, United States, 2019 Cycle - (09/15/21)
     
  2431. Behavioral and Clinical Characteristics of Persons Living with Diagnosed HIV Infection-Medical Monitoring Project, United States, 2019 Cycle - (09/15/21)
     
  2432. Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study - (09/14/21)
     
  2433. Ultra-long-acting removable drug delivery system for HIV treatment and prevention - (09/14/21)
     
  2434. Long-acting implants to treat and prevent HIV infection - (09/14/21)
     
  2435. IL-6 BLOCKADE DECREASES INFLAMMATION AND INCREASES CD127 EXPRESSION IN HIV INFECTION - (09/10/21)
     
  2436. HIV and antiretroviral therapy-related fat alterations - (09/02/21)
     
  2437. Fat & ART Effects in HIV, Comorbidities: Initiating ART Is Associated With Decreased Fat Density in People Living With HIV - (09/02/21)
     
  2438. Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials - (09/02/21)
     
  2439. IAS: Anxiety and Alcohol Consumption in the Miami Adult Studies on HIV (MASH) Cohort During the COVID-19 Pandemic - (09/01/21)
     
  2440. Food Insecurity Affects HIV+ Minorities & Associated with Comorbidities & Mortality - (09/01/21)
     
  2441. Managing frailty in people living with HIV: establishing and reviewing a new clinical service at Royal Free HIV Clinic London UK - (09/01/21)
     
  2442. Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV - (09/01/21)
     
  2443. IAS: Long-Acting Treatment: Cabotegravir/rilpivirine; Long-Acting Injectable PrEP HPTN 083, 084 - (08/31/21)
     
  2444. Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa - (08/31/21)
     
  2445. Heart Disease & HIV: statement from American Heart Association Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association - (08/31/21)
     
  2446. The challenge of HIV treatment in an era of polypharmacy - (08/31/21)
     
  2447. Aging, Comorbidities Screening Tests PWH Should Be Doing - (08/31/21)
     
  2448. IAS: DECLINE IN HIV TESTING AND CHANGES IN POSITIVITY RATES DURING THE COVID-19 PANDEMIC - (08/30/21)
     
  2449. IAS: Lenacapavir; Islatravir, Doravirine at IAS 2021 - (08/30/21)
     
  2450. IAS: Co-morbidity and HIV: What Matters to Patients ? - IAS Symposium - Growing old with HIV: Co-morbidities and ageing (CME) - (08/25/21)
     
  2451. Immunogenicity and safety of the BNT162b2 mRNA Covid-19 vaccine in people living with HIV-1 - (08/24/21)
     
  2452. Switch to Doravirine 2 Studies, DRIVE-SHIFT Real-Life Safety of Doravirine in Treatment-Experienced, Virologically Suppressed PLWHIV - (08/24/21)
     
  2453. Cerebrovascular Contributions to Neurocognitive Disorders in People Living With HIV - (08/24/21)
     
  2454. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine - FDA Grants Full Approval - (08/24/21)
     
  2455. IAS: HIV Immune Response to COVID - 2 studies: 1- Robust SARS-CoV-2-specific serological and functional t-cell immunity in PLWHIV, 2 - SARS-Cov-2 immunity in COVID-19 convalescent individuals living with HIV: bulk immune profiling and SARS-CoV-2 specific humoral and cellular immune responses - (08/24/21)
     
  2456. IAS: Virological suppression in people living with HIV infection is not protective of subclinical atherosclerosis - (08/24/21)
     
  2457. IAS: Low rates of testing for sexually transmitted infections in an insured cohort of men and women living with HIV - (08/24/21)
     
  2458. IAS: Chronic morphine administration alters gut-brain homeostasis in SHIV infected rhesus macaques - (08/24/21)
     
  2459. IAS: Food insecurity is associated with increased immune activation in people living with HIV - (08/24/21)
     
  2460. European Medicines Agency Validates Gilead's Marketing Authorization Application for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options - (08/23/21)
     
  2461. NYC Forum on Older People with HIV: Developing a Service Model for PWH Over 50 in NYC - (08/23/21)
     
  2462. IAS: Changes in Inflammation Scores Among People Living with HIV (PLWH) Under Different Antiretroviral Treatment (ART) Regimes - (08/23/21)
     
  2463. IAS: Baricitinib reduces macrophage-mediated inflammation in HIV infection - (08/23/21)
     
  2464. IAS: Ageing and renal insufficiency in persons living with and without HIV in AFRICOS - (08/23/21)
     
  2465. IAS: Daily Variations- HIV & Immunity, T-Cell Exhaustion in Vertically Acquired HIV-children/adolescents/adults - (08/23/21)
     
  2466. IAS: Circulating GDF15 levels [cellular stress] are associated with aging, risk of non-AIDS comorbidities and integrated HIV DNA in ART-treated people living with HIV - (08/23/21)
     
  2467. IAS: Stress & Aging, Sleep & Brain - (08/23/21)
     
  2468. IAS: Prioritizing the evaluation of HIV prevention interventions in pregnancy: Interim results from a randomized, open¬ label safety trial of dapivirine vaginal ring and oral tenofovir disoproxil fumarate/emtricitabine use in late pregnancy - (08/23/21)
     
  2469. IAS: Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention Among Women Who Engaged in Transactional Sex - (08/23/21)
     
  2470. Working HAND in HAND: Central nervous system complications in people with HIV - (08/21/21)
     
  2471. IAS: Dolutegravir + 3TC at IAS 2021 - (08/19/21)
     
  2472. IAS: Metabolics, Comorbidities & Aging at IAS 2021 - (08/15/21)
     
  2473. ACIP Aug 13 slides Immunocompromsed: Evidence to Recommendation Framework: An Additional Dose of mRNA COVID-19 Vaccine Following a Primary Series in Immunocompromised People - (08/13/21)
     
  2474. IAS: PSYCHOLOGICAL STRESS IS ASSOCIATED WITH CAROTID INFLAMMATION IN PERSONS WITH TREATED HIV INFECTION - (08/13/21)
     
  2475. IAS: Proteomic evidence of vesatolimod-induced enhancement of 'cross-talk' • between innate and adaptive immune cells in HIV controllers on ART - (08/11/21)
     
  2476. IAS: GS-9822, a preclinical LEDGIN, displays a block-and-lock phenotype in cell culture - (08/11/21)
     
  2477. IAS: LOWER HIV RESERVOIR SIZE IN INDIVIDUALS WHO MAINTAIN HIGHER CD4+ T CELL COUNTS PRIOR TO ANTIRETROVIRAL THERAPY INITIATION: THE STRATEGIC TIMING OF ANTIRETROVIRAL TREATMENT (START} HIV RESERVOIR STUDY. - (08/11/21)
     
  2478. IAS: Early treated individuals had lower reservoir size, lower viral diversity and higher susceptibility to bNAbs
    Evaluation of HIV-1 reservoir size and broadly neutralizing antibody (bNAb) susceptibility in individuals who initiated ART during acute and chronic infection     - (08/11/21)
     
  2479. Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States - (08/09/21)
     
  2480. Weight Change - Dolutegravir - Children, Adolescents - Intl Workshop on Pediatrics, HIV - (08/09/21)
     
  2481. HIV-1 PERSISTENCE IN THE CNS: MECHANISMS OF LATENCY, PATHOGENESIS AND AN UPDATE ON ERADICATION STRATEGIES - (08/09/21)
     
  2482. IAS: Switch to INSTI more than offset negative effects of weight gain on incidence of insulin resistance in people living with HIV - (08/09/21)
     
  2483. IAS: Combination of high liver and visceral fat predict diabetes in people living with HIV - (08/09/21)
     
  2484. B/F/TAF In Virologically Suppressed Adolescents and Children: Two-year Outcomes in 6 to <18 Year Olds and Six-month Outcomes in Toddlers - (08/06/21)
     
  2485. Long-term Safety & Efficacy of Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide Single-Tablet Regimen in Children and Adolescents Living With HIV - (08/06/21)
     
  2486. IAS: The association of coronary calcification with visceral adiposity in people living with HIV. Results from the Liverpool multiparametric imaging collaboration - (08/06/21)
     
  2487. IAS: Prevalence and predictors of elevated arterial blood pressure in ageing people living with HIV attending care in Zambia - (08/06/21)
     
  2488. IAS: Sexual Minority Stress and Accelerated Cellular aging in Treated HIV Infection - (08/06/21)
     
  2489. Weight Change - Dolutegravir - Children, Adolescents - Intl Workshop on Pediatrics, HIV - (08/05/21)
     
  2490. HIV-1 PERSISTENCE IN THE CNS: MECHANISMS OF LATENCY, PATHOGENESIS AND AN UPDATE ON ERADICATION STRATEGIES - (08/05/21)
     
  2491. IAS: Long-Acting Treatment & PrEP Key Studies at IAS 2021 - (08/04/21)
     
  2492. ACTG Starts New weight Gain, HIV Study Including Switch to Doravirine - (07/30/21)
     
  2493. Exposure to dolutegravir from two formulations in children in the ODYSSEY trial - Intl Pediatrics Workshop - (07/26/21)
     
  2494. Neuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trial - Intl Pediatrics Workshop - (07/26/21)
     
  2495. Efficacy, Safety and Tolerability of Guideline-Recommended ARVs from Pediatric Clinical Trials: A Systematic Review - Intl Pediatrics Workshop - (07/26/21)
     
  2496. Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial - Intl Pediatics Workshop - (07/26/21)
     
  2497. DOLUTEGRAVIR-BASED ART IS SUPERIOR TO STANDARD OF CARE IN YOUNG CHILDREN LIVING WITH HIV - Intl Pediatrics Workshop - (07/26/21)
     
  2498. ART & Cervical Cancer Women with HIV Risk - (07/26/21)
     
  2499. IAS: Immunoscenescence and HIV: mutual interactions? - (07/26/21)
     
  2500. IAS: Poor sleep quality in people with HIV linked to lower CSF amyloid beta 42 - (07/26/21)
     
  2501. IAS: HCV Reinfection Rate Almost 4% in Global Analysis of People With HIV - Mark Mascolini (07/26/21)
     
  2502. IAS: Drug Injecting Remains Barrier to HCV Elimination in Netherlands - Mark Mascolini (07/26/21)
     
  2503. IAS: HCV Cure Rate 92% in Hard-to-Reach Vietnam Drug-Injecting Group - Mark Mascolini (07/26/21)
     
  2504. Coronavirus Disease 2019 (COVID-19) Infection Among People With Human Immunodeficiency Virus in New York City: A Population-Level Analysis of Linked Surveillance Data - Commentary & paper 50% Higher COVID Deaths, hospitalizations & ICU due to COVID for PLWH vs HIV-Neg in NYC - (07/22/21)
     
  2505. IAS: Aging PLWH & Higher Readmission Hospital Rates than the General Population Hospital Readmissions Fall in Big HIV Group But Still High vs Non-HIV Patients - Mark Mascolini (07/23/21)
     
  2506. IAS: Good Adherence to Vaginal Ring and Daily PrEP in Half of Young African Women - Mark Mascolini (07/23/21)
     
  2507. IAS: Improving Hormone Levels in Transgenders Receiving Hormone Therapy - Mark Mascolini (07/23/21)
     
  2508. IAS: Fostemsavir Serious Adverse Events More Frequent in People Over 50, Men, North Americans - Mark Mascolini (07/23/21)
     
  2509. IAS: Integrase strand transfer inhibitor (INSTI) use and cancer incidence - Mark Mascolini (07/23/21)
     
  2510. IAS: Trichloroacetic Acid an Alternative to Electrocautery for Anal Cancer Precursor? - Mark Mascolini (07/23/21)
     
  2511. IAS: US MSM Seem Eager for Injectable PrEP-Side Effects, Cost Biggest Concerns - Mark Mascolini (07/23/21)
     
  2512. IAS: Achievement of Undetectable HIV-1 RNA in the B/F/TAF Treatment-Naïve Clinical Trials - (07/22/21)
     
  2513. IAS: Long-acting Capsid Inhibitor Effective as PrEP Against Vaginal SHIV Transmission in Macaques - (07/22/21)
     
  2514. IAS: Barriers to Expanding PrEP Uptake among cis-gender African American Women in the US South - (07/22/21)
     
  2515. IAS: Understanding participant experiences and preferences in an injectable PrEP trial: A qualitative substudy of barriers, facilitators, and preferences for PrEP use among MSM and TGW - (07/22/21)
     
  2516. IAS: CLINICAL IMPACT OF ANTIRETROVIRAL AGENTS USED IN OPTIMIZED BACKGROUND THERAPY WITH FOSTEMSAVIR IN HEAVILY TREATMENT-EXPERIENCED ADULTS WITH HIV-1: EXPLORATORY ANALYSES OF THE PHASE 3 BRIGHTE STUDY - (07/22/21)
     
  2517. IAS: LONG-TERM (96-WEEK) SAFETY OF FOSTEMSAVIR (FTR) IN HEAVILY TREATMENT-EXPERIENCED (HTE) ADULTS INFECTED WITH MULTIDRUG-RESISTANT (MDR) HIV-1 (BRIGHTE PHASE 3 STUDY) - (07/22/21)
     
  2518. IAS: Safety Analysis of Islatravir in Combination With Doravirine in Treatment-Naïve Adults With HIV-1 Infection Through 96 Weeks Islatravir/Doravirine Adverse Events Less Frequent in Second Half of 96-Week Trial - Mark Mascolini (07/22/21)
     
  2519. IAS: High interest in long-acting injectable HIV pre-exposure prophylaxis among nationwide online sample of United States men who have sex with men, 2019 - (07/22/21)
     
  2520. IAS: Variation in preferences for long-acting injectable PrEP among US men who have sex with men: a latent class analysis - (07/22/21)
     
  2521. IAS: Preferences for implementing long-acting injectable pre-exposure prophylaxis among cisgender men who have sex with men in the US - Online Survey - (07/22/21)
     
  2522. IAS: Safety Analysis of Islatravir in Combination With Doravirine in Treatment-Naïve Adults With HIV-1 Infection Through 96 Weeks - (07/22/21)
     
  2523. IAS: Safety and Pharmacokinetics of Oral Islatravir Once Monthly for HIV Pre-exposure Prophylaxis (PrEP): Week 24 Analysis of a Phase 2a Trial - (07/22/21)
     
  2524. IAS: Clinical characteristics and prognostic factors in people living with HIV hospitalized with COVID-19: findings from the WHO Global Clinical Platform - (07/22/21)
     
  2525. IAS: Unsuppressed plasma HIV-RNA is associated with worse COVID-19 outcomes among people living with HIV. - (07/22/21)
     
  2526. IAS: The association of cardiovascular risk factors and disease in people living with HIV in the UK: a retrospective matched cohort study - (07/21/21)
     
  2527. IAS: The association of cardiovascular risk factors and disease in people living with HIV in the UK: a retrospective matched cohort study Higher CVD Risk With HIV, Especially in People Younger Than 40 - Mark Mascolini - (07/21/21)
     
  2528. IAS: Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV - (07/21/21)
     
  2529. IAS: Higher comorbidity and comedication burden in women and young people living with HIV More Comorbidities, Polypharmacy With HIV-But Subgroup Differences Abound - (07/21/21)
     
  2530. IAS: Mitochondrial disorders in activated memory CD4+ T cells derived from HIV-infected immunological non-responders - (07/21/21)
     
  2531. IAS: Higher CVD Risk With HIV, Especially in People Younger Than 40 - Mark Mascolini - (07/21/21)
     
  2532. IAS: Real-world utilization of F/TDF and F/TAF for HIV Pre-exposure Prophylaxis during the COVID-19 pandemic in the US, December 2019-June 2020. - (07/21/21)
     
  2533. IAS: Outcomes of Participants Switching from F/TDF to F/TAF for PrEP: Week 48 Results from the DISCOVER Open Label Phase - (07/21/21)
     
  2534. IAS: Long-term Analysis of B/F/TAF in Treatment-Naïve Adults Living With HIV Through Four Years of Follow-up - (07/21/21)
     
  2535. IAS: Sub-40-Copy Virologic Hints May Favor DTG/3TC Over Multidrug Combos in TANGO - Mark Mascolini (07/21/21)
     
  2536. IAS: Only 1 More Virologic Failure on CAB + RPV in Weeks 96 to 124 of FLAIR - Mark Mascolini - (07/21/21)
     
  2537. IAS: CAB + RPV Failure Risk Factor in 10% of Large French Cohort - Mark Mascolini - (07/21/21)
     
  2538. IAS: Higher CVD Risk With HIV, Especially in People Younger Than 40 - Mark Mascolini - (07/21/21)
     
  2539. IAS: Impact of HIV on COVID-19 Outcomes among Hospitalized Adults in the U.S. - (07/21/21)
     
  2540. IAS: Long-acting injectable PrEP in women: laboratory analysis of HIV infections in HPTN 084 - (07/21/21)
     
  2541. IAS: WEEK 124 OF THE RANDOMIZED, OPEN-LABEL, PHASE 3 FLAIR STUDY EVALUATING LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR TREATMENT IN ADULTS WITH HIV-1 INFECTION - (07/21/21)
     
  2542. IAS: Low Proportion of Individuals Develop Metabolic Syndrome (MetS) or Hepatic Fibrosis After Switch to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed Patients: A Post Hoc Metabolic Analysis - (07/21/21)
     
  2543. IAS: Prevalence of genotypic baseline risk factors of Cabotegravir + Rilpivirine failure among ARV-naïve patients - (07/21/21)
     
  2544. IAS: Efficacy and safety of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV: week 26 results (Capella study) - (07/20/21)
     
  2545. IAS: CLINICAL OUTCOMES DURING CUSTOMIZE: A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY FOCUSED ON IMPLEMENTATION OF CABOTEGRAVIR PLUS RILPIVIRINE (CAB + RPV) LA IN US HEALTHCARE SETTINGS - (07/20/21)
     
  2546. IAS: CUSTOMIZE: OVERALL RESULTS FROM A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY EXAMINING IMPLEMENTATION OF CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING INJECTABLE FOR HIV TREATMENT IN US HEALTHCARE SETTINGS; FINAL PATIENT AND PROVIDER DATA - (07/20/21)
     
  2547. IAS: CAB + RPV LA IMPLEMENTATION OUTCOMES AND ACCEPTABILITY OF MONTHLY CLINIC VISITS IMPROVED DURING COVID-19 PANDEMIC ACROSS US HEALTHCARE CLINICS (CUSTOMIZE: HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY) - (07/20/21)
     
  2548. IAS: Every-6-Month Lenacapavir With F/TAF Controls HIV Through 28 Weeks - Mark Mascolini (07/20/21)
     
  2549. IAS: Single-Pill DTG/3TC Effective in Suppressed People for 48 Weeks: SALSA - Mark Mascolini (07/20/21)
     
  2550. IAS: Long-acting subcutaneous lenacapavir dosed every 6 months as part of a combination regimen in treatment-naïve people with HIV: interim 16-week results of a randomized, open-label, phase 2 induction-maintenance study (CALIBRATE) - (07/20/21)
     
  2551. IAS: lntegrase strand transfer inhibitor (INSTI) use and cancer incidence - (07/20/21)
     
  2552. IAS: FEASIBILITY, EFFICACY, AND SAFETY OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) AS A FIRST-LINE REGIMEN IN A TEST-AND-TREAT SETTING FOR NEWLY DIAGNOSED PEOPLE LIVING WITH HIV (PLWH): 48-WEEK RESULTS OF THE STAT STUDY - (07/20/21)
     
  2553. IAS: SWITCHING TO THE 2-DRUG REGIMEN OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) FIXED-DOSE COMBINATION IS NON-INFERIOR TO CONTINUING A 3-DRUG REGIMEN THROUGH 48 WEEKS IN A RANDOMIZED CLINICAL TRIAL (SALSA) - (07/20/21)
     
  2554. IAS: COMPARISON OF VIRAL REPLICATION FOR THE 2-DRUG REGIMEN (2DR) OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) VERSUS A 3/4-DRUG TENOFOVIR ALAFENAMIDE-BASED REGIMEN (TBR) IN THE TANGO STUDY THROUGH WEEK 96 - (07/20/21)
     
  2555. IAS: Comparing adherence to HIV Pre-Exposure Prophylaxis (PrEP) among new, male PrEP users initiating F/TAF vs. F/TDF - (07/20/21)
     
  2556. IAS: Long-term Efficacy Among Participants Switched to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) with Preexisting Resistance and Viral Blips - (07/20/21)
     
  2557. IAS: Week 72 Outcomes and COVID-19 Impact From the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in Black American Adults With HIV - (07/20/21)
     
  2558. IAS: Higher comorbidity and co-medication burden in women and young people living with HIV - (07/20/21)
     
  2559. IAS: Real-world utilization of F/TDF and F/TAF for HIV Pre-exposure Prophylaxis during the COVID-19 pandemic in the US, December 2019-June 2020 - Mark Mascolini (07/20/21)
     
  2560. IAS: METABOLIC HEALTH OUTCOMES AT WEEK 144 IN THE TANGO STUDY, COMPARING A SWITCH TO DTG/3TC VERSUS MAINTENANCE OF TAF-BASED REGIMENS - (07/20/21)
     
  2561. IAS: DTG + 3TC IN GEMINI-1 & -2: HIV-1 REPLICATION AT <50 C/ML AND VL 'BLIPS' THROUGH 144 WEEKS - (07/20/21)
     
  2562. IAS: Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged 65 years or older: week 96 results from an international, Phase 3b, open-label trial - (07/19/21)
     
  2563. IAS: The safety and efficacy of maintenance with doravirine/lamivudine/tenofovir through 192 weeks in adults with HIV-1: Results from the DRIVE-AHEAD clinical trial - (07/19/21)
     
  2564. IAS: Week 96 Metabolic and Bone Outcomes of a Phase 2b Trial of Islatravir and Doravirine - (07/19/21)
     
  2565. IAS: SARS-CoV-2 Rate Similar in TDF PrEP Users and Matched No-TDF Controls - Mark Mascolini (07/19/21)
     
  2566. IAS: ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19 - (07/19/21)
     
  2567. IAS: ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs - (07/19/21)
     
  2568. IAS: ViiV Healthcare to present new data from diverse portfolio and pipeline of 2-drug and long-acting regimens for HIV treatment and prevention at IAS 2021 - (07/19/21)
     
  2569. IAS: Four-Year Biktarvy® Data Presented at IAS 2021 Demonstrate High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults - (07/19/21)
     
  2570. IAS: New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor - (07/19/21)
     
  2571. IAS: Gilead to Present New Data at IAS 2021 Demonstrating the Company's Commitment to Advancing Innovation in HIV Research - (07/19/21)
     
  2572. WHO warns that HIV infection increases risk of severe and critical COVID-19 - (07/15/21)
     
  2573. ART & Cervical Cancer Women with HIV Risk - (07/14/21)
     
  2574. An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging - (07/14/21)
     
  2575. IAS: Gilead to Present New Data at IAS 2021 Demonstrating the Company's Commitment to Advancing Innovation in HIV Research - (07/12/21)
     
  2576. IAS: Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021 - (07/12/21)
     
  2577. 2 New studies: Diabetes-Depression-Women & High Suicide Rates PLWH - (07/09/21)
     
  2578. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M) - (07/09/21)
     
  2579. Moving on From HAND: Why We Need New Criteria for Cognitive Impairment in Persons Living With HIV and a Proposed Way Forward - (07/09/21)
     
  2580. EASL: Mortality risk following HCV cure among people with HCV/HIV co-infection (07/06/21)
     
  2581. ACTG Reports REPRIEVE Study HIV+ Heart Disease Risk with CT Angiography - (07/05/21)
     
  2582. Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options - (07/02/21)
     
  2583. ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV - (06/22/21)
     
  2584. Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial - (06/29/21)
     
  2585. Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir - (06/22/21)
     
  2586. Sudden Cardiac Death and Myocardial Fibrosis, Determined by Autopsy, in Persons with HIV - (06/21/21)
     
  2587. NYC Planning Council talk by Jules: Aging with HIV in the US & NYC-clinical & community care & services needs, unmet needs - (06/14/21)
     
  2588. Medicare PLWH: Blacks & Latinos 4-Fold Greater Risk - (06/14/21)
     
  2589. HHS-Older PLWH Reduced Survival by 3.6 times & More Comorbidities - (06/14/21)
     
  2590. Racial, ethnic, and gender disparities in hospitalizations among persons with HIV in the United States and Canada, 2005-2015 - (06/09/21)
     
  2591. Redistribution of brain glucose metabolism in people with HIV after antiretroviral therapy initiation - (06/09/21)
     
  2592. Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated Biomarkers - (06/09/21)
     
  2593. Assessing the health status and mortality of older people over 65 with HIV - greater mortality, more comorbidities - (06/07/21)
     
  2594. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study - (06/05/21)
     
  2595. Clinical features and outcomes of COVID-19 among people living with HIV in the United States: A multicenter study from a large global health research network (TriNetX) - PWH had higher rates of poor COVID outcomes - (06/05/21)
     
  2596. Bictegravir-Based Antiretroviral Therapy-Associated Accelerated Hyperglycemia and Diabetes Mellitus - (06/05/21)
     
  2597. Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial - (06/05/21)
     
  2598. HIV/AIDS at 40: COVID Could Increase by 10% Rates in HIV-related Deaths; PLWH with HIV & Undetectable HIV RNA may Experience 13 years Accelerated Aging, Fauci - (06/05/21)
     
  2599. HIV and Hepatitis C Linkage-to-Care Initiative for New Orleans Residents Experiencing Homelessness During the COVID-19 Pandemic - (06/01/21)
     
  2600. With No End in Sight on Omega-3 Debate, Nissen Calls for More Trials - Fish Oils/New Study "No strong evidence they prevent CVD events" - (05/18/21)
     
  2601. Organ Reserve, Excess Metabolic Capacity, and Aging - (05/18/21)
     
  2602. A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir - (05/16/21)
     
  2603. HIV disease duration, but not active brain infection, predicts cortical amyloid beta deposition - (05/11/21)
     
  2604. New Data on Colchicine Bring Conflicting Results - (05/10/21)
     
  2605. Cognitive change trajectories in virally suppressed HIV-infected individuals indicate high prevalence of disease activity - (05/10/21)
     
  2606. Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus - undetectable HIV viral load reduced risk - (05/10/21)
     
  2607. Kidney injury biomarkers during exposure to tenofovir-based preexposure prophylaxis - (05/10/21)
     
  2608. Changes in Glomerular Kidney Function Among HIV-1 Uninfected Men and Women Receiving Emtricitabine Tenofovir Disoproxil Fumarate Preexposure Prophylaxis -A Randomized Clinical Trial - (05/10/21)
     
  2609. HPV vaccination to prevent recurrence of Anal Intraepithelial Neoplasia in HIV+ MSM - a randomised, placebo-controlled multicentre trial - (05/10/21)
     
  2610. Changes in Fat Mitochondrial DNA and Function in Subjects Randomized to Abacavir-Lamivudine or Tenofovir DF-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: AIDS Clinical Trials Group Study A5224s, Substudy of A5202 - (05/10/21)
     
  2611. Cabotegravir for PrEP -083, 084 recent data - (05/04/21)
     
  2612. ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV - (05/04/21)
     
  2613. Risk of Hepatocellular Carcinoma with Hepatitis B Viremia among HIV/Hepatitis B Virus Coinfected Persons in North America - (05/03/21)
     
  2614. Accelerated Brain Aging and Cerebral Blood Flow Reduction in Persons With Human Immunodeficiency Virus - (04/29/21)
     
  2615. Genital Inflammation & HIV Acqusition Associated in Women.....STIs also associated with Inflammation & HIV Acquisition - new study - (06/26/15)
     
  2616. LATEST UPDATE ON HIV LIPODYSTROPHY: Interview with Dr Grace McComsey - (04/17/17)
     
  2617. 75-85% in SF-NY-Florida-Boston with HIV Are Over 40 Years Old....25% over 60 in SF-Florida-NY - (09/04/19)
     
  2618. CROI: COVID & HIV - Antiviral Molnupiravir, monoclonal antibody combinations, Convalesecent Plasma - (03/19/21)
     
  2619. CROI: CANNABIS USE ASSOCIATED WITH DECREASED ART ADHERENCE IN AGING PEOPLE WITH HIV - (05/10/21)
     
  2620. CROI: FEMINIZING THERAPY DECREASES D-DIMER BUT WORSENS INSULIN SENSITIVITY IN TRANS WOMEN - (05/08/21)
     
  2621. CROI: 28th Virtual Conference on Retroviruses and Opportunistic Infection March 7-10, 2021 Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center - (04/27/21)
     
  2622. CROI: CROI 2021 Highlights
    By Christina K. Psomas
    European Hospital Marseille, Marseille, France - (04/26/21)
     
  2623. CROI: Clinical Pharmacology at CROI 2021. New Drugs & Formulations; PrEP; HIV Treatment - Courtney V. Fletcher, Pharm.D. Professor UNMC Center for Drug Discovery University of Nebraska Medical Center 986000 Nebraska Medical Center - (04/21/21)
     
  2624. CROI: LOWER UPTAKE OF DOLUTEGRAVIR AMONG WOMEN OF REPRODUCTIVE POTENTIAL VS MEN-KENYA - (04/14/21)
     
  2625. CROI: DRAMATIC DECLINE IN PUBLIC SECTOR HIV/STI TESTING DURING SARS-CoV-2 PANDEMIC, OREGON - (04/13/21)
     
  2626. CROI: HIV Prevention at CROI 2021. NATAP Report by Renee Heffron, PhD and Connie Celum, MD, University of Washington - (04/13/21)
     
  2627. CROI: Summary from virtual CROI 2021 for HIV and liver disease HIV and the liver: hot topics - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (04/10/21)
     
  2628. CROI: SERUM BIOMARKERS IDENTIFY CARDIAC DYSFUNCTION IN (perinatally infected) YOUTH LIVING WITH HIV - (04/06/21)
     
  2629. CROI: QUINOLINIC ACID IS ASSOCIATED WITH CAROTID INTIMA-MEDIA THICKNESS IN HIV - (04/06/21)
     
  2630. CROI: DORAVIRINE CONCENTRATIONS AND HIV-1 RNA SUPPRESSION IN MALE AND FEMALE GENITAL FLUIDS - (04/06/21)
     
  2631. CROI: TRENDS IN TRUVADA AND DESCOVY PRESCRIPTIONS FOR PrEP IN THE UNITED STATES, 2014-2020 - (04/05/21)
     
  2632. CROI: TOTAL AND UNBOUND DORAVIRINE CONCENTRATIONS AND VIRAL SUPPRESSION IN CSF OF HIV+ PTS - (04/05/21)
     
  2633. CROI: VIRUS REMISSION WITH AN OPTIMIZED EARLY ART REGIMEN IN MACAQUES - (04/05/21)
     
  2634. CROI: IMPAACT 2014 24-WEEK PK AND SAFETY OF DORAVIRINE/3TC/TDF IN ADOLESCENTS WITH HIV-1 - (04/05/21)
     
  2635. CROI: REMDESIVIR VERSUS STANDARD OF CARE FOR SEVERE COVID-19 - (04/05/21)
     
  2636. CROI: ACUTE KIDNEY INJURY IN PATIENTS WITH MODERATE COVID-19 TREATED WITH RDV VERSUS SoC - (04/05/21)
     
  2637. CROI: TREATMENT AND OUTCOMES OF COVID-19 IN THE US: ARE THEY DIFFERENT ACCORDING TO RACE? - (04/05/21)
     
  2638. CROI: SAFETY AND EFFICACY OF REMDESIVIR IN A PEDIATRIC COVID-19 POPULATION - (04/05/21)
     
  2639. CROI: VASCULAR INJURY MARKERS ASSOCIATED WITH COGNITIVE IMPAIRMENT IN HIV PATIENTS ON ART - (03/30/21)
     
  2640. CROI: SEX DIFFERENCES IN WHITE-MATTER LOSS AND ASSOCIATED AXONAL INJURY IN PLWH - (03/30/21)
     
  2641. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV - A Cohort Study - (03/28/21)
     
  2642. CROI: RELATIONSHIP OF T-CELL MITOCHONDRIAL GENE EXPRESSION AND DIABETES IN PERSONS WITH HIV - (03/28/21)
     
  2643. CROI: ELUCIDATING THE ORIGINS OF HIV-1 IN THE CEREBROSPINAL FLUID - (03/28/21)
     
  2644. CROI: CORONARY ARTERY DISEASE, TRADITIONAL RISK, AND INFLAMMATION AMONG PWH IN REPRIEVE - (03/28/21)
     
  2645. CROI: Women & HIV at CROI - (03/28/21)
     
  2646. CROI: Neurocognition & PLWH - CROI 2021 - (03/28/21)
     
  2647. CROI: Laboratory Analysis of HIV Infections in HPTN 083: Injectable CAB for PrEP - (03/26/21)
     
  2648. CROI: HIV AMBULATORY CARE DURING COVID-19 PANDEMIC IN US: VISITS AND VIRAL LOAD TESTING - "dropped precipitously" - (03/20/21)
     
  2649. CROI: IMPACT OF COVID-19 ON COMMERCIAL LABORATORY TESTING FOR HIV IN THE UNITED STATES - (03/22/21)
     
  2650. CROI: COVID & HIV - Antiviral Molnupiravir, monoclonal antibody combinations, Convalesecent Plasma - (03/19/21)
     
  2651. CROI: Weight Gain / Loss - (03/19/21)
     
  2652. CROI: New PrEP at CROI 2021 - (03/19/21)
     
  2653. CROI: CROI 2021 - Complications: HIV, COVID - (03/19/21)
     
  2654. CROI: CROI 2021 - New HIV Drugs - (03/19/21)
     
  2655. CROI: Aging & HIV Highlights at CROI 2021 - (03/25/21)
     
  2656. CROI: STATIN USE AND COGNITIVE PERFORMANCE IN THE MULTICENTER AIDS COHORT STUDY - (03/26/21)
     
  2657. CROI: DECREASED HIV DIAGNOSES AMONG MSM OF COLOR IN THRIVE-FUNDED JURISDICTIONS, 2014-2018 - (03/25/21)
     
  2658. CROI: GENDER-AFFIRMING SURGERY ASSOCIATED WITH HIGH VIRAL SUPPRESSION AMONG TRANSGENDER PWH - (03/25/21)
     
  2659. CROI: IMPACT OF COMMON SIDE EFFECTS ON PrEP PERSISTENCE DURING PREGNANCY IN SOUTH AFRICA - (03/25/21)
     
  2660. CROI: COST-EFFECTIVENESS OF LONG-ACTING PrEP AMONG MSM/TGW IN THE US - (03/25/21)
     
  2661. CROI: EPIGENETIC AGING ASSOCIATED WITH COGNITIVE IMPAIRMENT IN OLDER BLACK ADULTS WITH HIV - (03/24/21)
     
  2662. CROI: DEMENTIA INCIDENCE AMONG ART-TREATED PEOPLE WITH HIV IN A PRIMARY CARE SETTING - (03/24/21)
     
  2663. CROI: NEUROCOGNITIVE DYSFUNCTION, INFLAMMATION, AND ADIPOSITY IN TREATED HIV PATIENTS - (03/24/21)
     
  2664. CROI: PWH AND ALZHEIMER'S DISEASE RISK: CLARIFYING THE HAND PHENOTYPE OVER TIME - (03/24/21)
     
  2665. CROI: HEPATITIS B SEROPROTECTION AMONG YOUNG ADULTS LIVING WITH PERINATALLY ACQUIRED HIV - (03/23/21)
     
  2666. CROI: BARRIERS IMPACTING TELEHEALTH MEDICAL-APPOINTMENT ADHERENCE AMONG PLWHA - (03/23/21)
     
  2667. CROI: PrEP USE AND REFERRAL: BLACK PARTNERS OF PEOPLE WITH HIV IN PARTNER SERVICES, 2019 - (03/22/21)
     
  2668. CROI: A SURVEY-BASED PILOT STUDY TO ASSESS THE EFFECTS OF COVID-19 ISOLATION ON OLDER PLWH - (03/22/21)
     
  2669. CROI: LOW PROPORTIONS OF LINKAGE & PRESCRIPTIONS OF PrEP IN BLACK WOMEN (THRIVE, 2015-2020) - (03/22/21)
     
  2670. CROI: CHANGES IN ACCESS TO CARE FOR WOMEN LIVING WITH HIV DURING THE COVID-19 PANDEMIC - (03/22/21)
     
  2671. CROI: PLWH AND CANCER EXHIBIT UNIQUE PATTERN OF ACTIVATED AND EXHAUSTED CD38+ T CELLS - (03/22/21)
     
  2672. CROI: RANDOMIZED CONTROLLED TRIAL OF MARAVIROC FOR HIV-ASSOCIATED NEUROCOGNITIVE IMPAIRMENT - (03/22/21)
     
  2673. CROI: THE USE OF LESS NEUROTOXIC ANTIRETROVIRALS: SECONDARY ENDPOINTS OF THE MARAND-X STUDY - (03/22/21)
     
  2674. CROI: IMMUNE MARKERS AND TO TIME TO REBOUND DURING HIV TREATMENT INTERRUPTION IN ACTG A5345 - (03/22/21)
     
  2675. CROI: PHARMACY REVERSALS: A NOVEL INDICATOR OF GAPS IN THE HIV PrEP CARE CASCADE - (03/21/21)
     
  2676. CROI: A NOVEL APPROACH TO MEASURE PrEP UPTAKE AMONG POPULATIONS WITH PERSISTENT HIV RISK - (03/21/21)
     
  2677. CROI: IMMUNE MARKERS AND TO TIME TO REBOUND DURING HIV TREATMENT INTERRUPTION IN ACTG A5345 - (03/21/21)
     
  2678. CROI: PREDICTORS OF PrEP UPTAKE IN A SEXUAL HEALTH CLINIC WITH IMMEDIATE PrEP INITIATION - (03/20/21)
     
  2679. CROI: RISK OF CANCER BY HIV STATUS AND BIRTH REGION: A NATIONWIDE REGISTER-BASED STUDY - (03/20/21)
     
  2680. CROI: ACTIVATING PKC-ε INDUCES HIV EXPRESSION WITH IMPROVED TOLERABILITY - (03/19/21)
     
  2681. CROI: HIV REBOUND IN CONTROLLERS IS ASSOCIATED WITH SPECIFIC FECAL MICROBIOME PROFILE - (03/19/21)
     
  2682. CROI: MATHEMATICAL MODELING OF PREDICTORS OF POSTTREATMENT CONTROL IN HIV CURE TRIALS - (03/19/21)
     
  2683. CROI: EVALUATION OF bNAb SENSITIVITY BY GENOTYPING AND PHENOTYPING FOR HIV CLINICAL TRIALS - (03/19/21)
     
  2684. CROI: ULTRASENSITIVE HIV-1 DRUG-RESISTANCE ANALYSIS IN THE DISCOVER PrEP TRIAL - (03/19/21)
     
  2685. CROI: THE ANTIRETOVIRAL PREGNANCY REGISTRY: 30 YEARS OF MONITORING FOR CONGENITAL ANOMALIES - (03/19/21)
     
  2686. CROI: SEX DIFFERENCES IN DIABETES PREVELANCE AMONG PERSONS WITH HIV IN THE UNITED STATES...40% of HIV+ Women >65 have diabetes. - (03/19/21)
     
  2687. CROI: IMPACT OF REPRODUCTIVE AGING ON HIV PERSISTENCE IN CISGENDER MEN AND WOMEN WITH HIV - (03/19/21)
     
  2688. CROI: ACCELERATED CEREBRAL BLOOD-FLOW REDUCTION AND BRAIN AGING IN PEOPLE LIVING WITH HIV PLWH associated with accelerated brain age - (03/18/21)
     
  2689. CROI: INCIDENT DIABETES ASSOCIATED WITH INTEGRASE STRAND TRANSFER INHIBITOR INITIATION - (03/18/21)
     
  2690. CROI: CSF MARKERS OF AD-RELATED PATHOLOGY AND MEMORY DEFICITS IN OLDER PEOPLE WITH HIV - (03/18/21)
     
  2691. CROI: Incidence of HIV infection with daily or on-demand oral PrEP with TDF/FTC in France - (03/18/21)
     
  2692. Burden of Hypertension, Diabetes, Cardiovascular Disease, and Lung Disease Among Women Living With Human Immunodeficiency Virus (HIV) in the United States - (03/18/21)
     
  2693. Global data shows increasing PrEP use and widespread adoption of WHO PrEP recommendations - (03/18/21)
     
  2694. CROI: Incidence of HIV infection with daily or on-demand oral PrEP with TDF/FTC in France - (03/17/21)
     
  2695. CROI: NEURON DAMAGE AND RESERVOIR ARE SECONDARY TO HIV TRANSCRIPTS DESPITE SUPPRESSIVE ART - (03/17/21)
     
  2696. CROI: DRUG-USE STIGMA AND HEPATITIS C VIRUS INFECTION AMONG PWID IN INDIA - (03/17/21)
     
  2697. CROI: ACCESS TO HCV CARE AMONG HIV/HCV-COINFECTED PEOPLE WHO INJECT DRUGS ACROSS CANADA - (03/16/21)
     
  2698. CROI: HIV/HCV COINFECTION TRENDS IN SPAIN (2015-2019) - (03/16/21)
     
  2699. CROI: NO CHANGE IN INCIDENCE OF RECENTLY ACQUIRED HCV IN HIV+ MSM IN GERMANY (NOCO COHORT) - (03/16/21)
     
  2700. CROI: HEPATITIS C CASCADE OF CARE IN HIV/HCV-COINFECTED PERSONS IN EUROPE IN THE DAA ERA - (03/16/21)
     
  2701. CROI: SELF-TESTING FOR HCV: MULTICOUNTRY EVIDENCE ON USABILITY AND ACCEPTABILITY - (03/16/21)
     
  2702. CROI: COST-EFFECTIVENESS OF HCV TESTING STRATEGIES FOR HCV ELIMINATION AMONG MSM IN THE US - (03/16/21)
     
  2703. CROI: REINFECTION WITH THE HEPATITIS C VIRUS IN MEN WHO HAVE SEX WITH MEN - (03/16/21)
     
  2704. CROI: PREVALENCE AND FACTORS ASSOCIATED WITH SARS-CoV-2 ANTIBODIES IN A SPANISH HIV COHORT - (03/16/21)
     
  2705. CROI: COVID-19 IN HOSPITALIZED HIV-POSITIVE AND HIV-NEGATIVE PATIENTS: A MATCHED STUDY - (03/16/21)
     
  2706. Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV - (03/15/21)
     
  2707. CROI: SECOND ANTIRETROVIRAL THERAPY REGIMEN IN VIREMIC PEOPLE WITH HIV IN THE US, 2008-2018 - (03/15/21)
     
  2708. CROI: CHARACTERIZING FIRST VIRAL FAILURES AMONG ANTIRETROVIRAL THERAPY INITIATORS IN THE US - (03/15/21)
     
  2709. CROI: Dual mAb Prevents Symptomatic COVID-19 in Household-Exposed Group: Interim Results of Placebo-Controlled Trial - Mark Mascolini (03/15/21)
     
  2710. CROI: RISK FACTORS FOR HOSPITALIZATION IN PEOPLE WITH HIV AND COVID-19 - (03/15/21)
     
  2711. CROI: T-CELL IMMUNE DYSREGULATION AND MORTALITY IN WOMEN WITH HIV - (03/15/21)
     
  2712. CROI: Risk factors for progression from prediabetes to diabetes in persons with HIV - Integrase Inhibitors Tied to Lower Risk of Progression from Prediabetes to Diabetes - HAILO - Mark Mascolini - (03/15/21)
     
  2713. CROI: PREDICTED 10-YEAR RISKS OF CARDIOVASCULAR DISEASE AND DIABETES IN THE ADVANCE TRIAL - (03/15/21)
     
  2714. CROI: CARDIOMETABOLIC HEALTH IN HIV+ AND HIV- PREGNANT SOUTH AFRICAN WOMEN - (03/15/21)
     
  2715. CROI: CASIRIVIMAB WITH IMDEVIMAB ANTIBODY COCKTAIL FOR COVID-19 PREVENTION: INTERIM RESULTS - (03/15/21)
     
  2716. CROI: PREDICTED LONG-TERM ADVERSE BIRTH AND CHILD HEALTH OUTCOMES IN THE ADVANCE TRIAL - (03/15/21)
     
  2717. CROI: In US Groups COVID Testing More Likely With HIV, But Positivity Similar With/Without HIV - Mark Mascolini (03/15/21)
     
  2718. CROI: HIV-1 DNA GENOTYPING IS OFTEN VARIABLE IN REPEAT TESTING FROM SINGLE BLOOD DRAWS - (03/15/21)
     
  2719. CROI: URINE MITOCHONDRIAL DNA, WEIGHT LOSS, AND BODY COMPOSITION IN OLDER ADULTS WITH HIV - (03/14/21)
     
  2720. CROI: COMORBIDITY BURDEN IS ASSOCIATED WITH HOSPITALIZATION FOR COVID-19 AMONG PWH - (03/14/21)
     
  2721. CROI: CHARACTERIZING COVID-19 PRESENTATION AND CLINICAL OUTCOMES IN HIV PATIENTS IN THE US - (03/14/21)
     
  2722. CROI: Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir - (03/14/21)
     
  2723. CROI: Online Mindfulness Lessons Ease Depression, Anxiety in Older HIV+ During COVID - Mark Mascolini (03/14/21)
     
  2724. CROI: IN VITRO MODEL TO ASSESS ANTIRETROVIRAL THERAPY ON ADIPOCYTE BIOLOGY - (03/14/21)
     
  2725. CROI: BEYOND PAIN: PRESCRIPTION OPIOID USE IN THE WOMEN'S INTERAGENCY HIV STUDY - (03/14/21)
     
  2726. CROI: ASSOCIATION BETWEEN INTEGRASE INHIBITORS (InSTIs) AND CARDIOVASCULAR DISEASE (CVD) - (03/14/21)
     
  2727. CROI: INFLAMMATORY AND ATHEROGENESIS MARKERS 148 WEEKS POSTSWITCH TO DTG+RPV IN SWORD-1/ -2 - (03/14/21)
     
  2728. CROI: RENAL/BONE OUTCOMES AFTER LONG-ACTING CABOTEGRAVIR + RILPIVIRINE IN ATLAS + ATLAS-2M - (03/14/21)
     
  2729. CROI: WEIGHT GAIN POST-ART IN HIV+ LATINOS/AS DIFFERS IN THE US, CANADA, AND LATIN AMERICA - (03/14/21)
     
  2730. CROI: CHARACTERISTICS OF HIV+ AND HIV- PATIENTS UNDERGOING BARIATRIC SURGERY: OBEVIH STUDY - (03/14/21)
     
  2731. CROI: HEROIN USE IS ASSOCIATED WITH HIGH-AORTIC BUT LOW-SPLEEN/ MARROW UPTAKE BY PET IN HIV - (03/14/21)
     
  2732. CROI: HIV Linked to 4.5-Fold Higher Risk of Aortic Aneurysm - Mark Mascolini (03/14/21)
     
  2733. CROI: BEYOND PAIN: PRESCRIPTION OPIOID USE IN THE WOMEN'S INTERAGENCY HIV STUDY - (03/12/21)
     
  2734. CROI: Acute Kidney Injury Less Frequent With Remdesivir Than Standard of Care - Mark Mascolini (03/12/21)
     
  2735. CROI: HIV REPLICATION IN THE CNS IS ASSOCIATED WITH NEUROCOGNITION AND DEPRESSION PRE-ART - (03/12/21)
     
  2736. CROI: FACTORS ASSOCIATED WITH SYSTEMIC IMMUNE ACTIVATION IN A GLOBAL HIV COHORT - (03/12/21)
     
  2737. CROI: INTRANASAL INSULIN IMPROVES ATTENTION AND MEMORY IN PEOPLE WITH HIV - (03/12/21)
     
  2738. CROI: HIV-1, INSUFFICIENT SLEEP, AND ENDOTHELIAL VASODILATOR FUNCTION - (03/12/21)
     
  2739. CROI: FTC-TP in Dried Blood Spots Predicts Future Detectable Viral Load in US Study - Mark Mascolini (03/12/21)
     
  2740. CROI: Resistance and Response in Phase 2a Study of HIV Maturation Inhibitor - Mark Mascolini (03/12/21)
     
  2741. CROI: Favipiravir Has Clinical Pluses vs Standard Care for In-Hospital COVID-19 - Mark Mascolini (03/12/21)
     
  2742. CROI: A PLACEBO-CONTROLLED ATI TRIAL OF HTI VACCINES IN EARLY TREATED HIV INFECTION - (03/12/21)
     
  2743. CROI: DIET QUALITY BY GLOBAL BURDEN OF DISEASE REGION IN PWH IN THE REPRIEVE TRIAL - (03/12/21)
     
  2744. CROI: MATERNAL WEIGHT AND ADVERSE PREGNANCY OUTCOMES AMONG WOMEN ON ART AT CONCEPTION - (03/11/21)
     
  2745. CROI: ANTEPARTUM WEIGHT GAIN AND ADVERSE PREGNANCY OUTCOMES IN IMPAACT 2010 - (03/11/21)
     
  2746. CROI: SAFETY/EFFICACY OF DTG VS EFV, TDF VS TAF IN PREGNANCY/POSTPARTUM: IMPAACT 2010 TRIAL - (03/11/21)
     
  2747. CROI: Complex Vaccine-Escape Mutation Profiles in 947 People With HBV - Mark Mascolini - (03/11/21)
     
  2748. CROI: PHASE 1 PK, SAFETY, AND ACCEPTABILITY STUDY OF 3-MONTH DAPIVIRINE VAGINAL RINGS - (03/11/21)
     
  2749. CROI: RCT OF AN ONLINE MENTAL HEALTH INTERVENTION AMONG OLDER PLWH DURING COVID-19 PANDEMIC - Improved Depression, Anxiety & Loneliness - (03/11/21)
     
  2750. CROI: HIGHER COMORBIDITY BURDEN PREDICTS WORSENING NEUROCOGNITION IN PEOPLE WITH HIV - (03/11/21)
     
  2751. CROI: New PrEP at CROI 2021 - (03/11/21)
     
  2752. CROI: WEEK 96 EFFICACY AND SAFETY OF CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS: ATLAS-2M - (03/11/21)
     
  2753. CROI: Three-Month Vaginal Ring Yields Higher Dapivirine Levels in US Study - Mark Mascolini (03/10/21)
     
  2754. CROI: Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021 - (03/10/21)
     
  2755. CROI: ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV - (03/10/21)
     
  2756. CROI: DOLUTEGRAVIR-BASED ART IS SUPERIOR TO NNRTI/PI-BASED ART IN CHILDREN AND ADOLESCENTS - (03/10/21)
     
  2757. CROI: BAMLANIVIMAB+ETESEVIMAB FOR TREATMENT OF COVID-19 IN HIGH- RISK AMBULATORY PATIENTS - (03/10/21)
     
  2758. CROI: Convalescent Plasma Has No Effect on Survival or Disease Course With Severe COVID-19 - Mark Mascolini (03/10/21)
     
  2759. CROI: mAb Bamlanivimab Lowers Odds of SARS-CoV-2 and Symptomatic COVID-19 in Nursing Facilities - Mark Mascolini - (03/10/21)
     
  2760. CROI: BAMLANIVIMAB PREVENTS COVID-19 MORBIDITY AND MORTALITY IN NURSING-HOME SETTING - (03/10/21)
     
  2761. CROI: REDUCTION IN INFECTIOUS SARS-CoV-2 IN TREATMENT STUDY OF COVID-19 WITH MOLNUPIRAVIR - (03/10/21)
     
  2762. CROI: DoLPHIN2 FINAL RESULTS DOLUTEGRAVIR VS EFAVIRENZ IN LATE PREGNANCY TO 72W POSTPARTUM - (03/10/21)
     
  2763. CROI: COVID Virus Can Linger in Gut a Half-Year After Symptoms Clear - Mark Mascolini - (03/10/21)
     
  2764. CROI: Disrupted Gut Integrity, Other Gut Factors, Tied to COVID-19 Severity - Mark Mascolini - (03/10/21)
     
  2765. CROI: Low New-HIV Rate With Both Daily and On-Demand PrEP in Paris MSM - Mark Mascolini - (03/10/21)
     
  2766. CROI: Resistance and Response in Phase 2a Study of HIV Maturation Inhibitor - Mark Mascolini - (03/10/21)
     
  2767. CROI: Gilead's Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI - (03/10/21)
     
  2768. CROI: Racial/Ethnic Minorities With HIV More Likely to Get COVID-19 in US - Mark Mascolini (03/09/21)
     
  2769. CROI: NNRTI MK-8507 Selects V106 Mutations, Active Against Common NNRTI Mutations - Mark Mascolini (03/09/21)
     
  2770. CROI: PHASE IIA PROOF-OF-CONCEPT TRIAL OF NEXT-GENERATION MATURATION INHIBITOR GSK3640254 - (03/09/21)
     
  2771. CROI: HIV AND COVID-19 INPATIENT OUTCOMES: A MATCHED RETROSPECTIVE MULTICENTRE ANALYSIS - (03/09/21)
     
  2772. CROI: In-Hospital COVID-19 Outcomes Not Worse With HIV in 6-Center UK Analysis - Mark Mascolini (03/09/21)
     
  2773. CROI: ACTIVITY AND RESISTANCE CHARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR - (03/09/21)
     
  2774. CROI: POTENT ANTIVIRAL ACTIVITY OF LENACAPAVIR IN PHASE 2/3 IN HEAVILY ART-EXPERIENCED PWH - (03/09/21)
     
  2775. CROI: RESISTANCE PROFILE OF MK-8507, A NOVEL NNRTI SUITABLE FOR WEEKLY ORAL HIV TREATMENT - (03/09/21)
     
  2776. CROI: ASSESSMENT OF OBESITY AND METABOLIC PROFILE BY INTEGRASE INHIBITOR USE IN REPRIEVE - (03/09/21)
     
  2777. CROI: Resistance Testing Did Not Boost HIV Control Rates in Randomized African Trial - Mark Mascolini - (03/09/21)
     
  2778. CROI: DISPARITIES IN TIMELY RECEIPT OF ART PRESCRIPTION IN HIV CARE IN THE US, 2012-2018 - (03/09/21)
     
  2779. CROI: Faster Time to Viral Suppression in US South, But Suppression Rates Still Modest - Mark Mascolini (03/09/21)
     
  2780. CROI: Time to ART Improves for Blacks, Southerners in US, But Still Lags for Drug Users - Mark Mascolini (03/09/21)
     
  2781. CROI: Second-Line DTG Noninferior to DRV/r in African NADIA Trial - Mark Mascolini (03/09/21)
     
  2782. CROI: COVID-19 HOSPITALIZATION AMONG PEOPLE WITH HIV OR SOLID ORGAN TRANSPLANT IN THE US - (03/09/21)
     
  2783. CROI: REDUCED SUSCEPTIBILITY TO TEMSAVIR IS NOT LINKED TO IBA OR MVC RESISTANCE - (03/09/21)
     
  2784. CROI: GSK3640254 IS A NOVEL MATURATION INHIBITOR WITH AN OPTIMIZED VIROLOGY PROFILE - (03/09/21)
     
  2785. CROI: ISLATRAVIR PK THRESHOLD & DOSE SELECTION FOR MONTHLY ORAL HIV-1 PrEP - (03/08/21)
     
  2786. CROI: NEXT-GENERATION ISLATRAVIR IMPLANTS PROJECTED TO PROVIDE YEARLY HIV PROPHYLAXIS - (03/08/21)
     
  2787. CROI: IDENTIFICATION OF UNIQUE PROTEINS PREDICTIVE OF MORTALITY AND MECHANISMS IN HIV - (03/08/21)
     
  2788. CROI: BIOLOGICAL PROFILES PREDICT CORONARY ARTERY DISEASE IN PWH AND RISK-MATCHED CONTROLS - (03/08/21)
     
  2789. CROI: Short-course alendronate for the prevention of art-associated bone loss Alendronate for 14 Weeks Before and During First ART Wards Off 48-Week Bone Loss - Mark Mascolini (03/08/21)
     
  2790. CROI: PREVENTION OF CARDIOVASCULAR DISEASE IN PERSONS WITH AND WITHOUT HIV - (03/08/21)
     
  2791. CROI: Control of Lipids and Diabetes-But Not BP-Cuts Cardio Risk With HIV - Mark Mascolini (03/08/21)
     
  2792. CROI: 12-Year Cognitive Decline is Associated with Lung Disease, Diabetes, and Depression - (03/08/21)
     
  2793. CROI: Diabetes, Lung Disease, Depression, Cannabis Tied to 12-Year Cognitive Drop With HIV - (03/08/21)
     
  2794. CROI: Avoid CYP, P-gp, UGT Inducers With HIV Capsid Inhibitor Lenacapavir - Mark Mascolini (03/08/21)
     
  2795. CROI: CLINICAL EVALUATION OF DRUG INTERACTIONS WITH ORAL LENACAPAVIR AND PROBE DRUGS - (03/08/21)
     
  2796. CROI: Multimorbidity in people with HIV using ART in the US: Projections to 2030 - (03/08/21)
     
  2797. CROI: Female Sex Modifies Link Between Inflammation and Non-AIDS Vascular Events - Mark Mascolini (03/08/21)
     
  2798. CROI: SEX MODIFIES THE ASSOCIATION BETWEEN INFLAMMATION AND VASCULAR EVENTS IN TREATED HIV - (03/08/21)
     
  2799. CROI: INTEGRASE INHIBITORS TARGET MITOCHONDRIA IN BROWN ADIPOCYTES DISRUPTING THERMOGENESIS - (03/08/21)
     
  2800. CROI: WEIGHT GAIN AMONG PWH WHO SWITCH TO ART-CONTAINING InSTIs OR TAF - (03/08/21)
     
  2801. CROI: HIV WITH TRANSMITTED DRUG RESISTANCE IS DURABLY SUPPRESSED BY B/F/TAF AT WEEK 144 - (03/08/21)
     
  2802. CROI: ASSESSMENT OF OBESITY AND METABOLIC PROFILE BY INTEGRASE INHIBITOR USE IN REPRIEVE - (03/07/21)
     
  2803. CROI: WEIGHT AND LIPID CHANGES IN PHASE 3 CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING TRIALS - (03/07/21)
     
  2804. CROI: IMPACT OF REPRODUCTIVE AGING ON IMMUNE FUNCTION IN CISGENDER MEN AND WOMEN WITH HIV - (03/07/21)
     
  2805. CROI: WEIGHT GAIN AFTER SWITCHING DIFFERENT INTEGRASE STRAND TRANSFER INHIBITORS (InSTIs) - (03/07/21)
     
  2806. CROI: ASSOCIATION BETWEEN NEWER ANTIRETROVIRALS AND INCREASE IN BODY MASS INDEX IN RESPOND - (03/07/21)
     
  2807. CROI: COMORBIDITY BURDEN IN PEOPLE LIVING WITH HIV IN THE UNITED STATES - (03/06/21)
     
  2808. CROI: HIV DIFFERENTIALLY IMPACTS AGE-RELATED COMORBIDITY BURDEN AMONG US WOMEN AND MEN - (03/06/21)
     
  2809. CROI: MODEL-INFORMED DOSE SELECTION FOR ISLATRAVIR/MK-8507 ORAL ONCE-WEEKLY PHASE 2B STUDY - (03/06/21)
     
  2810. CROI: WEEK 96 ANALYSIS OF VIRAL BLIPS FROM A PHASE 2B TRIAL OF ISLATRAVIR AND DORAVIRINE - (03/06/21)
     
  2811. CROI: 4-YEAR OUTCOMES OF B/F/TAF IN TREATMENT-NAIVE ADULTS - (03/06/21)
     
  2812. CROI: SWITCHING TO DTG/3TC FDC IS NONINFERIOR TO TBR FOR 96 WEEKS: TANGO SUBGROUP ANALYSES - (03/06/21)
     
  2813. CROI: DURABLE EFFICACY OF DTG+3TC IN GEMINI-1&2: YEAR 3 SUBGROUP ANALYSES - (03/06/21)
     
  2814. CROI: WEEKLY ORAL TENOFOVIR ALAFENAMIDE PROTECTS MACAQUES FROM VAGINAL SHIV INFECTION - (03/06/21)
     
  2815. CROI: LONG-ACTING HIV CAPSID INHIBITOR EFFECTIVE AS PrEP IN A SHIV RHESUS MACAQUE MODEL - (03/06/21)
     
  2816. CROI: LONG-ACTING CABOTEGRAVIR+RILPIVIRINE IN OLDER ADULTS: POOLED PHASE 3 WEEK-48 RESULTS - (03/06/21)
     
  2817. CROI: CABOTEGRAVIR PPK SIMULATION TO INFORM Q2M STRATEGIES FOLLOWING DOSING INTERRUPTIONS - (03/06/21)
     
  2818. CROI: POPPK MODELING OF Q2M IM RPV LA FOR MANAGING DOSING INTERRUPTIONS IN HIV-1 PATIENTS - (03/06/21)
     
  2819. CROI: ViiV Healthcare presents data for long-acting cabotegravir and rilpivirine for the treatment of HIV showing continued virologic suppression to 96 weeks - (03/06/21)
     
  2820. HIV PrEP Poor Persistence - (03/04/21)
     
  2821. Non-Viral Liver Disease in HIV+ - Increased Prevalence of Liver Fibrosis in PLWH Increased Prevalence of Liver Fibrosis in People Living With Human Immunodeficiency Virus Without Viral Hepatitis Compared to Population Controls - (03/02/21)
     
  2822. HIV+ Women Have Higher Burden of Comorbidities vs HIV- Women / Accelerated-Earlier by 10 Years - (03/02/21)
     
  2823. CROI: ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside pipeline advances at CROI 2021 - (03/02/21)
     
  2824. ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months - (02/26/21)
     
  2825. Cognitive ageing is premature among a community sample of optimally treated people living with HIV - (02/26/21)
     
  2826. Motor function declines over time in human immunodeficiency virus and is associated with cerebrovascular disease, while HIV-associated neurocognitive disorder remains stable - (02/26/21)
     
  2827. HIV+ Women & MSM: aging & other issues - (02/22/21)
     
  2828. Loss of viral suppression by 31% in SF is deleterious to the individual and hinders treatment-as-prevention: the COVID-19 pandemic is threatening the goals of the US EHE initiative. - (02/22/21)
     
  2829. Indirect HIV morbidity and mortality due to COVID-19- PLWH presenting with more advanced HIV - (02/22/21)
     
  2830. Aging Guidelines Called For by HIV Researchers /Women with HIV... "What It Means to Age With HIV Infection, Years Gained Are Not Comorbidity Free" - (02/13/21)
     
  2831. Incident Non-AIDS Comorbidity Burden among Women with or at-risk for HIV in the U.S - suggest high susceptibility to -premature aging - (02/13/21)
     
  2832. New PrEP Long-Acting Lenacapavir Trials - (02/13/21)
     
  2833. COVID Impact on Older HIV+ / Quality of Life NOT Viral suppression Is Endpoint !!!! - (02/11/21)
     
  2834. Impact of COVID on HIV & Aging in Era of ART - (02/11/21)
     
  2835. New PrEP Studies: Long-Acting HIV-1 Capsid Inhibitor Lenacapavir Every 6 Months - (02/10/21)
     
  2836. Resilience and frailty in people living with HIV during the COVID era: two complementary constructs? - (02/09/21)
     
  2837. Immunodeficiency and Cancer in 3.5 Million People Living with Human Immunodeficiency Virus: the South African HIV Cancer Match Study - (02/08/21)
     
  2838. Accelerated Aging, Senesence & New Senolytic Therapeutic drugs - (02/08/21)
     
  2839. New HIV "Cure" Strategy - (02/08/21)
     
  2840. GLS1 inhibitor selectively eliminates senescent cells, ameliorates age-associated disorders
  2841. HIVR4P: The AMP Studies: Phase 2b Proof-of-Concept Trials Designed to Test the Efficacy of VRC01 Antibody to Prevent HIV Acquisition - (02/05/21)
     
  2842. HIVR4P: Social, economic, mental health, and medical care impacts of COVID-19 in a US cohort of sexual and gender minority adolescents and young adults (SGM AYA) at-risk for HIV - (02/05/21)
     
  2843. HIVR4P: US COVID-19 Prevention Network Outlines Goals, Shows Moderna Trial Impact - Mark Mascolini - (02/04/21)
     
  2844. HIVR4P: With COVID Here, Mental Health, Money Woes Grow in US Sex- and Gender-Minority Youth - Mark Mascolini - (02/04/21)
     
  2845. HIVR4P: Low and Transient Rectal Dapivirine Levels in 7-Day Rectal Gel Trial - Mark Mascolini - (02/04/21)
     
  2846. HIVR4P: Higher Rectal Penetration Needed With PC-1005 Microbicide Gel - Mark Mascolini - (02/04/21)
     
  2847. HIVR4P: Climbing Rectal Gonorrhea Rate But Falling HIV Rate in British MSM - Mark Mascolini - (02/04/21)
     
  2848. HIVR4P: Bottoms are up at the HIV Research for Prevention Virtual Conference - (02/04/21)
     
  2849. HIVR4P: Only Half in Representative US Sample Intends to Get COVID Vaccine - Mark Mascolini - (02/03/21)
     
  2850. HIVR4P: More Than One Quarter of People Feel No COVID Symptoms Before Shedding Virus - Mark Mascolini - (02/03/21)
     
  2851. COVID-19 risk, disparities and outcomes in patients with chronic liver disease in the United States - (02/01/21)
     
  2852. HIVR4P: Most US MSM Unaware of-and Not Interested in-As-Needed PrEP - Mark Mascolini - (01/29/21)
     
  2853. HIVR4P: COVID Restraints Followed by More Condom-Free Sex, Less PrEP, in Amsterdam MSM - Mark Mascolini (01/29/21)
     
  2854. HIVR4P: Steep Dapivirine Drops in Vaginal Fluid With Cyclic Use of DPV/LNG Vaginal Ring - Mark Mascolini- (01/29/21)
     
  2855. HIVR4P: PK Goals Met With 90-Day TFV/LNG Vaginal Ring in 47-Woman Randomized Trial - Mark Mascolini - (01/29/21)
     
  2856. HIVR4P: Merck Presents Interim Findings from Phase 2a Clinical Trial Evaluating Investigational Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P 2021 - (01/29/21)
     
  2857. HIVR4P: Early Data Hint Once-Monthly Oral PrEP Feasible With Novel Antiretroviral - Mark Mascolini - (01/29/21)
     
  2858. HIVR4P: VARIABLE HIV SEROINCIDENCE RATES IN A COHORT OF HIGH-RISK MEN WHO HAVE SEX WITH MEN AND TRANSGENDER WOMEN IN CHINA - (01/29/21)
     
  2859. HIVR4P: Impact of UGT Induction by Rifampin and Rifabutin on Cabotegravir Long-Acting Pharmacokinetics for HIV Pre-exposure Prophylaxis (PrEP) using Population Pharmacokinetic Modeling and Simulation - (01/29/21)
     
  2860. HIVR4P: MRI EXAMINATION OF CABOTEGRAVIR LONG-ACTING FORMULATION DEPOT KINETICS IN HEALTHY ADULT VOLUNTEERS - (01/29/21)
     
  2861. HIVR4P: DISTRIBUTION OF LONG-ACTING (LA) CABOTEGRAVIR (CAB) IN PLASMA, MUCOSAL TISSUES, AND ASSOCIATED FLUIDS AFTER A SINGLE ULTRASOUND-GUIDED INTRAMUSCULAR (IM) INJECTION IN HEALTHY ADULT PARTICIPANTS - (01/29/21)
     
  2862. HIVR4P: Utilization Patterns and HIV Incidence Within the First Year of Initiation of TDF/FTC for HIV Pre-exposure Prophylaxis (PrEP) Among Insured Individuals in the US - (01/28/21)
     
  2863. HIVR4P: Biodegradable TAF Implants Protect 6 of 6 Macaques From Vaginal SHIV - Mark Mascolini - (01/28/21)
     
  2864. HIVR4P: Trial design, enrollment status, demographics, and pharmacokinetic (PK) data from a blinded interim analysis from a phase 2a trial of islatravir once monthly (QM) for HIV pre-exposure prophylaxis (PrEP) - (01/28/21)
     
  2865. HIVR4P: Over One Third of New HIV Diagnoses in North Carolina Involve Recent Infection - Mark Mascolini - (01/28/21)
     
  2866. HIVR4P: Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: results from HPTN 084 - (01/28/21)
     
  2867. HIVR4P: Design and testing of a cabotegravir reservoir implant for HIV prevention - (01/28/21)
     
  2868. HIVR4P: User Wish List for Microarray Patch to Prevent HIV and Pregnancy: Small, Discreet, Easy to Use, Long-Acting - Mark Mascolini - (01/28/21)
     
  2869. HIVR4P: High protection against vaginal SHIV infection in macaques by a biodegradable implant releasing tenofovir alafenamide - (01/27/21)
     
  2870. HIVR4P: Understanding HIV prevention from the perspective of adolescent girls and young women at high risk of HIV infection - (01/26/21)
     
  2871. HIVR4P: Sex work in the wake of SARSCoV2 in Zimbabwe: A qualitative study - (01/26/21)
     
  2872. HIVR4P: Shelter-in-place but at what cost? Barriers to healthcare and other social determinants of health among young women under South Africa's COVID-19 lockdown - (01/26/21)
     
  2873. HIVR4P: High resolution and 3D ultrasound imaging of implant and intravaginal ring drug delivery devices during HIV pre-exposure prophylaxis (PrEP) preclinical and clinical studies - (01/26/21)
     
  2874. HIVR4P: Switching from F/TDF to F/TAF for HIV Pre-exposure Prophylaxis: An Analysis of the Real-World Data - (01/26/21)
     
  2875. HIVR4P: Long-Acting CAB Superior to Daily Oral TDF/FTC in Preventing HIV in Women - Mark Mascolini - (01/26/21)
     
  2876. HIVR4P: Antibody Infusions Prevent Acquisition of Some HIV Strains, NIH Studies Find - (01/26/21)
     
  2877. Optimal Allocation of Societal HIV Prevention Resources to Reduce HIV Incidence in the United States - (01/25/21)
     
  2878. Prevalence and Incidence of Human Papillomavirus Infection in Men Having Sex With Men Enrolled in a Pre-exposure Prophylaxis Study: A Sub-study of the Agence Nationale de Recherches sur le SIDA et les Hepatites Virales "Intervention Preventive de l'Exposition aux Risques avec et pour les hommes Gays" Trial - (01/25/21)
     
  2879. J&J COVID Vaccine- Interim Results of a Phase 1 2a Trial of Ad26.COV2.S Covid-19 Vaccine - (01/15/21)
     
  2880. ViiV Healthcare receives EU Marketing Authorisation for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay, a treatment for children living with HIV in Europe - (01/14/21)
     
  2881. Five Year Lower Extremity Function is Associated with White Matter Abnormality in Older Adults - (01/14/21)
     
  2882. COVID-19 death in people with HIV: interpret cautiously - Comment - (01/12/21)
     
  2883. A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across Six Cities in the Women's Interagency HIV Study: Intersections with Current and Past Injectable Medication and Substance Use - (01/11/21)
     
  2884. AASLD: Efficacy and safety of subcutaneous semaglutide once-daily versus placebo in patients with nonalcoholic steatohepatitis
    Semaglutide Resolves NASH in Big Placebo-Controlled Trial     - (01/07/21)
     
  2885. IAC 2020 Virtual: 2 HIV Vaccine Studies/Functional Cure & mRNA Vaccine for HIV
    Functional HIV Cure in Monkey with 3 Monoconal antibodies     - (01/06/21)
     
  2886. Blunted muscle mitochondrial responses to exercise training in older adults with HIV - (01/05/21)
     
  2887. COVID/Long-Acting 2-Antibody Combination for prevention/Treatment by AstraZeneca - (01/05/21)
     
  2888. Discovery of Virus Variant in Colorado and California Alarms Scientists - (01/05/21)
     
  2889. How HIV Research Laid the Foundation for Covid Vaccines - (01/05/21)
     
  2890. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol - (01/05/21)
     
  2891. Viral suppression rates in a safety-net HIV clinic in San Francisco destabilized during COVID-19 - (01/05/21)
     
  2892. HPTN 078: High Prevalence of HCV Antibodies Among Urban U.S. Men Who Have Sex with Men (MSM) Independent of HIV Status - (01/05/21)
     
  2893. Disparities in HIV Viral Suppression in the USA - (01/05/21)
     
  2894. CROI: Summary from virtual CROI 2020 for HIV and liver disease HIV and the liver: what is new? - Written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany (03/25/20)
     
  2895. COVID-19 Susceptibility and Outcomes Among People Living With HIV in San Francisco - (12/21/20)
     
  2896. AASLD: HIGH PREVALENCE OF FATTY LIVER DISEASE [FLD] AND ADVANCED FIBROSIS IN AN URBAN MULTIETHNIC US COHORT OF PERSONS WITH HIV - (12/21/20)
     
  2897. AASLD: PREVALENCE AND RISK FACTORS OF HEPATIC STEATOSIS AND FIBROSIS IN AMERICAN ADULTS: A POPULATION-BASED STUDY - (12/21/20)
     
  2898. AASLD: GLOBAL PREVALENCE OF HEPATITIS C VIRUS IN WOMEN OF CHILDBEARING AGE IN 2019: A MODELING STUDY - (12/21/20)
     
  2899. AASLD: AUTOMATED VIRAL HEPATITIS (HCV AND HBV) SCREENING: LESSONS ON EXPANSION & SUSTAINABILITY AMIDST THE COVID-19 PANDEMIC - (12/21/20)
     
  2900. ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe - (12/21/20)
     
  2901. NIH Workshop on HIV-Associated Comorbidities, Coinfections, and Complications: Summary and Recommendation for Future Research - (12/21/20)
     
  2902. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study - (12/21/20)
     
  2903. Using health technology to capture digital phenotyping data in HIV-associated neurocognitive disorders - (12/21/20)
     
  2904. AASLD: AUTOMATED VIRAL HEPATITIS (HCV AND HBV) SCREENING: LESSONS ON EXPANSION & SUSTAINABILITY AMIDST THE COVID-19 PANDEMIC - (01/08/21)
     
  2905. AASLD: Distinct lipidomic signatures between persons living with HIV and seronegative persons: combined analysis of the ACTG 5260s and the MACS/WIHS Combined Cohort Study - (12/18/20)
     
  2906. AdverseReactComor: Distinct lipidomic signatures between persons living with HIV and seronegative persons: combined analysis of the ACTG 5260s and the MACS/WIHS Combined Cohort Study - (12/17/20)
     
  2907. Lenacapavir (GS-6207): A First-in-Class Long Acting HIV Capsid Inhibitor - (12/15/20)
     
  2908. Progress in long-acting Agents for HIV Treatment & PrEP: ViiV healthcare program: Focus on Cabotegravir Long-Acting Injection; Future ViiV LA programs at HIV-DART - (12/15/20)
     
  2909. AdverseReactComor: Non-alcoholic fatty liver disease (NAFLD) in HIV-monoinfected patients: results from the European ECHAM study - (12/14/20)
     
  2910. Islatravir Long-Acting Implant: RECENT PROGRESS IN DEVELOPMENT OF LONG-ACTING INJECTABLES FOR HIV TREATMENT at HIV DART - (12/14/20)
     
  2911. Life expectancy in HIV-positive persons in Switzerland - (12/14/20)
     
  2912. Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV - (12/14/20)
     
  2913. Pregnant Women/Poor outcomes & Neighborhood/Crime/violence/education - Association of Adverse Neighborhood Exposures With HIV Viral Load in Pregnant Women at Delivery - (12/14/20)
     
  2914. ViiV Healthcare announces positive CHMP opinion for Rukobia (fostemsavir), a first-in-class attachment inhibitor for the treatment of adults with multidrug-resistant HIV with few treatment options available - (12/11/20)
     
  2915. An Approach to Improve Diversity and Inclusion in Clinical Trials: The DEFINE Trial (D/C/F/TAF Evaluated As a Fixed-dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain) - (12/10/20)
     
  2916. HIV Infection, Cancer Treatment Regimens, and Cancer Outcomes Among Elderly Adults in the United States......HIV+ Elevated Cancer Mortality-BREAST/PROSTATE/Colorectal - (12/09/20)
     
  2917. AdverseReactComor: The Impact of Covid-19 and Its Response on the Psychosocial Wellbeing and Medical Care among Persons Living with HIV and COPD - (12/08/20)
     
  2918. AdverseReactComor: Attitudes Toward COVID-19 Among People Living with HIV Attending a Multiethnic Outpatient Center in Houston, Texas - (12/08/20)
     
  2919. Are LDL as Important in CVD ? Remnant Cholesterol and Atherosclerotic Cardiovascular Disease Risk - (12/08/20)
     
  2920. AdverseReactComor: Greater Incident Proteinuria in Pre-Diabetic Men with HIV than Without HIV: The Multicenter AIDS Cohort Study - (12/07/20)
     
  2921. AdverseReactComor: Greater Increases Over Time in BMI, Waist Circumference and Subcutaneous and Visceral Fat Area Among Men with HIV - (12/07/20)
     
  2922. AdverseReactComor: Prevalence of Silent Atherosclerosis and Other Comorbidities in an Outpatient Cohort of Adults Living with HIV - (12/07/20)
     
  2923. AdverseReactComor: Faster decline in lung function in treated HIV-positive vs. HIV negative AGEhIVcohort participants independent of smoking behavior - (12/07/20)
     
  2924. AdverseReactComor: Effect of tesamorelin on risk of development or progression of diabetic retinopathy and glycemic control in HIV-infected subjects with diabetes and central adiposity - (12/07/20)
     
  2925. AdverseReactComor: Vitamin D & Muscoskeletal Health Among Youth with HIV presented today at Comorbidities Workshop - (12/07/20)
     
  2926. AdverseReactComor: Hypertension Prevalence Higher in US vs Global reported today at Comorbidities Workshop - (12/07/20)
     
  2927. AdverseReactComor: Carotid Artherosclerosis in Suppressed HIV+ at Comorbidties Workshop - (12/07/20)
     
  2928. AdverseReactComor: NAFLD in HIV+ today at Comorbidities Workshop - (12/07/20)
     
  2929. AdverseReactComor: COVID Affect on HIV+ reported at Comorbidities Workshop - (12/07/20)
     
  2930. AdverseReactComor: Sleep & HIV - Presented Today at Comorbidities Workshop - (12/04/20)
     
  2931. AdverseReactComor: PrEP - FTC, TDF - Changes Mitochondria & Cardiovascular Function presented at Comorbidities Workshop - (12/04/20)
     
  2932. AdverseReactComor: Proteinuria 3 x Higher in HIV+ in MACS just presented at Comorbidities Workshop - (12/04/20)
     
  2933. AdverseReactComor: In vitro exposure of leukocytes to HIV pre-exposure prophylaxis (PrEP) decreases mitochondrial function and alters gene expression profiles. - (12/04/20)
     
  2934. AdverseReactComor: Mitochondria & Accelerated Aging in HIV - presented at the Comorbidities Workshop - (12/04/20)
     
  2935. IPM's Dapivirine Ring for Women's HIV Prevention Receives WHO Prequalification - (12/02/20)
     
  2936. A High Percentage of People with HIV on Antiretroviral Therapy Experience Detectable Low-Level Plasma HIV-1 RNA Following COVID-19 - (11/28/20)
     
  2937. AASLD: Can low liver fat be bad for your heart? Visceral Fat & Heart Disease - (11/24/20)
     
  2938. AASLD: Breastfeeding Linked to Lower Chance of Severe Fibrosis in US Women With NAFLD - Mark Mascolini - (11/24/20)
     
  2939. ViiV Healthcare announces results of the PROgress study demonstrating that the inclusion of patient reported outcomes into clinical practice can improve HIV care - (11/18/20)
     
  2940. ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention - (11/18/20)
     
  2941. Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1 - (11/18/20)
     
  2942. AASLD: Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis - (11/17/20)
     
  2943. AASLD: Sugary Drinks, High Trans Fats Lead Dietary Risks for Death With NAFLD - Mark Mascolini (11/17/20)
     
  2944. AASLD: The Lipidomics of HIV-related NAFLD - (11/17/20)
     
  2945. AASLD: Dietary Risks for Liver Related Morality Among Nonalcoholic Fatty Liver Disease (NAFLD) - (11/17/20)
     
  2946. AASLD: Treatment with Growth Hormone-Releasing Hormone Analog ReducesVEGFA, TGFβ1, and CSF1: Mechanisms of Tesamorelin Effect in Nonalcoholic Fatty Liver Disease - (11/17/20)
     
  2947. AASLD: Country and WHO Regional Trends for Hepatitis C Virus (HCV) Mortality, 1990-2019: An Analysis of the Global Burden of Disease (GBD) Study - (11/17/20)
     
  2948. AASLD: Statins Tied to Lower HCC Risk in HBV Group Without Cirrhosis - Mark Mascolini (11/17/20)
     
  2949. ViiV Healthcare announces CHMP positive opinion for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay, a treatment for children living with HIV in Europe - (11/13/20)
     
  2950. Treatment Is More Than Prevention: Perceived Personal and Social Benefits of Undetectable = Untransmittable Messaging Among Sexual Minority Men Living with HIV - (11/12/20)
     
  2951. Statement-NIH Study Finds Long-Acting Injectable Drug Prevents HIV Acquisition in Cisgender Women - (11/09/20)
     
  2952. ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women - (11/09/20)
     
  2953. Recent Weight Changes Studies - (11/05/20)
     
  2954. Antiretroviral Therapy-Induced Bone Loss Is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-Naive Persons with Human Immunodeficiency Virus Infection: A Phase IIB Trial - (11/04/20)
     
  2955. Additive effects of green tea and coffee on all-cause mortality in patients with type 2 diabetes mellitus: the Fukuoka Diabetes Registry - (11/04/20)
     
  2956. GLASGOW: Fat distribution and density in PLWH with ≥5% weight gain - (11/03/20)
     
  2957. Inflammation Marker D-Dimer Associated with cell-associated HIV RNA in Virally Suppressed HIV+..... Aging is associated with inflammation and non-significantly higher ca-HIV RNA levels - (11/03/20)
     
  2958. New NYC Funding for Care & Services for Black & Latino Older PLWH - Geriatric Clinic - Men & & Women, Transgender, Young - 5 Service Categories, including Hepatitis C - (11/03/20)
     
  2959. CDC: HIV Mortality - HIV+ Dying Increasingly Consist of Women, Blacks/African-Americans, South residents, older HIV+ - cancer, heart disease, suicide among leading causes of death - (11/03/20)
     
  2960. ID Week: Gilead Sciences' Commitment to the COVID-19 Pandemic - (11/03/20)
     
  2961. ID Week: Impact of Concomitant Hydroxychloroquine Use on Safety and Efficacy of Remdesivir in Moderate COVID-19 Patients - (11/03/20)
     
  2962. ID Week: Safety of Remdesivir vs Standard of Care in Patients With Moderate COVID-19 - (11/03/20)
     
  2963. ID Week: Baseline Characteristics Associated With Clinical Improvement in Hospitalized Patients With Moderate COVID-19 - (11/03/20)
     
  2964. ID Week: Remdesivir vs Standard Care in Patients With Moderate COVID-19 - (11/03/20)
     
  2965. ID Week: Geographical Disparities in Clinical Outcomes of Severe COVID-19 Patients Treated With Remdesivir - (11/03/20)
     
  2966. ID Week: Rates of COVID Testing, Diagnosis, and Hospital Admission Higher With HIV - Mark Mascolini (11/02/20)
     
  2967. ID Week: COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States - increased risk of COVID & had worse outcomes, heroin the worst - (11/02/20)
     
  2968. ID Week: HCV Treatment Less Likely for Women, Current Drug Users, Detectable HIV Load - Mark Mascolini (11/02/20)
     
  2969. ID Week: Opioid Clinic Use Doubles After COVID Arrives at Alabama HIV Center - Mark Mascolini (11/02/20)
     
  2970. ID Week: HAVES VS HAVE-NOTS IN HEALTHCARE COMMUNICATION: EXAMINING THE PARADOX WHERE PLHIV WHO NEED QUALITY DISCUSSIONS WITH THEIR PROVIDERS THE MOST, ACCESS IT THE LEAST - (11/02/20)
     
  2971. ID Week: Health Technology Assessment of New Long-Acting, Directly-Observed HIV Treatments in Canada: Impact of Real-World Adherence to Daily Oral Therapy on Treatment, Transmission and Cost-Effectiveness - (11/02/20)
     
  2972. ID Week: Forgiveness of BIC/FTC/TAF: In Vitro Simulations of Intermittent Poor Adherence Find Limited HIV-1 Breakthrough and High Barrier to Resistance - (11/02/20)
     
  2973. ID Week: Bone mineral density screening in veterans living with HIV : Only One Quarter of US HIV+ Veterans Group Screened for Low BMD - Mark Mascolini (11/02/20)
     
  2974. ID Week: IMPACT OF TREATMENT ADHERENCE ON EFFICACY OF DTG + 3TC AND DTG + TDF/FTC: POOLED ANALYSIS OF THE GEMINI-1 AND -2 CLINICAL STUDIES - (11/02/20)
     
  2975. ID Week: SAFETY, EFFICACY, AND DURABILITY OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE AS MAINTENANCE THERAPY FOR HIV-1 INFECTION: LATTE-2 WEEK 256 RESULTS - (11/02/20)
     
  2976. ID Week: HIV-1 RNA BLIPS AND LOW-LEVEL REPLICATION DURING PHASE III/IIIB CABOTEGRAVIR + RILPIVIRINE LONG-ACTING STUDIES ARE SIMILAR TO ORAL 3-DRUG THERAPY AND NOT ASSOCIATED WITH WEEK 48 VIROLOGIC OUTCOME - (11/02/20)
     
  2977. ID Week: LONG-TERM PATIENT ADHERENCE AND MANAGEMENT OF TREATMENT INTERRUPTIONS WITH LONG-ACTING INJECTABLE CABOTEGRAVIR + RILPIVIRINE FOR MAINTENANCE THERAPY IN PHASE 2B/3 STUDIES - (11/02/20)
     
  2978. ID Week: Association of Aging, Frailty and Place of Residence with Skin, Oral and Gut Microbiome Characteristics and Pathogenicity Reservoirs - (11/02/20)
     
  2979. ID Week: TREATMENT-RELATED PHYSICAL, EMOTIONAL, AND PSYCHOSOCIAL CHALLENGES AND THEIR IMPACT ON INDICATORS OF QUALITY OF LIFE - (10/30/20)
     
  2980. ID Week: NO DOSE ADJUSTMENT OF METFORMIN WITH FOSTEMSAVIR COADMINISTRATION BASED ON MECHANISTIC STATIC AND PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS - (10/30/20)
     
  2981. ID Week: HEALTH CARE RESOURCE UTILIZATION AND COST OF PEOPLE LIVING WITH HIV (PLWH) IN US COMMERCIAL AND MEDICARE ADVANTAGE HEALTH PLANS - (10/30/20)
     
  2982. ID Week: Regional and Racial Disparities in Response to Antiretroviral Therapy (ART) Among People Living with Human Immunodeficiency Virus (PLWH) - (10/30/20)
     
  2983. ID Week: Real World Community-Based HIV Rapid Start Antiretroviral with BFTAF Versus Conventional HIV Antiretroviral Therapy Start - The RoCHaCHa Study, a Pilot Study - (10/30/20)
     
  2984. ID Week: Increasing incidence of obstructive sleep apnea in patients with HIV: A nationwide database analysis - (10/30/20)
     
  2985. ID Week: PATIENT-REPORTED OUTCOMES ON LONG-ACTING CABOTEGRAVIR + RILPIVIRINE AS MAINTENANCE THERAPY: FLAIR 96-WEEK RESULTS - (10/30/20)
     
  2986. ID Week: Older Age, Comorbidities Predict Hospital Trip for COVID-19 in HIV Group - Mark Mascolini - (10/30/20)
     
  2987. ID Week: Four in 5 on ART Resume Therapy in Hospital, One Third Change ARVs - Impact of hospitalization on antiretroviral therapy for people living with HIV - Mark Mascolini - (10/30/20)
     
  2988. ID Week: B/F/TAF Controls HIV in 10 of 10 on Hemodialysis for Kidney Disease - (10/28/20)
     
  2989. ID Week: SUMMARY OF COVID-RELATED IMPACT ON CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING (CAB + RPV LA) DOSING ACROSS THE SIX ONGOING GLOBAL PHASE IIB and III CLINICAL TRIALS - (10/28/20)
     
  2990. ID Week: Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF) - (10/28/20)
     
  2991. ID Week: Increased Diagnosis Acute HIV Through Routine ED Screening & Rapid Linkage to Care & Initiation of HAARTDuring the COVID-19 Pandemic - (10/28/20)
     
  2992. ID Week: Using the F/TDF Adherence-Efficacy Relationship to Calculate Background HIV Incidence: Results From the DISCOVER Trial - (10/28/20)
     
  2993. ID Week: ViiV Healthcare presents positive new findings from two studies of its investigational, long-acting regimen of cabotegravir and rilpivirine, including five-year data showing long-term durability, efficacy, safety, and tolerability - (10/28/20)
     
  2994. ID Week: Database Links Bictegravir and Dolutegravir to Metabolic Problems - Mark Mascolini (10/28/20)
     
  2995. ID Week: ViiV Healthcare announces analysis showing no antiretroviral therapy interruptions due to COVID-19 across its clinical development programme for investigational, long-acting cabotegravir and rilpivirine - (10/28/20)
     
  2996. ID Week: ViiV Healthcare presents continued positive findings from first-ever implementation science study on integrating an investigational once-monthly injectable HIV treatment into US healthcare practices - (10/28/20)
     
  2997. ID Week: Database Links Bictegravir and Dolutegravir to Metabolic Problems - Mark Mascolini (10/28/20)
     
  2998. ID Week: PATIENT PERSPECTIVES ON IMPLEMENTATION OF A LONG-ACTING INJECTABLE ANTIRETROVIRAL THERAPY REGIMEN IN HIV US HEALTHCARE SETTINGS: INTERIM RESULTS FROM THE CUSTOMIZE STUDY - (10/28/20)
     
  2999. ID Week: Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline - (10/28/20)
     
  3000. ID Week: Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine - (10/28/20)
     
  3001. ID Week: Gastrointestinal (GI) Adverse Events With Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Through Week 96: An AMBER Post Hoc Analysis - (10/26/20)
     
  3002. ID Week: Who does not show up for followup in an HIV PrEP clinic? More Education Favors Steady PrEP-Bisexuals, Heterosexuals Need More Support - Mark Mascolini (10/26/20)
     
  3003. ID Week: Week-48 Outcomes From the BRAAVE 2020 Study: a Randomized Switch to B/F/TAF in African-American Adults With HIV - (10/26/20)
     
  3004. ID Week: Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline - (10/26/20)
     
  3005. ID Week: Efficacy and Safety of Doravirine in Treatment-Naïve Adults ≥50 Years Old With HIV-1 - (10/26/20)
     
  3006. ID Week: IMPACT OF TREATMENT ADHERENCE ON EFFICACY OF DTG + 3TC AND DTG + TDF/FTC: POOLED ANALYSIS OF THE GEMINI-1 AND -2 CLINICAL STUDIES - (10/26/20)
     
  3007. ID Week: Preexisting resistance and week 48 virologic outcomes after switching to B/F/TAF in African American adults with HIV - Frequent Resistance Before B/F/TAF Does Not Dim Week-48 Viral Response - Mark Mascolini (10/26/20)
     
  3008. ID Week: Empiric Antibiotics Frequent-But Usually Not Needed-for COVID-19 - Mark Mascolini (10/26/20)
     
  3009. ID Week: Pain in Two Thirds of Older US HIV Group Tied to Comorbidities - Mark Mascolini (10/26/20)
     
  3010. ID Week: Effect of Early Administration of Systemic Corticosteroids on Outcomes in Patients with Severe COVID-19 Pneumonia Early Steroids Cut Need for Ventilation, Shorten ICU Stay, With COVID - Mark Mascolini (10/26/20)
     
  3011. ID Week: Increasing incidence of obstructive sleep apnea in patients with HIV: A nationwide database analysis- Sleep Apnea Rate Rises 5-Fold Among Hospital Inpatients With HIV - (10/26/20)
     
  3012. ID Week: One Quarter of 65+ Group With HIV and Polypharmacy Fall, 10% Seek Emergency Care - (10/26/20)
     
  3013. ID Week: One Quarter of 65+ Group With HIV and Polypharmacy Fall, 10% Seek Emergency Care - (10/23/20)
     
  3014. ID Week: Persistence on F/TDF for HIV Pre-exposure Prophylaxis: Insights from Real-world Evidence - (10/23/20)
     
  3015. ID Week: Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study - (10/23/20)
     
  3016. ID Week: Impact of Age and Medical Comorbidities on Renal Outcomes in the DISCOVER Trial - (10/23/20)
     
  3017. ID Week: QUALITATIVE FINDINGS FROM A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY TO EXPLORE PERSPECTIVES OF HEALTHCARE STAFF ON EARLY IMPLEMENTATION OF CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING INJECTABLE IN THE UNITED STATES (CUSTOMIZE) - (10/22/20)
     
  3018. ID Week: Weight change associated with switching to bictegravir/emtricitabine/tenofovir alafenamide in virally suppressed people with HIV Weight Climbs With Switch to Bictegravir Across Baseline Regimens - Mark Mascolini - (10/22/20)
     
  3019. ID Week: Congestive heart failure in persons living with HIV: are we providing standard of care? Most People With HIV and CHF Get Correct CHF Care-With Notable Exceptions - Mark Mascolini - (10/22/20)
     
  3020. ID Week: Persistence on F/TDF for HIV Pre-exposure Prophylaxis: Insights from Real-world Evidence - (10/22/20)
     
  3021. ID Week: HIV Control With Ibalizumab for 7.8 to 9.5 Years With Few Regimen Tweaks - Mark Mascolini - (10/22/20)
     
  3022. ID Week: Increasing incidence of obstructive sleep apnea in patients with HIV: A nationwide database analysis Sleep Apnea Rate Rises 5-Fold Among Hospital Inpatients With HIV - Mark Mascolini - (10/22/20)
     
  3023. ID Week: Risk Factors and Metabolic Implications of Integrase Inhibitor Associated Weight Gain - Mark Mascolini - (10/22/20)
     
  3024. ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV - (10/20/20)
     
  3025. Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine - (10/20/20)
     
  3026. HRSA New Resources Available on HIV and Aging: Care, Screening Tools & Staff Training - (10/20/20)
     
  3027. GLASGOW: Cancer, transplantation, and other immunocompromising conditions were not significantly associated with severe COVID-19 or death in hospitalized COVID-19 patients in Chicago - (10/20/20)
     
  3028. GLASGOW: Integrase based first-line HIV antiretroviral treatment in the Mediterranean Resistance (MeditRes) HIV collaboration - (10/20/20)
     
  3029. GLASGOW: FOSTEMSAVIR AND ETHINYL ESTRADIOL DRUG INTERACTION: CLINICAL APPLICATION FOR CO-ADMINISTRATION - (10/20/20)
     
  3030. GLASGOW: MODEL-BASED APPROACH OF DOSE SELECTION AND OPTIMAL PK SAMPLING OF FOSTEMSAVIR FOR PEDIATRIC PATIENTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION - (10/20/20)
     
  3031. GLASGOW: EVALUATION AND CLINICAL APPLICATION OF FOSTEMSAVIR CO-ADMINISTRATION WITH TUBERCULOSIS MEDICATIONS - (10/20/20)
     
  3032. GLASGOW: FOSTEMSAVIR EXPOSURE-RESPONSE RELATIONSHIPS IN TREATMENT EXPERIENCED HIV PATIENTS - (10/20/20)
     
  3033. GLASGOW: CLINICAL SIGNIFICANCE OF GP120 POLYMORPHISMS, TMR IC50 FC, AND HIV-1 SUBTYPE IN BRIGHTE - (10/20/20)
     
  3034. GLASGOW: Starting or switching to bictegravir/ emtricitabine/ tenofovir alafenamide (B/F/TAF) in clinical practice: Pooled 12-month results from the global BICSTaR study - (10/20/20)
     
  3035. GLASGOW: Long-Term Follow-Up After a Switch to Bictegravir, Emtricitabine, Tenofovir Alafenamide (B/F/TAF) from a Boosted Protease Inhibitor-Based Regimen - (10/20/20)
     
  3036. GLASGOW: The clinical relevance of potential drug-drug interactions (DDIs) with bictegravir/ emtricitabine/ tenofovir alafenamide (B/F/TAF) -Real-world data from the German IQVIA prescription database - (10/20/20)
     
  3037. GLASGOW: FACTORS ASSOCIATED WITH INTEREST IN A LONG-ACTING HIV REGIMEN: PERSPECTIVES OF PEOPLE LIVING WITH HIV, AND PHYSICIANS IN WESTERN EUROPE - (10/15/20)
     
  3038. GLASGOW: Bictegravir/ emtricitabine/ tenofovir alafenamide (B/F/TAF)shows high efficacy in clinical study participants infected with HIV-1 subtype F - (10/15/20)
     
  3039. GLASGOW: CABOTEGRAVIR + RILPIVIRINE LONG-ACTING AS HIV-1 MAINTENANCE THERAPY: ATLAS WEEK 96 RESULTS - (10/15/20)
     
  3040. GLASGOW: Rapid DTG/3TC Safe and Usually Effective in US Test-and-Treat Trial - Mark Mascolini (10/15/20)
     
  3041. GLASGOW: Lenacapavir resistance analysis in a phase Ib clinical proof of-concept study: Resistance to HIV Capsid Inhibitor Rare and Linked to Single Mutation - Mark Mascolini (10/15/20)
     
  3042. GLASGOW: Islatravir in Combination With Doravirine Maintains HIV-1 Viral Suppression Through 96 Weeks - (10/15/20)
     
  3043. GLASGOW: Associations with weight change and patient reported outcomes after switching from efavirenz/ emtricitabine/ tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/ emtricitabine/ tenofovir alafenamide (BIC/FTC/TAF) - (10/15/20)
     
  3044. GLASGOW: Unmet Needs PLWH, ViiV Positive Perspectives Global Study - (10/15/20)
     
  3045. GLASGOW: SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN (TBR) IN MAINTAINING VIROLOGIC SUPPRESSION THROUGH 96 WEEKS (TANGO STUDY) - (10/15/20)
     
  3046. GLASGOW: A COMBINATION OF VIRAL AND PARTICIPANT FACTORS INFLUENCE VIROLOGIC OUTCOME TO LONG-ACTING CABOTEGRAVIR + RILPIVIRINE: MULTIVARIABLE AND BASELINE FACTOR ANALYSES ACROSS ATLAS, FLAIR AND ATLAS-2M PHASE 3 STUDIES - (10/15/20)
     
  3047. GLASGOW: SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN (TBR) IN MAINTAINING VIROLOGIC SUPPRESSION THROUGH 96 WEEKS (TANGO STUDY) - (10/15/20)
     
  3048. GLASGOW: Increased levels of immune activation and exhaustion in vertically HIV-1 infected young adults - (10/12/20)
     
  3049. GLASGOW: SAFETY AND EFFICACY OF CABOTEGRAVIR + RILPIVIRINE LONG-ACTING WITH AND WITHOUT ORAL LEAD-IN: FLAIR WEEK 124 RESULTS - (10/12/20)
     
  3050. GLASGOW: Frailty of Greek PLWHIV in association with clinical markers and psychological factors; Preliminary results of a nationwide study. - (10/12/20)
     
  3051. GLASGOW: Multidrug Resistance Still Boosts Death Risk in 31,000-Person Italian Study - Mark Mascolini (10/12/20)
     
  3052. GLASGOW: Clinically Relevant Transmitted Integrase Resistance Low in Mediterranean Countries - Mark Mascolini - (10/12/20)
     
  3053. GLASGOW: Lenacapavir Resistance Analysis in a Phase 1b Proof-of-Concept Clinical Study - (10/12/20)
     
  3054. GLASGOW: The clinical relevance of potential drug-drug interactions (DDIs) with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) - Real-world data from the German IQVIA prescription database - (10/12/20)
     
  3055. GLASGOW: Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol (UK): a prospective observational study - (10/12/20)
     
  3056. GLASGOW: Safety, Tolerability and Pharmacokinetics Following Single- and Multiple-Dose Administration of the Novel NNRTI MK-8507 With a Midazolam Interaction Arm - (10/12/20)
     
  3057. GLASGOW: Lenacapavir Resistance Analysis in a Phase 1b Clinical Proof-Of-Concept Study - (10/12/20)
     
  3058. GLASGOW: SINGLE DOSES OF MK-8507, A NOVEL HIV-1 NNRTI, REDUCED HIV VIRAL LOAD FOR AT LEAST A WEEK - (10/09/20)
     
  3059. GLASGOW: Islatravir Plus Doravirine Maintains HIV Control Through 96 Weeks - Mark Mascolini - (10/09/20)
     
  3060. GLASGOW: Patient-reported outcomes (PROs) after 1 year of routine clinical practice with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): The BICSTaR cohort - (10/09/20)
     
  3061. GLASGOW: Starting or switching to bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) in clinical practice: Pooled 12-month results from the global BICSTaR study - (10/09/20)
     
  3062. GLASGOW: Switching to Bictegravir/Emtricitabine/TenofovirAlafenamide(B/F/TAF) in Adults Aged ≥ 65 Years: Week 72 Results from a Phase 3b, Open-Label Trial (GS-US-380-4449) - (10/09/20)
     
  3063. GLASGOW: Sustained Viral Suppression After Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Among Clinical Trial Participants With Preexisting M184V/I - (10/09/20)
     
  3064. GLASGOW: 12-month outcome of Dolutegravir/Rilpivirine in virologically suppressed HIV-infected patients: Real-world data from the German JUNGLE cohort - (10/09/20)
     
  3065. GLASGOW: Real-world data from the prospective URBAN cohort study on the use of Dolutegravir (DTG) + Lamivudine (3TC) in ART-naïve and pre-treated people living with HIV in Germany - (10/08/20)
     
  3066. GLASGOW: FEASIBILITY, EFFICACY, AND SAFETY OF USING DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) AS A FIRST-LINE REGIMEN IN A TEST-AND-TREAT SETTING FOR NEWLY DIAGNOSED PEOPLE LIVING WITH HIV (PLWH): THE STAT STUDY - (10/08/20)
     
  3067. GLASGOW: EFFICACY AND SAFETY OF DOLUTEGRAVIR IN TREATMENT-NAIVE PEOPLE LIVING WITH HIV-1 STRATIFIED BY AGE (>50): META-ANALYSIS OF 48-WEEK RESULTS FROM ARIA, FLAMINGO, SINGLE, AND SPRING-2 - (10/08/20)
     
  3068. GLASGOW: Persistence of antiretroviral therapy regimens among veterans with HIV newly initiating treatment in the US - Mark Mascolini (10/08/20)
     
  3069. GLASGOW: DURABLE EFFICACY OF DOLUTEGRAVIR (DTG) PLUS LAMIVUDINE (3TC) IN ANTIRETROVIRAL TREATMENT-NAIVE ADULTS WITH HIV-1 INFECTION- 3-YEAR RESULTS FROM THE GEMINI STUDIES - (10/08/20)
     
  3070. GLASGOW: Real-word characterization of the Portuguese population living with HIV who initiated Raltegravir based-regimen between 2015 and 2017 -REALITY Study - RAL Persistence 49 Yr Olds with Comorbidities - (10/08/20)
     
  3071. GLASGOW: Islatravir Selects for HIV-1 Variants in MT4-GFP Cells That Profoundly Reduce Replicative Capacity in Peripheral Blood Mononuclear Cells - (10/08/20)
     
  3072. GLASGOW: Analysis of Protocol-Defined Virologic Failure Through Week 96 From a Phase 2 Trial (P011) of Islatravir and Doravirine in Treatment-Naïve Adults WithHIV-1 Infection - (10/08/20)
     
  3073. GLASGOW: Long-term Treatment Efficacy and Safety Following Switch to Doravirine/ Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF): Week 144 Results of the DRIVE-SHIFT Trial - (10/08/20)
     
  3074. GLASGOW: Comorbidity Rate Does Not Affect F/TAF Persistence Through 24 Months - Mark Mascolini - (10/06/20)
     
  3075. GLASGOW: The relationship between smoking, current CD4, viral load and cancer in PLWH - (10/06/20)
     
  3076. GLASGOW: "WHAT ABOUT ME?" THE UNMET NEEDS OF MEN WHO HAVE SEX WITH WOMEN AND DIFFERENCES IN HIV TREATMENT EXPERIENCES, PERCEPTIONS, AND BEHAVIORS BY GENDER AND SEXUAL ORIENTATION IN 25 COUNTRIES - (10/06/20)
     
  3077. GLASGOW: Prevalence of pain in women living with HIV aged 45-60: associated factors and impact on patient-reported outcomes - (10/06/20)
     
  3078. GLASGOW: Impact of adherence on viral suppression with bictegravir and dolutegravir (DTG) containing triple therapy in clinical practice - Mark Mascolini (10/06/20)
     
  3079. GLASGOW: Merck to Present New Data from the Company's Diverse HIV Portfolio and Pipeline at HIV Glasgow 2020 - (10/06/20)
     
  3080. GLASGOW: OUTCOMES FOR WOMEN RECEIVING LONG-ACTING CABOTEGRAVIR + RILPIVIRINE MONTHLY AND EVERY 2 MONTHS: ATLAS-2M STUDY WEEK 48 RESULTS - (10/05/20)
     
  3081. GLASGOW: Highest Cancer Risk in HIV+ Current Smokers and Those With Poor HIV Control - Mark Mascolini - (10/05/20)
     
  3082. GLASGOW: SUBGROUP ANALYSIS OF PATIENT-REPORTED OUTCOMES AMONG PARTICIPANTS IN 2 PHASE III CLINICAL TRIALS OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE (ATLAS AND FLAIR) - (10/05/20)
     
  3083. GLASGOW: Fat Distribution and density in PLWH with ≥ 5% weight gain - (10/05/20)
     
  3084. GLASGOW: Renal Safety Through 96 Weeks in a Phase 2 Trial (P011) of Islatravir and Doravirine in Treatment-Naïve Adults With HIV-1 - (10/05/20)
     
  3085. GLASGOW: COMPARABILITY OF 48-WEEK EFFICACY AND SAFETY OF CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING EVERY 8 WEEKS TO STANDARD OF CARE IN SUPPRESSED PEOPLE LIVING WITH HIV-1 - (10/05/20)
     
  3086. GLASGOW: Virologic and CD4 Responses to DTG Generally Steady With Advancing Age - Mark Mascolini (10/05/20)
     
  3087. GLASGOW: GILEAD SCIENCES PRESENTS DATA FROM HIV RESEARCH AND DEVELOPMENT PROGRAMS AT HIV GLASGOW 2020 - (10/05/20)
     
  3088. GLASGOW: Gilead Presents Biktarvy® Findings From Switch Studies & Analysis of Real-World BICSTaR Study At HIV Glasgow 2020 - (10/05/20)
     
  3089. GLASGOW: ViiV Healthcare announces dolutegravir plus lamivudine three-year data confirming long-term viral suppression non-inferior to a 3-drug regimen for treatment-naïve adults with HIV-1 - (10/05/20)
     
  3090. GLASGOW: Over Half in UK HIV Women's Study Report Moderate or Severe Pain - Mark Mascolini - (10/05/20)
     
  3091. GLASGOW: Switch to Integrase Drug Incites BMI Gain But Perhaps Improved "Fat Quality" - Mark Mascolini (10/05/20)
     
  3092. GLASGOW: ViiV Healthcare to present long-term safety and efficacy data for 2-drug regimen Dovato (dolutegravir/lamivudine) alongside other key research advances at the HIV Glasgow 2020 congress - (09/28/20)
     
  3093. AGE Wrkshp: Dozing or Napping Has Bigger Cognitive Impact in People With HIV - By Mark Mascolini - (10/05/20)
     
  3094. AGE Wrkshp: A Study of Neurocognitive Performance in Women Living With and Without HIV in South Africa - (10/05/20)
     
  3095. AGE Wrkshp: Polypharmacy in 94% of Older HIV Group, Inappropriate Meds Frequent - By Mark Mascolini - (10/05/20)
     
  3096. AGE Wrkshp: Aging with HIV in Latin America and The Caribbean: a systematic review - (10/05/20)
     
  3097. AGE Wrkshp: Urine mtDNA Signals Lower Muscle, Fat Mass, Weight in Older Group With HIV - By Mark Mascolini - (10/05/20)
     
  3098. AGE Wrkshp: Effects of HIV and Aging on the brain - (10/05/20)
     
  3099. AGE Wrkshp: Age-Related Trajectories of C-Reactive Protein Among Men With and Without HIV Infection in the Multicenter AIDS Cohort Study - (10/05/20)
     
  3100. AGE Wrkshp: Bictegravir/FTC/TAF Effective at 48 Weeks in Elderly: 4-Trial Analysis - By Mark Mascolini (10/02/20)
     
  3101. AGE Wrkshp: HIV & Aging Geriatric Clinics - (10/02/20)
     
  3102. AGE Wrkshp: Increased Neuropathy in Older PLWH - (10/02/20)
     
  3103. AGE Wrkshp: Should we still care about bone? Screening, treatment, TDF vs TAF - (10/02/20)
     
  3104. AGE Wrkshp: Sex Hormone-Binding Globulin Tied to Frailty, Low BMD in Women, Not Men - By Mark Mascolini (10/02/20)
     
  3105. AGE Wrkshp: Frailty Common in HIV+ Middle-Aged: Tied to Depression, HCV, Substance Use - By Mark Mascolini (10/02/20)
     
  3106. ViiV Healthcare presents a new podcast about the Power of Being Seen - (10/01/20)
     
  3107. AGE Wrkshp: Latent Class Analysis--Unique Predictor of Hospitalization, Death in Older HIV+ - (10/01/20)
     
  3108. AGE Wrkshp: Getting HIV Infection Speeds Up Epigenetic Clock (and Biologic Aging) Right Away - By Mark Mascolini - (10/01/20)
     
  3109. AGE Wrkshp: Heart Failure Diagnosed 6 to 16 Years Earlier in Veterans With vs Without HIV - By Mark Mascolini - (10/01/20)
     
  3110. AGE Wrkshp: A Multidisciplinary Approach (Exercise Program) to Chronic Pain and Frailty Among Those Aging with HIV: Lessons Learned - (10/01/20)
     
  3111. AGE Wrkshp: ART-Associated Issues, Fat & Muscle Density, The Significance of ART-associated Weight Gain in HIV - (10/01/20)
     
  3112. AGE Wrkshp: Associations between Frailty and Clinical Characteristics, Comorbidities, and Substance Abuse Among PLWH.....12% frailty in CNICS Cohort (CAR).....past drug use associated with frailty....average age only 47 - (10/01/20)
     
  3113. AGE Wrkshp: Lack of Transportation Tied to Array of Health Measures in Aging US HIV Group - By Mark Mascolini - (10/01/20)
     
  3114. Clin Pharm: Ledipasvir Exposure Linked to SVR, But Overall Response Rate High - By Mark Mascolini (10/01/20)
     
  3115. Clin Pharm: Neonatal Liquid Dolutegravir Comparable to Pediatric Dispersible Tablets - By Mark Mascolini (10/01/20)
     
  3116. Clin Pharm: Comparison of Relative Bioavailability of TIVICAY Neonatal Liquid Formulations to Pediatric Dispersible Tablets - (10/01/20)
     
  3117. Clin Pharm: Population pharmacokinetic (PopPK) modeling and simulation of monthly intramuscular (IM) long-acting rilpivirine (RPV LA) to inform strategies following dosing interruptions in HIV-1 infected subjects - (10/01/20)
     
  3118. GLASGOW: ViiV Healthcare to present long-term safety and efficacy data for 2-drug regimen Dovato (dolutegravir/lamivudine) alongside other key research advances at the HIV Glasgow 2020 congress - (09/28/20)
     
  3119. Clin Pharm: No Interactions Between HIV-1 Maturation Inhibitor and TAF/FTC - By Mark Mascolini (09/30/20)
     
  3120. Clin Pharm: Levels of Long-Acting Anti-HIV bNAb High in Infants After 1 or 2 Doses--But Not High Enough - By Mark Mascolini (09/30/20)
     
  3121. Clin Pharm: Model Predicts Long-Acting IM Rilpivirine Safe With Liver Impairment - By Mark Mascolini (09/30/20)
     
  3122. Clin Pharm: Antiretroviral Drug-Drug Interaction Profile of Long-Acting Cabotegravir and Rilpivirine - (09/30/20)
     
  3123. Clin Pharm: Three Phase I Drug Interaction Studies Investigating the Next-Generation Maturation Inhibitor GSK3640254 With Oral Contraceptive Ethinyl Estradiol/Levonorgestrel, Dolutegravir, and Tenofovir Alafenamide/Emtricitabine - (09/30/20)
     
  3124. Clin Pharm: Dolutegravir (DTG) plasma concentrations under different combinations regimens for ART-pre-treated adults living with HIV - (09/30/20)
     
  3125. Clin Pharm: FOSTEMSAVIR DRUG-DRUG INTERACTION PROFILE, AN ATTACHMENT INHIBITOR AND ORAL PRODRUG OF TEMSAVIR, FOR PATIENTS WITH MULTIDRUG-RESISTANT HIV-1 INFECTION - (09/30/20)
     
  3126. Clin Pharm: No Adverse Pregnancy Outcome Patterns With Common Antiretrovirals - By Mark Mascolini (09/30/20)
     
  3127. Clin Pharm: PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF DOLUTEGRAVIR/RILPIVIRINE (JULUCA) IN HEALTHY JAPANESE ADULTS - (09/28/20)
     
  3128. Clin Pharm: THE PHARMACOKINETICS (PK) OF DOVATO (50 MG DOLUTEGRAVIR [DTG]/ 300 MG LAMIVUDINE [3TC]) FIXED-DOSE COMBINATION IN HIV-INFECTED PATIENTS - (09/28/20)
     
  3129. Clin Pharm: TFV Levels Far Lower in Milk Than Plasma With Dried Milk and Blood Spots - Mark Mascolini - (09/28/20)
     
  3130. Clin Pharm: FTC Exposure Higher in Young Transgender Men Than Cisgender Controls - Mark Mascolini - (09/28/20)
     
  3131. ViiV Healthcare announces start of implementation science study to identify and evaluate approaches to integrating its investigational, every-two-month, injectable HIV treatment in European healthcare practices press release - (09/28/20)
     
  3132. Rates of Detectable Viral Load & condomless Sex Among HIV+ MSM, Discordant Couples - (09/25/20)
     
  3133. Cost of Comorbidities/HIV: Mean costs of care increased from $30,312 for those without an identified comorbidity to over $46,000 for those with 2 comorbidities, and up to $219,000 for people with 11 or more. - (09/25/20)
     
  3134. TAF vs TDF in DISCOVER PrEP Trial - Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial - (09/24/20)
     
  3135. Cost Analysis Questions Value of F/TAF vs Generic F/TDF for PrEP - Mark Mascolini (09/25/20)
     
  3136. TAF vs TDF in DISCOVER PrEP Trial - Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial - (09/24/20)
     
  3137. Quantifying the reduction in sexual transmission of HIV-1 among MSM by early initiation of ART: A mathematical model. - (09/23/20)
     
  3138. Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016 - Updated HIV Life Expectancy Study: 9 yrs difference; 6.8 for HIV+ >500 CD4 at ART start - (09/23/20)
     
  3139. Cost of Comorbidities/HIV: Mean costs of care increased from $30,312 for those without an identified comorbidity to over $46,000 for those with 2 comorbidities, and up to $219,000 for people with 11 or more. - (09/21/20)
     
  3140. Gaps in Monitoring Older HIV+ in UK - (09/21/20)
     
  3141. Structural and functional brain abnormalities in HIV disease revealed by multimodal MRI fusion: association with cognitive function - (09/21/20)
     
  3142. Aging HIV+ in SF & NYC: 58% in NYC & 69% in SF >50 - A tale of 2 different epidemics - (09/21/20)
     
  3143. Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016 - Updated HIV Life Expectancy Study: 9 yrs difference; 6.8 for HIV+ >500 CD4 at ART start - (09/18/20)
     
  3144. Rapid ART - (09/17/20)
     
  3145. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials - (09/16/20)
     
  3146. EDITORIAL: Is Modern Antiretroviral Therapy Causing Weight Gain? - (09/16/20)
     
  3147. (Vascepa) Final EVAPORATE Results for Vascepa Raise Eyebrows - (09/16/20)
     
  3148. ADHOC Aging-HIV Database Community Call Today Sept 3 2020 - (09/16/20)
     
  3149. Sexual transmission of an extensively drug-resistant HIV-1 strain - (09/16/20)
     
  3150. Cardiovascular disease risk among transgender women living with HIV in the United States - (09/16/20)
     
  3151. EASL THERATECHNOLOGIES TO DEVELOP TESAMORELIN FOR THE TREATMENT OF NASH IN THE GENERAL POPULATION - (09/15/20)
     
  3152. Risk of Cataract Surgery in HIV-Infected Individuals: A Danish Nationwide Population-Based Cohort Study - (08/25/20)
     
  3153. New HIV ART & Long-Acting Drugs - (08/25/20)
     
  3154. CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS IS NONINFERIOR TO MONTHLY: ATLAS-2M STUDY - (08/25/20)
     
  3155. ViiV Healthcare announces data demonstrating the feasibility of Dovato (dolutegravir/lamivudine) as a treatment option for rapid initiation after diagnosis in adults with HIV-1 - PRESS RELEASE - (08/25/20)
     
  3156. FEASIBILITY, EFFICACY, AND SAFETY OF USING DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) AS A FIRST-LINE REGIMEN IN A TEST-AND-TREAT SETTING FOR NEWLY DIAGNOSED PEOPLE LIVING WITH HIV (PLWH): THE STAT STUDY - (08/25/20)
     
  3157. IAC 2020 Virtual: The first long-term remission of chronic HIV-1 infection without myeloablation? (nicotinemide + maraviroc) - (08/24/20)
     
  3158. IAC 2020 Virtual: IAC 2020: Aging, Comorbidities, weight changes, HCV-MSM, NAFLD, Challenges-Unmet Needs of elderly PLWH - (08/24/20)
     
  3159. IAC 2020 Virtual: Characteristics and Predictors of Death among Hospitalized Patients with COVID-19 in Spain - (08/14/20)
     
  3160. Cabenva (cabotegravir/rilpivirine Resubmitted for FDA Approval - (08/10/20)
     
  3161. Lower CD4 Increased Risk: Frailty and HIV Disease Severity Synergistically Increase Risk of HIV-Associated Neurocognitive Disorders - (08/10/20)
     
  3162. Sociodemographic, ecological, and spatiotemporal factors associated with HIV drug resistance in Florida: a retrospective analysis implications for 'End AIDS' - (08/10/20)
     
  3163. IAC 2020 Virtual: Is NAFLD the same disease in HIV infected patients? - (08/10/20)
     
  3164. IAC 2020 Virtual: Early weight changes associated with bictegravir-based regimens compared to other integrase inhibitors following ART-initiation in ART-naïve people living with HIV - (08/10/20)
     
  3165. ViiV Healthcare announces FDA approval of an expanded indication for Dovato (dolutegravir/lamivudine), a complete two-drug regimen for virologically suppressed adults with HIV-1 - (08/07/20)
     
  3166. APLA Health Announces Statewide Strategic Planning Meeting to Address Urgent Needs of People Aging with HIV - (08/05/20)
     
  3167. IAC 2020 Virtual: Patterns of Antiretroviral Use and Immunologic Correlates at Study Entry in the REPRIEVE Trial - (08/04/20)
     
  3168. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy - (08/03/20)
     
  3169. IAC 2020 Virtual: Illicit Opioid Use After Changes in Opioids Prescribed for Chronic Pain Among People Living With and Without HIV - (08/01/20)
     
  3170. IAC 2020 Virtual: Plenary: Casualties on the road to ending HIV: Context matters in addressing HIV disparities. From the very beginning of the 40-year HIV pandemic until today, HIV disparities have remained an intractable issue. - (08/01/20)
     
  3171. IAC 2020 Virtual: Cabotegravir+Rilpivirine Long-Acting Injectable Treatment and Cabotegravir for PrEP study HPTN 083 at IAC 2020 - (08/01/20)
     
  3172. Aging/HIV AIDS United Policy/Advocacy Paper - (07/31/20)
     
  3173. Worse Short-Term Memory Predicts Poor COVID Distancing in US - Mark Mascolini (07/27/20)
     
  3174. The changing HIV epidemic: a view from the front line in the United States -holistic care needed - (07/29/20)
     
  3175. Black Cisgender Women's PrEP Knowledge, Attitudes, Preferences, and Experience in Chicago - (07/29/20)
     
  3176. Ending Epidemic??? - HIV+ MSM Condomless Sex/Detectable Viral Load Behavior USA - Blind Spot ? For Ending the Epidemic....efforts not good enough - (07/29/20)
     
  3177. Antiretroviral drug concentrations in brain tissue of adult decedents - (07/29/20)
     
  3178. High Stigma Towards Those Living with HIV Remains, GLAAD Survey: State of HIV Stigma Survey - stigma persists - GLAAD survey - (07/29/20)
     
  3179. High Stigma Towards Those Living with HIV Remains, GLAAD Survey: State of HIV Stigma Survey - stigma persists - GLAAD survey - (07/28/20)
     
  3180. from the NIH Comorbidities Workshop held Sept 2019 at NIH - Report Pathogenesis of Aging and Age-related Comorbidities in People with HIV: Highlights from the HIV ACTION Workshop - (07/27/20)
     
  3181. IAC 2020 Virtual: Persons Living With HIV (PLWH) in Japan on 2-Drug Regimen Reveal More Complex Patient Profiles Than That of 3-Drug Regimen Cohort - (07/27/20)
     
  3182. IAC 2020 Virtual: Cardiovascular and metabolic comorbidities in HIV-infected patients in Colombia: A multicenter study - (07/27/20)
     
  3183. IAC 2020 Virtual: Vesatolimod induces dose-dependent immune responses in HIV controllers - (07/27/20)
     
  3184. IAC 2020 Virtual: Changes in Body Mass Index Over Time in Persons With and Without HIV - Kaiser - (07/27/20)
     
  3185. IAC 2020 Virtual: COVID-19 in the Largest US HIV Cohort - (07/19/20)
     
  3186. IAC 2020 Virtual: To Dose-Adjust or Not to Dose-Adjust: 3TC Dose in Renal Impairment - (07/19/20)
     
  3187. ViiV Healthcare announces new strategic alliance to enable greater access to antiretroviral medicines in Brazil - PRESS RELEASE - (07/17/20)
     
  3188. Moderna's Covid-19 Vaccine Moves to Bigger Study - (07/17/20)
     
  3189. IAC 2020 Virtual: PUTTING THE HEART BACK INTO HAART: GREATER HCP-PATIENT ENGAGEMENT IS ASSOCIATED WITH BETTER HEALTH OUTCOMES AMONG PERSONS LIVING WITH HIV (PLHIV) ON TREATMENT - (07/17/20)
     
  3190. IAC 2020 Virtual: Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana - (07/16/20)
     
  3191. IAC 2020 Virtual: Overdose Deaths Cut 10 Years Off HIV Life Expectancy: British Columbia - Mark Mascolini (07/16/20)
     
  3192. IAC 2020 Virtual: Characteristics of Patients Living with HIV (PLWH) and HIV Treatment Outcomes in Community Practices in Southern vs Non-Southern US Regions - (07/16/20)
     
  3193. IAC 2020 Virtual: FACTORS ASSOCIATED WITH RESILIENCE AMONG OLDER PEOPLE LIVING WITH HIV - (07/16/20)
     
  3194. IAC 2020 Virtual: HIV-1 DNA Testing in Viremic Patients Demonstrates a Greater Ability to Detect Drug Resistance Compared to Plasma Virus Testing - (07/16/20)
     
  3195. IAC 2020 Virtual: MODEL-BASED APPROACH OF DOSE SELECTION AND OPTIMAL PK SAMPLING OF FOSTEMSAVIR FOR PEDIATRIC PATIENTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION - (07/16/20)
     
  3196. IAC 2020 Virtual: COVID-19 Rate No Higher With HIV in Largest US HIV+/HIV- Cohort - Mark Mascolini (07/16/20)
     
  3197. Cognitive disorders in people living with HIV - (07/16/20)
     
  3198. Dewpoint Therapeutics Collaborates with Merck to Evaluate Novel Approach for the Treatment of HIV (cure) - (07/16/20)
     
  3199. PrEP in YBMSM Atlanta -. high rates of discontinuation - (07/16/20)
     
  3200. COVID Congress: Baseline Characteristics Associated With Clinical Improvement and Mortality in Hospitalized Patients With Severe COVID-19 Treated With Remdesivir - (07/16/20)
     
  3201. COVID Congress: Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care - (07/16/20)
     
  3202. GILEAD SCIENCES STATEMENT ON THE INITIATION OF CLINICAL TESTING OF AN INHALED SOLUTION OF REMDESIVIR FOR POTENTIAL OUTPATIENT TREATMENT OF COVID-19 - (07/16/20)
     
  3203. European Commission Grants Conditional Marketing Authorization for Gilead's Veklury® (remdesivir) for the Treatment of COVID-19 - (07/16/20)
     
  3204. IAC 2020 Virtual: Population pharmacokinetic (PopPK) modeling and simulation of monthly intramuscular (IM) long-acting rilpivirine (RPV LA) to inform strategies following dosing interruptions in HIV-1 infected subjects - (07/16/20)
     
  3205. IAC 2020 Virtual: ADEQUATE PLASMA LEVELS OF DOLUTEGRAVIR IN COMBINATION WITH RITONAVIR-BOOSTED DARUNAVIR: A PHARMACOKINETIC SUBGROUP-ANALYSIS OF THE DUALIS STUDY - (07/16/20)
     
  3206. IAC 2020 Virtual: The BICSTaR prospective cohort: Real-world effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine clinical practice in people living with HIV (PLWH) - (07/15/20)
     
  3207. IAC 2020 Virtual: Global Positive Perspectives Study, Wave 2: Understanding the Unmet Needs of People Living with HIV - (07/15/20)
     
  3208. IAC 2020 Virtual: Cardiovascular Risk Estimation is Sub-optimal Across Two HIV Cohort - (07/15/20)
     
  3209. IAC 2020 Virtual: COMPARATIVE EFFICACY AND SAFETY OF A COMBINATION THERAPY OF DOLUTEGRAVIR AND LAMIVUDINE VS 3-DRUG ANTIRETROVIRAL REGIMENS IN TREATMENT-NAIVE HIV-1 INFECTED PATIENTS AT 96 WEEKS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS - (07/15/20)
     
  3210. IAC 2020 Virtual: Dolutegravir With TAF or TDF Could Increase Adverse Pregnancy Outcomes - Mark Mascolini (07/15/20)
     
  3211. IAC 2020 Virtual: COVID-19 Rate No Higher With HIV in Largest US HIV+/HIV- Cohort - Mark Mascolini (07/15/20)
     
  3212. IAC 2020 Virtual: The ADVANCE trial: Phase 3, randomised comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection. - Mark Mascolini (07/15/20)
     
  3213. IAC 2020 Virtual: COVID-19 Disrupts PrEP Starts, Refills, HIV/STI Testing in Boston Clinic - Mark Mascolini (07/15/20)
     
  3214. IAC 2020 Virtual: With COVID Here, 90% of Australian MSM Have Less Sex, 40% Stop PrEP - Mark Mascolini (07/15/20)
     
  3215. IAC 2020 Virtual: High HCV Rate in Both Young and Older Drug Injectors--HIV Ups HCV Risk - Mark Mascolini (07/15/20)
     
  3216. IAC 2020 Virtual: FEASIBILITY OF IMPLEMENTING LONG-ACTING INJECTABLE ANTI-RETROVIRAL THERAPY TO TREAT HIV: A SURVEY OF HEALTH PROVIDERS FROM THE 13 COUNTRIES PARTICIPATING IN THE ATLAS-2M TRIAL - (07/15/20)
     
  3217. IAC 2020 Virtual: PrEP Halves New HIV Rate When Offered in Contraceptive Trial - Mark Mascolini - (07/15/20)
     
  3218. IAC 2020 Virtual: Doravirine Resistance Profile in Clinical Isolates and Impact of Baseline NNRTI Resistance-Associated Mutations Observed in Treatment-Naïve Participants from Phase 2 and 3 Clinical Trials - (07/15/20)
     
  3219. IAC 2020 Virtual: IS DTG+3TC EFFECTIVE AND SAFE IN CLINICAL PRACTICE? EVIDENCE FROM REAL WORLD DATA - (07/15/20)
     
  3220. IAC 2020 Virtual: COMPARISON OF VIRAL REPLICATION AT <40 C/ML FOR 2-DRUG REGIMEN (2DR) OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC FDC) VERSUS 3-DRUG REGIMEN (3DR) BASED ON TENOFOVIR ALAFENAMIDE (TAF) (TBR) IN THE TANGO STUDY - (07/15/20)
     
  3221. IAC 2020 Virtual: Is DTG+3TC effective and safe in clinical practice? Evidence from real world data - (07/15/20)
     
  3222. IAC 2020 Virtual: Almost Half of Older HIV+ Adults Report Poor Overall Health in 25-Country Survey - (07/15/20)
     
  3223. IAC 2020 Virtual: HCV Drugs for COVID-19? Three Small Studies Have Positive Hints - Mark Mascolini (07/15/20)
     
  3224. IAC 2020 Virtual: The ADVANCE trial: Phase 3, randomised comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection - More Weight, Trunk Fat, Metabolic Syndrome With DTG+TAF/FTC in South African Trial - Mark Mascolini (07/15/20)
     
  3225. IAC 2020 Virtual: Faster virological suppression with dolutegravir versus efavirenz in pregnancy does not lower the risk of HIV mother-to-child-transmission: A meta-analysis of 5 clinical trials in 1074 pregnant women - Mark Mascolini (07/15/20)
     
  3226. IAC 2020 Virtual: The predicted risk of adverse pregnancy outcomes from treatment-induced obesity in the ADVANCE trial. - Dolutegravir With TAF or TDF Could Increase Adverse Pregnancy Outcomes - Mark Mascolini (07/15/20)
     
  3227. IAC 2020 Virtual: Racial Disparities, Communal Living in Boston COVID-19 Patients With HIV - Mark Mascolini (07/15/20)
     
  3228. IAC 2020 Virtual: Prevalence and Incidence of Hepatitis C Virus Infection in Men Who Have Sex With Men: A Global Systematic Review - (07/13/20)
     
  3229. IAC 2020 Virtual: Incidence of HCV reinfection among HIV-positive MSM and its association with sexual risk behavior: A longitudinal analysis - (07/13/20)
     
  3230. IAC 2020 Virtual: HCV Reinfection Rate 40% in Netherlands HIV+ MSM 5 Years After Clearance - Mark Mascolini (07/13/20)
     
  3231. IAC 2020 Virtual: Global HCV Burden Greater in MSM, Especially HIV+ Men: Meta-Analysis - Mark Mascolini (07/13/20)
     
  3232. IAC 2020 Virtual: Impact of COVID-19 on HIV preexposure prophylaxis care at a Boston community health center - (07/13/20)
     
  3233. IAC 2020 Virtual: Gilead Sciences Presents Survey Findings on PrEP Access and Utilization in the U.S. During COVID-19 Shelter-in-Place Orders - (07/11/20)
     
  3234. IAC 2020 Virtual: Rapid Initiation of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Acute and Early Human Immunodeficiency Virus (HIV)-1 Infection: A DIAMOND Subgroup Analysis - (07/11/20)
     
  3235. IAC 2020 Virtual: Switching to dolutegravir plus lamivudine (DTG+3TC) is non-inferior to and as safe as continuing standard triple antiretroviral therapy (TAR) - (07/11/20)
     
  3236. IAC 2020 Virtual: Weight change among treatment naive women initiating dolutegravir in the ARIA study - (07/11/20)
     
  3237. IAC 2020 Virtual: COMPASSIONATE USE OF LONG-ACTING (LA) CABOTEGRAVIR (CAB) AND RILPIVIRINE (RPV) FOR PATIENTS IN NEED OF PARENTERAL ANTIRETROVIRAL THERAPY - (07/11/20)
     
  3238. IAC 2020 Virtual: PATIENT-REPORTED OUTCOMES THROUGH WEEK 48 OF ATLAS-2M: A STUDY OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE ADMINISTERED EVERY FOUR OR EIGHT WEEKS - (07/11/20)
     
  3239. IAC 2020 Virtual: Same COVID Mortality With/Without HIV at NY Center--More Intubations With HIV - Mark Mascolini (07/11/20)
     
  3240. IAC 2020 Virtual: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Treatment-naïve (AMBER) and Virologically Suppressed (EMERALD) Patients With Neurologic and/or Psychiatric Comorbidities: Week 96 Subgroup Analysis - (07/11/20)
     
  3241. IAC 2020 Virtual: Perceived Implementation Barriers Decrease During Initial Stages of an Implementation Science Hybrid III Study (CUSTOMIZE) of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in US Healthcare Settings: Healthcare Team Perspective - (07/10/20)
     
  3242. IAC 2020 Virtual: WEIGHT CHANGE AMONG TREATMENT-NAIVE WOMEN INITIATING DOLUTEGRAVIR IN THE ARIA STUDY - (07/10/20)
     
  3243. IAC 2020 Virtual: Double Drug Use, Double No-Condom Sex Boost HIV Risk With Already-Positive Partner - Mark Mascolini (07/10/20)
     
  3244. IAC 2020 Virtual: MSM Testing Drive Works Well in Australia-Except for One Thing - Mark Mascolini (07/10/20)
     
  3245. IAC 2020 Virtual: Prescribed Opioid Dose Increase Tied to Future Heroin Use in HIV+ People - Mark Mascolini - (07/10/20)
     
  3246. IAC 2020 Virtual: Perceived Implementation Barriers Decrease During Initial Stages of an Implementation Science Hybrid III Study (CUSTOMIZE) of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in US Healthcare Settings: Healthcare Team Perspective - (07/10/20)
     
  3247. IAC 2020 Virtual: HIV Risk and Treatment Disparities Persist in US Hispanic vs White MSM - Mark Mascolini (07/10/20)
     
  3248. IAC 2020 Virtual: Neuropathy and Neuropathic Pain Still on Rise in HIV+, But No Clear Links to ART - Mark Mascolini (07/10/20)
     
  3249. IAC 2020 Virtual: Quarter Million More With HIV in US-Mostly Women-Should Get Hep A Vaccine: CDC Now Recommends HAV Vax for Everyone With HIV at Least 1 Year Old - Mark Mascolini (07/10/20)
     
  3250. IAC 2020 Virtual: Deep Sequencing With Unique Molecular Identifiers for Evaluation of HIV-1 Drug Resistance in the DISCOVER Pre-Exposure Prophylaxis Trial - (07/10/20)
     
  3251. IAC 2020 Virtual: Prevalence and Risk Factors of Preexisting NNRTI Resistance Among Suppressed PLWH in B/F/TAF Switch Studies - (07/10/20)
     
  3252. IAC 2020 Virtual: Clinical and sociodemographic characteristics associated with poor self-rated health across multiple domains among older adults living with HIV - (07/10/20)
     
  3253. IAC 2020 Virtual: Weight gain and hyperglycemia during the dolutegravir transition in Africa - (07/10/20)
     
  3254. IAC 2020 Virtual: Prevalence and risk factors of pre-existing NNRTI resistance among suppressed PLWH in B/F/TAF switch studies - (07/10/20)
     
  3255. IAC 2020 Virtual: Baseline NRTI resistance in suppressed participants did not lead to viral blips on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir (DTG)+F/TAF through week 48 in study 380-4030 - (07/10/20)
     
  3256. IAC 2020 Virtual: Lenacapavir Sustained Delivery Formulation Supports 6-Month Dosing Interval - (07/10/20)
     
  3257. IAC 2020 Virtual: Improved metabolic parameters after switching from TAF-based 3- or 4-drug regimen to the 2-drug regimen of DTG/3TC (dolutegravir/lamivudine): The TANGO study - (07/10/20)
     
  3258. IAC 2020 Virtual: HPTN 083: Efficacy of Pre-exposure Prophylaxis (PrEP) containing Long-acting injectable cabotegravir (CAB-LA) is maintained across regions and key populations - (07/10/20)
     
  3259. IAC 2020 Virtual: Projecting the burden of multimorbidity among men who have sex with men living with HIV in the US - (07/09/20)
     
  3260. IAC 2020 Virtual: Lenacapavir (GS-6207) Sustained Delivery Formulation Supports 6-Month Dosing Interval - (07/09/20)
     
  3261. IAC 2020 Virtual: Merck Announces New Analyses Showing Additional Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection - (07/09/20)
     
  3262. IAC 2020 Virtual: Islatravir Safety Through 48 Weeks With Doravirine in Phase 2 Trial - Mark Mascolini (07/09/20)
     
  3263. IAC 2020 Virtual: Almost Half in US Women's Group Make PrEP Visit--But Only 10% Start PrEP - Mark Mascolini - (07/09/20)
     
  3264. IAC 2020 Virtual: UNDERSTANDING THE CHANGING TREATMENT CONCERNS OF OLDER PEOPLE LIVING WITH HIV (PLHIV) AND DIFFICULTIES WITH PATIENT-PROVIDER COMMUNICATION - (07/09/20)
     
  3265. IAC 2020 Virtual: Pooled Analysis of 4 International Trials of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Adults Aged ≥ 65 Years Demonstrating Safety and Efficacy: Week 48 Results - (07/09/20)
     
  3266. IAC 2020 Virtual: Doravirine, Islatravir at AIDS2020 IAC - (07/09/20)
     
  3267. IAC 2020 Virtual: DISCOVER Study for HIV Pre-exposure Prophylaxis: No Evidence of Risk Compensation in Participants Taking F/TDF or F/TAF for PrEP Through 96 Weeks - (07/09/20)
     
  3268. IAC 2020 Virtual: Weight/Body Mass Index Gains Following Initiation of Integrase Strand Transfer Inhibitor Versus Protease Inhibitor Among People Living With Human Immunodeficiency Virus in the United States - (07/09/20)
     
  3269. IAC 2020 Virtual: Weight/Body Mass Index Gains Following Initiation of Integrase Strand Transfer Inhibitor Versus Protease Inhibitor Among People Living With Human Immunodeficiency Virus in the United States - (07/09/20)
     
  3270. IAC 2020 Virtual: Lenacapavir (GS-6207) Sustained Delivery Formulation Supports 6-Month Dosing Interval - (07/09/20)
     
  3271. IAC 2020 Virtual: One Third in US Stopped PrEP During COVID Shutdown, 90% Trimmed HIV Risk - Mark Mascolini (07/09/20)
     
  3272. ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available - PRESS RELEASE - (07/08/20)
     
  3273. IAC 2020 Virtual: Baseline NRTI Resistance in Suppressed Participants Did Not Lead to Viral Blips on Bictegravir/Emtricitabine/Tenofovir Alafenamide B/F/TAF or Dolutegravir DTG + F/TAF Through Week 48 in Study 380-4030 - (07/08/20)
     
  3274. IAC 2020 Virtual: The BICSTaR prospective cohort: Real-world effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine clinical practice in people living with HIV (PLWH) - (07/08/20)
     
  3275. IAC 2020 Virtual: Comparative efficacy and safety of a combination therapy of dolutegravir and lamivudine vs 3-drug antiretroviral regimens in treatment-naïve HIV-1 infected patients at 96 weeks: A systematic review and network meta-analysis. - (07/08/20)
     
  3276. IAC 2020 Virtual: Sexually Transmitted Infections in the DISCOVER HIV PrEP Trial - (07/08/20)
     
  3277. IAC 2020 Virtual: IMPROVED METABOLIC PARAMETERS AFTER SWITCHING FROM TAF-BASED 3- OR 4-DRUG REGIMEN TO THE 2-DRUG REGIMEN OF DTG/3TC (DOLUTEGRAVIR/LAMIVUDINE): THE TANGO STUDY - (07/08/20)
     
  3278. IAC 2020 Virtual: Prevalence and Risk Factors of Preexisting NNRTI Resistance Among Suppressed PLWH in B/F/TAF Switch Studies - (07/08/20)
     
  3279. IAC 2020 Virtual: HPTN 083 FINAL RESULTS: Pre-exposure Prophylaxis containing long-acting injectable cabotegravir is safe and highly effective for cisgender men and transgender women who have sex with men - (07/08/20)
     
  3280. IAC 2020 Virtual: Doravirine resistance profile in clinical isolates and impact of baseline NNRTI resistance-associated mutations observed in treatment-naïve participants from phase 3 clinical trials - (07/08/20)
     
  3281. IAC 2020 Virtual: ANALYSIS OF PROTOCOL DEFINED VIROLOGIC FAILURE THROUGH WEEK 48 FROM A PHASE 2 TRIAL (P011) OF ISLATRAVIR AND DORAVIRINE IN TREATMENT-NAÏVE ADULTS WITH HIV-1 INFECTION - (07/08/20)
     
  3282. IAC 2020 Virtual: Challenges faced by a population aging with HIV: Baseline data from the CORE healthy aging initiative (CHAI) - (07/07/20)
     
  3283. IAC 2020 Virtual: Pooled analysis of 4 international trials of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older demonstrating safety and efficacy: Week 48 results - (07/07/20)
     
  3284. IAC 2020 Virtual: WEIGHT CHANGES AFTER SWITCH TO DORAVIRINE/LAMIVUDINE/TDF IN THE DRIVE-SHIFT TRIAL - (07/07/20)
     
  3285. IAC 2020 Virtual: Reducing ART to less than 3-ARV regimen linked to increased systemic inflammation - (07/07/20)
     
  3286. IAC 2020 Virtual: ANALYSIS OF PROTOCOL DEFINED VIROLOGIC FAILURE THROUGH WEEK 48 FROM A PHASE 2 TRIAL (P011) OF ISLATRAVIR AND DORAVIRINE IN TREATMENT-NAïVE ADULTS WITH HIV-1 INFECTION - (07/07/20)
     
  3287. IAC 2020 Virtual: Weight gain before and after switch from TDF to TAF - (07/07/20)
     
  3288. IAC 2020 Virtual: New Findings on Gilead's Biktarvy® Presented at AIDS 2020: Virtual Include Positive Switch Data in Older Adults (and pre-existing resistance) - (07/06/20)
     
  3289. IAC 2020 Virtual: Early Weight Gain Up to 4.5 Kg/Year With Switch From TDF to TAF: Data Suggest Independent Effect of TAF on Weight - Mark Mascolini (07/06/20)
     
  3290. IAC 2020 Virtual: ViiV Healthcare presents positive data from first-ever implementation research study on how best to integrate an investigational once-monthly injectable HIV treatment in US healthcare practices - (07/06/20)
     
  3291. IAC 2020 Virtual: Gilead Sciences Presents Data Supporting a Potential Six-Month Dosing Interval for Investigational HIV-1 Capsid Inhibitor Lenacapavir (GS-6207) - (07/06/20)
     
  3292. IAC 2020 Virtual: Heavily Pretreated US HIV Patients Face Clinical Hurdles, Higher Death Risk - Mark Mascolini (07/06/20)
     
  3293. IAC 2020 Virtual: No HIV Infections in PrEP Adherers, But Only 56% Continue PrEP 5 Years - Mark Mascolini (07/06/20)
     
  3294. IAC 2020 Virtual: High STI Rate in IPERGAY PrEP Study, But Concentrated in Subgroup - Mark Mascolini (07/06/20)
     
  3295. IAC 2020 Virtual: Viral Rebound No Slower When Stopping Modern ART Combinations - Mark Mascolini (07/06/20)
     
  3296. IAC 2020 Virtual: People With HIV Gaining Weight 3 Times Faster Than HIV-Negatives in US - Mark Mascolini (07/06/20)
     
  3297. IAC 2020 Virtual: Time to HIV Diagnosis Falling in US, But Half With HIV Undiagnosed After 3 Years - (07/06/20)
     
  3298. IAC 2020 Virtual: Time to HIV Diagnosis Falling in US, But Half With HIV Undiagnosed After 3 Years - Mark Mascolini (07/06/20)
     
  3299. IAC 2020 Virtual: Only Small Weight Gains After Trial Switch to Doravirine/3TC/TDF - Mark Mascolini (07/06/20)
     
  3300. IAC 2020 Virtual: ViiV Healthcare shares new data from Positive Perspectives, Wave 2 study, confirming a more holistic approach to HIV care can improve quality of life - (07/06/20)
     
  3301. IAC 2020 Virtual: Kidney Disease, Diabetes Could Jump in US MSM With HIV - But Not High Lipids - Mark Mascolini (07/06/20)
     
  3302. IAC 2020 Virtual: Cigarette Smoking and Substance Use Each Independently Cuts Chances of HIV Control - Mark Mascolini (07/06/20)
     
  3303. IAC 2020 Virtual: ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual) - PRESS RELEASE - (07/06/20)
     
  3304. IAC 2020 Virtual: Gilead Sciences Demonstrates Commitment to Scientific Innovation In HIV With New Prevention, Treatment and Cure Research Data Presented At AIDS 2020: Virtual - press release - (07/06/20)
     
  3305. IAC 2020 Virtual: Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual - (07/06/20)
     
  3306. IAC 2020 Virtual: ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual) - PRESS RELEASE - (07/02/20)
     
  3307. IAC 2020 Virtual: Gilead Sciences Demonstrates Commitment to Scientific Innovation In HIV With New Prevention, Treatment and Cure Research Data Presented At AIDS 2020: Virtual - press release - (07/02/20)
     
  3308. Hypertension/79% in >65 HIV+ Causes-Risk Factors - (07/01/20)
     
  3309. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients - (07/01/20)
     
  3310. Disparate Impact of HIV/Aging on women - (06/30/20)
     
  3311. HIV Neuropathy: Women & Men/Prevalence-Risk Factors - (06/30/20)
     
  3312. ViiV Healthcare announces grantees selected as part of 3 million Fund dedicated to HIV research and community-based programmes during COVID-19 pandemic - PRESS RELEASE - (06/30/20)
     
  3313. Remdesivir Pricing - - An Open Letter from Daniel O'Day, Chairman & CEO, Gilead Sciences - press release - (06/30/20)
     
  3314. Combination of healthy lifestyle traits may substantially reduce Alzheimer's disease risk & Dietary flavonols too - (06/29/20)
     
  3315. Pericardial Adipose Tissue Volume Is Independently Associated With Human Immunodeficiency Virus Status and Prior Use of Stavudine, Didanosine, or Indinavir - (06/29/20)
     
  3316. HIV-Aging/Senescence/CAR-T-Cells. Senolytic Agents or Senolytic Therapeutics - (06/25/20)
     
  3317. Senolytic drugs reverse damage caused by senescent cells in mice - (06/25/20)
     
  3318. Urine Tenofovir Levels Measured by a Novel Immunoassay Predict HIV Protection - (06/25/20)
     
  3319. IAC: Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual - (06/24/20)
     
  3320. CROI: GUT INTEGRITY MARKERS AND ASSOCIATIONS WITH ADIPOSITY IN PEOPLE WITH AND WITHOUT HIV - (06/24/20)
     
  3321. Risk of Increased Physical Inactivity During COVID 19 Outbreak in Older People: A Call for Actions - Editorial - (06/22/20)
     
  3322. Burden of Aging with HIV: "better Care Systems Needed" UCSF - (06/22/20)
     
  3323. Fatty Liver in HIV: what the HIV Clinician Needs to Know - (06/19/20)
     
  3324. Lean NAFLD in HIV+ 14% - Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus - (06/19/20)
     
  3325. HCV Testing for HIV+ - Only 50% Are Tested - (06/18/20)
     
  3326. Older Adults on ART Have Double the Mortality Risk of Their HIV-Negative Counterparts.....Survival of people aged 50 years and older by HIV and HIV treatment status: findings from three waves of the SAGE-Wellbeing of Older People Study (SAGE-WOPS) in Uganda - (06/18/20)
     
  3327. Senolytics improve physical function and increase lifespan in old age - (06/17/20)
     
  3328. Senescent cells: an emerging target for diseases of ageing - Senotherapeutics for healthy ageing - (06/17/20)
     
  3329. senolytics might become an entirely new path for alleviating currently untreatable chronic diseases and enhancing human health span. - (06/17/20)
     
  3330. HIV and cardiovascular disease - Review - (06/16/20)
     
  3331. ART Reduced HPV Prevalence - Association of antiretroviral therapy with anal high-risk human papillomavirus, anal intraepithelial neoplasia, and anal cancer in people living with HIV: a systematic review and meta-analysis - (06/16/20)
     
  3332. FDA Approves Merck's GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers - (06/16/20)
     
  3333. HIV & Neurocognitive Impairment - 2 recent studies - (06/15/20)
     
  3334. On-demand HIV prevention pills worked well for San Francisco patients, Kaiser - (06/15/20)
     
  3335. Early Adopters of Event-driven Human Immunodeficiency Virus Pre-exposure Prophylaxis in a Large Healthcare System in San Francisco - (06/15/20)
     
  3336. Questioning statin therapy for older patients - (06/12/20)
     
  3337. ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV - (06/12/20)
     
  3338. HIV infects astrocytes in vivo and egresses from the brain to the periphery - After ATI - (06/12/20)
     
  3339. Metabolic Syndrome and Neurocognitive Deficits in HIV Infection - 'Metabolic syndrome most strongly associated with neurocognitive impairment......' - (06/11/20)
     
  3340. Senotherapeutics and HIV-1 Persistence & Aging/Senescence - (06/09/20)
     
  3341. Metabolic Syndrome and Neurocognitive Deficits in HIV Infection - (06/09/20)
     
  3342. Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO) - (06/09/20)
     
  3343. Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy - (06/09/20)
     
  3344. Statin use is associated with insulin resistance in participants of the Canadian Multicentre Osteoporosis Study - (06/08/20)
     
  3345. Frailty in People Living with HIV - new review following several CROI reports on frailty, mitochondrial damage & brain function & frailty - (06/01/20)
     
  3346. Letter from Gilead: Update on HIV PrEP Research Among Cisgender Women - (05/28/20)
     
  3347. Fatty Liver in HIV - (05/28/20)
     
  3348. New Merck COVID Efforts-2 Vaccines+Antiviral Drug EIDD-2801; Acquisition & Collaborations - (05/26/20)
     
  3349. Long-acting drug acts like a short-term AIDS vaccine (Cabotegravir injectable long-acting HPTN-083 study) - (05/22/20)
     
  3350. Cabotegravir Injectable Long Acting PrEP Study HPTN-083 Stopped Due To Higher Efficacy - (05/22/20)
     
  3351. Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial - (05/21/20)
     
  3352. CROI: Creation of Long - Acting Nanoformulated Tenofovir Prodrugs - (05/21/20)
     
  3353. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection FLAIR - (05/21/20)
     
  3354. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression ATLAS - (05/21/20)
     
  3355. CROI: Study Suggests PrEP Access Issue: Disparity in Prior Authorizations Across US Regions - (05/20/20)
     
  3356. CROI: INFILTRATION OF VRC01 INTO THE CEREBROSPINAL FLUID IN HUMANS IN THE RV397 STUDY - (05/20/20)
     
  3357. CROI: Tenofovir Diphosphate in Dried Blood Spots Predicts Virologic Failure and Resistance - (05/20/20)
     
  3358. CROI: REAL-LIFE MANAGEMENT OF DRUG-DRUG INTERACTIONS BETWEEN ANTIRETROVIRALS AND STATINS - (05/20/20)
     
  3359. Reported preexposure prophylaxis use among male sex partners of HIV-positive men 2016-2018 - (05/19/20)
     
  3360. COVID & Genetics - CCR5 Leronlimab therapy checked COVID-19 inflammation - (05/19/20)
     
  3361. CROI: Use of an HIV Prediction Model to Evaluate PrEP Coverage in a Large Healthcare System - (05/19/20)
     
  3362. CROI: Implementation of On-Demand PrEP in a Large Integrated Healthcare System - (05/19/20)
     
  3363. CROI: Non-Daily Use of HIV Preexposure Prophylaxis in a Large Online Sample in the U.S. - (05/19/20)
     
  3364. CROI: Clinical Pharmacology at CROI 2020 - Courtney V. Fletcher, Pharm.D. Professor UNMC Center for Drug Discovery University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE 68198 - (05/19/20)
     
  3365. CROI: Biodegradable Implant for Sustained Delivery of Antiretroviral (ARV) - (05/18/20)
     
  3366. Leaning on Community-Based Participatory Research to Respond During COVID-19 - Aging HIV+ - (05/18/20)
     
  3367. CROI: Bictegravir/FTC/TAF CSF Diffusion in HIV-Infected Patients with CNS Impairment - (05/18/20)
     
  3368. CROI: Safety and Tolerability of Once Daily BIC/FTC/TAF for Post-Exposure Prophylaxis - (05/18/20)
     
  3369. CROI: There is a long Long History of Sexual Transmission of HCV in MSM, Heterosexual Men, Women, IDUs & Reinfection too - (05/18/20)
     
  3370. CROI: TFV-DP in DBS for pregnant/postpartum adolescent and young women on PrEP in Africa - (05/18/20)
     
  3371. Long-acting injectable drug prevents HIV infections - (05/18/20)
     
  3372. Global HIV prevention study to stop early after ViiV Healthcare's long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP - (05/18/20)
     
  3373. Long-acting injectable cabotegravir is highly effective for the prevention of HIV infection in cisgender men and transgender women who have sex with men - (05/18/20)
     
  3374. CROI: TFV-DP in DBS for pregnant/postpartum adolescent and young women on PrEP in Africa - (05/18/20)
     
  3375. Low-Level Viremia Increased Mortality & Comorbidities - (05/15/20)
     
  3376. Highlights of the 9th edition of the Conference on HIV Persistence During Therapy, 10-13 December 2019, Miami, USA - ATI Risks, Functional Not Sterilizing Cure the Goal - (05/15/20)
     
  3377. NIH begins clinical trial of hydroxychloroquine and azithromycin to treat COVID-19 - (05/15/20)
     
  3378. New HCV Infections Tripled: 4 times Higher than in 2009 - (05/14/20)
     
  3379. COBRA/Europe-Aging Epidemic/ Increased Brain Aging in HIV+ - (05/13/20)
     
  3380. Older HIV+ Women Have Worse Increasing Comorbidities / HOPS 95% >50 Years Old Have Increasing Numbers of Comorbidities - (05/13/20)
     
  3381. High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis - (05/13/20)
     
  3382. HIV Preexposure Prophylaxis Among Adolescents in the USA Review - (05/12/20)
     
  3383. Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated NAFLD - (05/12/20)
     
  3384. Cognitive Impairment among HIV-Infected Men with Longitudinal Follow-ups - (05/11/20)
     
  3385. Heart Disease in HIV - (05/11/20)
     
  3386. CROI: Effect of Integrase Inhibitors on Weight Gain in Children and Adolescents with HIV - (05/11/20)
     
  3387. CROI: Fat & HIV was a big part of CROI 2020 - (05/11/20)
     
  3388. CROI: Body Composition Changes Over The Menopausal Transition In Women With and At Risk For HIV - (05/11/20)
     
  3389. Hepatic Fibrosis Determined with MRE Significantly Predicts Cognitive Impairment - (05/08/20)
     
  3390. The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen - (05/08/20)
     
  3391. HIV health system in South Africa is ill-equipped to handle the rising tide of HTN , CVD, Aging, Comorbities - Prevention of cardiovascular disease among people living with HIV in sub-Saharan Africa - (05/08/20)
     
  3392. PrEP & Lipids, Weight Gain - (05/08/20)
     
  3393. CROI: TELMISARTAN DECREASES MONOCYTE CX3CR1 EXPRESSION IN TREATED HIV - (05/07/20)
     
  3394. CROI: Cognitive Impairment among HIV-Infected Men with Longitudinal Follow-ups - (05/07/20)
     
  3395. CROI: RESISTIN GENE POLYMORPHISM RELATED TO WEIGHT GAIN AND PSYCHIATRIC SYMPTOMS ON InSTI - (05/07/20)
     
  3396. CROI: MEASURES OF ADIPOSE TISSUE REDISTRIBUTION AND ATHEROSCLEROTIC CORONARY PLAQUE IN HIV - (05/06/20)
     
  3397. CROI: Fat/Weight Gain/Aging Faster-mitochondria/Fat Tissue/Genetics/Metabolic Rate-Calorie Intake - (05/06/20)
     
  3398. CROI: INCREASED INFLAMMATORY CX3CR1+GPR56+CD57+ CD4+ T CELLS IN FAT FROM HIV+ DIABETICS - (05/06/20)
     
  3399. CROI: FAT GAINS OCCUR AFTER ART WITHOUT CHANGES IN METABOLIC RATE OR CALORIC INTAKE - (05/06/20)
     
  3400. CROI: Cardiac Events in HIV-infected Patients Who Use Tenofovir-Alafenamide - (05/06/20)
     
  3401. CROI: CYP2B6 GENOTYPE AND WEIGHT-GAIN DIFFERENCES BETWEEN DOLUTEGRAVIR AND EFAVIRENZ - (05/06/20)
     
  3402. CROI: Pharmacogenetics of Weight Gain after Switch from Efavirenz to Integrase Inhibitors - (05/06/20)
     
  3403. CROI: ViiV COVID-19 Community Response Fund - May 15 Deadline for Research & Community Organizations - (05/05/20)
     
  3404. Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection - (05/05/20)
     
  3405. Heart Disease in HIV - (05/05/20)
     
  3406. CROI: Kidney Disease Rates in DAD & West Africa at Young Ages: VALIDATION OF THE D:A:D CHRONIC KIDNEY DISEASE (CKD) RISK SCORE IN A LARGE AFRICAN COHORT - (05/05/20)
     
  3407. CROI: Unexpectedly High Rate of Intolerance for Dolutegravir in Real Life Setting - (05/05/20)
     
  3408. CROI: HIV Prevention at CROI 2020 - Written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (05/05/20)
     
  3409. IAS AIDS 2020 Virtual - (05/01/20)
     
  3410. New York City by Far has the Highest Rates of PLWH >55 in the USA, SF 2nd Rates by City - (04/29/20)
     
  3411. Rates HIV+ Over 55/60 Mapped, NYC, USA, by County - (04/29/20)
     
  3412. Rates by Race/Aging: Over 55 HIV+ - (04/29/20)
     
  3413. Accelerated Aging - HIV+ Appear to be 5-17 Years Older Chronologic Age - (04/28/20)
     
  3414. Depressive Disorders in HIV/AIDS:....older PLWH, social isolation, stigma, survivor guilt, shame & guilt, existential issues - (04/28/20)
     
  3415. Rates HIV+ Over 55/60 Mapped - (04/28/20)
     
  3416. NATAP: Rates by Race/Aging: Over 55 HIV+ - (04/28/20)
     
  3417. CROI: HIV Stigma Predicts Retention in Care Among US Patients in Care - (04/27/20)
     
  3418. CROI: Postpartum weight changes in women initiating DTG vs EFV in pregnancy: DolPHIN-2 - (04/27/20)
     
  3419. CROI: Dolutegravir+3TC - 2 Drug ART at CROI 2020 - (04/27/20)
     
  3420. A RANDOMIZED TRIAL OF THE IMPACT OF 3BNC117 AND ROMIDEPSIN ON THE HIV-1 RESERVOIR - (04/24/20)
     
  3421. PrEP at CROI / AIDSVu Releases Landmark County-Level Data and Interactive Maps on PrEP Use Across the U.S. - (04/22/20)
     
  3422. HIV-Experienced Clinician Workforce Capacity: Urban-Rural Disparities in the US South - (04/22/20)
     
  3423. New Long-Acting PrEP: MK-8591 - (04/22/20)
     
  3424. Theratechnologies responses to current COVID-19 pandemic - (04/22/20)
     
  3425. CROI: Cardiovascular Risk Profile: A Clinic-Based Sample of Youth Living with HIV in the US - (04/20/20)
     
  3426. CROI: Low Bone Mineral Density in Older People Living with HIV: the Renal-Bone Axis and ART - (04/20/20)
     
  3427. CROI: Comorbidities at CROI - mortality, aging..... - (04/20/20)
     
  3428. CROI: PrEP at CROI 2020 - (04/20/20)
     
  3429. CROI: INTACT PROVIRAL DNA LEVELS DECLINE IN PEOPLE WITH HIV ON ANTIRETROVIRAL THERAPY - new intact proviral DNA assay - (04/20/20)
     
  3430. Company Statements Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials - (04/16/20)
     
  3431. WHO Report: HIV+ COVID Responses - (04/16/20)
     
  3432. WHO Report: HIV+ COVID Responses - (04/14/20)
     
  3433. CROI: THE LONG AND THE SHORT OF IT: WHAT'S NEXT FOR LONG-ACTING DRUGS (04/13/20)
     
  3434. CROI: Trends in Marijuana, Alcohol, and Opioid Use in Pregnant and Postpartum Women with HIV (04/13/20)
     
  3435. CROI: MK-8504 and MK-8583 (Tenofovir Prodrugs) Single-Dose PK and Antiviral Activity in HIV Infection (04/13/20)
     
  3436. CROI: Barriers To Direct-Acting Antiviral Therapy Among HIV/HCV-Coinfected Adults (04/10/20)
     
  3437. CROI: COMPARABLE EFFICACY OF IBALIZUMAB IN COMBINATION WITH ONE OR TWO FULLY ACTIVE AGENTS (04/10/20)
     
  3438. CROI: HIV VIRAL BLIPS IN ADULTS TREATED WITH InSTI-BASED REGIMENS THROUGH 144 WEEKS........no real difference in blips between arms, non-adherence found to cause blips. (04/10/20)
     
  3439. CROI: CLINICAL AND LABORATORY OUTCOMES 24 WEEKS AFTER STARTING DTG VERSUS EFV IN ACUTE HIV (04/10/20)
     
  3440. CROI: NOD2 and TLR8 Agonists Enhance IL-15 Mediated Activation of HIV Expression (04/10/20)
     
  3441. CROI: SAFETY AND EFFICACY OF DTG VS EFV AND TDF VS TAF IN PREGNANCY: IMPAACT 2010 TRIAL (04/10/20)
     
  3442. CROI: RENAL IMPAIRMENT IN A PREEXPOSURE PROPHYLAXIS IMPLEMENTATION COHORT IN AUSTRALIA (04/10/20)
     
  3443. CROI: SUSTAINED HIV REMISSION IN THE LONDON PATIENT: THE CASE FOR HIV CURE (04/09/20)
     
  3444. CROI: PGT121 AND VESATOLIMOD IN CHRONICALLY TREATED SHIV-INFECTED RHESUS MONKEYS (04/09/20)
     
  3445. CROI: Post-Discharge Outcomes Following Acute Coronary Syndrome in HIV [ Disparities for PLWH ] (04/09/20)
     
  3446. CROI: HIV-1 Drug Resistance in the DISCOVER Pre-exposure Prophylaxis Trial (04/09/20)
     
  3447. CROI: COMBINED ACTIVE AND PASSIVE IMMUNIZATION IN SHIV-INFECTED RHESUS MONKEYS (04/09/20)
     
  3448. CROI: PREVALENCE OF RESISTANCE AND LIMITED THERAPEUTIC OPTIONS IN PATIENTS VIREMIC ON ART (04/09/20)
     
  3449. CROI: Drug Resistance is USA & Europe: 2 studies at CROI 2020 (04/09/20)
     
  3450. CROI: MK-8591/Islatravir vs ART Resistance / Metabolics (04/09/20)
     
  3451. CROI: PRO 140 IN VITRO ACTIVITY IN HTE SUBJECTS WITH A 4-CLASS DRUG-RESISTANT HIV-1 VIRUS (04/08/20)
     
  3452. CROI: CLEARANCE OF HPV ANAL HIGH-GRADE INTRAEPITHELIAL LESIONS WITH LOW-DOSE POMALIDOMIDE (04/08/20)
     
  3453. CROI: ON-DEMAND HIV POSTEXPOSURE PROPHYLAXIS BY TAF/EVG VAGINAL INSERTS IN MACAQUES (04/08/20)
     
  3454. CROI: CROI ART/HIV Drug Studies (04/08/20)
     
  3455. CROI: BRAIN AGE BASED ON SLEEP ENCEPHALOGRAPHY IS ELEVATED IN HIV+ ADULTS ON ART (04/08/20)
     
  3456. CROI: Dolutegravir in Malawai (04/08/20)
     
  3457. CROI: HIV TRANSCRIPTION PROFILE IN BLOOD, GUT, LIVER, AND GENITAL TRACT IN SUPPRESSED WOMEN (04/08/20)
     
  3458. CROI: Need for optimization of screening methods for anal intraepithelial neoplasia in people living with HIV (04/08/20)
     
  3459. CROI: High Resolution Anoscopy (HRA) in the Real World: Predictors of Guideline-Based Follow Up at a Large Academic Medical Center (04/08/20)
     
  3460. CROI: ANAL PRECANCER SCREENING AMONG MSM: WHAT IS THE BEST STRATEGY? (04/08/20)
     
  3461. CROI: START OR SWITCH OF INTEGRASE INHIBITORS ON DEPRESSIVE SYMPTOMS IN WOMEN WITH HIV (04/08/20)
     
  3462. CROI: CLINICAL SIGNIFICANCE OF gp120 POLYMORPHISMS, TMR IC50FC AND HIV-1 SUBTYPE IN BRIGHTE (04/08/20)
     
  3463. CROI: 2-Drug Regimen Comparable to 3-Drug Regimens up to 18 Months in a Real-World Setting (04/07/20)
     
  3464. CROI: INTEGRASE INHIBITOR START OR SWITCH IMPACTS LEARNING IN WOMEN WITH HIV (04/07/20)
     
  3465. CROI: Anal Cancer Screening: Is it Time for Cytology and High-risk HPV Co-testing? (04/07/20)
     
  3466. CROI: IN VITRO IMPACT OF TAF ON MITOCHONDRIAL FUNCTION IN IMMUNE CELLS (04/07/20)
     
  3467. CROI: TRICARBOXYLIC ACID METABOLITES PREDICT METABOLIC COMORBIDITIES AND DEATH IN AGING PWH (04/07/20)
     
  3468. CROI: TRICARBOXYLIC ACID METABOLITES PREDICT METABOLIC COMORBIDITIES AND DEATH IN AGING PWH (04/07/20)
     
  3469. CROI: Baseline and Acquired Comorbidities in Patients Initiating ART in the HOPS, 2008-2018 (04/07/20)
     
  3470. CROI: Race Impact on Dolutegravir-Associated Weight Gain Among Previously ART-Naïve People Living with HIV (04/07/20)
     
  3471. CROI: MORTALITY AMONG PEOPLE WITH HIV WITH A HISTORY OF INJECTION DRUG USE, NEW YORK CITY, 2008-2017 (04/07/20)
     
  3472. CROI: Results from a PrEP Demonstration Project for At-Risk Cisgender Women in the US - PrEP/PEP at CROI (04/06/20)
     
  3473. CROI: IMPACT OF ANTIRETROVIRAL THERAPY INITIATION ON EPIGENETIC AGING AND TELOMERE LENGTH (04/06/20)
     
  3474. CROI: VIROLOGIC FAILURE AND RESISTANCE IN DOLUTEGRAVIR-BASED MAINTENANCE DUAL REGIMENS (04/06/20)
     
  3475. CROI: Dolutegravir+3TC - 2 Drug ART at CROI (04/06/20)
     
  3476. J&J COVID Vaccine: "We are counting on a 10 euro vaccine against coronavirus" - (04/06/20)
     
  3477. Letter from Gilead: Message from Amy Flood: Supporting our friends and partners - (04/06/20)
     
  3478. COVID & HIV+ China Report Preliminary Data, How do PLWH Fare? - (04/06/20)
     
  3479. CROI: Results from a PrEP Demonstration Project for At-Risk Cisgender Women in the US - PrEP/PEP at CROI (04/04/20)
     
  3480. CROI: DOLUTEGRAVIR USE IS ASSOCIATED WITH HIGHER POSTPARTUM WEIGHT COMPARED TO EFAVIRENZ (04/04/20)
     
  3481. CROI: GREATER INCIDENCE OF DIABETES OVER 10 YEARS AMONG DEPRESSED US VETERANS WITH HIV (04/04/20)
     
  3482. CROI: Diabetes, Weight Gain, & Integrase Inhibitor Use in North American HIV+ Persons (04/04/20)
     
  3483. CROI: Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Disease "LIFE HIV Study" (04/04/20)
     
  3484. CROI: Low-level viremia during ART and the risk of death, AIDS, and serious non-AIDS events (04/04/20)
     
  3485. CROI: EFFECTS OF VIRAL LOAD ON NEUROIMAGING AND NEUROPSYCHOLOGICAL PERFORMANCE (04/04/20)
     
  3486. CROI: EXPLAINING RACIAL DISPARITIES IN VIRAL SUPPRESSION AMONG MSM LIVING WITH HIV (04/04/20)
     
  3487. CROI: EXPLOSIVE HIV AND HCV EPIDEMICS DRIVEN BY NETWORK VIREMIA (04/04/20)
     
  3488. CROI: Long Island has 6,649 cases with both counties combined. (04/04/20)
     
  3489. CROI: HCV INCIDENCE AMONG HIV-INFECTED MSM IN FRANCE: RESULTS FROM THE FHDH-ANRS CO4 COHORT (04/04/20)
     
  3490. CROI: Clinical Features and Outcomes of Patients Stopping DTG for Neuropsychiatric Symptoms (04/04/20)
     
  3491. CROI: INVESTIGATION OF CLASSIC AND HIV-RELATED FACTORS FOR HEPATIC STEATOSIS AMONG PWID - 20% ALIVE Cohort (04/02/20)
     
  3492. CROI: NAFLD AND LIVER FIBROSIS PREDICT HIGH CARDIOVASCULAR RISK IN HIV-MONOINFECTED PATIENT (04/02/20)
     
  3493. Letter from Gilead: Message from Amy Flood: Supporting our friends and partners - (04/02/20)
     
  3494. CROI: EFFECTS OF VIRAL LOAD ON NEUROIMAGING AND NEUROPSYCHOLOGICAL PERFORMANCE (04/01/20)
     
  3495. CROI: Understanding Who Does and Does Not Gain Weight with Integrase Inhibitors (INSTI) (04/01/20)
     
  3496. CROI: Adipocyte Dysfunction Despite Reduced Adipose Inflammation in Diabetics with HIV (04/01/20)
     
  3497. CROI: Once-daily etravirine/raltegravir (400/800 mg) as maintenance regimen (04/01/20)
     
  3498. CROI: Losartan does not improve lymphatic tissue fibrosis or T-cell recovery in HIV infection (04/01/20)
     
  3499. CROI: EFFECTS OF HIV, AGE, AND SEX ON SKELETAL MUSCLE MASS AND DENSITY (04/01/20)
     
  3500. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? - (04/01/20)
     
  3501. Dysregulation of immune response in patients with COVID-19 in Wuhan, China - (04/01/20)
     
  3502. ViiV Healthcare Announces First Global Regulatory Approval of CABENUVA; the First Complete, Long-acting, Regimen for the Treatment of HIV - (04/01/20)
     
  3503. CROI: EXPLOSIVE HIV AND HCV EPIDEMICS DRIVEN BY NETWORK VIREMIA AMONG PWID (03/31/20)
     
  3504. CROI: EFFECTS OF VIRAL LOAD ON NEUROIMAGING AND NEUROPSYCHOLOGICAL PERFORMANCE (03/31/20)
     
  3505. CROI: IMPACT OF ANTIRETROVIRAL THERAPY INITIATION ON EPIGENETIC AGING AND TELOMERE LENGTH (03/31/20)
     
  3506. CROI: Women with HIV Have High Overall Burden and Early Accrual of Non-AIDS Comorbidities (03/31/20)
     
  3507. CROI: VIROLOGIC FAILURE AND RESISTANCE IN
    DOLUTEGRAVIR-BASED MAINTENANCE DUAL REGIMENS     (03/31/20)
     
  3508. CROI: VIROLOGIC OUTCOMES BY RESISTANCE CATEGORY AND PRE-TREATMENT IN THE DUALIS STUDY (dolutegravir+bDarunavir) (03/31/20)
     
  3509. CROI: DTG + 3TC VS DTG + TDF/FTC (GEMINI-1 & -2): CONFIRMED VIROLOGIC WITHDRAWALS THROUGH WEEK 96 (03/31/20)
     
  3510. CROI: Low-level viremia during ART and the risk of death, AIDS, and serious non-AIDS events (03/31/20)
     
  3511. CROI: (03/31/20)
     
  3512. ViiV Healthcare Announces First Global Regulatory Approval of CABENUVA; the First Complete, Long-acting, Regimen for the Treatment of HIV - (03/31/20)
     
  3513. CROI: Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Disease "LIFE HIV Study" (03/30/20)
     
  3514. CROI: EFFICACY AND DURABILITY OF 2-DRUG VS 3-DRUG INSTI-BASED REGIMENS: DATA FROM REAL-LIFE (03/30/20)
     
  3515. CROI: SHALL WE DANCE? EXTENDING TANGO'S RESULTS TO CLINICAL PRACTICE (03/30/20)
     
  3516. CROI: EFFECT OF PAST VIROLOGICAL FAILURE ON DOLUTEGRAVIR + LAMIVUDINE AS MAINTENANCE REGIMEN (03/30/20)
     
  3517. CROI: VIROLOGIC OUTCOMES BY RESISTANCE CATEGORY AND PRE-TREATMENT IN THE DUALIS STUDY (03/30/20)
     
  3518. CROI: LONG-TERM DTG+3TC SWITCH EFFICACY IN PATIENTS WITH ARCHIVED 3TC RESISTANCE (03/30/20)
     
  3519. CROI: Rising BMI Tied to Risk of Diabetes But Not CVD in D:A:D Analysis - Mark Mascolini (03/30/20)
     
  3520. CROI: Retinal Thinning in Well-Controlled HIV-infected Patients (03/30/20)
     
  3521. CROI: Retinal Thinning in Well-Controlled HIV-infected Patients (03/30/20)
     
  3522. CROI: EFFECTS OF HIV INFECTION AND IMMUNE REGULATION ON LONGITUDINAL LUNG FUNCTION DECLINE (03/30/20)
     
  3523. CROI: Modifiable Risk Factors for Kidney and Heart Disease Have Less Impact in HIV+ Than HIV- - Mark Mascolini (03/30/20)
     
  3524. CROI: Increased overall life expectancy but not comorbidity-free years for people with HIV - Mark Mascolini (03/27/20)
     
  3525. CROI: HIV DNA DETECTED IN IMMUNE CELL SUBSETS IN CSF DURING ART (03/27/20)
     
  3526. CROI: 50% PREVALENCE OF PHYSICAL FUNCTION IMPAIRMENT AND FRAILTY IN MIDDLE-AGED PWH - age 46-55 (03/27/20)
     
  3527. CROI: Effects of HIV on Myelin Maps (03/27/20)
     
  3528. CROI: NOVEL ANTIRETROVIRAL AGENTS: TRANSFORMING THE CARE OF PEOPLE WITH HIV (03/27/20)
     
  3529. CROI: EFFECTS OF HIV INFECTION AND IMMUNE REGULATION ON LONGITUDINAL LUNG FUNCTION DECLINE (03/27/20)
     
  3530. CROI: RAPID START LEADS TO SUSTAINED VIRAL SUPPRESSION IN YOUNG PEOPLE IN THE SOUTH (03/26/20)
     
  3531. CROI: Assessment of Immediate Initiation of Antiretroviral Therapy (ART) in New York City (03/26/20)
     
  3532. CROI: ASSESSMENT OF IMMEDIATE INITIATION OF ANTIRETROVIAL THERAPY IN NYC (03/26/20)
     
  3533. CROI: Summary from virtual CROI 2020 for HIV and liver disease HIV and the liver: what is new? - Written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany (03/25/20)
     
  3534. CROI: TRENDS AND CHARACTERISTICS OF HIV-1 DRUG RESISTANCE IN THE UNITED STATES (2012-2018) (03/25/20)
     
  3535. CROI: Retinal Thinning in Well-Controlled HIV-infected Patients (03/23/20)
     
  3536. CROI: EFFECT OF ANTICHOLINERGIC MEDICATIONS ON BRAIN INTEGRITY IN OLDER HIV-POSITIVE ADULTS (03/23/20)
     
  3537. CROI: BENEFITS OF RILPIVIRINE FOR LIVER FIBROSIS IN HIV/HCV COINFECTED SUBJECTS (03/23/20)
     
  3538. CROI: Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated Nonalcoholic Fatty Liver Disease (03/23/20)
     
  3539. CROI: Fibrosis Progression Over 6-Fold Higher in NAFLD With vs Without HIV - Mark Mascolini (03/23/20)
     
  3540. CROI: VISCERAL FAT IS A PREDICTOR OF LIVER FIBROSIS AND FIBROSIS PROGRESSION IN PEOPLE LIVING WITH HIV (03/23/20)
     
  3541. RAPID START LEADS TO SUSTAINED VIRAL SUPPRESSION IN YOUNG PEOPLE IN THE SOUTH (03/26/20)
     
  3542. CROI: CLINICAL PREDICTORS OF LIVER FIBROSIS PRESENCE & PROGRESSION IN HIV-ASSOCIATED NAFLD (03/23/20)
     
  3543. CROI: Bictegravir/Emtricitabine/Tenofovir Alafenamide Low-Dose Tablet Relative Bioavailability in Healthy Volunteers and PK in Children With HIV (03/20/20)
     
  3544. CROI: Much Higher Death Rate After Cancer Diagnosis in People With HIV - Mark Mascolini (03/20/20)
     
  3545. CROI: HIV DNA DETECTED IN IMMUNE CELL SUBSETS IN CSF DURING ART (03/20/20)
     
  3546. CROI: CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS IS NONINFERIOR TO MONTHLY DOSING: WEEK 48 RESULTS FROM THE ATLAS-2M STUDY (03/20/20)
     
  3547. CROI: CROI ART/HIV Drug Studies (03/20/20)
     
  3548. CROI: PET IMAGING OF SYNAPTIC DENSITY IN HIV: PRELIMINARY FINDINGS FROM A PILOT STUDY (03/20/20)
     
  3549. CROI: 50% PREVALENCE OF PHYSICAL FUNCTION IMPAIRMENT AND FRAILTY IN MIDDLE-AGED PWH - age 46-55 (03/20/20)
     
  3550. CROI: PWH had a greater burden (5x) of primarily eccentric arterial wall enhancement compared with persons without HIV (03/20/20)
     
  3551. CROI: HIV DNA DETECTED IN IMMUNE CELL SUBSETS IN CSF DURING ART (03/27/20)
     
  3552. CROI: PWH had a greater burden (5x) of primarily eccentric arterial wall enhancement compared with persons without HIV (03/27/20)
     
  3553. CROI: PET IMAGING OF SYNAPTIC DENSITY IN HIV: PRELIMINARY FINDINGS FROM A PILOT STUDY (03/27/20)
     
  3554. CROI: SINGLE-CELL GENOMIC ANALYSIS OF BLOOD AND CSF T CELLS IN HIV+ AND HIV- ADULTS......T Cell Exhaustion in CNS HIV (03/17/20)
     
  3555. CROI: HIV-1 REPLICATION AT <50 C/ML TO 148 WEEKS FOR SWORD 1 TO 148 WEEKS FOR SWORD-1/SWORD-2 Studies with DTG+RPV (03/17/20)
     
  3556. CROI: MITOCHONDRIAL DNA, COGNITIVE FUNCTION, AND FRAILTY IN OLDER ADULTS WITH HIV (03/17/20)
     
  3557. CROI: CABOTEGRAVIR PHARMACOKINETIC TAIL IN PREGNANCY AND NEONATAL OUTCOMES (03/17/20)
     
  3558. CROI: BICTEGRAVIR DISTRIBUTION AND BICTEGRAVIR/FTC/TAF ACTIVITY IN GENITAL TRACT AND RECTUM (03/17/20)
     
  3559. CROI: Bictegravir/Emtricitabine/Tenofovir Alafenamide Low-Dose Tablet Relative Bioavailability in Healthy Volunteers and PK in Children With HIV (03/17/20)
     
  3560. CROI: Less Coronary Intervention, Higher Mortality in HIV+ People With Acute Coronary Syndrome - Mark Mascolini (03/17/20)
     
  3561. CROI: Starting ART With a PI or an InSTI (Mainly Raltegravir) May Heighten Risk of Diabetes - Mark Mascolini (03/17/20)
     
  3562. CROI: METABOLIC COMPLICATIONS OF HIV AND ITS THERAPIES (03/17/20)
     
  3563. CROI: Rising BMI Tied to Risk of Diabetes But Not CVD in D:A:D Analysis - Mark Mascolini (03/17/20)
     
  3564. CROI: Predicted 10-year risks of diabetes and cardiovascular disease in the ADVANCE trial (03/17/20)
     
  3565. CROI: Testosterone Use Tied to Signals of Atherosclerosis Progression in Men With HIV (03/17/20)
     
  3566. CROI: VISCERAL FAT IS A PREDICTOR OF LIVER FIBROSIS AND FIBROSIS PROGRESSION IN PEOPLE LIVING WITH HIV (03/17/20)
     
  3567. CROI: Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated Nonalcoholic Fatty Liver Disease (03/17/20)
     
  3568. CROI: BICTEGRAVIR DISTRIBUTION AND BICTEGRAVIR/FTC/TAF ACTIVITY IN GENITAL TRACT AND RECTUM (03/16/20)
     
  3569. CROI: Safety, PK, and Efficacy of Low-Dose B/F/TAF in Children ≥2 Years Old Living With HIV (03/16/20)
     
  3570. CROI: Impact of anti-PD-1 and anti-CTLA-4 on the HIV reservoir in vivo: The AMC-095 Study (03/16/20)
     
  3571. CROI: Use of D/C/F/TAF With Neurologic/Psychiatric Comorbidities: AMBER Subgroup Analysis (03/16/20)
     
  3572. CROI: DISCOVER: NO EFFECT OF HORMONES ON F/TAF OR F/TDF PK, EFFICACY & SAFETY IN TRANSWOMEN (03/16/20)
     
  3573. CROI: IMPLEMENTATION OF MOBILE PrEP, STI, AND HIV PREVENTION SERVICES IN SOUTH FLORIDA (03/16/20)
     
  3574. CROI: PK, Food Effect, and Safety of Oral GS-6207, a Novel HIV-1 Capsid Inhibitor (03/16/20)
     
  3575. CROI: Cabotegravir + Rilpivirine PK Following Long-Acting HIV Treatment Discontinuation (03/16/20)
     
  3576. CROI: Preexisting Resistance and B/F/TAF Switch Efficacy in African Americans (03/16/20)
     
  3577. CROI: ABSENCE OF GS-6207 PHENOTYPIC RESISTANCE IN HIV Gag CLEAVAGE SITE AND OTHER MUTANTS (03/16/20)
     
  3578. CROI: DOSE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS LONG-ACTING HIV CAPSID INHIBITOR GS-6207 (03/16/20)
     
  3579. CROI: CABOTEGRAVIR AND RILPIVIRINE PK FOLLOWING LONG-ACTING HIV TREATMENT DISCONTINUATION (03/16/20)
     
  3580. CROI: FOSTEMSAVIR EXPOSURE-RESPONSE RELATIONSHIPS IN TREATMENT EXPERIENCED HIV PATIENTS (03/16/20)
     
  3581. CROI: DTG + 3TC VS DTG + TDF/FTC (GEMINI-1 & -2): CONFIRMED VIROLOGIC WITHDRAWALS THROUGH WEEK 96 (03/16/20)
     
  3582. CROI: IMPACT OF PrEP AND TasP ON INCIDENCE OF HIV DIAGNOSES IN 48 HIGHEST-BURDEN US AREAS (03/16/20)
     
  3583. CROI: Preexisting Resistance and B/F/TAF Switch Efficacy in African Americans (03/13/20)
     
  3584. CROI: ASSESSING THE VIROLOGIC IMPACT OF ARCHIVED RESISTANCE IN AN HIV-1 Switch Study TANGO Through Week 48 (03/13/20)
     
  3585. CROI: INSOMNIA AND RISK OF INCIDENT MYOCARDIAL INFARCTION AMONG PEOPLE LIVING WITH HIV (03/13/20)
     
  3586. CROI: DRUG LEVELS, ADHERENCE, AND RISKS FOR LOW ADHERENCE IN THE DISCOVER PrEP STUDY (03/13/20)
     
  3587. NYS & NYC COVID-19 Announcements - Prescriptions for Uninsured & More - (03/13/20)
     
  3588. CROI: Predicted Rise in Diabetes Risk With TAF/FTC+DTG Versus TDF/FTC+DTG - Mark Mascolini (03/12/20)
     
  3589. Phase 3 Doravirine/Islatravir - (03/12/20)
     
  3590. CROI: Modeling-Supported Islatravir Dose Selection for Phase 3 - (03/12/20)
     
  3591. CROI: CLINICAL PREDICTORS OF LIVER FIBROSIS PRESENCE & PROGRESSION IN HIV-ASSOCIATED NAFLD - (03/12/20)
     
  3592. CROI: 144-Week Efficacy and Safety of B/F/TAF in Treatment-Naive Adults Age ≥50 Years - (03/12/20)
     
  3593. CROI: NOVEL ANTIRETROVIRAL AGENTS: TRANSFORMING THE CARE OF PEOPLE WITH HIV - (03/11/20)
     
  3594. CROI: HORMONE USE AND HIV ALTER CARDIOVASCULAR BIOMARKER PROFILES IN TRANSGENDER WOMEN - (03/11/20)
     
  3595. CROI: Testosterone Use Tied to Signals of Atherosclerosis Progression in Men With HIV - Mark Mascolini (03/11/20)
     
  3596. CROI: DISCOVER: 96-Week Follow-up of Black and Hispanic/Latinx Study Participants - (03/11/20)
     
  3597. CROI: Themed Discussion FAT IN FOCUS - (03/11/20)
     
  3598. CROI: Pre-ART CD4% and HIV Load Tied to Reservoir Size in Early-Treated Infants - Mark Mascolini (03/11/20)
     
  3599. CROI: GREATER WEIGHT GAIN AFTER SWITCH TO INSTI-BASED REGIMEN FROM NNRTI VS. PI REGIMENS - (03/11/20)
     
  3600. CROI: Life Expectancy With HIV Improving--But Added Years Often Not Healthy - Mark Mascolini (03/11/20)
     
  3601. CROI: Community- Versus Clinic-Based ART Boosts HIV Control in African Study - Mark Mascolini (03/11/20)
     
  3602. CROI: Low Adherence to Treatment and Follow-up of Anal Cancer Precursor - Mark Mascolini (03/11/20)
     
  3603. CROI: Doubled Risk of non-HIV Mortality in US People at Risk for HIV - Mark Mascolini (03/11/20)
     
  3604. CROI: Intact Proviral HIV DNA Drops During Long-Term Suppressive ART - Mark Mascolini (03/11/20)
     
  3605. CROI: Weekly Islatravir Protects Monkeys Against IV Challenge With SIV - Mark Mascolini (03/11/20)
     
  3606. CROI: Losartan Does Not Improve Inflammation or Fibrosis Markers in Older People on ART - Mark Mascolini (03/11/20)
     
  3607. CROI: Pomalidomide Clears Anal Cancer Precursor in High Proportion With or Without HIV - Mark Mascolini (03/11/20)
     
  3608. CROI: Lower CD4/CD38 Ratio Boosts Cancer Risk in US/Canada HIV Group - Mark Mascolini (03/11/20)
     
  3609. CROI: F/TAF and F/TDF Efficacy and Safety as PrEP for 96 Weeks - Mark Mascolini (03/11/20)
     
  3610. CROI: Initial Weight, Low CD4/CD38, Low Activity Drive Weight Gains After InSTI Switch - Mark Mascolini (03/11/20)
     
  3611. CROI: DTG + 3TC VS DTG + TDF/FTC (GEMINI-1 & -2): CONFIRMED VIROLOGIC WITHDRAWALS THROUGH WEEK 96 - (03/11/20)
     
  3612. CROI: WEEKLY ORAL ISLATRAVIR PROVIDES EFFECTIVE PEP AGAINST IV CHALLENGE WITH SIVMAC251 - (03/11/20)
     
  3613. CROI: FTC/TAF + BIC Postexposure Prophylaxis Protects Macaques Against Rectal SHIV Infection - (03/11/20)
     
  3614. CROI: Longer Term Efficacy and Safety of F/TAF and F/TDF For HIV PrEP: DISCOVER Trial Week 96 Results - (03/11/20)
     
  3615. CROI: ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership - (03/11/20)
     
  3616. CROI: ViiV Healthcare presents positive long-term data from phase III study demonstrating efficacy and safety of cabotegravir and rilpivirine, its investigational, long-acting injectable treatment regimen in adults living with HIV-1 - (03/11/20)
     
  3617. CROI: Glucose Upsets Tied to Worse Physical Function in Men With or Without HIV - Mark Mascolini (03/11/20)
     
  3618. CROI: LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV TREATMENT: FLAIR WEEK 96 RESULTS - (03/11/20)
     
  3619. CROI: STRUCTURAL ANALYSES OF A BOUND ANTI-CD4 ADNECTIN INHIBITOR OF HIV-1 [Combinectin GSK3732394] - (03/11/20)
     
  3620. CROI: Mortality 4-Fold Higher With HIV in Canadian Group--in Sync With Comorbidity Tally - Mark Mascolini (03/11/20)
     
  3621. CROI: Safety & Analytic Treatment Interruption Outcomes of Vesatolimod in HIV Controllers - (03/11/20)
     
  3622. CROI: HIV Severity and Incident Heart Failure Among Adults in a Large Healthcare System - (03/11/20)
     
  3623. CROI: WEEKLY ORAL ISLATRAVIR PROVIDES EFFECTIVE PEP AGAINST IV CHALLENGE WITH SIVMAC251 - (03/11/20)
     
  3624. CROI: ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing - (03/11/20)
     
  3625. CROI: New Data on Gilead's Biktarvy® Presented at CROI 2020, Including Data in Black Americans and Older Adults - (03/11/20)
     
  3626. CROI: HIV cure from bench to bedside.....and to community - (03/11/20)
     
  3627. Could Colchicine Be the New Aspirin? - (03/09/20)
     
  3628. HIV Itself Ages PLWH - Immunosenescence - (03/09/20)
     
  3629. HIV Causes Aging In HIV & Contributes to the Onset Prematurelly & in Greater Rates of Comorbidities - (03/09/20)
     
  3630. Bone Update: Is It Still an Issue Without Tenofovir Disoproxil Fumarate? - (03/09/20)
     
  3631. CROI: Islatravir Metabolic Outcomes in a Phase 2b Trial of Treatment-Naïve Adults with HIV-1 - (03/09/20)
     
  3632. CROI: SAFETY & PHARMACOKINETICS OF GS-9722 IN HIV-NEGATIVE PARTICIPANTS AND PEOPLE WITH HIV - (03/09/20)
     
  3633. CROI: A RANDOMIZED TRIAL OF THE IMPACT OF 3BNC117 AND ROMIDEPSIN ON THE HIV-1 RESERVOIR - (03/09/20)
     
  3634. CROI: Greater Population-Level Viral Control Tied to Lower HIV Incidence in 4 Large Trials - Mark Mascolini - (03/09/20)
     
  3635. CROI: Every-2-Month Maintenance CAB + RPV Noninferior to Monthly Dosing for 48 Weeks. ATLAS-2M study - Mark Mascolini (03/09/20)
     
  3636. CROI: ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing - press release - (03/09/20)
     
  3637. CROI: Merck Announces New Data from Broad HIV Program at CROI 2020 - (03/02/20)
     
  3638. Geriatric model & screening assessments ALL HIV clinics should have - (02/28/20)
     
  3639. Increased Prevalence of Neurocognitive Impairment in Aging People Living With Human Immunodeficiency Virus: The ANRS EP58 HAND 55-70 Study - (02/27/20)
     
  3640. FDA approves drug that lowers cholesterol in a new way
    Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance     - (02/24/20)
     
  3641. CROI: Changes in markers of T-cell Senescence and Exhaustion With HIV Therapy - (02/21/20)
     
  3642. Aging of HIV+ in US.....an epidemic coming - (02/21/20)
     
  3643. Multiple roles for HIV broadly neutralizing antibodies - (02/21/20)
     
  3644. Understanding The Relationship Between HPV and Anal Cancer - (02/14/20)
     
  3645. Loss of Preexisting Immunological Memory Among Human Immunodeficiency Virus-Infected Women Despite Immune Reconstitution With Antiretroviral Therapy - (02/14/20)
     
  3646. Novel Antiretroviral Agents - (02/14/20)
     
  3647. Increased Healthcare Costs for Older HIV+ - (02/10/20)
     
  3648. The HIV Continuum of Care for Adolescents and Young Adults Attending 13 Urban US HIV Care Centers of the NICHD-ATN-CDC-HRSA SMILE Collaborative..... - (02/10/20)
     
  3649. Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV - (02/10/20)
     
  3650. Preexposure Prophylaxis Indication Criteria Underidentify Black and Latinx Persons and Require Revision - (02/07/20)
     
  3651. Functional Interval Training for Veterans Exercising Through Telehealth. (FIT-VET) - (02/06/20)
     
  3652. Antiretroviral therapy in older people with HIV - HIV AND AGING: Edited by Kristine M. Erlandson - (02/04/20)
     
  3653. Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV - (02/04/20)
     
  3654. Regional brain volumetric changes despite 2 years of treatment initiated during acute HIV infection - (02/03/20)
     
  3655. New End AIDS CDC Funding for Health Departments - (02/03/20)
     
  3656. HIV postexposure prophylaxis-in-pocket "PIP" - (02/03/20)
     
  3657. Weight Gain in HIV+ - (01/29/20)
     
  3658. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV - (01/29/20)
     
  3659. Weight GAIN - ARTs, Integrase - (01/29/20)
     
  3660. Harvard HIV and Aging Workshop: Perspectives and Priorities from Claude D. Pepper Centers and Centers for AIDS Research - (01/28/20)
     
  3661. Gender & Racial Aging/HIV Disparities - (01/28/20)
     
  3662. AGE: Food Insecurity and Frailty among Women Living with or At-risk for HIV in the U.S. - (01/24/20)
     
  3663. NIAID Launches First Clinical Trial to Test Antibody-Drug Combination for Long-Acting HIV Treatment - (01/27/20)
     
  3664. AGE: Can Frailty Be Prevented or Reversed???? - (01/24/20)
     
  3665. Epidemiological studies have identified a potential temporal link between marijuana use and myocardial infarction - (01/24/20)
     
  3666. Frailty & 5x Higher Mortality in HIV+ Women (WIHS) & Men (MACS) with HIV; frailty doubles fracture rate in older women with HIV; Ever opiate or cocaine use was also associated with increased risk - (01/24/20)
     
  3667. A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living with HIV-1 A Multicenter Trial of the AIDS Clinical Trials Group (ACTG) - A5357 - (01/24/20)
     
  3668. CROI: Longitudinal Phenotyping of Declarative Memory Among Women Living with HIV - (01/24/20)
     
  3669. Aging in NYC: Black/Latino 25% >60 Yrs Old; 75% >40. 23,000 >60 - (01/23/20)
     
  3670. HIV/Aging in NYC 80%+ over 40 Yrs Old/IDUs 95%/HIGH Death Rates for Older HIV - (01/23/20)
     
  3671. AGE: Frailty and Aging (worse mortality): The last 10 years of aging research, and next steps. - (01/23/20)
     
  3672. EACS: Aging with HIV (01/22/20)
     
  3673. AGE: Loneliness & Social Isolation in HIV: Reduces Mental & Physical Health. The "Village Model in HIV study: pilot in San Diego, app" - (01/22/20)
     
  3674. Despite ART/Faster Immune Aging in HIV+ - (01/17/19)
     
  3675. New MK-8591 Publication - (01/17/19)
     
  3676. Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017 - (01/17/19)
     
  3677. Aging Successfully in WIHS...BUT. Prevalence and Correlates of Self-Rated Successful Aging Among Older Women Living With HIV - (01/17/19)
     
  3678. Alzheimers & Amyloid, Mild Cognitive Impairment in HIV - (01/17/19)
     
  3679. Dovato (dolutegravir/lamivudine), the once-daily, single-pill, 2-drug regimen for the treatment of HIV-1 infection, granted marketing approval by Japan Ministry of Health, Labour and Welfare - (01/16/19)
     
  3680. Increased Prevalence of Hepatic Steatosis in Young Adults With Lifelong HIV - (01/13/19)
     
  3681. 9th HIV Persistance During Therapy Workshop; Reservoirs & Eradication Strategies Workshop - (01/13/19)
     
  3682. Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University - (01/13/19)
     
  3683. Long-Term Impact of Calcium and Vitamin D Supplementation on Bone Density in HIV+ Patients with Documented Deficiencies - (01/06/19)
     
  3684. Prescribing in Elderly PLWH - Top Ten Drug Classes to Avoid in Elderly PLWH - (01/06/19)
     
  3685. Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017..... three times higher than in the general population - (12/20/19)
     
  3686. Doravrine - a relatively New ART [NNRTI] - (12/20/19)
     
  3687. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV [London]....'although there appear to be outliers' - (12/18/19)
     
  3688. HIV drug resistance in a cohort of HIV-infected MSM in the United States - (12/18/19)
     
  3689. HIV and African American Gay and Bisexual Men: HV incidence 8 Times Higher for African-Americans & 3 times Higher for Hispanics than whites. - (12/18/19)
     
  3690. Fauci: Comorbidities in Persons With HIV - The Lingering Challenge - (12/18/19)
     
  3691. The elusive end to HIV in the USA - Editorial - (12/16/19)
     
  3692. ViiV Healthcare files submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV - (12/16/19)
     
  3693. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back - (12/16/19)
     
  3694. HIV and the Aging Brain - Miami CFAR Aging Conference - (12/12/19)
     
  3695. Multimorbidity in Elderly Subjects according to the year of diagnosis of HIV-Infection - A Cross-Sectional DATAIDS Cohort Study....'40% diabetes, 10% cancers, 80% elevated cholesterol, 30% low kidney function eGFR <60, 20% osteoporosis, 80% high blood pressure - (12/12/19)
     
  3696. Increased Prevalence of Neurocognitive Impairment in Aging People Living With Human Immunodeficiency Virus: The ANRS EP58 HAND 55-70 Study; Commentary: Thinking About Getting Older With Human Immunodeficiency Virus "HIV Clinics Need To Expand Services" - (12/12/19)
     
  3697. Ruth M. Rothstein CORE Center and Cook County Health HIV Integrated Program launch 'CORE Healthy Aging Initiative 2.0' - (12/12/19)
     
  3698. EACS: Integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in adipose tissue and adipocytes (12/12/19)
     
  3699. EACS: Comparable effectiveness of Raltegravir-based dual therapy versus other regimes in patients switched for maintenance (12/09/19)
     
  3700. EACS: Real World Utilisation of Raltegravir 1200mg Once Daily (The RETRO Study) (12/09/19)
     
  3701. Prevalence and 1-year incidence of frailty among women with and without HIV in the Women's Interagency HIV Study - (12/09/19)
     
  3702. Inflammaging: Discover the Fountain of Youth CFAR Miami Conference - (12/09/19)
     
  3703. ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available - (12/05/19)
     
  3704. People ageing with HIV face an uncertain future - (12/05/19)
     
  3705. HIV Outcomes Beyond Viral Suppression - Series Lancet HIV, - (12/05/19)
     
  3706. New Survey of Young Adults Uncovers Low Levels of Accurate Knowledge About HIV Transmission Coupled with High-Risk Sexual Behaviors - (12/05/19)
     
  3707. CT Fat Density Accurately Reflects Histologic Fat Quality in Adults With HIV On and Off Antiretroviral Therapy - Adipose/Fat Density & Quality - (12/05/19)
     
  3708. EACS: Depression and kynurenine/tryptophan ratio in people living with HIV (12/04/19)
     
  3709. EACS: Restless legs syndrome and health-related quality of life in HIV: results from the POPPY sleep substudy (12/04/19)
     
  3710. EACS: AIDS DEFINING AND NON-DEFINING CANCERS IN PERSONS LIVING WITH HIV IN A SINGLE CENTER COHORT FOLLOWED SINCE 1986 (12/04/19)
     
  3711. EACS: Non-Alcoholic Fatty Liver Disease is a significant predictor of cardiovascular risk in HIV-mono-infected patients (12/04/19)
     
  3712. EACS: Long-acting antiretroviral drugs / Marta Boffito MD (12/04/19)
     
  3713. Bisphosphonates and lower mortality risk, Heart Disease & Bone Disease Associated in HIV+ - (12/04/19)
     
  3714. Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults - (12/04/19)
     
  3715. EACS: Pharmacokinetics of Cabotegravir and Rilpivirine Long-Acting Injectables in HIV-Infected Individuals Through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies (12/02/19)
     
  3716. EACS: Prevalence of InSTI resistance and effectiveness of InSTI-based regimens in HIV-infected patients: results from a European cohort study (12/02/19)
     
  3717. EACS: HIV infection in individuals seeking post-exposure prophylaxis (PEP): a retrospective data linkage study (12/02/19)
     
  3718. EACS: Injectable Long Acting Antiretroviral for HIV Treatment or Prevention: The ANRS CLAPT Study (12/02/19)
     
  3719. EACS: Will HIV-infected patients Taking Oral ARV Switch to Long-Acting Injectable ART when It Becomes Available? (12/02/19)
     
  3720. IDWeek: Population Pharmacokinetic (PPK) Modeling and Simulation of Long-Acting (LA) Cabotegravir (CAB) to Inform Strategies Following Dosing Interruptions in HIV-1 Infected Subjects - (12/02/19)
     
  3721. EACS: POPULATION PHARMACOKINETIC ANALYSIS OF DOLUTEGRAVIR IN HIV/TB COINFECTED PEOPLE WITH AND WITHOUT RIFAMPICIN (11/26/19)
     
  3722. EACS: Dolutegravir-based regimens are associated with weight gain over two years following ART-initiation in ART-naïve people living with HIV (PLWH) (11/26/19)
     
  3723. EACS: POPULATION PHARMACOKINETIC ANALYSIS OF DOLUTEGRAVIR IN HIV/TB COINFECTED PEOPLE WITH AND WITHOUT RIFAMPICIN (11/26/19)
     
  3724. EACS: Characterizations of weight gain following antiretroviral regimen initiation in treatment-naïve individuals living with HIV (11/26/19)
     
  3725. EACS: Comparison of a Two-Drug Regimen (Dolutegravir/Rilpivirine) to Standard Three-Drug Regimens in Virologically Suppressed, Treatment Experienced Individuals in the Real World (11/26/19)
     
  3726. EACS: COPEDOL: a two-year French multicentric, observational, longitudinal retro-prospective study in pretreated HIV-1-infected patients starting dolutegravir based regimen due to treatment failure (11/26/19)
     
  3727. EACS: Baseline characteristics in JUNGLE, a German observational cohort study of Juluca as 2-Drug Regimen in virologically suppressed patients, compared to the phase-3 SWORD 1 & 2 study populations (11/26/19)
     
  3728. EACS: SWORD-1&-2: MAINTENANCE OR IMPROVEMENT IN RENAL FUNCTION IN PLWH THROUGH 148 WEEKS AFTER SWITCH TO THE DOLUTEGRAVIR + RILPIVIRINE 2-DRUG REGIMEN (11/26/19)
     
  3729. IWCADRH: Targeting Liver Fibrosis in Chronic Treated HIV with MitoQ - (11/26/19)
     
  3730. IWCADRH: Integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in adipose tissue and adipocytes - (11/26/19)
     
  3731. IWCADRH: Colonic microbiota exhibits disparate associations with HIV infection and sexual practices - (11/26/19)
     
  3732. IWCADRH: BESIDE - Age- and sex-related differences in concomitant diseases and use of co-medication in patients with treated HIV-infection in Germany - (11/26/19)
     
  3733. IWCADRH: Correlation between cerebrospinal fluid and plasma NfL in treated HIV infection in the COBRA study - (11/25/19)
     
  3734. EACS: A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) in Virologically-Suppressed HIV-1 Infected Adults Harboring the NRTI Resistance Mutation M184V/I (GS-US-292-1824): Week 24 Results (11/25/19)
     
  3735. EACS: Changes in LDL After Switch from TDF to TAF in the U.S. (11/25/19)
     
  3736. EACS: Biologic Sex Is Not the Only Difference Between Men and Women: Data From the Doravirine Phase 2/3 Clinical Trials (11/25/19)
     
  3737. EACS: Islatravir Efficacy and Safety for Selected Demographic and Baseline Subgroups From a Phase 2 Trial In Treatment-naïve Adults With HIV-1 Infection (11/25/19)
     
  3738. EACS: Subclinical atherosclerosis burden by ultrasound in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors (11/22/19)
     
  3739. EACS: Retrospective analysis of co-medication patterns among patients treated for HIV, and potential interactions with antiviral treatment, in Norway during 2012-2018 using the Norwegian population-based prescription database (11/22/19)
     
  3740. EACS: Untreated HCV in HIV/HCV-Coinfected US Population Despite an Abundance of Curative Therapies (11/22/19)
     
  3741. EACS: Unsupressed HIV in USA: 40% >55 Years Old Unsuppressed - CDC Reports (11/22/19)
     
  3742. EACS: Comparison of changes in bone microarchitecture with abacavir-lamivudine versus tenofovir disoproxil fumarate-emtricitabine in adults living with HIV Greater BMD Decline With TDF Than ABC, But Similar Drop in Trabecular Bone Score - Mark Mascolini (11/21/19)
     
  3743. EACS: The ADVANCE trial: the impact of DXA-assessed bone mineral density of TDF/FTC/EFV and TDF/FTC+DTG versus TAF/FTC+DTG South Africa - Mark Mascolini (11/21/19)
     
  3744. EACS: More Antimicrobial Prescriptions May Be Clue to Undiagnosed HIV - Mark Mascolini- (11/21/19)
     
  3745. EACS: Only 1% HIV Diagnosis Rate More Than 6 Months After PEP in 975 People - Mark Mascolini (11/21/19)
     
  3746. EACS: Incidence of CKD With TDF and Non-TDF Containing Antiretroviral Regimens by Baseline D:A:D CKD Risk In People Living With HIV - (11/20/19)
     
  3747. EACS: Outcomes of antiretrovirals used as the third drug in subgroups of treatment naïve individuals living with HIV - (11/18/19)
     
  3748. EACS: Baseline and Emergent Genotypic and Phenotypic Results in HIV-1-Infected, Heavily Treatment-Experienced (HTE) Participants Meeting Protocol-Defined Virologic Failure (PDVF) Criteria Through Week 96 in the Fostemsavir (FTR) Phase 3 BRIGHTE Study - (11/18/19)
     
  3749. EACS: Impact of Susceptibility Scoring on Virologic Response in Heavily Treatment-Experienced Participants with HIV-1 Receiving a Fostemsavir-Based Antiretroviral Regimen: Week 96 Results from the Randomized Cohort of the Phase 3 BRIGHTE Study - (11/18/19)
     
  3750. EACS: Absence of Naturally Existing Resistance Against The HIV-1 Capsid Inhibitor GS-6207 in HIV-1 Primary Isolates - (11/18/19)
     
  3751. EACS: Impact of Susceptibility Scoring on Virologic Response in Heavily Treatment-Experienced Participants with HIV-1 Receiving a Fostemsavir-Based Antiretroviral Regimen: Week 96 Results from the Randomized Cohort of the Phase 3 BRIGHTE Study - (11/18/19)
     
  3752. EACS: Absence of Naturally Existing Resistance Against The HIV-1 Capsid Inhibitor GS-6207 in HIV-1 Primary Isolates - (11/18/19)
     
  3753. EACS: HIV-1 from antiretroviral-naïve and experienced patients lack capsid substitutions associated with GS-6207 in vitro resistance - (11/18/19)
     
  3754. EACS: Phase 3 Randomized, Controlled DISCOVER Study of Daily F/TAF or F/TDF for HIV Pre-exposure Prophylaxis: Week 96 Results - (11/14/19)
     
  3755. EACS: Longer ART Linked to Clearance of High-Risk HPV in MSM With HIV - Mark Mascolini - (11/14/19)
     
  3756. EACS: Rapid Initiation of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Patients With Human Immunodeficiency Virus (HIV)-1 Infection: Age, Race/Ethnicity, and Gender Subgroup Analyses From the DIAMOND Study - (11/14/19)
     
  3757. EACS: Prevalence of Archived HIV-1 DNA Resistance-associated Mutations and their Lack of Effect on Virologic Outcome at Week 96 in Antiretroviral Treatment-experienced, Virologically Suppressed Patients Receiving the Once-daily, Single-tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in the EMERALD Phase III Trial - (11/14/19)
     
  3758. EACS: Short-term Neuropsychiatric Tolerability of Bictegravir Combined with FTC/TAF in Clinical Practice - (11/14/19)
     
  3759. EACS: EACS New Aging/Screening Guidelines / HIV+ Case 69 Year Old Aging in Spain - Brighton UK Geriatric HV Clinic - (11/14/19)
     
  3760. EACS: Maintenance DTG/3TC Controls HIV in People With Historical 3TC Resistance "Dolutegravir and lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a pilot clinical trial (ART-PRO)" - Mark Mascolini - (11/14/19)
     
  3761. EACS: More Than Half of Adult Group With Perinatal HIV Have Neurocognitive Impairment - Mark Mascolini - (11/13/19)
     
  3762. EACS: Fibrosis, Steatosis, and NAFLD Boost Odds of Frailty in HIV Group - Mark Mascolini (11/13/19)
     
  3763. EACS: Short-term Neuropsychiatric Tolerability of Bictegravir Combined with FTC/TAF in Clinical Practice - (11/13/19)
     
  3764. EACS: Real world data of using Triumeq (dolutegravir/abacavir/lamivudine; DTG/ABC/3TC): final outcomes of the 3-year German TRIUMPH cohort show good virologic effectiveness and safety in routine clinical practice - (11/13/19)
     
  3765. EACS: Dolutegravir (DTG) Use During Pregnancy and Birth Outcomes: Data from the Antiretroviral Pregnancy Registry (APR) - (11/13/19)
     
  3766. EACS: SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN THROUGH 48 WEEKS: SUBGROUP ANALYSES FROM THE TANGO STUDY - (11/13/19)
     
  3767. EACS: Precancer Anal Lesion Arises in 10% of Australian MSM--But Clearance Common - Mark Mascolini - (11/13/19)
     
  3768. EACS: Phase 3 Randomized, Controlled DISCOVER Study of Daily F/TAF or F/TDF for HIV Pre-exposure Prophylaxis: Week 96 Results - (11/13/19)
     
  3769. EACS: Safety and Efficacy of Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People With HIV Aged 50 Years and Older - (11/12/19)
     
  3770. EACS: DISCOVER in Europe: a Subanalysis of the Phase 3, Randomized, Controlled Trial of Daily Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-exposure Prophylaxis - (11/12/19)
     
  3771. EACS: Long-term Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in ART-Naïve Adults - (11/12/19)
     
  3772. EACS: Switching to Bictegravir/Emtricitabine/TenofovirAlafenamide(B/F/TAF) in Adults Aged ≥ 65 Years: Week 48 Results from a Phase 3b, Open-Label Trial (GS-US-380-4449) - (11/12/19)
     
  3773. EACS: Sustained Viral Suppression among Participants with Pre-existing M184V/I Who Switched to Bictegravir/Emtricitabine/TenofovirAlafenamide - (11/12/19)
     
  3774. EACS: Risk Score Predicts Diabetes Better Than HOMA-IR and Other Equations "Comparing a risk score against physiological markers for predicting diabetes incidence in HIV+ individuals" - (11/12/19)
     
  3775. EACS: New HIV Comorbidity Index Linked to Mortality, Can Outperform Other Tools - (11/12/19)
     
  3776. EACS: One Third of MSM PrEP Users in French Analysis Quit in 30 Months - Mark Mascolini - (11/12/19)
     
  3777. EACS: Switch From TDF to TAF in HIV/HBV+ Maintains Viral Control, Helps Kidneys - Mark Mascolini (11/12/19)
     
  3778. EACS: INI Resistance Remains Rare in INI-Naive--Initial CD4, Viral Load Predict Failure - Mark Mascolini - (11/12/19)
     
  3779. EACS: Integrase Inhibitors Tied to Weight Gain, Hepatic Steatosis in Longitudinal Cohort - Mark Mascolini - (11/12/19)
     
  3780. EACS: Is modern antiretroviral therapy causing weight gain? - (11/12/19)
     
  3781. EACS: Prevalence of and risk factors for low Bone Mineral Density assessed by Quantitative Computed Tomography in people living with HIV and uninfected controls Very Low BMD More Frequent With HIV--But Not After Statistical Adjustment - Mark Mascolini - (11/12/19)
     
  3782. EACS: Single Doses of Long-Acting Capsid Inhibitor GS-6207 Administered by Subcutaneous Injection Are Safe and Efficacious in People Living With HIV - (11/12/19)
     
  3783. EACS: GS-6207 Long Acting Capsid Inhibitor Safety & PK Subcutaneous - (11/12/19)
     
  3784. EACS: Safety and Efficacy of Triple Therapy with Dolutegravir plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Patients - 48 weeks results from a Phase II Study in Portugal - (11/12/19)
     
  3785. EACS: Non inferiority of dolutegravir+emtricitabine dual therapy to standard combination antiretroviral therapy in maintaining HIV suppression throughout 48 weeks: The SIMPL'HIV study - (11/12/19)
     
  3786. EACS: The ADVANCE clinical trial: changes from baseline to week 96 in DXA-assessed body composition in TAF/FTC+DTG compared to TDF/FTC+DTG, and TDF/FTC/EFV Weight Keeps Rising Through 96 Weeks With TAF/FTC+DTG in Black Africans - (11/12/19)
     
  3787. EACS: ASSESSMENTS OF VERY-LOW-LEVEL HIV REPLICATION FOR DOLUTEGRAVIR + LAMIVUDINE (DTG + 3TC) VS DOLUTEGRAVIR + TENOFOVIR DISOPROXIL/EMTRICITABINE (DTG + TDF/FTC) IN THE GEMINI-1&-2 STUDIES THROUGH WEEK 96 - (11/08/19)
     
  3788. EACS: Uptake and discontinuation of Integrase Inhibitors (INSTIs) in a large cohort setting (DTG, EVG, RAL) DTG Easily Most Popular INI Across Europe, With Lowest Quitting Rate - Mark Mascolini (11/08/19)
     
  3789. EACS: Changes in bone mineral density in men who have sex with men on tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis: longitudinal cohort data - (11/08/19)
     
  3790. EACS: BMD Drops More Than 3% in up to One Third of MSM Using TDF PrEP for 2 Years - Mark Mascolini - (11/08/19)
     
  3791. EACS: Maintenance DTG/3TC Controls HIV in People With Historical 3TC Resistance "Dolutegravir and lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a pilot clinical trial (ART-PRO)" - Mark Mascolini - (11/08/19)
     
  3792. EACS: Changes in weight after switching to dolutegravir containing antiretroviral therapy in the Swiss HIV Cohort Study - (11/08/19)
     
  3793. EACS: Shorter time to treatment failure in PLHIV switched to dolutegravir plus either rilpivirine or lamivudine compared to integrase inhibitor-based triple therapy in a large Spanish cohort - VACH Doubled Failure Risk After Switch to DTG/RPV or DTG/3TC Versus Triple-INI Regimen - Mark Mascolini - (11/08/19)
     
  3794. EACS: Menopause Does Not Affect HIV or CD4 Response in Multicenter Spanish Group - Mark Mascolini - (11/08/19)
     
  3795. EACS: Pregnancies and Live Births Stable/Rising Since 2002 in European Women With HIV - Mark Mascolini - (11/08/19)
     
  3796. EACS: Outcomes for Women in Phase 3 Trials of Long-Acting Cabotegravir + Rilpivirine: Pooled ATLAS and FLAIR Week 48 Results - (11/08/19)
     
  3797. EACS: Are new antiretroviral treatments increasing the risks of obesity? - (11/08/19)
     
  3798. EACS: Long-term Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in ART-Naïve Adults - (11/08/19)
     
  3799. EACS: Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide vs comparators in cis-women and girls (living with HIV): an analysis of 5 clinical trials - Mark Mascolini - (11/07/19)
     
  3800. EACS: Switching to DTG/3TC Fixed-Dose Combination (FDC) Is Non-inferior to Continuing a TAF-Based Regimen Through 48 Weeks: Subgroup Analyses From the TANGO Study - (11/07/19)
     
  3801. EACS: Once-a-Month CAB/RPV Effective in Women--Fewer Adverse Events Than Men - Mark Mascolini - (11/07/19)
     
  3802. EACS: Incidence of CKD with TDF and non-TDF containing antiretroviral regimens by baseline D:A:D CKD risk in people living with HIV (PLWH) - Mark Mascolini - (11/07/19)
     
  3803. EACS: Modest 96-Week Weight Gain in Trials of Doravirine, Darunavir, Efavirenz "EFFECT OF DORAVIRINE ON BODY WEIGHT AND BODY MASS INDEX IN TREATMENT NAïVE ADULTS WITH HIV-1" - Mark Mascolini - (11/07/19)
     
  3804. EACS: Weight Keeps Rising Through 96 Weeks With TAF/FTC+DTG in Black Africans - ADVANCE Study - Mark Mascolini - (11/07/19)
     
  3805. EACS: Delayed Weight Gain in Immediate Versus Deferred ART Arm in START - "Antiretroviral therapy and body weight in the START (Strategic Timing of Antiretroviral Treatment) trial" - Mark Mascolini - (11/07/19)
     
  3806. EACS: Switch to INI Does Not Affect Average Weight Gain in Middle-Aged/Older Group - Mark Mascolini - (11/07/19)
     
  3807. EACS: Will HIV-infected patients Taking Oral ARV Switch to Long-Acting Injectable ART when It Becomes Available? - (11/06/19)
     
  3808. EACS: Outcomes of antiretrovirals used as the third drug in subgroups of treatment naïve individuals living with HIV - (11/06/19)
     
  3809. EACS: Gilead's Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical Trials - (11/06/19)
     
  3810. EACS: Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP™ Compared With Truvada For PrEP® - (11/06/19)
     
  3811. EACS: EACS 2019: ViiV Healthcare to present 17 abstracts from its portfolio addressing the diverse needs of people living with HIV - PRESS RELEASE - (11/06/19)
     
  3812. EACS: Screening Program Cuts Anal Cancer Precursor Rate in 405 MSM With HIV - Mark Mascolini (11/06/19)
     
  3813. EACS: Long-term Antilipid Therapy Tied to 70% Lower Death Risk in VA Cohort - Mark Mascolini (11/06/19)
     
  3814. EACS: French Studies Find Eagerness for Long-Term Injectables--With Key Cautions - Mark Mascolini (11/06/19)
     
  3815. EACS: No Change in Kidney Function, Cholesterol Ratio, or Weight When 60+ Group Switches to TAF - Mark Mascolini (11/06/19)
     
  3816. EACS: Response Differences Between First-Line Regimens in Large European Group - Mark Mascolini (11/06/19)
     
  3817. Letter from Gilead to Community: Facts About Gilead's PrEP Medications Donation to Help Support Ending the HIV Epidemic Efforts - (11/04/19)
     
  3818. Screening for Anal Cancer in the Population Living With Human Immunodeficiency Virus: A Step Closer? - EDITORIAL - (11/04/19)
     
  3819. Adjudicated Heart Failure in HIV-Infected and Uninfected Men and Women - (11/04/19)
     
  3820. Heart Failure among People with HIV: Evolving Risks, Mechanisms, and Preventive Considerations - (11/04/19)
     
  3821. Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era - Results From the Veterans Aging Cohort Study - (11/04/19)
     
  3822. AGE: Aging Workshop Report : DNA Methylation : Heart Disease ; Kidney Disease - Christina K. Psomas MD - (11/01/19)
     
  3823. AGE: The Utility of Olfactory Function in Distinguishing Early Stage Alzheimer's Disease from HIV-associated Neurocognitive Disorder: A Pilot Study - (11/01/19)
     
  3824. AGE: Lipidome abnormalities and altered macrophage phenotype may contribute to cardiovascular disease risk in the aging HIV population - (11/01/19)
     
  3825. AGE: FRAILTY PHENOTYPE IN OLDER VIROLOGICALLY SUPPRESSED PLWH IS STRONGLY CORRELATED WITH SPECIFIC COMORBIDITIES AND TOBACCO USE - (11/01/19)
     
  3826. Bictegravir with Pre-Existing NRTI Resistance - (10/29/19)
     
  3827. Time to change cardiovascular prevention in people with HIV - A more pragmatic approach is the direct measurement of cIMT to construct cIMT-based monitoring and prevention guidelines for HIV-positive people - comment - (10/25/19)
     
  3828. Editorial - Antiretroviral Monotherapy for HIV: Game Over or Future Perspectives? - (10/25/19)
     
  3829. Brain Dysfunction/HIV-Neurologic Decline Shifting - (10/25/19)
     
  3830. Tesamorelin, liver fat, and NAFLD in the setting of HIV - Comment / Tesamorelin Prevented Progression to Liver Fibrosis in NIH Study - (10/25/19)
     
  3831. AGE: Pharmacokinetics of Cabotegravir and Rilpivirine Long-Acting Injectables in HIV-Infected Individuals Through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies - (10/24/19)
     
  3832. AGE: Frailty, Physical Function Impairment, Comorbidity Burden, and Falls are Predictive of Mortality Among Middle-Aged Adults with HIV - (10/24/19)
     
  3833. AGE: Slide Presentations - 10th HIV & Aging 2019 - (10/24/19)
     
  3834. AGE: Senescence-Associated β-Galactosidase Activity and Other Markers of Senescence in Human Peripheral Blood Immune Cells During Healthy Aging and HIV-Infection - (10/24/19)
     
  3835. IDWeek 2019: Diabetes/Weight Gain; NASH, Ethnicity in HIV+ at IDWeek 2019 Oct 2-6 Wash DC (10/24/19)
     
  3836. IDWeek 2019: Experiences and Emotional Challenges of Antiretroviral Treatment - Findings from the Positive Perspectives Study (10/24/19)
     
  3837. IDWeek 2019: "I feel empowered": Women's perspectives on and experiences with long-acting injectable anti-retroviral therapy in the United States and Spain (10/24/19)
     
  3838. IDWeek 2019: Qualitative Thematic Analysis of Social Media Data to Assess Perceptions of Route of Administration for Antiretroviral Treatment Among People Living With HIV (10/24/19)
     
  3839. IDWeek 2019: PERCEPTIONS OF AND PREFERENCES FOR ORAL OR LONG-ACTING INJECTABLE ANTIRETROVIRAL TREATMENT REGIMENS IN THE UNITED STATES AND CANADA (10/24/19)
     
  3840. AGE: LONG-TERM PRE-HAART SURVIVORS OF HIV: A SPECIFIC GROUP WITH SPECIFIC NEEDS - 'high rates of mental & physical impairments' - (10/23/19)
     
  3841. AGE: Food Insecurity and Frailty among Women Living with or At-risk for HIV in the U.S. - 40% WIHS Women Have Food Insecurity - where us Ryan White Care Act? - No Safety Net - (10/23/19)
     
  3842. AGE: What is the lived experience of loneliness in older men living with HIV? A qualitative analysis to guide service development - (10/23/19)
     
  3843. AGE: Magnetic Resonance Spectroscopy Evidence of Accelerated Aging in Virally-Suppressed HIV - (10/23/19)
     
  3844. AGE: Poorer Muscle Quality and Quantity with ART Initiation is Associated with Greater Inflammation and Immune Activation - (10/21/19)
     
  3845. AGE: Blunted Increase in Muscle Mass After Exercise Training in People Aging with HIV - (10/21/19)
     
  3846. AGE: Frailty But Not HIV Tied to Falls in Large Group of Older US Women - Mark Mascolini (10/21/19)
     
  3847. IDWeek 2019: Grindr™ Use Correlates with HIV Risk & PrEP Use in Men who Have Sex with Men, San Diego (10/21/19)
     
  3848. IDWeek 2019: Clinical outcomes of patients treated with Dolutegravir functional monotherapy or Dolutegravir plus an active non-cytosine nucleoside analog: a retrospective observational cohort study of treatment-experienced patients (10/21/19)
     
  3849. IDWeek 2019: Pooled Resistance Analyses of Darunavir (DRV) Once-daily (QD) Regimens and Formulations Across 10 Clinical Studies of Treatment-naïve (TN) and Treatment-experienced (TE) Patients With Human Immunodeficiency Virus (HIV)-1 Infection (10/21/19)
     
  3850. IDWeek 2019: Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance associated mutations through 48 weeks of treatment (10/21/19)
     
  3851. IDWeek 2019: Epigenetic Age Acceleration and Non-AIDS Defining Cancers Among HIV Infected Adults (10/21/19)
     
  3852. IDWeek 2019: The Utility of Olfactory Function in Distinguishing Early Stage Alzheimer's Disease from HIV-associated Neurocognitive Disorder: A Pilot Study........"supports that these PLWH may be on an AD-like cognitive trajectory" (10/21/19)
     
  3853. ViiV HEALTHCARE SUBMITS NEW DRUG APPLICATION TO US FDA FOR THE FIRST MONTHLY, INJECTABLE, TWO-DRUG REGIMEN OF CABOTEGRAVIR AND RILPIVIRINE FOR TREATMENT OF HIV - (10/18/19)
     
  3854. Diabetes/Weight Gain; NASH, Ethnicity in HIV+ at IDWeek 2019 Oct 2-6 Wash DC - (10/18/19)
     
  3855. Injectable Cabotegravir/Rilpivirine, Oral - FDA, EMA - (10/18/19)
     
  3856. Letter from Gilead - PrEP Study in Cisgender Women and Adolescent Females - (10/18/19)
     
  3857. FDA NEWS RELEASE - FDA approves second drug (TAF) to prevent HIV infection as part of ongoing efforts to end the HIV epidemic - (10/18/19)
     
  3858. Ageing with and without HIV: will advanced age bring equity or greater disparity? Perspective by Amy Justice - (10/18/19)
     
  3859. AGE: Blunted Increase in Muscle Mass After Exercise Training in People Aging with HIV - (10/17/19)
     
  3860. AGE: Frailty phenotype is associated with antiretroviral exposure among older persons living with HIV. - (10/17/19)
     
  3861. AGE: Comorbidities Are Key Frailty Risk Factors in Older French Group With HIV - Mark Mascolini (10/17/19)
     
  3862. AGE: Real-World Use of Ibalizumab in Physician Office infusion Centers (POICs) - (10/17/19)
     
  3863. AGE: The association between mitochondrial DNA copy number and longitudinal lung function decline among people with or at risk of HIV - Mark Mascolini (10/17/19)
     
  3864. AGE: Supplemental Testosterone Contributes to Strength Differences in Men With vs Without HIV - Mark Mascolini (10/17/19)
     
  3865. AGE: Characteristics Associated with Exercise Adherence in the Setting of a Supervised Intervention - (10/17/19)
     
  3866. AGE: HIV+ People Who Need Exercise More Are Less Likely to Adhere to Program - Mark Mascolini (10/17/19)
     
  3867. AGE: Physical Function, Falls, Comorbidity > Predict Death in Middle-Aged With HIV - Mark Mascolini (10/17/19)
     
  3868. AGE: Elevated Cardiac Risk Score by ASCVD Calculation is Associated with Albuminuria in Older People Living with HIV - (10/17/19)
     
  3869. AGE: Elevated Cardiac Risk Score by ASCVD Calculation is Associated with Albuminuria in Older People Living with HIV - (10/17/19)
     
  3870. AGE: Elevated Albuminuria Tied to ASCVD Risk in Older People With HIV - (10/17/19)
     
  3871. IDWeek 2019: FRAILTY PHENOTYPE IN OLDER VIROLOGICALLY SUPPRESSED PLWH IS STRONGLY CORRELATED WITH SPECIFIC COMORBIDITIES AND TOBACCO USE (10/17/19)
     
  3872. IDWeek 2019: Real-World Use of Ibalizumab in Physician Office infusion Centers (POICs) (10/17/19)
     
  3873. IDWeek 2019: Do People With HIV Have to Exercise Harder to Get Same Muscle Benefit? - Mark Mascolini (10/17/19)
     
  3874. IDWeek 2019: Implementation of an HIV and Aging Clinical Program / A Geriatrician's Approach To Aging With HIV (10/16/19)
     
  3875. IDWeek 2019: Iceland Making Progress Toward Eliminating HCV--But Challenges Remain - Mark Mascolini (10/16/19)
     
  3876. IDWeek 2019: Attaining SVR Drives Lower Liver Mortality With Treatment of HCV - Mark Mascolini (10/16/19)
     
  3877. IDWeek 2019: BMI Jumps Slightly With Major Maintenance Regimens, Not Just Integrase Drugs - Mark Mascolini (10/16/19)
     
  3878. IDWeek 2019: Hepatic Steatosis in People Living with HIV - Effect of Sex and Race/Ethnicity - (10/16/19)
     
  3879. IDWeek 2019: T Cell Subsets Associated with Diabetes in Veterans With and Without HIV - (10/16/19)
     
  3880. IDWeek 2019: Online US/Canada Survey Finds Preference for Long-Acting Injectable ART - Mark Mascolini (10/16/19)
     
  3881. IDWeek 2019: Gilead Presents New Data From the Company's HIV Clinical Development Program and Latest Findings on the Impact of HIV Pre-exposure Prophylaxis (PrEP) at IDWeek 2019 - (10/16/19)
     
  3882. IDWeek 2019: The Effect of Initiating INSTI-based vs. NNRTI-based Antiretroviral Therapy on Progression to Diabetes among North American Persons in HIV Care - (10/16/19)
     
  3883. AGE: Physical Function, Falls, Comorbidity Predict Death in Middle-Aged With HIV - Mark Mascolini - (10/15/19)
     
  3884. IDWeek 2019: Household Income and its Relationship with Patient-reported Outcomes among Older People Living with HIV - (10/15/19)
     
  3885. IDWeek 2019: Characteristics Associated with Pre-Frailty in Older People Living with HIV (47% Pre-Frailty) - (10/15/19)
     
  3886. IDWeek 2019: Poor Mental Health & Quality of Life in Virally Suppressed HIV+ - (10/15/19)
     
  3887. IDWeek 2019: Durable Efficacy of Two-Drug Regimen of DTG + 3TC in Antiretroviral Treatment-Naive Adults With HIV-1 Infection at 96 Weeks: Subgroup Analyses in the GEMINI Studies - (10/15/19)
     
  3888. IDWeek 2019: Long-Term Efficacy, Safety and Durability of CAB and RPV as Two-Drug Oral Maintenance Therapy - LATTE Week 312 Results - (10/15/19)
     
  3889. IDWeek 2019: Antiretroviral Therapy Anchor-based Trends in Body Mass Index following Treatment Initiation among Military Personnel with HIV - (10/11/19)
     
  3890. IDWeek 2019: Weight Change Associated with Switching to Integrase Strand Transfer Inhibitor-based Antiretroviral Regimens in HIV-positive Subjects - (10/11/19)
     
  3891. IDWeek 2019: Real world utilization of ibalizumab (IBA) without an optimized background regimen (OBT) - (10/11/19)
     
  3892. IDWeek 2019: IBALIZUMAB EFFICACY AND SAFETY THROUGH 48 WEEKS OF TREATMENT: RESULTS OF AN EXPANDED ACCESS PROTOCOL (TMB-311) - (10/11/19)
     
  3893. IDWeek 2019: Drug Injectors Accept and Use Naloxone Offered at HCV Visits - Mark Mascolini (10/11/19)
     
  3894. IDWeek 2019: BMI and ASCVD Risk Score Changes in Virologically Suppressed Patients with HIV Infection Switching from TDF to TAF Containing ART - (10/11/19)
     
  3895. IDWeek 2019: PrEP Linked to Lower HIV Incidence in US, Independent of TasP - Mark Mascolini (10/11/19)
     
  3896. IDWeek 2019: Long-Term Efficacy, Safety and Durability of CAB and RPV as Two-Drug Oral Maintenance Therapy - LATTE Week 312 Results - (10/8/19)
     
  3897. IDWeek 2019: Effects of Integrase Strand-Transfer Inhibitor Use on Lipids, Glycemic Control, and Insulin Resistance in the Women's Interagency HIV Study (WIHS) - (10/8/19)
     
  3898. IDWeek 2019: A Geriatrician's Approach to People Aging with HIV - Co-Morbidities and Aging - (10/8/19)
     
  3899. IDWeek 2019: The prevalence and burden of non-aids comorbidities in women with or at-risk for hiv infection in the united states - (10/8/19)
     
  3900. IDWeek 2019: Risk of type-2 diabetes mellitus after initiating integrase and protease inhibitors in individuals living with HIV in the United States - (10/8/19)
     
  3901. IDWeek 2019: Changes in BMI associated with antiretroviral regimens in treatment-experienced, virologically suppressed individuals living with HIV - (10/8/19)
     
  3902. IDWeek 2019: Renal Outcomes for Participants Taking F/TAF versus F/TDF for HIV PrEP in the DISCOVER Trial - (10/8/19)
     
  3903. IDWeek 2019: Longer-Term Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Virologically-Suppressed Adults Living With HIV and End Stage Renal Disease on Chronic Hemodialysis - (10/8/19)
     
  3904. IDWeek 2019: Oral Cabotegravir and Rilpivirine Durable for 5.5 Years in LATTE Trial - Mark Mascolini (10/8/19)
     
  3905. IDWeek 2019: PrEP Significantly Reduces the Rate of New HIV Diagnoses in US Metropolitan Statistical Areas independent of Treatment as Prevention (2012-2017) - (10/8/19)
     
  3906. IDWeek 2019: A Comparison Study of Prevalence and Risk Factors for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) by Transient Elastography (TE) in HIV Infected Patients - (10/8/19)
     
  3907. IDWeek 2019: Initial DTG+3TC Noninferior to DTG+TDF/FTC - Mark Mascolini (10/8/19)
     
  3908. IDWeek 2019: Pregnancy outcomes following raltegravir exposure - Mark Mascolini (10/8/19)
     
  3909. IDWeek 2019: Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies - (10/8/19)
     
  3910. IDWeek 2019: Experiences and Emotional Challenges of Antiretroviral Treatment - Findings from the Positive Perspectives Study - (10/8/19)
     
  3911. IDWeek 2019: Fostemsavir Interaction Study Flags Strong CYP3A Inducers, Statins, Oral Contraceptives - Mark Mascolini (10/8/19)
     
  3912. IDWeek 2019: Older and Transgender People Less Likely to Get Integrase Drugs in Big DC Cohort - Mark Mascolini (10/8/19)
     
  3913. IDWeek 2019: HIV Care Continuum Outcomes among newly diagnosed PLWH in Washington, DC - (10/7/19)
     
  3914. IDWeek 2019: ART Adherence Falls Over 4 Years in 15,000 Insured People in US - Mark Mascolini (10/7/19)
     
  3915. IDWeek 2019: Bone Safety Outcomes With F/TAF vs F/TDF for PrEP in the DISCOVER Trial - (10/7/19)
     
  3916. IDWeek 2019: Durable Efficacy of Two-Drug Regimen of DTG + 3TC in Antiretroviral Treatment-Naive Adults With HIV-1 Infection at 96 Weeks: Subgroup Analyses in the GEMINI Studies - (10/7/19)
     
  3917. IDWeek 2019: Weight Rises--But Lipids and HbA1c Don't--After Switch to Integrase Drugs - Mark Mascolini (10/7/19)
     
  3918. IDWeek 2019: High PrEP Uptake, Good Follow-up, With Mobile Screening in Florida - Mark Mascolini (10/7/19)
     
  3919. IDWeek 2019: Mental Health, Quality of Life, and Accessibility to Care Among Virally-Suppressed People Living With HIV in the United States - (10/7/19)
     
  3920. IDWeek 2019: High Rates of Virologic Suppression Achieved in HIV-1-infected Adults Rapidly Starting Antiretroviral Therapy (ART) With the Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) 800/150/200/10 mg Regardless of Baseline Disease Characteristics: Week 48 Subgroup Analyses From the Phase 3 DIAMOND Trial - (10/7/19)
     
  3921. IDWeek 2019: The Effect of Initiating INSTI-based vs. NNRTI-based Antiretroviral Therapy on Progression to Diabetes among North American Persons in HIV Care - (10/7/19)
     
  3922. IDWeek 2019: Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate in Hispanic/Latinx and Black Participants: Efficacy, Bone and Renal Safety Results From a Pooled Analysis of 7 Clinical Trials - (10/7/19)
     
  3923. IDWeek 2019: Bone Safety Outcomes With F/TAF vs F/TDF for PrEP in the DISCOVER Trial - (10/7/19)
     
  3924. IDWeek 2019: Switching From TDF to TAF Tied to Higher BMI and Cardio Risk - Mark Mascolini (10/7/19)
     
  3925. IDWeek 2019: Online US/Canada Survey Finds Preference for Long-Acting Injectable ART - Mark Mascolini (10/4/19)
     
  3926. IDWeek 2019: Community Clinics Control HIV as Well as Hospital Clinic in Chicago MSM - Mark Mascolini (10/4/19)
     
  3927. IDWeek 2019: Possible Higher Diabetes Risk With INSTIs or PIs Than NNRTIs - Mark Mascolini (10/4/19)
     
  3928. IDWeek 2019: AIDS Mortality Does Not Differ by Race in US Group--But "Room for Improvement" - Mark Mascolini (10/4/19)
     
  3929. IDWeek 2019: MSM Grindr Users Take More Sex Risks But Seem More Open to PrEP - Mark Mascolini (10/4/19)
     
  3930. IDWeek 2019: Over Half of Mostly Black US HIV Group Has NAFLD--and Many Have NASH - Mark Mascolini (10/4/19)
     
  3931. IDWeek 2019: High HIV Control Rate With Rapid D/C/F/TAF in Newly Diagnosed - Mark Mascolini (10/4/19)
     
  3932. IDWeek 2019: HIV Suppression and Safety With Ibalizumab at 48 Weeks in Expanded Access - Mark Mascolini (10/4/19)
     
  3933. IDWeek 2019: Women With HIV and Prolonged Amenorrhea Run Higher Risk of Hip Bone Loss - Mark Mascolini (10/4/19)
     
  3934. IDWeek 2019: Lower Statin Prescription Rate for Blacks, Hispanics With HIV in US Military - Mark Mascolini (10/4/19)
     
  3935. IDWeek 2019: Syphilis, Gonorrhea Tied to HCV in MSM and Trans Women With HIV - Mark Mascolini (10/4/19)
     
  3936. IDWeek 2019: Higher Steatosis Risk in HIV+ Hispanics, But No Link to Integrase Inhibitors - Mark Mascolini (10/4/19)
     
  3937. IDWeek 2019: Lower Screening Rates for Breast and Cervical Cancer in Women With HIV - Mark Mascolini (10/4/19)
     
  3938. IDWeek 2019: High HIV Control Rate With Rapid D/C/F/TAF in Newly Diagnosed - Mark Mascolini (10/4/19)
     
  3939. IDWeek 2019: IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV - (10/03/19)
     
  3940. IDWeek 2019: IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV - (10/03/19)
     
  3941. Ageing with and without HIV: will advanced age bring equity or greater disparity? Perspective by Amy Justice - (10/03/19)
     
  3942. Reversal of epigenetic aging and immunosenescent trends in humans - (09/25/19)
     
  3943. HIV and Aging - Primary and secondary prevention of coronary artery disease among People living with HIV - HIV+ higher death risk after stroke or MI - (09/25/19)
     
  3944. Coronary atherosclerosis characteristics in HIV-infected patients on long-term antiretroviral therapy insights from coronary computed tomography-angiography - (09/24/19)
     
  3945. Excess heart age in adult outpatients in routine HIV care (HOPS) - excess heart age by 10-13 Years in HIV+ - (09/24/19)
     
  3946. Merck's PIFELTRO (doravirine) and DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate) Receive US FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically Suppressed - (09/23/19)
     
  3947. Aging with HIV in the US / Proposed Research Implementation Study: clinical & community care & services needs, unmet needs - Jules Levin (09/23/19)
     
  3948. Two Thirds Higher Risk of Death After MI or Stroke With HIV in Sweden - Mark Mascolini (09/19/19)
     
  3949. New Analysis Challenges FRAX Use to Predict Osteoporosis in 40-to-49 HIV Group - Mark Mascolini (09/19/19)
     
  3950. Rates and Drivers of Quality of Life With HIV Differ in Netherlands and UK - Mark Mascolini (09/19/19)
     
  3951. Quality of Life in HIV+ in US & Globally: most unhappy - (09/13/19)
     
  3952. NEF, HIV Protein Causes CVD, Metabolic Abnormalities, Brain Disease - found in Reservoir - (09/13/19)
     
  3953. Inflammation in HIV+ Causes Mood Emotions Changes & Alters Social Interaction - (09/09/19)
     
  3954. Doxycycline prophylaxis for bacterial sexually transmitted infections - Review - (09/09/19)
     
  3955. Stigma and mental health challenges remain barriers to good quality of life for people living with HIV in urban settings - (09/09/19)
     
  3956. Mental health and HIV/AIDS the need for an integrated response. Depression Doubles Mortality in WIHS Women - (09/09/19)
     
  3957. Impact of inclisiran on LDL-C over 18 months in patients with ASCVD or risk-equivalent - Results of the Phase 3 ORION-11 trial - (09/09/19)
     
  3958. siRNA drug safely halved LDL cholesterol in phase 3 ORION-11 - (09/09/19)
     
  3959. (Phase 2 ) Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol (single dosing) - (09/09/19)
     
  3960. Treating Disease at the RNA Level with Oligonucleotides (siRNA) - Review - (09/09/19)
     
  3961. In People Living with HIV (PLWH), Menopause (natural or surgical) Contributes to the Greater Symptom Burden in Women: results from an online US survey - (09/06/19)
     
  3962. 9th Annual International Workshop on HIV & Aging 2018 Summary / Review
    Current Challenges and Solutions in Research and Clinical Care of Older Persons Living with HIV: Findings Presented at the 9th International Workshop on HIV and Aging     - (09/06/19)
     
  3963. Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV - (09/05/19)
     
  3964. Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV - (09/05/19)
     
  3965. ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months - (09/05/19)
     
  3966. Cannabis Anti-Inflammatory/Reservoir Reduction(Cure)? - (09/05/19)
     
  3967. New ways of developing treatment of chronic inflammation - (09/04/19)
     
  3968. People Living With HIV in New York City Still Dying From Infections, Not Just Old Age - (09/04/19)
     
  3969. What is Frailty ? Burden of frailty in the elderly population: perspectives for a public health challenge - (09/04/19)
     
  3970. HIV+ 70-74 Have Same # of Comorbidities as HIV-Neg >85, Similarly for polypharmacy. Medicare study Non-HIV Comorbid Conditions and Polypharmacy Among People Living with HIV Age 65 or Older Compared with HIV-Negative Individuals Age 65 or Older in the United States: A Retrospective Claims-Based Analysis - (09/04/19)
     
  3971. HIV in Atlanta/Georgia-Aging - (09/04/19)
     
  3972. 75-85% in SF-NY-Florida-Boston with HIV Are Over 40 Years Old....25% over 60 in SF-Florida-NY - (09/04/19)
     
  3973. Cardiovascular risk of smoking may last up to 25 years, new study - (09/04/19)
     
  3974. Neurpoathy Predictors in HIV in CHARTER Group - (09/04/19)
     
  3975. IAS: Hormonal control of HIV-1 latency by estrogen imparts gender-specific restrictions on the latent reservoir - (09/03/19)
     
  3976. IAS: Symptom Burden and Inflammatory Cytokines in PLWH in the US: an analysis by sex, menopause stage and menstrual cycle phase - (09/03/19)
     
  3977. IAS: Smoking and High HIV Viremia Damage Mitochondrial DNA and May Accelerate mtDNA Aging - (09/03/19)
     
  3978. IAS: 10th International AIDS Society Conference on HIV Science - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA (09/03/19)
     
  3979. IAS: TDF/FTC Pre-Exposure Prophylaxis (PrEP) from 2012 to 2018 in the OPERA Cohort - (08/16/19)
     
  3980. IAS: Cost-effectiveness of Dolutegravir in HIV-1 Treatment-Naive Patients in Mexico - (08/16/19)
     
  3981. IAS: Changing Rates of Heavily Treatment Experienced Persons with HIV in the United States, 2000-2017 - (08/16/19)
     
  3982. IAS: Is DTG+3TC and DTG+RPV Effective and Safe in Clinical Practice? Evidence From Real World Data - (08/16/19)
     
  3983. IAS: High HIV incidence among young women in South Africa: data from the ECHO trial - (08/14/19)
     
  3984. A Novel Therapeutic (NTRX-07) Targeting Neuroinflammation in Alzheimer's disease is Undergoing Phase I trials - (08/14/19)
     
  3985. Dementia/Sleep Aids-Drugs/Women HIV+ More Vulnerable - "Sleep aids and dementia: Studies find both risks and benefits" - (08/14/19)
     
  3986. Increased Risk of Subjective Cognitive Decline in the LGBT Community - (08/14/19)
     
  3987. 18-Month Results (Open Label Extension) of a Phase 2/3 Trial of Inhaled Insulin in People With MCI or Mild Alzheimer's - (08/14/19)
     
  3988. IAS: Shorter CD38 T Cell Subset Telomeres and Lower Proliferative:Senescent CD38 Ratio in People with Chronic/Latent Viral Coinfections - (08/13/19)
     
  3989. IAS: PrEP use in young African women in HPTN 082: Effect of drug level feedback - (08/13/19)
     
  3990. IAS: HIV Prevention at IAS 2019 10th IAS Conference on HIV Science, Mexico City, Mexico 21-24 July 2019 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington (08/12/19)
     
  3991. HIV Prevention Trials Network (HPTN) Announces Initiation of HPTN 084: First Large-Scale Study in Women of a Long-Acting Injectable to Prevent HIV - (08/09/19)
     
  3992. HIV Prevention Trials Network Launches HPTN 083 - (08/09/19)
     
  3993. Gilead $17 Million RFP & ViiV Aging Projects - (08/09/19)
     
  3994. FDA Hearing Ongoing Wed Aug 7 2019 on Descovy for PrEP Vote - (08/08/19)
     
  3995. IAS: Substance Use--Especially Meth--Tied to Depression in Young HIV+/HIV- MSM - Mark Mascolini (08/06/19)
     
  3996. What Aging With HIV Means in the Year 2019 - (08/06/19)
     
  3997. IAS: "Dual epidemics: the impact of HIV and obesity on pregnancy outcomes among women in South Africa"
    'The impact of HIV and obesity on pregnancy outcomes among women in South Africa'
    Obesity in 36% of Pregnant HIV+ South African Women--But No Impact on Outcomes     - (08/05/19)
     
  3998. IAS: Adverse pregnancy outcomes among HIV-positive women in the era of universal antiretroviral therapy (ART) remain elevated compared with HIV-negative women in Lesotho - (08/05/19)
     
  3999. IAS: Higher Immune Activation With Methadone Than Naltrexone in Opioid Users With HIV - Mark Mascolini (08/05/19)
     
  4000. IAS: Inflammatory Marker and Immune Upsets After Single Forced Vaginal Penetration - Mark Mascolini (08/05/19)
     
  4001. IAS: DMPA May Have STI Advantage Over Copper IUD and Levonorgestrel Implant - Mark Mascolini (08/05/19)
     
  4002. IAS: Comorbidities Canadians: >70 HIGH Rates - (08/05/19)
     
  4003. IAS: Perspectives from the Front Lines: Encouraging Community Engagement in the Performance of Research at the Intersection of HIV and Aging - (08/05/19)
     
  4004. High CNS Penetration Increased HIV Dementia - (08/02/19)
     
  4005. CROI: CEREBRAL FUNCTION PARAMETERS IN PEOPLE LIVING WITH HIV SWITCHING INTEGRASE INHIBITOR - (08/02/19)
     
  4006. IAS: A SWITCH TO DOLUTEGRAVIR IN COMBINATION WITH BOOSTED DARUNAVIR IS SAFE AND EFFECTIVE IN SUPPRESSED PATIENTS WITH HIV - A SUBANALYSIS OF THE DUALIS STUDY - (08/02/19)
     
  4007. IAS: Five Times Higher Risk of ART Nonadherence on Days of Heavy Drinking - Mark Mascolini (08/02/19)
     
  4008. IAS: Dolutegravir use at conception: Additional surveillance data from Botswana (smaller signal) - (08/02/19)
     
  4009. IAS: No occurrences of neural tube defects among 382 women on Dolutegravir at pregnancy conception in Brazil - (08/02/19)
     
  4010. IAS: Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana - (08/02/19)
     
  4011. Treatment Adherence and Virologic Response Over 48 Weeks Among Patients Rapidly Initiating Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in the DIAMOND Study - (08/02/19)
     
  4012. IAS: A SWITCH TO DOLUTEGRAVIR IN COMBINATION WITH BOOSTED DARUNAVIR IS SAFE AND EFFECTIVE IN SUPPRESSED PATIENTS WITH HIV - A SUBANALYSIS OF THE DUALIS STUDY - (08/01/19)
     
  4013. IAS: HCV Reinfection Rate in People With HCV/HIV 13% Across Europe - Mark Mascolini - (08/01/19)
     
  4014. IAS: Inconsistent Testing in HIV+ for Top Liver Cancer Risk Factors: HBV, HCV, Alcohol - Mark Mascolini (08/01/19)
     
  4015. IAS: Biomarkers Good at Predicting NAFLD or Excluding Advanced Fibrosis With HIV (FibroScan, CAP Score) - Mark Mascolini (08/01/19)
     
  4016. IAS: Virologic Failure In ART-Naive HIV Patients With High Pre-Therapy Viral Load Burden Initiating On Common Core Agents - (08/01/19)
     
  4017. IAS: Biomarkers Good at Predicting NAFLD or Excluding Advanced Fibrosis With HIV (FibroScan, CAP Score) - Mark Mascolini (07/31/19)
     
  4018. IAS: Collaborative Care Improves HIV Provider Confidence in Managing Chronic Opioid Therapy - Mark Mascolini (07/31/19)
     
  4019. IAS: Preventive HIV vaccine Enters Phase 3 Global Study - (07/30/19)
     
  4020. IAS: More Acute HIV Diagnoses, Shorter Time to Undetectable HIV, in Amsterdam MSM Program - Mark Mascolini (07/30/19)
     
  4021. IAS: Substance Use--Especially Meth--Tied to Depression in Young HIV+/HIV- MSM - Mark Mascolini (07/30/19)
     
  4022. IAS: HIV Control Rate Lower in Women Than Men in Inner-City Vancouver - Mark Mascolini (07/30/19)
     
  4023. IAS: Meta-Analysis Confirms Aerobic Exercise Benefit on Depression With HIV - Mark Mascolini (07/30/19)
     
  4024. IAS: Week 96 Resistance and Adherence Analyses of the Once-daily, Single-tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in the AMBER and EMERALD Phase III Trials - (07/30/19)
     
  4025. IAS: Change in Kidney Function After TDF-to-TAF Switch: Who Benefits Most? - Mark Mascolini (07/30/19)
     
  4026. IAS: In Vitro Resistance Profile of GS-6207, a First-in-Class Picomolar HIV Capsid Inhibitor in Clinical Development as a Novel Long-Acting Antiretroviral Agent - (07/30/19)
     
  4027. IAS: Johnson & Johnson Announces New Clinical Data on Mosaic-based HIV Preventive Vaccine Regimen - (07/30/19)
     
  4028. IAS: Johnson & Johnson Announces New Public-Private Partnership to Support First Phase 3 Efficacy Study of Janssen's Investigational Prophylactic HIV Vaccine - (07/30/19)
     
  4029. IAS: Long-Acting MK-8591 at IAS 2019, , New ART for Treatment, PrEP - (07/30/19)
     
  4030. IAS: Prevalence and Outcomes for Heavily Treatment-Experienced (HTE) Individuals Living with HIV in a European Cohort EuroSIDA - (07/28/19)
     
  4031. IAS: WHO recommends dolutegravir as preferred HIV treatment option in all populations - (07/28/19)
     
  4032. IAS: HPTN 078: Primary results of a randomized study to engage men who have sex with men (MSM) living with HIV who are virally unsuppressed in the USA - (07/28/19)
     
  4033. IAS: ViiV Healthcare submits regulatory application to European Medicines Agency for investigational cabotegravir to be used in combination with rilpivirine as the first monthly, injectable treatment for HIV - (07/28/19)
     
  4034. IAS: Efficacy of on-demand PrEP or PEP with single oral doses of combination tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat in macaques - (07/28/19)
     
  4035. IAS: Polypharmacy in Nearly All of 65+ HIV Group Tied to Inappropriate Prescribing - (07/28/19)
     
  4036. IAS: Loneliness Among Older People (44%) Living with HIV: Why the ''Older Old'' are Less Lonely Than the ''Younger Old'' (53%) - (07/28/19)
     
  4037. IAS: "There's no retirement plans for us": Re-analysis from a qualitative study of HIV-positive MSM who use substances - (07/27/19)
     
  4038. IAS: The ADVANCE trial: Phase 3, randomized comparison of TAF/FTC/DTG, TDF/FTC/DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection - (07/27/19)
     
  4039. IAS: Dolutegravir (DTG) Plus Lamivudine (3TC) Versus DTG Plus Tenofovir/Emtricitabine (TDF/FTC) Fixed-Dose Combination in the GEMINI Studies -Viral Load Rebound Including 'Blips' Through 48 Weeks - (07/27/19)
     
  4040. IAS: ARTS 4 Days A Week Instead of 7, not good, Jules. - "ANRS 170 QUATUOR 4/7 days maintenance strategy in antiretroviral treated adults with HIV-1 infection: an open randomised parallel non-inferiority phase III trial" - (07/27/19)
     
  4041. IAS: Twice-Daily 400-mg Raltegravir Not Noninferior to Efavirenz for HIV With TB - "Virologic efficacy of raltegravir vs. efavirenz-based antiretroviral treatment in HIV1-infected adults with tuberculosis: W48 results of the ANRS 12300 REFLATE TB2 trial" - (07/27/19)
     
  4042. IAS: Twice-Daily 400-mg Raltegravir Not Noninferior to Efavirenz for HIV With TB - "Virologic efficacy of raltegravir vs. efavirenz-based antiretroviral treatment in HIV1-infected adults with tuberculosis: W48 results of the ANRS 12300 REFLATE TB2 trial" - (07/27/19)
     
  4043. IAS: Rosuvastatin Does Not Slow Atherosclerosis in HIV+ With Moderate Risk - (07/27/19)
     
  4044. IAS: SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN IN MAINTAINING VIROLOGIC SUPPRESSION THROUGH 48 WEEKS (TANGO STUDY) - (07/26/19)
     
  4045. IAS: Out-of-Care HIV+ US MSM Will Resume Treatment, But Only Half Control HIV in 12 Months - Mark Mascolini - (07/26/19)
     
  4046. IAS: A Pooled Analysis of the Effect of Adherence on the Renal Safety of FTC/TDF (Truvada) for Prep: 7 International Demonstration Projects - (07/26/19)
     
  4047. IAS: ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance - PRESS RELEASE - (07/26/19)
     
  4048. IAS: Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019 - (07/26/19)
     
  4049. IAS: ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection - PRESS RELEASE - (07/26/19)
     
  4050. IAS: Vesatolimod (GS-9620) Is Safe and Pharmacodynamically Active in HIV-Infected Individuals - (07/26/19)
     
  4051. IAS: ISLATRAVIR (ISL, MK-8591) at doses of 0.25 to 2.25 mg QD in combination with doravirine maintains viral suppression through 48 weeks in adults with HIV-1 infection - (07/26/19)
     
  4052. IAS: Gilead Announces Latest Data in Ongoing HIV Cure Research Program - (07/25/19)
     
  4053. IAS: Gilead Presents New Findings on Profile of Descovy for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada - (07/25/19)
     
  4054. IAS: Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV - (07/25/19)
     
  4055. IAS: Incidence of HIV-Infection with Daily or On Demand PrEP with TDF/FTC in the Paris Area: An Update of the Prevenir Study - (07/25/19)
     
  4056. IAS: Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV: ADVANCE and NAMSAL trials - (07/25/19)
     
  4057. IAS: Oral TLR7 Agonist Administration Induces an Immunostimulatory Response in SIV-Infected ART-Suppressed Infant Rhesus Macaques - (07/25/19)
     
  4058. IAS: Out-of-Care HIV+ US MSM Will Resume Treatment, But Only Half Control HIV in 12 Months - Mark Mascolini - (07/25/19)
     
  4059. IAS: Vision Impairment More Frequent in Older HIV+ Men--With Functional Consequences - Mark Mascolini - (07/25/19)
     
  4060. IAS: Lower HIV Rate With F/TAF Than F/TDF in Double-Blind Noninferiority Trial - Mark Mascolini - (07/25/19)
     
  4061. IAS: Neural Tube Defect Rate 0.40% With Dolutegravir in Pregnancy--But Data Still Slim - Mark Mascolini - (07/25/19)
     
  4062. IAS: High STI Prevalence in German MSM, But Low Rates of HIV, HCV, HBV - Mark Mascolini - (07/25/19)
     
  4063. IAS: About 10% With HIV in Europe Have Heavy Treatment Experience, Few Options - "Prevalence and outcomes for heavily treatment-experienced (HTE) individuals living with HIV in a European cohort" - Mark Mascolini - (07/25/19)
     
  4064. IAS: Almost No New HIV Infections in Paris Comparison of Daily vs As-Needed PrEP - Mark Mascolini - (07/25/19)
     
  4065. IAS: Higher GI Disorder Risk When Switching to RAL or DRV Versus DTG - Mark Mascolini - (07/25/19)
     
  4066. IAS: Young Men Driving Expanding HIV Epidemic in Latin America - Mark Mascolini - (07/25/19)
     
  4067. IAS: Better Predictive Power When Combining Traditional and HIV-Specific Cardio Risk Factors - "Impact of HIV specific and traditional risk factors on the incidence of cardiovascular events in HIV-positive males over time" - Mark Mascolini - (07/25/19)
     
  4068. IAS: Viral Suppression in 60% for 96 Weeks With Fostemsavir Salvage in BRIGHTE - Mark Mascolini - (07/25/19)
     
  4069. IAS: Week-96 Potency of Dolutegravir/3TC in GEMINI Trials of First-Line ART - "Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naive adults with HIV-1 infection--96-week results from the GEMINI studies" - Mark Mascolini - (07/25/19)
     
  4070. IAS: Sharp Drops in HIV Load After 10 Days of Capsid Inhibitor Monotherapy - Mark Mascolini - (07/25/19)
     
  4071. IAS: Simulated Driving Worse in Pro Drivers With Than Without HIV - "Cognitive functioning and driving ability in HIV-infected professional drivers" - Mark Mascolini - (07/25/19)
     
  4072. IAS: HIV Infection Rate Jumps 7.5-fold When US PrEP Users Stop - Mark Mascolini - (07/25/19)
     
  4073. IAS: Differential Detection of M184V/I Between Plasma Historical HIV Genotypes and Proviral DNA from PBMCs - (07/25/19)
     
  4074. IAS: Switching to a Single-tablet Regimen of Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) from Dolutegravir plus Either F/TAF or F/TDF - (07/25/19)
     
  4075. IAS: A Subgroup Analysis of the Week 96 Efficacy and Safety Results Evaluating Fostemsavir in Heavily Treatment-Experienced HIV-1 Infected Participants in the Phase 3 BRIGHTE Study: Results From The Randomized Cohort - (07/25/19)
     
  4076. IAS: First-in-Human Trial of MK-8591-Eluting Implants Demonstrates Concentrations Suitable for HIV Prophylaxis for at Least One Year - (07/25/19)
     
  4077. IAS: Keeping the Pressure on Archived NRTI Resistance: Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Triple Therapy in Study 4030 - (07/25/19)
     
  4078. IAS: Week 96 safety and efficacy of the novel HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants infected with multi-drug-resistant HIV-1 (BRIGHTE Study) - (07/25/19)
     
  4079. IAS: Previously Undocumented Pre-existing Resistance and Maintenance of Virologic Suppression in HIV-1 RNA-Suppressed Patients Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) - (07/25/19)
     
  4080. IAS: Tolerability, Safety, and Efficacy of Islatravir (MK-8591) at Doses of 0.25 to 2.25 mg QD, in Combination With Doravirine and Lamivudine Through 24 Weeks in Treatment-Naïve AdultsWith HIV-1 Infection - (07/25/19)
     
  4081. IAS: Longer-term (96-week) Efficacy and Safety of Switching to Bictegravir, Emtricitabine and Tenofovir Alafenamide (B/F/TAF) in Women - (07/25/19)
     
  4082. IAS: Utilization of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) for HIV Pre-Exposure Prophylaxis (PrEP) in the United States by Age, Gender and Race/Ethnicity (2014 - 2017) - (07/25/19)
     
  4083. IAS: Long-Acting Cabotegravir and Rilpivirine is Noninferior to Oral ART as Maintenance Therapy for HIV-1 Infection: Week 48 Pooled Analysis From the Phase 3 ATLAS and FLAIR Studies - (07/25/19)
     
  4084. IAS: Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 48-Week Results - (07/25/19)
     
  4085. IAS: Patient Views on Long-Acting HIV Treatment: Cabotegravir + Rilpivirine as Maintenance Therapy (ATLAS 48-Week Results) - (07/25/19)
     
  4086. IAS: DISCOVER STUDY for HIV Pre-Exposure Prophylaxis: F/TAF has a more Rapid Onset and Longer Sustained Duration of HIV Protection Compared with F/TDF - (07/25/19)
     
  4087. IAS: Forgiveness of Antiretroviral Regimens: In Vitro HIV-1 Viral Breakthrough with 2-Drug versus 3-Drug Regimens Simulating Variable Adherence to Treatment - (07/23/19)
     
  4088. IAS: Viral Suppression in 60% for 96 Weeks With Fostemsavir Salvage in BRIGHTE - Mark Mascolini - (07/23/19)
     
  4089. IAS: ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV - (07/23/19)
     
  4090. IAS: Gilead Presents New Data on Biktarvy for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance - (07/23/19)
     
  4091. IAS: Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV - (07/23/19)
     
  4092. Scales Tip Toward 'Fish Oil' PUFA Intake for Heart Failure Prevention Predicting Risk for Incident Heart Failure With Omega-3 Fatty Acids From MESA - 1 - (07/17/19)
     
  4093. Elderly HIV+ Physiologic Changes, Polypharmacy, Prescribing Issues - (07/17/19)
     
  4094. IAS: Gilead to Present New Data on HIV Prevention, Treatment and Cure Research at IAS 2019 - (07/18/19)
     
  4095. Elderly HIV+ Physiologic Changes, Polypharmacy, Prescribing Issues Prescribing issues in elderly individuals living with HIV REVIEW - (07/17/19)
     
  4096. 2-3 Times Greater MI & Heart Failure Risk in HIV+ / "rates of CVD hospitalization were double in HIV infected" - "HIV Infection and Incidence of Cardiovascular Diseases: An Analysis of a Large Healthcare Database" - (07/16/19)
     
  4097. Persistent HIV in central nervous system linked to cognitive impairment - (07/16/19)
     
  4098. IAS: IAS 2019: ViiV Healthcare showcasing innovation in HIV science - PRESS RELEASE - (07/16/19)
     
  4099. ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen - (07/11/19)
     
  4100. ViiV Healthcare begins study on implementation of once-monthly injectable HIV treatment - (07/10/19)
     
  4101. 2 News Reports on this story - Researchers have eliminated HIV in mice for the first time. Is a cure for humans next? - (07/10/19)
     
  4102. Acceptability and Preferences for Long-Acting Antiretroviral Formulations Among People Living with HIV infection - (07/10/19)
     
  4103. Merck Highlights Commitment to HIV Research with Presentations for Investigational Anti-HIV Agent MK-8591 at IAS 2019 - (07/10/19)
     
  4104. 20th Intnl Wrkshp Clin Pharm: Tenofovir-diphosphate in PBMC following increasing TAF vs. TDF dosing under directly observed therapy - (07/10/19)
     
  4105. CROI: TOCILIZUMAB (monoclonal antibody) ALTERS LIPIDS IN HIV+ INDIVIDUALS IN A RANDOMIZED, DOUBLE-BLIND STUDY - (07/10/19)
     
  4106. Calcium Supplements May Damage the Heart - (07/09/19)
     
  4107. Most dietary supplements do not protect against heart attack and stroke - (07/09/19)
     
  4108. Effects of Nutritional Supplements and Dietary Interventions on Cardiovascular Outcomes: An Umbrella Review and Evidence Map - (07/09/19)
     
  4109. Dispense With Supplements for Improving Heart Outcomes - Editorials - (07/09/19)
     
  4110. HIV eliminated from the genomes of living animals - "Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice" - (07/09/19)
     
  4111. Aging/HIV & Senescence; NASH - (07/08/19)
     
  4112. Doubling of Rates of HIV in Nursing Homes - Nursing Home Residents by Human Immunodeficiency Virus Status: Characteristics, Dementia Diagnoses, and Antipsychotic Use - (07/08/19)
     
  4113. Fast Forward to Viral Suppression: Immediate Initiation of ARVs Following Reactive HIV+ Test Result or Engagement in HIV Care for the First Time at a Community Health Center in Washington, DC - (07/08/19)
     
  4114. Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection - (07/02/19)
     
  4115. Women - greater weight gain than men associated with integrase inhibitors - all future ART studies should include looks at weight gain. - (07/02/19)
     
  4116. CROI: Cardiovascular Update from CROI 2019 - by Priscilla Hsue MD Professor of Medicine, UCSF (07/01/19)
     
  4117. Increased Prevalence of Hepatic Steatosis in Young Adults With Lifelong HIV...33% hepatic steatosis >/= grade 1 vs 10% controls - > grade 2 28% vs 5% controls - belly, metabolics - (06/28/19)
     
  4118. 20th Intnl Wrkshp Clin Pharm: The 20th International Workshop on Clinical Pharmacology of Antiviral Therapy - Courtney V. Fletcher, Pharm.D. Professor and Director, Antiviral Pharmacology Laboratory UNMC Center for Drug Discovery University of Nebraska Medical Center - (05/26/19)
     
  4119. Effect of HIV infection and antiretroviral therapy on immune cellular functions - integrase, mitochondria - (06/25/19)
     
  4120. When to use CT Angiography - Diagnosis of obstructive coronary artery disease using computed tomography angiography in patients with stable chest pain depending on clinical probability and in clinically important subgroups: meta-analysis of individual patient data - (06/25/19)
     
  4121. Kidney Disease "Risk Factor for CVD" - (06/19/19)
     
  4122. Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base - (06/18/19)
     
  4123. Activation and Senescence Markers in HIV Patients with Chronic Kidney Disease - (06/17/19)
     
  4124. NEW DATA RELEASED BY THERATECHNOLOGIES DEMONSTRATE POSITIVE IMPACT OF TESAMORELIN IN PATIENTS WITH LIVER FIBROSIS - (06/17/19)
     
  4125. Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity - (06/14/19)
     
  4126. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in HIV-Infected Adults - (06/14/19)
     
  4127. Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation A Randomized Clinical Trial - (06/14/19)
     
  4128. Cancer Risk in Older Persons Living With Human Immunodeficiency Virus Infection in the United States - (06/14/19)
     
  4129. Aging Grant - NIH Grant Funds $23 Million Study of Diseases Affecting People Living with HIV - (06/12/19)
     
  4130. PrEP Recommended - "Preexposure Prophylaxis for the Prevention of HIV Infection - US Preventive Services Task Force Recommendation Statement" - (06/12/19)
     
  4131. New USPSTF Guidelines for HIV Screening and Preexposure Prophylaxis (PrEP)Straight A's - Editorial - (06/12/19)
     
  4132. HIV Screening Recommended - Screening for HIV Infection - US Preventive Services Task Force Recommendation Statement - (06/12/19)
     
  4133. Preexposure Prophylaxis for the Prevention of HIV Infection Evidence Report and Systematic Review for the US Preventive Services Task Force - (06/12/19)
     
  4134. The Changing Face of HIV-Associated Malignancies: Advances, Opportunities, and Future Directions / Treatment Access Denied to HIV+ - (06/10/19)
     
  4135. HIV/Safe PD-1 Cancer Treatment / Studies Should Include HIV+ - (06/10/19)
     
  4136. New PrEP Long-Acting MK-8591, for HIV Treatment Too - (06/10/19)
     
  4137. Excess Vitamin D Linked to Kidney Damage - (06/10/19)
     
  4138. Interferon Stops Parkinson Disease: Association of Antiviral Therapy With Risk of Parkinson Disease in Patients With Chronic Hepatitis C Virus Infection - (06/07/19)
     
  4139. Short-term outcomes for lung cancer resection surgery in HIV infection - (06/05/19)
     
  4140. Cardiac ageing: extrinsic and intrinsic factors in cellular renewal and senescence - (06/05/19)
     
  4141. ACTG Long-Acting (LA) ART (Rilpivirine/Cabotegravir to Standard of Care (SOC) in persons living with HIV (PLWH) who have had barriers for adherence / LATITUDE Study Health Care Provider Fact Sheet - (06/05/19)
     
  4142. CROI: Lower bone strength by peripheral quantitative CT (pQCT) in children living with HIV - (06/05/19)
     
  4143. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association - (06/05/19)
     
  4144. Congestive Heart Failure and Chronic Kidney Disease The CardioRenal/NephroCardiology Connection - EDITORIAL COMMENT - (06/05/19)
     
  4145. Heart Disease Risk Factors in HIV+ This study just published: "Factors Associated With Excess Myocardial Infarction Risk in HIV-Infected Adults" But there are key crucial points NOT covered in this meta-analysis study...... - (06/05/19)
     
  4146. Arterial Stiffness in the Heart Disease of CKD - Kidney/Cardio Connection - (06/05/19)
     
  4147. Metabolic Bone Disease in Chronic Kidney Disease - Kidney-Bone-Cardio Connection - (06/03/19)
     
  4148. Impact of HIV/simian immunodeficiency virus infection and viral proteins on adipose tissue fibrosis and adipogenesis - (06/03/19)
     
  4149. Intranasal Insulin for Cognition / New study in HIV+ - (06/03/19)
     
  4150. Energy Drinks: Another Cause of QT Prolongation? - (06/03/19)
     
  4151. CROI: HIV Infection and the Risk of Fracture among Fallers - (06/03/19)
     
  4152. CROI: Senescence & Exhaustion of T Cell Memory Subsets Increased in Aging Persons with HIV - (06/03/19)
     
  4153. CROI: Mood Disorders & Increased Risk of Non-communicable Diseases in Adults Aging with HIV.....more HIV+ females had mood disorders 27% vs 22% - (05/31/19)
     
  4154. CROI: Bone, Frailty, and Aging at CROI 2019 - Todd Brown, MD, PhD Division of Endocrinology, Diabetes, & Metabolism Johns Hopkins University - (05/31/19)
     
  4155. Ageing with HIV: Emerging importance of chronic comorbidities in patients over 75: 2-3 times the numbers of Comorbidities vs 50-74 - (05/28/19)
     
  4156. Ageing with HIV: Emerging importance of chronic comorbidities in patients over 75: 2-3 times the numbers of Comorbidities vs 50-74 - (05/28/19)
     
  4157. Type 2 diabetes prevalence [doubled] and its risk factors in HIV: A cross-sectional study - (05/28/19)
     
  4158. "The absurdly high cost of insulin" - as high as $350 a bottle, often 2 bottles per month needed by diabetics - (05/28/19)
     
  4159. Diabetes Risk 39% Higher: BMI, Obesity, Old PIs and NRTIs Associated; Insulin Cost Tripled; Competition Limited - (05/28/19)
     
  4160. 20th Intnl Wrkshp Clin Pharm: Utilization of physiologically based pharmacokinetic modelling (PBPK) to predict the effect of UGT enzyme inhibition and induction on the systemic exposure of Cabotegravir - (05/26/19)
     
  4161. Clinical significance of elevated liver transaminases in HIV-infected patients: clinicians practicing HIV care should promptly approach the finding of elevated liver transaminases for its diagnostic and prognostic implications. - (05/24/19)
     
  4162. Ageing with HIV: Emerging importance of chronic comorbidities in patients over 75 - (05/24/19)
     
  4163. Chronic kidney disease is associated with < low BMD at the hip but not at the spine - (05/24/19)
     
  4164. Long-Acting Once A Month Injection of Cabotegravi/rilpivirine in PLWH with History of Sub-Optimal Adherence Enrolling - (05/24/19)
     
  4165. Positive Action Southern Initiative Funding Announcement: Grants for Direct Linkage & Adherence Services in AR, FL, KY, NC, SC, TN, TX, VA - (05/24/19)
     
  4166. 20th Intnl Wrkshp Clin Pharm: Short-term intravenous proton pump inhibitors and histamine H2 antagonists do not negatively affect sustained virologic response in hepatitis C cirrhotic patients treated with ledipasvir or velpatasvir containing antiviral regimens: a case series (05/23/19)
     
  4167. 20th Intnl Wrkshp Clin Pharm: PLASMA AND INTRACELLULAR PHARMACOKINETICS OF COBICISTAT IN THE CLINICAL SETTING (05/23/19)
     
  4168. SWITCHING FROM ATAZANAVIR/RITONAVIR (ATV/RTV) TO ATV/COBICISTAT (COBI) IS ASSOCIATED WITH DECREASE OF PLASMA LIPIDS AND LIVER FIBROSIS - (05/21/19)
     
  4169. Beneficial associations of low and large doses of leisure time physical activity with all-cause, cardiovascular disease and cancer mortality: a national cohort study of 88,140 US adults - (05/21/19)
     
  4170. Recommendations [listed just below] for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting - (05/21/19)
     
  4171. 20th Intnl Wrkshp Clin Pharm: DRUGS ABUSE AND CHEMSEX: A NEW CHALLENGE FOR ANTIRETROVIRAL DRUG-DRUG INTERACTION - (05/20/19)
     
  4172. 20th Intnl Wrkshp Clin Pharm: An exploration of adherence measures to detect recent changes in Truvada® dosing patterns - (05/20/19)
     
  4173. 20th Intnl Wrkshp Clin Pharm: Population Pharmacokinetics of VRC01 in Infants and Adults - (05/20/19)
     
  4174. 20th Intnl Wrkshp Clin Pharm: Pharmacokinetics of Tenofovir Alafenamide 25mg with PK Boosters During Pregnancy & Postpartum - (05/20/19)
     
  4175. 20th Intnl Wrkshp Clin Pharm: Sofosbuvir and 007 Pharmacokinetics Among Persons with HCV and Active Drug Use - (05/20/19)
     
  4176. 20th Intnl Wrkshp Clin Pharm: Comparison of Relative Bioavailability of Pediatric Triumeq and Pediatric Dolutegravir/Lamivudine Dispersible Tablets to Conventional Film Coated Tablets in Healthy Adults - (05/20/19)
     
  4177. 20th Intnl Wrkshp Clin Pharm: Predose concentrations of DTG and RPV steady through 100 weeks in SWORD trials - "Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Characterization of the Two-drug Anti-Retroviral Regimen (2DR) Dolutegravir/Rilpivirine Following Switch From Current Anti-Retroviral Therapy in the SWORD-1 and SWORD-2 Phase 3 Studies" - Mark Mascolini (05/20/19)
     
  4178. 20th Intnl Wrkshp Clin Pharm: The Initial Phase I Evaluation of the Safety, Tolerability, and Pharmacokinetics of GSK3640254, a Next-Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects - (05/20/19)
     
  4179. 20th Intnl Wrkshp Clin Pharm: PHARMACOKINETICS OF ATAZANAVIR BOOSTED WITH COBICISTAT DURING PREGNANCY AND POSTPARTUM - (05/20/19)
     
  4180. 20th Intnl Wrkshp Clin Pharm: Two thirds of Montreal in-hospital HCV group have interactions with DAAs - Mark Mascolini (05/20/19)
     
  4181. 20th Intnl Wrkshp Clin Pharm: Proportion of serious drug interactions dropping on Liverpool antiretroviral website - Mark Mascolini (05/20/19)
     
  4182. 20th Intnl Wrkshp Clin Pharm: Lower cobicistat and atazanavir troughs in smokers with HIV - Mark Mascolini (05/20/19)
     
  4183. 20th Intnl Wrkshp Clin Pharm: Reported dolutegravir-valproic acid interaction probably not clinically relevant - Mark Mascolini (05/20/19)
     
  4184. 20th Intnl Wrkshp Clin Pharm: Model suggests physiologic changes with aging underlie ritonavir PK shifts - Mark Mascolini (05/20/19)
     
  4185. 20th Intnl Wrkshp Clin Pharm: Other than dolutegravir, no antiretroviral interactions with valproic acid in 134 people - Mark Mascolini (05/16/19)
     
  4186. Gilead Donating 2.4 Million Bottles of Truvada to CDC for PrEP - (05/17/19)
     
  4187. Osteoarthritis in HIV May Be Accelerated - new study - (05/17/19)
     
  4188. Mediterranean/Low Carb Diet Superior in Reducing Hepatic Fat for Fatty Liver/NAFLD & Non-NAFLD too - (05/17/19)
     
  4189. 20th Intnl Wrkshp Clin Pharm: Physiologically based pharmacokinetic modelling to determine pharmacokinetic alterations driving ritonavir exposure changes in aging people living with HIV - (05/16/19)
     
  4190. 20th Intnl Wrkshp Clin Pharm: Management of antiretrovirals in Seniors - The importance of assisted treatment for adherence to treatment - (05/16/19)
     
  4191. 20th Intnl Wrkshp Clin Pharm: One third of French HIV group uses illicit drugs, often risking antiretroviral interactions - Mark Mascolini - (05/16/19)
     
  4192. 20th Intnl Wrkshp Clin Pharm: IV PPIs and H2 antagonists did not thwart response to ledipasvir or velpatasvir - Mark Mascolini - (05/16/19)
     
  4193. 20th Intnl Wrkshp Clin Pharm: Two thirds of Montreal in-hospital HCV group have interactions with DAAs - Mark Mascolini - (05/16/19)
     
  4194. 20th Intnl Wrkshp Clin Pharm: Lower cobicistat and atazanavir troughs in smokers with HIV - Mark Mascolini - (05/16/19)
     
  4195. 20th Intnl Wrkshp Clin Pharm: Sofosbuvir exposure higher in opioid users, lower with darunavir - Mark Mascolini - (05/16/19)
     
  4196. 20th Intnl Wrkshp Clin Pharm: Predose concentrations of DTG and RPV steady through 100 weeks in SWORD trials - Mark Mascolini - (05/16/19)
     
  4197. 20th Intnl Wrkshp Clin Pharm: Phase 1 results show safety and once-daily potential of new HIV maturation inhibitor - Mark Mascolini - (05/16/19)
     
  4198. EASL: CANCER RISK AMONG PEOPLE WITH HIV, HBV AND/OR HCV INFECTIONS - (05/16/19)
     
  4199. Mediterranean/Low Carb Diet Superior in Reducing Hepatic Fat for Fatty Liver/NAFLD & Non-NAFLD too - (05/17/19)
     
  4200. MECHANISMS OF WHITE-MATTER LOSS DUE TO HIV INFECTION AND ANTIRETROVIRAL THERAPY - (05/13/19)
     
  4201. RELAPSE OF SYMPTOMATIC CSF HIV ESCAPE UPON PREVIOUSLY OPTIMIZED cART REGIMEN CHANGES / CNS Eradication Reservoir - (05/13/19)
     
  4202. EASL: Is it possible to successfully link migrants to HBV, HCV and HIV services upon arrival in the European Union? - (05/13/19)
     
  4203. Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication - (05/13/19)
     
  4204. NAFLD in lipodystrophy - (05/10/19)
     
  4205. Increasing Cognitive Aging in HIV+ WIHS Women Despite Viral Suppression, MACS Men - (05/10/19)
     
  4206. HIV+ Women & Aging: worse for women with HIV - (05/10/19)
     
  4207. NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens - (05/10/19)
     
  4208. Increasing Cognitive Aging in HIV+ WIHS Women Despite Viral Suppression, MACS Men - (05/09/19)
     
  4209. Increasing Cognitive Aging in HIV+ WIHS Women Despite Viral Suppression, MACS Men - (05/09/19)
     
  4210. HIV+ Women & Aging: worse for women with HIV - (05/09/19)
     
  4211. NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens - (05/09/19)
     
  4212. Bictegravir and dolutegravir: head to head at 96 weeks, Comment + study - (05/08/19)
     
  4213. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial - (05/08/19)
     
  4214. AdverseReactComor: MSM Associated with Lower CD4/CD38 Ratio - (05/01/19)
     
  4215. New HIV Cure Approach - Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1 - (05/01/19)
     
  4216. 35% of HIV+ Taking > 10 Comedications at Northwestern ID Clinic - (05/01/19)
     
  4217. 50% Polypharmacy Rates in HIV MACS >5 Comoedications / Prevalence and trends of polypharmacy among HIV-positive and -negative men in the Multicenter AIDS Cohort Study from 2004 to 2016 - (05/01/19)
     
  4218. Frailty phenotype in older people living with HIV: concepts, prevention and issues - (04/29/19)
     
  4219. ViiV HEALTHCARE ANNOUNCES CHMP POSITIVE OPINION FOR DOVATO® (DOLUTEGRAVIR/LAMIVUDINE) AS A ONCE-DAILY, SINGLE-PILL, TWO-DRUG REGIMEN FOR THE TREATMENT OF HIV INFECTION - (04/29/19)
     
  4220. ViiV HEALTHCARE SUBMITS NEW DRUG APPLICATION TO US FDA FOR THE FIRST MONTHLY, INJECTABLE, TWO-DRUG REGIMEN OF CABOTEGRAVIR AND RILPIVIRINE FOR TREATMENT OF HIV - (04/29/19)
     
  4221. Complicated Complications at CROI - David Alain Wohl, MD - The University of North Carolina Institute of Global Health and Infectious Diseases - (04/26/19)
     
  4222. HIV is Associated with Lung Function Impairment in the Multicenter AIDS Cohort Study - (04/23/19)
     
  4223. 2 Studies on Sudden Cardiac Death in HIV+ at CROI 2019 with surprising findings regarding causes of deaths - (04/23/19)
     
  4224. PSYCHOLOGICAL BURDEN AND THE IMPACT ON ENGAGEMENT WITH CARE AMONG ETHNICALLY DIVERSE OLDER WOMEN WITH HIV - (04/23/19)
     
  4225. People living with HIV in the UK have a higher risk of progression to CNS disorders and other comorbidities than matched counterparts - (04/23/19)
     
  4226. FATTY LIVER in HIV+, alcohol, 50% have NAFLD, 27% Liver Fibrosis - The prevalence of liver fibrosis in HIV infected patients with abnormal liver function tests - (04/23/19)
     
  4227. Multimorbidity burden in an HIV population aged over 50 in South-East England - (04/23/19)
     
  4228. "I'm 51 but living in the body of a 65-year old":Exploring the experiences and needs of those living with HIV and multiple comorbidities - (04/23/19)
     
  4229. Comorbidities Prevalence & Clustering Together in 2 European Aging/HIV Cohorts - POPPY & AGEHIV - (04/18/19)
     
  4230. Expanded Access - Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection - (04/18/19)
     
  4231. Study Finds No Benefit for Dietary Supplements - (04/18/19)
     
  4232. Aging & HIV: Gilead Funds 30 Organizations with $17 Million; ViiV Project - "Aging/HIV has become the #1 issue from at least a clinical perspective" - (04/17/19)
     
  4233. HIV and aging: time to bridge the gap between clinical research and clinical care - Editorial "PLWH seem to be biologically older than their chronological age..... something has to be done to bridge the gap between clinical research and clinical care." - (04/17/19)
     
  4234. Why are people with HIV considered "older adults" in their fifties? "immunosenescence" - (04/17/19)
     
  4235. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Rapid Initiation for HIV-1 Infection: Primary Analysis of the DIAMOND Study at ACTHIV - (04/15/19)
     
  4236. Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet Regimen in a Rapid Initiation Model of Care Demonstrating Safety and Efficacy with SYMTUZA® through 48 Weeks - (04/15/19)
     
  4237. EASL: HIV-infected individuals at high risk of non-alcoholic fatty liver disease (NAFLD) and progressive liver disease- ILC 2019: Latest studies confirm increasing burden of NAFLD in people with HIV infection as viral hepatitis prevalence and associated mortality decline - (04/12/19)
     
  4238. American Heart Association Recommends Depression Screening for Cardiovascular Disease Patients Cardiovascular Disease / 'Double the Concern in Older HIV+' - (04/10/19)
     
  4239. ViiV HEALTHCARE ANNOUNCES JULUCA (DOLUTEGRAVIR/RILPIVIRINE) MAINTAINS HIV VIRAL SUPPRESSION AT 148-WEEKS - (04/10/19)
     
  4240. Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to DTG + RPV 2-Drug Regimen: SWORD-1 and -2 Studies at BHIVA - (04/10/19)
     
  4241. US FDA APPROVES ViiV HEALTHCARE'S DOVATO (DOLUTEGRAVIR/LAMIVUDINE), THE FIRST, ONCE-DAILY, SINGLE-TABLET, TWO-DRUG REGIMEN FOR TREATMENT-NAïVE HIV-1 ADULTS (dolutegravir/3TC) - (04/10/19)
     
  4242. Clinical Pharmacology at CROI 2019 - Courtney V. Fletcher, Pharm.D. Professor UNMC Center for Drug Discovery University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE (04/09/19)
     
  4243. Updates New ARTs/ New ART Data - CROI including Bictegravir, Dolutegravir+Rilpivirine, Dolutegravir+3TC, Doravirine; Fostemsavir & MK-8591 - (04/10/19)
     
  4244. US FDA APPROVES ViiV HEALTHCARE'S DOVATO (DOLUTEGRAVIR/LAMIVUDINE), THE FIRST, ONCE-DAILY, SINGLE-TABLET, TWO-DRUG REGIMEN FOR TREATMENT-NAïVE HIV-1 ADULTS (dolutegravir/3TC) - (04/10/19)
     
  4245. How all-type dementia risk factors and modifiable risk interventions may be relevant to the first-generation aging with HIV infection? Dementia Risk in HIV+ is Higher - (04/09/19)
     
  4246. Working memory revived in older adults by synchronizing rhythmic brain circuits - (04/09/19)
     
  4247. CROI: GS-6207, A POTENT AND SELECTIVE FIRST-IN-CLASS LONG-ACTING HIV-1 CAPSID INHIBITOR - (04/08/19)
     
  4248. CROI: Weight Gain in HIV - Integrase - (04/08/19)
     
  4249. New VIDEO - Staying Golden: Aging With HIV - (04/05/19)
     
  4250. Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies - (04/05/19)
     
  4251. Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy for HIV Pre-Exposure Prophylaxis - (04/05/19)
     
  4252. Letter from the OAR Director - (04/05/19)
     
  4253. CROI: HIGH RATES OF VIROLOGIC SUPPRESSION AFTER RAPID ART START IN A SAFETY-NET CLINIC - (04/05/19)
     
  4254. AMCP - Long-Term Benefits of Rapid Antiretroviral Therapy Initiation Among Medicaid-Covered Patients With Human Immunodeficiency Virus - (04/04/19)
     
  4255. AMCP - Rapid Initiation of Antiretroviral Treatment Following Diagnosis of Human Immunodeficiency Virus Among Commercially-Insured Patients in the United States - (04/04/19)
     
  4256. AMCP - Estimating Costs of Health Resource Utilization for Patients Living With Human Immunodeficiency Virus - (04/04/19)
     
  4257. CROI: Aging At CROI 2019 - (04/02/19)
     
  4258. Weight gain, blood pressure rise seen with JAK inhibitor therapy - (04/02/19)
     
  4259. Study Confirms Tesamorelin Significantly Reduces Liver Fat in HIV Patients With NAFLD - press announcement - (04/02/19)
     
  4260. CROI: EFFECT ON PLASMA NFL, A MARKER OF NEURONAL INJURY, AFTER SWITCHING FROM TDF TO TAF - (04/01/19)
     
  4261. CROI: EFFECTS OF PROBIOTIC VISBIOME ES ON COLONIC MUCOSAL CD4 CELLS: RESULTS FROM A5352S - (04/01/19)
     
  4262. CROI: BENEFICIAL EFFECT OF 6 MONTHS OF PROBIOTICS ON ASYMPTOMATIC NEUROCOGNITIVE IMPAIRMENT - (04/01/19)
     
  4263. CROI: 26th Conference on Retroviruses and Opportunistic Infections (CROI) Seattle, WA - Eric S. Daar, M.D. - (03/29/19)
     
  4264. CROI: HIV Prevention at CROI 2019 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/29/19)
     
  4265. CROI: Changes in Kidney Function Among MSM Initiating On-Demand TDF/FTC for HIV Pre-Exposure Prophylaxis - (03/29/19)
     
  4266. CROI: I Keep Forgetting HIV, Aging, and Cognitive Disorders - (03/29/19)
     
  4267. CROI: THE PROJECTED AGE DISTRIBUTION OF WHITE, BLACK, AND HISPANIC MSM ON ART, 2009-2030 / 20% White MSM Projected to be over 70 by 2030 - (03/28/19)
     
  4268. CROI: THE PROJECTED AGE DISTRIBUTION OF WHITE, BLACK, AND HISPANIC MSM ON ART, 2009-2030 - (03/28/19)
     
  4269. CROI: Earlier Age of Onset and Higher Prevalence of Comorbidities in People Living with HIV: A Population-Based Cohort Study in British Columbia, Canada - (03/28/19)
     
  4270. CROI: PROJECTED GROWTH AND NEEDS OF AGING PLWH IN HRSA'S RYAN WHITE HIV/AIDS PROGRAM .....from 2010 through 2030 % > 50 years old doubles with curve sharply increasing-see graph below - (03/28/19)
     
  4271. CROI: Suicide rates among adults living with HIV, 2000-2015 - (03/28/19)
     
  4272. NHPC: Trends in HIV Testing, Diagnosis, and Linkage to Care among Transgender Women Tested in Tested in CDC-Funded Sites, 2012-2017 - (03/27/19)
     
  4273. NHPC: CDC Reports 57% Viral Suppression Rates - (03/27/19)
     
  4274. NHPC: CDC Viral Load Suppression Reporting - (03/27/19)
     
  4275. NHPC: Dental Care for HIV Difficult To Secure / Is Very Important - (03/27/19)
     
  4276. NHPC: CDC Prevention Conference: 9 Highlights - 50% Tested for HIV / Transmission Rate 0 if Undetectable / Florida: 73% in care - (03/27/19)
     
  4277. NHPC: HIV care engagement and sustained viral suppression among persons with diagnosed HIV Infection in Medicaid expansion and non-expansion states, United States, 2015 - (03/27/19)
     
  4278. NHPC: HIV care engagement and sustained viral suppression among persons with diagnosed HIV Infection in Medicaid expansion and non-expansion states, United States, 2015 - (03/27/19)
     
  4279. CROI: Delayed HCC Diagnosis in HIV/HCV Coinfected: HIV not linked to worse liver cancer survival in people with HCV - (03/26/19)
     
  4280. CROI: AIDS illness, living in US South, lower CD4s linked to longer hospital stay with HIV - (03/26/19)
     
  4281. CROI: Factors associated with therapeutic failure of 2-drug regimens, DAT'AIDS cohort: Two-antiretroviral maintenance failure--raltegravir regimens seem most vulnerable - Mark Mascolini (03/26/19)
     
  4282. Neurocognitive SuperAging (SA) in Older Adults Living With HIV: Demographic, Neuromedical and Everyday Functioning Correlates (CHARTER) - (03/25/19)
     
  4283. CROI: Integrase Strand Transfer Inhibitors are Associated With Weight Gain in Women - (03/25/19)
     
  4284. CROI: Can HBV Be Cured? - "Single hepatocyte analysis in HIV-HBV co-infection shows transcriptional silencing" - (03/22/19)
     
  4285. CROI: Integrase Inhibitor Exposure and Central Nervous System & Neural Tube Defects - Data from the Antiretroviral Pregnancy Registry - (03/20/19)
     
  4286. NHPC: HIV risk in MSM, transgender people, high-school students, new mothers - Mark Mascolini (03/25/19)
     
  4287. NHPC: PrEP prescribers multiply as adherence and persistence get high marks - Mark Mascolini (03/22/19)
     
  4288. NHPC: US trends in HIV testing, linkage to care, and transmission - Mark Mascolini (03/22/19)
     
  4289. CROI: High maternal HBV with HIV tied to low infant weight and HIV transmission - Mark Mascolini (03/22/19)
     
  4290. NY Times article: This is Not A Cure for My H.I.V. - (03/22/19)
     
  4291. Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors - (03/22/19)
     
  4292. Aspirin Use Discourged / 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease - (03/22/19)
     
  4293. Ten Things I Learned About Aspirin at ESC 2018, 3 studies on aspirin use COMMENTARY - BOTH STUDIES ARE BELOW - (03/22/19)
     
  4294. CROI: Real-life efficacy and safety of Glecaprevir/Pibrentasvir in a large cohort of HCV-infected patients: the MISTRAL study - (03/20/19)
     
  4295. CROI: Liver stiffness at SVR predicts hepatic complications in HCV-infected patients - (03/20/19)
     
  4296. CROI: Integrase Inhibitor Exposure and Central Nervous System & Neural Tube Defects - Data from the Antiretroviral Pregnancy Registry - (03/20/19)
     
  4297. CROI: Inflammation, Arterial Stiffness and Directly-Acting ntivirals in HCV and HIV/HCV, no beneft observed in this study - (03/20/19)
     
  4298. CROI: Successful HCV treatment does not affect rate of heart disease or non-AIDS cancer - Mark Mascolini (03/20/19)
     
  4299. CROI: DAA therapy for HCV lowers risk of cardiovascular disease at all fibrosis stages - (03/20/19)
     
  4300. CROI: Maternal HBV Viremia Is Associated With Adverse Infant Outcomes In HIV/HBV Women: Post-Hoc Analysis of HPTN 046 - (03/20/19)
     
  4301. CROI: HCV treatment with DAAs halves risk of new diabetes diagnosis - Mark Mascolini (03/20/19)
     
  4302. CROI: High maternal HBV with HIV tied to low infant weight and HIV transmission - Mark Mascolini (03/20/19)
     
  4303. CROI: High endothelial dysfunction rate with recent HIV in young adults with low cardiovascular risk - Mark Mascolini (03/19/19)
     
  4304. CROI: ART IN EARLY INFECTION IMPROVES NEUROCOGNITION REGARDLESS OF INFECTION DURATION - (03/19/19)
     
  4305. CROI: GENOTYPIC AND PHENOTYPIC SUSCEPTIBILITY TO FOSTEMSAVIR IN MULTIDRUG-RESISTANT HIV-1 - (03/19/19)
     
  4306. CROI: DOLUTEGRAVIR: ABSENCE OF DEVELOPMENTAL TOXICITY INCLUDING NTDs IN ANIMAL STUDIES - (03/19/19)
     
  4307. CROI: NO INCREASE IN BIRTH DEFECTS IN INFANTS EXPOSED TO INTEGRASE INHIBITORS AT CONCEPTION - (03/19/19)
     
  4308. CROI: Integrase Inhibitor Exposure and CNS and Neural Tube Defects: Data from the Antiretroviral Pregnancy Registry (APR) - (03/19/19)
     
  4309. CROI: Reports of Neural Tube Defects for 8 ARVs in FDA, WHO, EMA and UK Pharmacovigilance Safety Databases - (03/19/19)
     
  4310. CROI: Antiretroviral Adherence and HIV-1 Drug Resistance in the US - (03/19/19)
     
  4311. CROI: RELAPSE OF SYMPTOMATIC CSF HIV ESCAPE UPON PREVIOUSLY OPTIMIZED C-ART REGIMEN CHANGES - (03/18/19)
     
  4312. CROI: Combination of CRISPR and LASER ART Eliminates Replication Competent Rebound in Humanized Mice - (03/18/19)
     
  4313. CROI: Lymphoid Tissue Pharmacokinetics of Tenofovir-alafenamide vs. disoproxil fumarate - (03/18/19)
     
  4314. CROI: MODERATE EFFICACY OF ORAL SINGLE-AGENT TAF AGAINST VAGINAL SHIV INFECTION IN MACAQUES - (03/18/19)
     
  4315. CROI: USING EHR DATA TO IDENTIFY POTENTIAL PREP CANDIDATES IN A LARGE HEALTH CARE SYSTEM - (03/18/19)
     
  4316. CROI: Prediction of Renal OAT1 and OAT3 Inhibition by Cabotegravir Using PBPK Modelling - (03/18/19)
     
  4317. CROI: Hormonal Contraceptives Do Not Alter Cabotegravir PK in HIV Uninfected Women: HPTN 077 - (03/18/19)
     
  4318. CROI: Immediate PrEP Initiation at New York City Sexual Health Clinics - (03/18/19)
     
  4319. CROI: One in 50 in NYC with recently diagnosed HIV used PrEP in preceding months..... PrEP Use in Persons With Undetected HIV Infections Contributes to Resistance - Mark Mascolini (03/18/19)
     
  4320. CROI: Sex-specific Patterns in HIV-associated Cardiovascular Mortality in New York City - (03/18/19)
     
  4321. CROI: New HIV/ART Drugs at CROI 2019 - (03/18/19)
     
  4322. CROI: THERAPEUTIC ACTIVITY OF PGT121 MONOCLONAL ANTIBODY IN HIV-INFECTED ADULTS - (03/18/19)
     
  4323. CROI: THERAPEUTIC ACTIVITY OF PGT121 MONOCLONAL ANTIBODY IN HIV-INFECTED ADULTS - (03/15/19)
     
  4324. CROI: GS-9722: First-in-Class, Effector-Enhanced, Broadly Neutralizing Antibody for HIV Cure - and PGT121 in HIV+ / PGT121 bNAb in HIV+ - (03/15/19)
     
  4325. CROI: CHARACTERIZING THE HIV DNA RESERVOIRS IN WHOLE-BODY TISSUES IN THE "LAST GIFT" COHORT - (03/15/19)
     
  4326. CROI: A Phase IIa Study of a Novel Maturation Inhibitor GSK2838232 in HIV patients - (03/15/19)
     
  4327. CROI: Long-Term B/F/TAF Switch Efficacy in Patients with Archived Pre-Existing Resistance - (04/08/19)
     
  4328. CROI: Susceptibility to Bictegravir in Highly ARV Experienced Patients After